0001275187-19-000026.txt : 20191004 0001275187-19-000026.hdr.sgml : 20191004 20191004153751 ACCESSION NUMBER: 0001275187-19-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20190831 FILED AS OF DATE: 20191004 DATE AS OF CHANGE: 20191004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC CENTRAL INDEX KEY: 0001275187 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113146460 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-50761 FILM NUMBER: 191138556 BUSINESS ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 BUSINESS PHONE: 5187981215 MAIL ADDRESS: STREET 1: 14 PLAZA DRIVE CITY: LATHAM STATE: NY ZIP: 12110 10-Q 1 ango-083119x10q.htm 10-Q Document
P30Dfalse--05-31Q120200001275187true190600014340001.000.050.660.040.010.01750000007500000037984382383598753761438237989875P5YP15YP7YP5YP2Y56000000.010.01500000050000000000370000370000 0001275187 2019-06-01 2019-08-31 0001275187 2019-10-02 0001275187 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 ango:PreferredStockPurchaseRightsMember 2019-06-01 2019-08-31 0001275187 2018-06-01 2018-08-31 0001275187 2019-08-31 0001275187 2019-05-31 0001275187 2018-08-31 0001275187 2018-05-31 0001275187 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 us-gaap:TreasuryStockMember 2019-05-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 us-gaap:CommonStockMember 2019-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-01 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0001275187 us-gaap:RetainedEarningsMember 2019-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0001275187 us-gaap:RetainedEarningsMember 2019-08-31 0001275187 us-gaap:CommonStockMember 2019-08-31 0001275187 us-gaap:TreasuryStockMember 2019-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-31 0001275187 us-gaap:RetainedEarningsMember 2019-06-01 2019-08-31 0001275187 ango:RadiaDyneMember 2018-09-21 0001275187 ango:RadiaDyneMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember 2019-08-31 0001275187 ango:RadiaDyneMember ango:TechnicalMilestonesMember 2018-09-21 0001275187 ango:BioSentryMember 2018-08-14 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2018-09-21 2018-09-21 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember 2018-06-01 2019-05-31 0001275187 ango:BioSentryMember 2018-06-01 2019-05-31 0001275187 ango:RadiaDyneMember ango:RevenueBasedPaymentMember 2018-09-21 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-08-14 2018-08-14 0001275187 ango:BioSentryMember 2018-08-14 2018-08-14 0001275187 ango:RadiaDyneMember ango:RadiaDyneTrademarkMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:RadiaDyneTechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:RadiaDyneMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:OarTracTechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:OarTracTrademarkMember 2019-05-31 0001275187 ango:BioSentryMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-08-14 2018-08-14 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-06-01 2019-08-31 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-03-01 2019-05-31 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-05-31 0001275187 ango:MedlineMember 2019-03-01 2019-05-31 0001275187 ango:OncologyMember country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:OncologyMember 2018-06-01 2018-08-31 0001275187 us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:OncologyMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2018-06-01 2018-08-31 0001275187 srt:MaximumMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember 2019-06-01 2019-08-31 0001275187 country:US 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember 2019-06-01 2019-08-31 0001275187 us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 srt:MinimumMember 2019-06-01 2019-08-31 0001275187 ango:AcculisInventoryMember 2019-08-31 0001275187 2018-12-31 2018-12-31 0001275187 us-gaap:TrademarksMember 2019-05-31 0001275187 us-gaap:LicenseAgreementTermsMember 2019-05-31 0001275187 us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 ango:ProductTechnologiesMember 2019-05-31 0001275187 ango:ProductTechnologiesMember 2019-08-31 0001275187 us-gaap:LicenseAgreementTermsMember 2019-08-31 0001275187 us-gaap:TrademarksMember 2019-08-31 0001275187 us-gaap:CustomerRelationshipsMember 2019-08-31 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-08-31 0001275187 ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-06-03 2019-06-03 0001275187 srt:MinimumMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 0001275187 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-06-03 2019-06-03 0001275187 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 ango:The2004PlanandEmployeeStockPurchasePlanMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 ango:ClinicalDevicesBvMember 2019-06-01 2019-08-31 0001275187 srt:MaximumMember 2019-08-31 0001275187 srt:MinimumMember 2019-08-31 0001275187 ango:TechnicalMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:ValuationTechniqueEstimatedProbabilityMember 2019-08-31 0001275187 ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel3Member ango:ContingentConsiderationEarnOutLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 ango:TwoYearBuildingLeaseMember us-gaap:BuildingMember 2019-08-31 0001275187 ango:SevenYearBuildingLeaseMember us-gaap:BuildingMember 2019-08-31 0001275187 us-gaap:AccountingStandardsUpdate201602Member 2019-06-01 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2019-06-01 2019-08-31 0001275187 us-gaap:CostOfSalesMember 2019-06-01 2019-08-31 0001275187 ango:TheUtahActionMember 2012-01-11 2012-01-11 0001275187 ango:TheUtahActionMember 2016-03-24 2016-03-24 0001275187 ango:TheUtahActionMember 2016-03-29 2016-03-29 0001275187 ango:TheUtahActionMember 2016-03-11 0001275187 ango:CrBardIncMember 2012-01-11 2012-01-11 0001275187 ango:C.R.BardInc.Member ango:TheUtahActionMember us-gaap:PendingLitigationMember 2016-03-30 2017-01-31 0001275187 ango:TheDelawareActionMember 2019-03-07 2019-03-07 0001275187 ango:TheUtahActionMember 2016-03-24 0001275187 ango:ConstructionIssuesMember 2019-08-31 0001275187 ango:TheDelawareActionMember 2015-06-01 2015-06-01 0001275187 ango:TheUtahActionMember 2016-03-11 2016-03-11 0001275187 ango:TheUtahActionMember 2012-01-11 0001275187 us-gaap:RestructuringChargesMember 2019-06-01 2019-08-31 0001275187 us-gaap:OtherExpenseMember 2018-06-01 2018-08-31 0001275187 ango:DivestitureMember 2018-06-01 2018-08-31 0001275187 us-gaap:OtherExpenseMember 2019-06-01 2019-08-31 0001275187 ango:MergersandAcquisitionsMember 2019-06-01 2019-08-31 0001275187 ango:MergersandAcquisitionsMember 2018-06-01 2018-08-31 0001275187 ango:LegalCostsMember 2018-06-01 2018-08-31 0001275187 ango:TransitionserviceagreementMember 2019-06-01 2019-08-31 0001275187 ango:TransitionserviceagreementMember 2018-06-01 2018-08-31 0001275187 ango:LegalCostsMember 2019-06-01 2019-08-31 0001275187 us-gaap:RestructuringChargesMember 2018-06-01 2018-08-31 0001275187 ango:DivestitureMember 2019-06-01 2019-08-31 0001275187 2017-02-01 2019-08-31 0001275187 ango:BiolitecBankruptcyMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-05-31 0001275187 ango:EximoMedicalLtd.Member us-gaap:SubsequentEventMember 2019-10-02 2019-10-02 0001275187 ango:EximoMedicalLtd.Member ango:TechnologyAndRevenueMilestonesMember us-gaap:SubsequentEventMember 2019-10-02 ango:covenant xbrli:pure ango:segment ango:motion ango:Petition iso4217:USD xbrli:shares iso4217:USD ango:reexamination_appeal ango:patent xbrli:shares ango:claim

    
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended August 31, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 0-50761

 
AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)
angologoa23.gif
 
 

Delaware
 
11-3146460
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)

14 Plaza Drive, Latham, New York 12110
(Address of principal executive offices and zip code)
(518) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common stock, par value $.01
 
ANGO
 
NASDAQ Global Select Market
Preferred Stock Purchase Rights
 
 
 
NASDAQ Global Select Market




Securities registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes      No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes      No  
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
  
Accelerated filer
 
 
 
 
 
Non-accelerated filer
 
 
Smaller reporting company
 
 
 
 
 
 
 
 
Emerging growth company
 
 
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date.
Class
 
Outstanding as of October 2, 2019
Common Stock, par value $.01
 
37,619,875
 




AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
 
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
Item 5.
 
 
 
Item 6.

2


PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands of dollars, except per share data)
 
 
 
Three Months Ended
 
 
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
$
66,042

 
$
63,943

Cost of sales (exclusive of intangible amortization)
 
27,825

 
27,990

Gross profit
 
38,217

 
35,953

Operating expenses:
 
 
 
 
Research and development
 
6,292

 
7,374

Sales and marketing
 
19,380

 
18,405

General and administrative
 
8,453

 
8,435

Amortization of intangibles
 
3,868

 
3,434

Change in fair value of contingent consideration
 
(448
)
 
12

Acquisition, restructuring and other items, net
 
1,500

 
4,422

Total operating expenses
 
39,045

 
42,082

Operating loss
 
(828
)
 
(6,129
)
Other (expenses) income:
 
 
 
 
Interest expense, net
 
(465
)
 
(917
)
Other income (expense), net
 
(98
)
 
114

Total other expenses, net
 
(563
)
 
(803
)
Loss from continuing operations before income tax benefit
 
(1,391
)
 
(6,932
)
Income tax benefit
 
(116
)
 
(1,228
)
Net loss from continuing operations
 
(1,275
)
 
(5,704
)
Income from discontinued operations, net of income tax
 

 
5,235

Net loss
 
$
(1,275
)
 
$
(469
)
Loss per share - continuing operations
 
 
 
 
Basic
 
$
(0.03
)
 
$
(0.15
)
Diluted
 
$
(0.03
)
 
$
(0.15
)
Income per share - discontinued operations
 
 
 
 
Basic
 
$
0.00

 
$
0.14

Diluted
 
$
0.00

 
$
0.14

Loss per share
 
 
 
 
Basic
 
$
(0.03
)
 
$
(0.01
)
Diluted
 
$
(0.03
)
 
$
(0.01
)
Weighted average shares outstanding
 
 
 
 
Basic
 
37,783

 
37,323

Diluted
 
37,783

 
37,323

The accompanying notes are an integral part of these consolidated financial statements.

3


AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in thousands of dollars)
 
 
 
Three Months Ended
 
 
Aug 31, 2019
 
Aug 31, 2018
Net loss
 
$
(1,275
)
 
$
(469
)
Other comprehensive loss, before tax:
 
 
 
 
Unrealized gain on marketable securities
 

 
33

Foreign currency translation
 
(151
)
 
(125
)
Other comprehensive loss, before tax
 
(151
)
 
(92
)
Income tax expense related to items of other comprehensive income
 

 

Other comprehensive loss, net of tax
 
(151
)
 
(92
)
Total comprehensive loss, net of tax
 
$
(1,426
)
 
$
(561
)
The accompanying notes are an integral part of these consolidated financial statements.


4


AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
 
Aug 31, 2019
 
May 31, 2019
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
83,649

 
$
227,641

Accounts receivable, net of allowances of $1,434 and $1,906 respectively
32,540

 
43,577

Inventories
45,229

 
40,071

Prepaid expenses and other
4,939

 
4,003

Total current assets
166,357

 
315,292

Property, plant and equipment, net
25,334

 
24,258

Other assets
9,352

 
3,835

Intangible assets, net
141,655

 
145,387

Goodwill
347,666

 
347,666

Total assets
$
690,364

 
$
836,438

Liabilities and stockholders' equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
16,870

 
$
22,829

Accrued liabilities
22,693

 
38,338

Current portion of long-term debt

 
7,500

Current portion of contingent consideration
878

 
4,635

Other current liabilities
6,731

 

Total current liabilities
47,172

 
73,302

Long-term debt, net of current portion

 
124,407

Contingent consideration, net of current portion
10,952

 
8,851

Deferred income taxes
14,367

 
14,542

Other long-term liabilities
3,800

 
521

Total liabilities
76,291

 
221,623

Commitments and contingencies (Note 15)

 

Stockholders' equity
 
 
 
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,359,875 and 37,984,382 shares issued and 37,989,875 and 37,614,382 shares outstanding at August 31, 2019 and May 31, 2019, respectively
373

 
372

Additional paid-in capital
555,723

 
555,040

Retained earnings
65,194

 
66,469

Treasury stock, 370,000 shares at August 31, 2019 and May 31, 2019, respectively
(5,714
)
 
(5,714
)
Accumulated other comprehensive loss
(1,503
)
 
(1,352
)
Total Stockholders’ Equity
614,073

 
614,815

Total Liabilities and Stockholders' Equity
$
690,364

 
$
836,438

The accompanying notes are an integral part of these consolidated financial statements.

5


AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
 
Three Months Ended
 
Aug 31, 2019
 
Aug 31, 2018
Cash flows from operating activities:
 
 
 
Net loss
$
(1,275
)
 
$
(469
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 
 
 
Depreciation and amortization
5,207

 
5,599

Stock based compensation
1,984

 
2,150

Change in fair value of contingent consideration
(448
)
 
12

Deferred income taxes
(175
)
 
(10
)
Change in accounts receivable allowances
(453
)
 
(228
)
Fixed and intangible asset impairments and disposals
99

 

              Write-off of other assets
593

 

Other
(8
)
 
25

Changes in operating assets and liabilities:

 

Accounts receivable
11,474

 
(562
)
Inventories
(5,153
)
 
(761
)
Prepaid expenses and other
(746
)
 
(1,200
)
Accounts payable, accrued and other liabilities
(17,633
)
 
(13,429
)
Net cash used in operating activities
(6,534
)
 
(8,873
)
Cash flows from investing activities:
 
 
 
Additions to property, plant and equipment
(1,391
)
 
(682
)
Acquisition of intangibles
(150
)
 

Cash paid for acquisitions

 
(37,000
)
Net cash used in investing activities
(1,541
)
 
(37,682
)
Cash flows from financing activities:
 
 
 
Repayment of long-term debt
(132,500
)
 
(1,250
)
Deferred financing costs on long-term debt
(741
)
 

Payment of acquisition related contingent consideration
(1,208
)
 
(2,100
)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan
(1,300
)
 
705

Net cash used in financing activities
(135,749
)
 
(2,645
)
Effect of exchange rate changes on cash and cash equivalents
(168
)
 
(134
)
Decrease in cash and cash equivalents
(143,992
)
 
(49,334
)
Cash and cash equivalents at beginning of period
227,641

 
74,096

Cash and cash equivalents at end of period
$
83,649

 
$
24,762

 
 
 
 
Supplemental disclosure of non-cash investing and financing activities:
 
 
 
 
 
 
 
Accrual for capital expenditures incurred during the period
$
477

 
$
38

The accompanying notes are an integral part of these consolidated financial statements.

6


AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)

 
 
Common Stock
 
Additional
paid in
capital
 
Retained earnings
 
Accumulated
other
comprehensive
loss
 
Treasury Stock
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
Total
Balance at May 31, 2019
37,984,382

 
$
372

 
$
555,040

 
$
66,469

 
$
(1,352
)
 
(370,000
)
 
$
(5,714
)
 
$
614,815

Net loss


 


 


 
(1,275
)
 


 


 


 
(1,275
)
Exercise of stock options
48,136

 
1

 
530

 


 


 


 


 
531

Issuance/Cancellation of restricted stock units
287,087

 


 
(2,459
)
 


 


 


 


 
(2,459
)
Purchases of common stock under ESPP
40,270

 


 
628

 


 


 


 


 
628

Stock-based compensation


 


 
1,984

 


 


 


 


 
1,984

Other comprehensive loss, net of tax


 


 


 


 
(151
)
 


 


 
(151
)
Balance at August 31, 2019
38,359,875

 
$
373

 
$
555,723

 
$
65,194

 
$
(1,503
)
 
(370,000
)
 
$
(5,714
)
 
$
614,073






































7


AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - continued
(unaudited)
(in thousands of dollars, except share data)

 
Common Stock
 
Additional
paid in
capital
 
Retained earnings (deficit)
 
Accumulated
other
comprehensive
loss
 
Treasury Stock
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
Total
Balance at May 31, 2018
37,594,493

 
$
370

 
$
543,762

 
$
5,129

 
$
(952
)
 
(370,000
)
 
$
(5,714
)
 
$
542,595

Net loss
 
 
 
 
 
 
(469
)
 
 
 
 
 
 
 
(469
)
Exercise of stock options
71,336

 
1

 
607

 
 
 
 
 
 
 
 
 
608

Issuance/Cancellation of restricted stock units
149,446

 
 
 
(460
)
 
 
 
 
 
 
 
 
 
(460
)
Issuance/Cancellation of performance share units
5,235

 
 
 
 
 
 
 
 
 
 
 
 
 

Purchases of common stock under ESPP
40,547

 
1

 
556

 
 
 
 
 
 
 
 
 
557

Stock-based compensation
 
 
 
 
2,150

 
 
 
 
 
 
 
 
 
2,150

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
(92
)
 
 
 
 
 
(92
)
Balance at August 31, 2018
37,861,057

 
$
372

 
$
546,615

 
$
4,660

 
$
(1,044
)
 
(370,000
)
 
$
(5,714
)
 
$
544,889


The accompanying notes are an integral part of these consolidated financial statements.

8


AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Balance Sheet as of August 31, 2019, the Consolidated Statements of Operations, Consolidated Statements of Comprehensive Loss, Consolidated Statements of Cash Flows, and the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2019 and 2018, have been prepared by us and are unaudited. The Consolidated Balance Sheet as of May 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2019 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three months ended August 31, 2019 and 2018 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.”  Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.
2. ACQUISITIONS

RadiaDyne Acquisition

On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of $22.3 million in contingent consideration is comprised of $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The $4.6 million indemnification holdback is recorded in accrued liabilities at August 31, 2019 and the $0.2 million purchase price holdback was initially recorded in accrued liabilities, and was paid during the third quarter of fiscal year 2019.
This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.
The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately $1.6 million in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:

9


(in thousands)
Final allocation
Accounts receivable
$
900

Inventory
732

Prepaid and other current assets
98

Property, plant and equipment
133

Intangible assets:
 
RadiaDyne trademark
400

OARtrac trademark
200

RadiaDyne legacy product technology
1,500

OARtrac product technology
18,900

RadiaDyne customer relationships
4,600

Goodwill
47,982

Total assets acquired
$
75,445

Liabilities assumed
 
Accounts payable
$
352

Accrued expenses
106

Total liabilities assumed
$
458

Net assets acquired
$
74,987


The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.
The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five to seven years and the product technologies are deemed to have a useful life of seven to ten years. Both are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
BioSentry Acquisition
On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC.
The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately $1.0 million in fiscal year 2019. The following

10


table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:
(in thousands)
Final allocation
Inventory
$
50

Property, plant and equipment
10

Intangible assets:

    BioSentry trademark
2,500

    BioSentry product technology
20,900

    Customer relationships
2,600

Goodwill
13,740

Net assets acquired
$
39,800


The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.
The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen year useful life and are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
3. DIVESTITURES    

Fluid Management
On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. The gain was recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.
Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed 24 months.
As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying Consolidated Statements of Operations as “Income from discontinued operations, net of income tax” for the

11


three months ended August 31, 2018. The following table summarizes the financial results of our discontinued operations:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net sales
$
21,397

Cost of sales (exclusive of amortization)
12,882

Gross profit
8,515

Operating expenses
 
Research and development
288

Sales and marketing
1,028

General and administrative
62

Amortization of intangibles
682

Total operating expenses
2,060

Operating income
6,455

 
 
Income from discontinued operations before income taxes
6,455

Income tax expense
1,220

Income from discontinued operations
$
5,235


In accordance with accounting principles generally accepted in the United States (“GAAP”), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio.
Total operating and investing cash flows of discontinued operations for the three months ended August 31, 2018 is comprised of the following, which excludes the effect of income taxes:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net cash provided by operating activities
$
524

Net cash provided by investing activities
224


4. REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three months ended August 31, 2019 and 2018:

12


 
Three months ended August 31, 2019
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,676

 
$
3,237

 
$
28,913

Vascular Access
19,284

 
3,875

 
23,159

Oncology
7,977

 
5,993

 
13,970

Total
$
52,937

 
$
13,105

 
$
66,042

 
Three months ended August 31, 2018
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,851

 
$
2,747

 
$
28,598

Vascular Access
20,447

 
3,343

 
23,790

Oncology
5,198

 
6,357

 
11,555

Total
$
51,496

 
$
12,447

 
$
63,943

Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.

13


Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the three months ended August 31, 2019, such product returns were not material.
Contract Balances with Customers
A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Receivables
$
32,540

 
$
43,577

Contract assets
$

 
$

Contract liabilities
$
607

 
$
681


During the three months ended August 31, 2019, the Company recognized $0.2 million in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of $0.1 million.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

14



5. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Raw materials
$
17,443

 
$
16,045

Work in process
8,539

 
6,786

Finished goods
19,247

 
17,240

Inventories
$
45,229

 
$
40,071



The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at August 31, 2019 and May 31, 2019 was $4.1 million and $4.2 million, respectively. Of the $4.1 million reserve as of August 31, 2019 and the $4.2 million reserve as of May 31, 2019, $0.4 million relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017 and $0.7 million relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018.

6. GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.

The Company's annual testing for impairment of goodwill was completed as of December 31, 2018. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

Even though the Company determined that there was no goodwill impairment as of December 31, 2018, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2019. There were no adjustments to goodwill for the three months ended August 31, 2019.
Intangible assets consisted of the following:
 
Aug 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,968

 
$
(77,967
)
 
$
105,001

Customer relationships
60,147

 
(26,995
)
 
33,152

Trademarks
9,300

 
(6,470
)
 
2,830

Licenses
5,887

 
(5,215
)
 
672

 
$
258,302

 
$
(116,647
)
 
$
141,655


15


 
May 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,971

 
$
(75,412
)
 
$
107,559

Customer relationships
60,166

 
(25,950
)
 
34,216

Trademarks
9,300

 
(6,404
)
 
2,896

Licenses
5,752

 
(5,036
)
 
716

 
$
258,189

 
$
(112,802
)
 
$
145,387


Amortization expense for the three months ended August 31, 2019 and 2018 was $3.9 million and $3.4 million, respectively.
Expected future amortization expense related to the intangible assets is as follows:
(in thousands)

Remainder of 2020
$
11,308

2021
14,022

2022
13,406

2023
13,369

2024
11,813

2025 and thereafter
77,737


$
141,655




16


7. ACCRUED LIABILITIES
Accrued liabilities consisted of the following: 
(in thousands)
Aug 31, 2019
 
May 31, 2019
Payroll and related expenses
$
5,970

 
$
14,987

Royalties
1,439

 
2,088

Accrued severance
616

 
504

Sales and franchise taxes
3,417

 
807

Outside services
1,781

 
3,514

Litigation matters

 
2,700

Indemnification holdback
4,866

 
4,807

Other
4,604

 
8,931

 
$
22,693

 
$
38,338



8. LONG TERM DEBT

On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.
The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries.
The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.

The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019.
The Company was in compliance with the Credit Agreement covenants as of August 31, 2019.
As of August 31, 2019, there was no outstanding balance on the Revolving Facility. As of May 31, 2019 the carrying value of long-term debt approximates its fair market value.



17


9. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 8.3% in the first quarter of fiscal 2020, as compared to 17.8% for the same period in fiscal 2019. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation).

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.

Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of August 31, 2019. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

10. SHARE-BASED COMPENSATION

The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan.

For the three months ended August 31, 2019 and 2018, share-based compensation expense was $1.9 million and $2.2 million, respectively.

During the three months ended August 31, 2019 and 2018, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.

As of August 31, 2019, there was $16.6 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.

11. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.

18


The following table reconciles basic to diluted weighted-average shares outstanding for the three months ended August 31, 2019 and 2018 (in thousands):
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Basic
37,783

 
37,323

Effect of dilutive securities

 

Diluted
37,783

 
37,323

 
 
 
 
Securities excluded as their inclusion would be anti-dilutive
2,503

 
2,309



12. SEGMENT AND GEOGRAPHIC INFORMATION

The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
The table below summarizes net sales by Global Business Unit: 
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
Vascular Interventions & Therapies 
$
28,913

 
$
28,598

Vascular Access
23,159

 
23,790

Oncology
13,970

 
11,555

Total
$
66,042

 
$
63,943


The table below presents net sales by geographic area based on external customer location:
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
United States
$
52,937

 
$
51,496

International
13,105

 
12,447

Total
$
66,042

 
$
63,943



13. FAIR VALUE

On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

19



The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2019 and May 31, 2019:
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at August 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
11,830

 
$
11,830

Total Financial Liabilities
$

 
$

 
$
11,830

 
$
11,830

 
 
 
 
 
 
 
 
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at May 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
13,486

 
$
13,486

Total Financial Liabilities
$

 
$

 
$
13,486

 
$
13,486



There were no transfers between Level 1, 2 and 3 for the three months ended August 31, 2019.

The table below presents the changes in fair value components of Level 3 instruments in the three months ended August 31, 2019:

Three Months Ended August 31, 2019
(in thousands)
Fair Value Measurements
Using Significant
Unobservable Inputs
(Level 3)
Balance, May 31, 2019
$
13,486

Total gains or losses (realized/unrealized):


Change in present value of contingent consideration (1)
(448
)
Contingent consideration payments
(1,208
)
Balance, August 31, 2019
$
11,830


(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Contingent Consideration for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.

The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.


20


The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2019:
(in thousands)
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
Revenue based payments
$
8,533

 
Discounted cash flow
 
Discount rate
 
4% - 5%
 
 
 
 
 
Probability of payment
 
66% - 100%
 
 
 
 
 
Projected fiscal year of payment
 
2023
Technical milestones
$
3,297

 
Estimated probability
 
Estimated probability
 
90%
 
 
 
 
 
Projected year of payment
 
2020 - 2022
Total
$
11,830

 
 
 
 
 
 


At August 31, 2019, the range of estimated potential undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is $14.0 million to $34.0 million. The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2020 to 2023 in order for the associated consideration to be paid.

14. LEASES

Adoption of ASU No. 2016-02, Leases (Topic 842)
On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted.

The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.

The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately $5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows.

Leases
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.

Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

The following table presents supplemental balance sheet information related to our leases:
(in thousands)
Balance Sheet Location
 
Aug 31, 2019
Assets
 
 
 
Operating lease ROU asset
Other assets
 
$
5,104

Liabilities
 
 
 
Current operating lease liabilities
Other current liabilities
 
1,606

Non-current operating lease liabilities
Other long-term liabilities
 
3,489

Total lease liabilities
 
 
$
5,095


The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a

21


collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
 
Aug 31, 2019
Weighted average remaining term (in years)
3.7

Weighted average discount rate
4.3
%

The following table presents the maturities of the lease liabilities:
(in thousands)
Aug 31, 2019
Remainder of 2020
$
1,142

2021
1,251

2022
1,118

2023
1,138

2024
576

2025 and thereafter

Total lease payments
$
5,225

Less: Imputed Interest
130

Total lease obligations
$
5,095

Less: Current portion of lease obligations
1,606

Long-term lease obligations
$
3,489



The Company recognized $0.7 million of operating lease expense during the three months ended August 31, 2019, which includes immaterial short-term leases. Within the accompanying Consolidated Statements of Operations, $0.3 million is classified in cost of sales and $0.4 million is classified as general and administrative.

In addition to the total lease obligations presented in the table above, we have a 7-year building operating lease with undiscounted payment obligations of $6.5 million and a 2-year building operating lease with undiscounted payment obligations of $0.4 million that are expected to commence during fiscal year 2020.

Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:
(in thousands)
May 31, 2019
2020
$
2,920

2021
2,338

2022
2,133

2023
2,131

2024 and thereafter
3,227

Total lease payments
$
12,749



The following table presents supplemental cash flow and other information related to our leases:
 
Three Months Ended August 31, 2019
(in thousands)
Aug 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
563

ROU assets obtained in exchange for lease liabilities
 
Operating leases



22



15. COMMITMENTS AND CONTINGENCIES    

Legal Proceedings

The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
 
C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947,022) the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. 

Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company filed Cross-Appeals for the ‘302 and the ‘615 reexams and completed briefing.  Medcomp also filed an Amicus Brief in support of the Company on November 22, 2017.  An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 6-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent (confirming validity of claims 1-10) on June 10, 2019, and for the ‘022 patent (confirming validity of claims 1-20) on July 2, 2019, and for the ‘615 patent on August 26, 2019.   The Company has since filed a Motion to Unstay the Utah Case; that motion is fully briefed and awaiting decision by the Utah Court. Meanwhile, on July 12, 2017, Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as Co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action.  The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.

On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.

On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case

23


dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case (Plaintiff), Judge Bataillon granted judgment as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was served on September 27, 2019 and the Company's answering brief is currently due on November 6, 2019. We maintain our belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  The parties are currently engaged in discovery, which is set to close in February 2020.
Merz North America Settlement

On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of $2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter.  Merz filed a stipulation of dismissal with the Court on July 23, 2019.

16. ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET

Acquisition, Restructuring and Other Items
For the three months ended August 31, 2019 and 2018 acquisition, restructuring and other items, net consisted of:
 
Three months ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Legal (1)
$
669

 
$
2,880

Mergers and acquisitions (2)
246

 
1,318

Transition service agreement (3)
(737
)
 

Divestiture (4)
758

 

Restructuring
26

 
130

Other
538

 
94

Total
$
1,500

 
$
4,422


(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.
(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.
(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.

Included in the $0.7 million in legal for the three months ended August 31, 2019 is a $0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.

24


Restructuring

The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations.
Operational Consolidation
On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate its manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan were completed in the fourth quarter of fiscal year 2018 with immaterial regulatory filing costs to be incurred.
The Company recorded restructuring charges related to the plan during the three months ended August 31, 2019 and 2018 of less than $0.1 million and $0.1 million, respectively. Total restructuring charges recorded to date are $6.3 million. The Company’s remaining restructuring liability is comprised of regulatory expenses which are expected to be paid in the next twelve months and are included in "accrued liabilities" on the Consolidated Balance Sheet.
17. ACCUMULATED OTHER COMPREHENSIVE LOSS

Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three months ended August 31, 2019:
 
Three months ended August 31, 2019
(in thousands)
Foreign currency translation loss
Balance at May 31, 2019
$
(1,352
)
Other comprehensive loss before reclassifications, net of tax
(151
)
Amounts reclassified from accumulated other comprehensive loss

Net other comprehensive loss
$
(151
)
Balance at August 31, 2019
$
(1,503
)





25


18. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
Recently Issued Accounting Pronouncements - Adopted
Standard
Description
Date Adopted
Effect on the Consolidated Financial Statements
ASU 2016-02, Leases (Topic 842)
This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.
June 1, 2019
Refer to Note 14, Leases, for the required disclosures related to adopting this standard.



Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
Standard
Description
Effective Date
Effect on the Consolidated Financial Statements
ASU 2018-13, Fair Value Measurement (Topic 820)

This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.






26


19. SUBSEQUENT EVENTS

On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology, for an aggregate purchase price of $45.8 million with up to $20.0 million of potential future contingent consideration related to technical and revenue milestones. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.


27


Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

EXECUTIVE OVERVIEW

Company and Market

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical device; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.
We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.
On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received

28


by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. A portion of the net proceeds were used on June 3, 2019 to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.
In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three months ended August 31, 2019 compared to the three months ended August 31, 2018 follows:
Three months ended August 31, 2019:

Revenue increased by 3.3% to $66.0 million
Gross margin increased 170 bps to 57.9%
Operating loss decreased by $5.3 million to $0.8 million
Loss per share from continuing operations improved by $0.12 to a loss of $0.03

New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 18 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

Results of Operations for the Three Months Ended August 31, 2019 and 2018

For the three months ended August 31, 2019, the Company reported net loss of $1.3 million, or $0.03 per diluted share, on net sales of $66.0 million, compared with net loss of $5.7 million, or $0.15 loss per diluted share, on net sales of $63.9 million during the same quarter of the prior year.

Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts and returns.

Net sales for the three months ended August 31, 2019 and 2018:

 
Three months ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
 
% Growth
Net Sales by Global Business Unit
 
 
 
 
 
       Vascular Interventions & Therapies
$
28,913

 
$
28,598

 
1.1%
       Vascular Access
23,159

 
23,790

 
(2.7)%
       Oncology
13,970

 
11,555

 
20.9%
            Total
$
66,042

 
$
63,943

 
3.3%
 
 
 
 
 
 
Net Sales by Geography
 
 
 
 
 
       United States
$
52,937

 
$
51,496

 
2.8%
       International
13,105

 
12,447

 
5.3%
           Total
$
66,042

 
$
63,943

 
3.3%
For the three months ended August 31, 2019, net sales increased $2.1 million to $66.0 million compared to the same period in the prior year.
Vascular Interventions & Therapies

Total Vascular Interventions & Therapies sales increased $0.3 million primarily attributable to strong performance with the AngioVac business which grew $1.0 million year over year. The Company continues to see strong case volumes in AngioVac, which increased 38% from the prior year due to increased adoption of the Company's unique technology. These increases were partially offset by the decline in our Sclerotherapy business due to the termination of the Asclera distribution agreement.

29


U.S. Vascular Interventions & Therapies sales decreased $0.2 million due to the decline in our Sclerotherapy business as a result of the termination of the Asclera distribution agreement and Core Peripheral products. This was partially offset by increased case volume in AngioVac.
International Vascular Interventions & Therapies sales increased $0.5 million due to increased volume in Angiographic catheters primarily in EMEA (Europe, the Middle East and Africa).

Vascular Access

Total Vascular Access sales decreased $0.6 million due to decreases in PICCs and Ports partially offset by growth in the Dialysis business of $0.5 million and the launch of the BIIM ultrasound product in fiscal year 2019 which contributed $0.2 million in growth year over year. BioFlo product lines comprise 50% of overall Vascular Access sales, which is consistent with a year ago.
U.S. Vascular Access sales decreased by $1.1 million due to competitive pressures in the PICC product lines and lower Port sales. This was partially offset by growth in Dialysis products which continue to gain traction in the marketplace.
International Vascular Access sales increased by $0.5 million as the Company continues to expand its global reach of its Vascular Access product offerings.

Oncology

Total Oncology sales increased $2.4 million year over year primarily due to $1.7 million in sales of RadiaDyne products along with $1.0 million in sales of BioSentry products. This was partially offset by decreased sales of Radiofrequency Ablation.
U.S. Oncology sales increased by $2.8 million, driven by RadiaDyne sales of $1.7 million and BioSentry sales of $0.9 million. This was partially offset by a decrease in RadioFrequency Ablation sales.
International Oncology sales decreased by $0.4 million year over year as a result of decreased NanoKnife disposable sales of $0.6 million and decreased RadioFrequency and Microwave Ablation product sales of $0.2 million. This was partially offset by an increase in NanoKnife capital sales of $0.6 million.
Gross Profit, Operating expenses, and Other income (expense)
 
 
Three months ended
(in thousands)
 
Aug 31, 2019
 
Aug 31, 2018
 
% Change
Gross profit
 
$
38,217

 
$
35,953

 
6.3
 %
Gross profit % of sales
 
57.9
%
 
56.2
%
 
 
Research and development
 
$
6,292

 
$
7,374

 
(14.7
)%
% of sales
 
9.5
%
 
11.5
%
 
 
Selling and marketing
 
$
19,380

 
$
18,405

 
5.3
 %
% of sales
 
29.3
%
 
28.8
%
 
 
General and administrative
 
$
8,453

 
$
8,435

 
0.2
 %
% of sales
 
12.8
%
 
13.2
%
 
 

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $2.3 million compared to the prior year. The increase is primarily attributable to the following:
    
Sales volume of BioSentry and RadiaDyne products contributed $2.2 million to gross profit.
Sales volume and mix positively contributed $0.7 million year over year.
Net productivity contributed $0.5 million of favorability.
Currency and pricing headwinds negatively impacted gross margin by $0.5 million year over year, primarily driven by pricing.
The termination of the Asclera distribution agreement negatively impacted gross margin by $0.6 million.



30


Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense decreased $1.1 million compared to the prior year. The decrease is primarily attributable to the following:

Outside consultant spend decreased $0.5 million.
Compensation and benefits decreased approximately $0.1 million due to decreased headcount as part of a process to streamline the R&D function.
Other R&D expenses, including facilities, samples and project initiatives timing resulted in a decrease of $0.5 million.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $1.0 million compared to the prior year. The increase is primarily attributable to the following:

Compensation and benefits increase of approximately $0.7 million which is primarily attributed to increased headcount as a result of the BioSentry and RadiaDyne acquisitions.
Other sales and marketing expenses increased $0.3 million.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense remained consistent to the prior year. Even though G&A remained consistent, there were the following changes in the types of expenses incurred:

Compensation and benefits decrease of approximately $0.6 million primarily as a result of the timing of fully vested stock based compensation awards and lower high cost benefit claims.
Legal and professional fees relating to ongoing litigation that is within the normal course of business increased $0.3 million.
Outside consultant spend increased $0.2 million.
 
 
Three months ended
(in thousands)
 
Aug 31, 2019
 
Aug 31, 2018
 
$ Change
Amortization of intangibles
 
$
3,868

 
$
3,434

 
$
434

Change in fair value of contingent consideration
 
$
(448
)
 
$
12

 
$
(460
)
Acquisition, restructuring and other items, net
 
$
1,500

 
$
4,422

 
$
(2,922
)
Other expense
 
$
(563
)
 
$
(803
)
 
$
240


Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

The change in amortization expense from the prior year is due to intangible asset additions as a result of the BioSentry and RadiaDyne acquisitions. The BioSentry acquisition increased intangible assets by $26.0 million and resulted in additional amortization expense of $0.5 million. The RadiaDyne acquisition increased intangible assets by $25.6 million and resulted in additional amortization expense of $0.6 million. This was partially offset by the write-off of the Merz intangible in the fourth quarter of fiscal year 2019 and other intangibles that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

The change from the prior year is due to the gain of $0.6 million that was recorded on the technical milestones and revenue milestones for the RadiaDyne contingent consideration. This gain was partially offset by normal amortization

31


of $0.1 million. In addition, the final minimum payment of $1.2 million was paid for the Microsulis contingent consideration during the first quarter of fiscal 2020.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $2.9 million compared to the prior year. The decrease is primarily attributable to the following:

M&A expense of $0.2 million was incurred in the first quarter of fiscal year 2020 compared to $1.3 million in the prior year.
Legal expense, related to litigation that is outside of the normal course of business, of $1.1 million was recorded in the first quarter of fiscal year 2020, partially offset by the Biolitec bankruptcy settlement of $0.4 million, compared to $2.9 million in the prior year.
In the first quarter of fiscal year 2020, the Company incurred $0.8 million of expense to move manufacturing facilities as a result of the sale of the Fluid Management business.
As part of the sale of the Fluid Management business, the Company entered into a transition services agreement with Medline for certain legal, human resource, tax, accounting and information technology services from the Company for a period not to exceed 24 months. As a result of the transition services agreement, the Company invoiced Medline $0.7 million in the first quarter of fiscal year 2020.
Other expenses of $0.5 million in the first quarter of fiscal year 2020 consists of expenses to move the manufacturing of BioSentry products and severance associated with the sale of the Fluid Management business.

Other expenses, net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

The decrease in other expenses from the prior year of $0.2 million is due to decreased interest expense of $0.9 million as the Credit Facility was paid down in full at the beginning of the first quarter of fiscal year 2020. In addition to the decrease in interest expense, interest income increased $0.2 million from the prior year as a result of increased cash due to proceeds from the sale of the Fluid Management business. These increases are partially offset by the write-off of the deferred financing fees that were associated with the old Credit Facility of $0.6 million. Other expenses also include foreign currency fluctuations which increased by $0.3 million.

Income Tax Provision (Benefit)
 
 
Three months ended
(in thousands)
 
Aug 31, 2019
 
Aug 31, 2018
Income tax expense (benefit)
 
$
(0.1
)
 
$
(1.2
)
Effective tax rate including discrete items
 
8.3
%
 
17.7
%

Our effective tax rate including discrete items for the three month periods ended August 31, 2019 and 2018 was 8.3% and 17.7%, respectively. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation).

The estimated annual effective tax rate, however, prior to discrete items was 8.3% in the first quarter of fiscal 2020, as compared to 17.8% for the same period in fiscal 2019.

Liquidity and Capital Resources

Our cash and cash equivalents totaled $83.6 million as of August 31, 2019, compared with $227.6 million as of May 31, 2019. As of August 31, 2019 there was no principal debt outstanding and as of May 31, 2019 there was $132.5 million principal debt outstanding. The fair value of contingent consideration liability as of August 31, 2019 and May 31, 2019, was $11.8 million and $13.5 million, respectively.
The table below summarizes our cash flows for the three months ended August 31, 2019 and 2018:
 

32


 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Cash used in:
 
 
 
Operating activities
$
(6,534
)
 
$
(8,873
)
Investing activities
(1,541
)
 
(37,682
)
Financing activities
(135,749
)
 
(2,645
)
Effect of exchange rate changes on cash and cash equivalents
(168
)
 
(134
)
Net change in cash and cash equivalents
$
(143,992
)
 
$
(49,334
)

During the three months ended August 31, 2019 and 2018, cash flows consisted of the following:

Cash used in operating activities

Three months ended August 31, 2019:

Net loss of $1.3 million plus the non-cash items, primarily driven by depreciation and amortization, contributed to cash used in operations of $6.5 million.
Working capital was negatively impacted by increased inventory on hand of $5.2 million and decreased accounts payable and accrued liabilities of $17.6 million. Accounts receivable had a favorable impact on working capital as a result of the sale of the Fluid Management business.

Three months ended August 31, 2018:

Net loss was driven by higher operating expenses in research and development, selling and marketing and general administrative as well as costs related to our acquisition and restructuring activities. Partially offsetting the higher operating expenses was an increase in gross profit.
The Company continues to focus on optimizing its cash conversion cycle. In the first quarter of fiscal year 2019 working capital was negatively impacted by increased inventory on hand of $0.8 million. Additionally, days sales outstanding ("DSO") increased by two days for a $0.6 million impact. Also, the $12.5 million DOJ settlement payment that was made during the first quarter of fiscal year 2019 negatively impacted working capital from accounts payable and accrued liabilities.

Cash used in investing activities

Three months ended August 31, 2019 and 2018:

$1.4 million in fixed asset additions versus $0.7 million in the prior year.
$37.0 million cash payment in the prior year to acquire the BioSentry product from SSC as described in Note 2 to the financial statements.

Cash used in financing activities

Three months ended August 31, 2019 and 2018:

$132.5 million repayment of long-term debt in conjunction with the new Credit Agreement that was entered into at the beginning of the first quarter of fiscal year 2020. Refer to Note 8 of the financial statements.
$1.3 million repayment on the Term Loan in the prior year. This was consistent with the required amortization payment on the Term Loan.
$1.3 million of outlays from stock option and ESPP activity versus $0.7 million in proceeds in the prior year.
$1.2 million payment on earn-out liabilities in the current year compared to $2.1 million in the prior year.
On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement. The Credit Agreement provides for a $125.0 million secured revolving credit facility, which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  We believe that our current cash and investment balances, together with cash generated from operations and access to our revolving credit facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least

33


the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

34



Item 3.
Quantitative and Qualitative Disclosures About Market Risk.

Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our sales in the first quarter of fiscal 2020 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

Interest Rate Risk

On June 3, 2019, we entered into the Credit Agreement which provides for a $125 million Revolving Facility. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. In the event of default, the interest rate may be increased by 2.0%.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

35


Item 4.
Controls and Procedures.

Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting for the fiscal quarter ended August 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


36


AngioDynamics, Inc. and Subsidiaries
PART II: OTHER INFORMATION
Item 1.
Legal Proceedings.

C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947,022) the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. 

Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company filed Cross-Appeals for the ‘302 and the ‘615 reexams and completed briefing.  Medcomp also filed an Amicus Brief in support of the Company on November 22, 2017.  An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 6-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent (confirming validity of claims 1-10) on June 10, 2019, and for the ‘022 patent (confirming validity of claims 1-20) on July 2, 2019, and for the ‘615 patent on August 26, 2019.   The Company has since filed a Motion to Unstay the Utah Case; that motion is fully briefed and awaiting decision by the Utah Court. Meanwhile, on July 12, 2017, Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as Co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action.  The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.

On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.

On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case (Plaintiff), Judge Bataillon granted judgment as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s

37


suit.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was served on September 27, 2019 and the Company's answering brief is currently due on November 6, 2019. We maintain our belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  The parties are currently engaged in discovery, which is set to close in February 2020.
Merz North America Settlement

On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of $2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter.  Merz filed a stipulation of dismissal with the Court on July 23, 2019.


38


Item 1A.
Risk Factors.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2019 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

39


Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
The following table provides information with respect to the shares of the Company’s common stock repurchased during the three months ended August 31, 2019:
 
 
Issuer Purchases of Equity Securities
 
Total
Number of
Shares
Purchased
 
Average
Price Paid
per Share
 
Total
Number of
Shares
Purchased
as Part of
Publicly
Announced
Programs (1)
 
Maximum
Approximate
Dollar Value
of Shares
that May Yet
Be
Purchased
Under Plans
or Programs (1)
June 1, 2019 - June 30, 2019

 
$

 

 
$

July 1, 2019 - July 31, 2019
10,496

 
$
20.99

 

 
$

August 1, 2019 - August 31, 2019
103,309

 
$
19.39

 

 
$

Total
113,805

 
$
19.54

 

 

(1)
These amounts are not applicable as the Company currently does not have a share repurchase program in effect.

Item 3.
Defaults on Senior Securities.
None.
Item 4.
Mine Safety Disclosures.
None.
Item 5.
Other Information.
None.

40


Item 6.
Exhibits.
EXHIBIT INDEX
 
No.
  
Description
 
 
 
 
 
21

 
 
 
 
31.1

 
 
 
31.2

 
 
 
32.1

 
 
 
32.2

 
 
 
 
101.INS

 
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document

 
 
101.SCH

 
XBRL Schema Document
 
 
101.CAL

 
XBRL Calculation Linkbase Documents
 
 
101.DEF

 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
101.LAB

 
XBRL Labels Linkbase Documents
 
 
101.PRE

 
XBRL Presentation Linkbase Documents


41


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
ANGIODYNAMICS, INC.
 
 
 
 
(Registrant)
 
 
 
 
 
Date:
 
October 4, 2019
 
/ S /    JAMES C. CLEMMER      
 
 
 
 
James C. Clemmer, President,
Chief Executive Officer
(Principal Executive Officer)
 
 
 
Date:
 
October 4, 2019
 
/ S /    MICHAEL C. GREINER       
 
 
 
 
Michael C. Greiner, Executive Vice President,
Chief Financial Officer
(Principal Financial and Accounting Officer)


42
EX-21 2 ex2183119.htm EXHIBIT 21 Exhibit
Exhibit 21
Subsidiaries of AngioDynamics, Inc.

 
 
 
Subsidiary
 
State of Incorporation or Organization
Vortex Medical
 
Delaware
NM Holding Company, Inc.
 
Delaware
Navilyst Medical Holdings, Inc.
 
Delaware
Navilyst Medical, Inc.
 
Delaware
AngioDynamics UK Limited
 
United Kingdom
AngioDynamics Netherlands B. V.
 
Netherlands
RITA Medical Systems, LLC
 
Delaware
AngioDynamics France, SARL
 
France
AngioDynamics Canada Inc.
 
British Columbia
AngioDynamics Medical Brasil Participacoes Ltda.
 
Sao Paulo
RadiaDyne LLC
 
Texas
Eximo Medical, Ltd.
 
Israel



EX-31.1 3 a083119-exx3111.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

CERTIFICATION

I, James C. Clemmer, certify that:
1.
 
I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2.
 
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
 
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
 
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(b)
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
 
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 4, 2019

/ S / JAMES C. CLEMMER
James C. Clemmer, President,
Chief Executive Officer


EX-31.2 4 a083119-exx3121.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

CERTIFICATION

I, Michael C. Greiner, certify that:
1.
 
I have reviewed this quarterly report on Form 10-Q of AngioDynamics, Inc.;
2.
 
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
 
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
 
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(b)
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
 
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 4, 2019

/ S / MICHAEL C. GREINER
Michael C. Greiner Executive Vice President,
Chief Financial Officer



EX-32.1 5 a083119-exx3211.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:
1.
 
the quarterly report on Form 10-Q of the Company for the fiscal quarter ended August 31, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.
 
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 4, 2019

/ s / James C. Clemmer
 
James C. Clemmer, President,
Chief Executive Officer
 



EX-32.2 6 a083119-exx3221.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO TITLE 18,
UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael C. Greiner, Executive Vice President and Chief Financial Officer of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:
1.
 
the quarterly report on Form 10-Q of the Company for the fiscal quarter ended August 31, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.
 
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 4, 2019

/ s / Michael C. Greiner
 
Michael C. Greiner, Executive Vice President and
Chief Financial Officer
 



EX-101.SCH 7 ango-20190831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Schedule (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Acquisition, Restructuring and Other Items, Net link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Acquisition, Restructuring and Other Items, Net - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Acquisition, Restructuring and Other Items, Net - Summary (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Commitments and Coontingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Consolidated Financial Statements link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Divestitures Divestitures link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Divestitures - Results of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Fair Value - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Inventories - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Leases Leases link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Leases - Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Leases - Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Leases - Non-Cancelable Payments Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Long Term Debt - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2221201 - Disclosure - Recently Issued Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2321302 - Disclosure - Recently Issued Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Share-Based Compensation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ango-20190831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 ango-20190831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 ango-20190831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue from Contract with Customer [Abstract] Revenue from Contracts with Customers Revenue from Contract with Customer [Text Block] Leases [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of Sales Cost of Sales [Member] General and Administrative Expense General and Administrative Expense [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Building Building [Member] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements [Domain] Lease Arrangements [Domain] [Domain] for Lease Arrangements [Axis] Seven Year Building Lease Seven Year Building Lease [Member] Seven Year Building Lease [Member] Two Year Building Lease Two Year Building Lease [Member] Two Year Building Lease [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Operating lease ROU asset Operating Lease, Right-of-Use Asset Total lease liabilities Operating Lease, Liability Lease expense Operating Lease, Expense Lease term (years) Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lease payments Lessee, Operating Lease, Lease Note Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Note Yet Commenced, Undiscounted Amount Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Clinical Devices Bv Clinical Devices Bv [Member] Clinical Devices B.V. [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Financial liabilities, begining balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Change in present value of contingent consideration Change in Fair Value of Contingent Consideration The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions. Contingent consideration payments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Contingent Consideration, Liabilities, Payments Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Contingent Consideration, Liabilities, Payments Financial liabilities, ending balance Debt Disclosure [Abstract] Long Term Debt Long-term Debt [Text Block] Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] C.R. Bard, Inc. Cr Bard Inc [Member] C.R. Bard, Inc. [Member] The Utah Action The Utah Action [Member] The Utah Action The Delaware Action The Delaware Action [Member] The Delaware Action Construction Issues Construction Issues [Member] Construction Issues [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] C.R. Bard, Inc. C.R. Bard, Inc. [Member] C.R. Bard, Inc. [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending Litigation Pending Litigation [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of petitions filed for reexamination of patents Number of Patents Asserted for Reexamination Number of patents asserted for reexamination. Number of claims dismissed Loss Contingency, Claims Dismissed, Number Number of reexaminations Loss Contingency, Reexaminations, Number Loss Contingency, Reexaminations, Number Number of pending claims Loss Contingency, Pending Claims, Number Number of claims reversed Loss Contingency, Claims Reversed, Number Loss Contingency, Claims Reversed, Number Number of patents allegedly infringed upon Loss Contingency, Patents Allegedly Infringed, Number Loss contingency accrual Loss Contingency Accrual Payment of final settlements Loss Contingency Accrual, Payments Goodwill and Intangible Assets Disclosure [Abstract] Remainder of 2020 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2025 and thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net carrying value, finite intangible items Finite-Lived Intangible Assets, Net Restructuring and Related Activities [Abstract] Acquisition, Restructuring and Other Items, Net Restructuring and Related Activities Disclosure [Text Block] Operating cash flows from operating leases Operating Lease, Payments Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Equity [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock based compensation Share-based Compensation Change in fair value of contingent consideration Change In Fair Value Of Contingent Consideration One Change In Fair Value Of Contingent Consideration Gain on contingent consideration for IPR&D Write-off Deferred Income Tax Expense (Benefit) Change in accounts receivable allowances Provision for Doubtful Accounts Fixed and intangible asset impairments and disposals Impairment of Long-Lived Assets to be Disposed of Write-off of other assets Other Asset Impairment Charges Other Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Additions to property, plant and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of intangibles Payments to Acquire Intangible Assets Cash paid for acquisitions Payments to Acquire Businesses, Net of Cash Acquired Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of long-term debt Repayments of Long-term Debt Deferred financing costs on long-term debt Payments of Debt Issuance Costs Payment of acquisition related contingent consideration Payment Of Contingent Consideration Payment Of Contingent Consideration Proceeds (outlays) from exercise of stock options and employee stock purchase plan Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Accrual for capital expenditures incurred during the period Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Statement of Comprehensive Income [Abstract] Net loss Other comprehensive loss, before tax: Other Comprehensive Income (Loss), before Tax [Abstract] Unrealized gain on marketable securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Other comprehensive loss, before tax Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Income tax expense related to items of other comprehensive income Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total comprehensive loss, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] RadiaDyne RadiaDyne [Member] RadiaDyne [Member] BioSentry BioSentry [Member] BioSentry [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Revenue milestones Revenue Based Payment [Member] Revenue Based Payment [Member] Technical milestones Technical Milestones [Member] Technical Milestones [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Trademark Trademarks [Member] Product technology Technology-Based Intangible Assets [Member] Customer relationships Customer Relationships [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Aggregate purchase price Business Combination, Consideration Transferred Payments to acquire business Payments to Acquire Businesses, Gross Contingent consideration, liabilities Business Combination, Contingent Consideration, Liability Other long-term liabilities Other Liabilities, Noncurrent Accrued liabilities Accrued Liabilities, Current Acquisition, restructuring and other items, net Acquisition Restructuring and Other Items Net Acquisition Restructuring And Other Items Net. Useful life Finite-Lived Intangible Asset, Useful Life Acquisition related costs Business Combination, Acquisition Related Costs Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional paid in capital Additional Paid-in Capital [Member] Retained earnings Retained Earnings [Member] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Treasury Stock Treasury Stock [Member] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Statement [Line Items] Statement [Line Items] Beginning Balance Stockholders' Equity Attributable to Parent Beginning Balance, Shares Shares, Issued Beginning Balance,Treasury Shares Treasury Stock, Shares Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options, Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance/Cancellation of restricted stock units Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Issuance/Cancellation of performance share units and restricted stock units, net, Shares Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Purchases of common stock under ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Purchase of common stock under ESPP, Shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Ending Balance Ending Balance, Shares Ending Balance,Treasury Shares Remainder of 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five 2025 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Imputed Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease obligations Less: Current portion of lease obligations Operating Lease, Liability, Current Long-term lease obligations Operating Lease, Liability, Noncurrent Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Vascular Interventions & Therapies Vascular Interventions and Therapies [Member] Vascular Interventions and Therapies [Member] Vascular Access Vascular Access [Member] Vascular access. Oncology Oncology [Member] Oncology [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Net sales Revenues Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Potential amount of undiscounted future contingent consideration Undiscounted Contingent Consideration Disclosure Undiscounted Contingent Consideration Disclosure Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] NAMIC Fluid Management Business NAMIC Fluid Management Business [Member] NAMIC Fluid Management Business [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Net sales Disposal Group, Including Discontinued Operation, Revenue Cost of sales (exclusive of amortization) Disposal Group, Including Discontinued Operation, Costs of Goods Sold Gross profit Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Research and development Disposal Group, Including Discontinued Operation, Research And Development Expense Disposal Group, Including Discontinued Operation, Research And Development Expense Sales and marketing Disposal Group, Including Discontinued Operation, Sales And Marketing Expense Disposal Group, Including Discontinued Operation, Sales And Marketing Expense General and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Amortization of intangibles Disposal Group, Including Discontinued Operation, Depreciation and Amortization Total operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Operating income Disposal Group, Including Discontinued Operation, Operating Income (Loss) Income from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Income from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net cash provided by operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by investing activities Cash Provided by (Used in) Investing Activities, Discontinued Operations Fair Value of Assets and Liabilities Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Fair Value Measurements Using Significant Unobservable Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Segment Reporting [Abstract] Summary of Net Sales by Product Category Schedule of Net Revenue by Product Group [Table Text Block] Schedule of net revenue by product group. Summary of Net Sales by Geographic Area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] 2020 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2021 Operating Leases, Future Minimum Payments, Due in Two Years 2022 Operating Leases, Future Minimum Payments, Due in Three Years 2023 Operating Leases, Future Minimum Payments, Due in Four Years 2024 and thereafter Operating Leases, Future Minimum Payments, Due After Four Years Operating Leases, Future Minimum Payments, Due After Four Years Total lease payments Operating Leases, Future Minimum Payments Due Commitments and Contingencies Legal Matters and Contingencies [Text Block] Accounting Policies [Abstract] Consolidated Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Earnings Per Share [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities (shares) Weighted Average Number Diluted Shares Outstanding Adjustment Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Securities excluded as their inclusion would be anti-dilutive (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Preliminary Aggregate Purchase Price Schedule of Business Acquisitions, by Acquisition [Table Text Block] Intangible Assets Schedule of Intangible Assets [Table Text Block] Schedule of intangible assets. Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Payment term Revenue, Performance Obligation, Payment Term Revenue, Performance Obligation, Payment Term Days after purchase after which pre-approval is required for product return Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval Restocking charge (as percent) Contract with Customer, Right of Return, Restocking Charge Contract with Customer, Right of Return, Restocking Charge Minimum remaining period prior to product expiration Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return Revenue recognized from contract liability balances in respective periods Contract with Customer, Liability, Revenue Recognized Additions to contract liabilities Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Contract Balances with Customers Contract with Customer, Asset and Liability [Table Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Financial Liabilities Liabilities, Fair Value Disclosure [Abstract] Contingent consideration for acquisition earn outs Total Financial Liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Weighted average remaining term (in years) Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate (percent) Operating Lease, Weighted Average Discount Rate, Percent Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding Schedule of Weighted Average Number of Shares [Table Text Block] Accounting Changes and Error Corrections [Abstract] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Table Text Block] New Accounting Pronouncements, Policy [Table Text Block] Fair Value Fair Value Disclosures [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Acquisitions Business Combination Disclosure [Text Block] Payables and Accruals [Abstract] Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Receivables Accounts Receivable, Net, Current Contract assets Contract with Customer, Asset, Net Contract liabilities Contract with Customer, Liability Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Statement of Financial Position [Abstract] Accounts receivable, allowances Allowance for Doubtful Accounts Receivable, Current Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) RadiaDyne trademark RadiaDyne Trademark [Member] RadiaDyne Trademark [Member] OarTrac trademark OarTrac Trademark [Member] OarTrac Trademark [Member] RadiaDyne legacy product technology RadiaDyne Technology-Based Intangible Assets [Member] RadiaDyne Technology-Based Intangible Assets [Member] OarTrac product technology OarTrac Technology-Based Intangible Assets [Member] OarTrac Technology-Based Intangible Assets [Member] Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Goodwill Goodwill Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Liabilities assumed Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Estimated useful life of intangible assets other than goodwill Number of reporting units Number of Reportable Segments Goodwill impairment Goodwill, Impairment Loss Amortization of intangibles Amortization of Intangible Assets Results of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Leases Lessee, Operating Leases [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Credit Facility Line of Credit [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Line of credit Line of Credit Facility, Maximum Borrowing Capacity Line of credit accordion feature Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature Debt instrument term (years) Debt Instrument, Term Basis spread on variable rate (percentage) Debt Instrument, Basis Spread on Variable Rate Debt default interest rate increase (percentage) Debt Instrument, Debt Default, Interest Rate Increase Debt Instrument, Debt Default, Interest Rate Increase Commitment fee (percentage) Line of Credit Facility, Commitment Fee Percentage Number of covenants Line Of Credit Facility, Number Of Covenants Line Of Credit Facility, Number Of Covenants Maximum total leverage ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio Maximum total leverage ratio subsequent to material acquisitions Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions Minimum fixed charge coverage ratio Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio Borrowings outstanding Long-term Line of Credit Supplemental balance sheet information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Lease liability schedule Lessee, Operating Lease, Liability, Maturity [Table Text Block] Lease liability schedule as of prior year end Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Supplemental cash flow information Lease, Cost [Table Text Block] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net of allowances of $1,434 and $1,906 respectively Inventories Inventory, Net Prepaid expenses and other Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total assets Assets Liabilities and stockholders' equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Current portion of long-term debt Long-term Debt, Current Maturities Current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current portion Loans Payable, Noncurrent Deferred income taxes Deferred Income Taxes and Other Liabilities, Noncurrent Contingent consideration, net of current portion Business Combination, Contingent Consideration, Liability, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 15) Commitments and Contingencies Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,359,875 and 37,984,382 shares issued and 37,989,875 and 37,614,382 shares outstanding at August 31, 2019 and May 31, 2019, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Treasury stock, 370,000 shares at August 31, 2019 and May 31, 2019, respectively Treasury Stock, Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Stockholders’ Equity Total Liabilities and Stockholders' Equity Liabilities and Equity Other Liabilities Disclosure [Abstract] Payroll and related expenses Employee-related Liabilities, Current Royalties Accrued Royalties, Current Accrued severance Restructuring Reserve, Current Sales and franchise taxes Sales and Excise Tax Payable, Current Outside services Accrued Professional Fees Litigation matters Accrued Litigation Accrued Litigation Indemnification holdback Accrued Recall Liability Accrued Recall Liability Other Other Accrued Liabilities, Current Total Segment and Geographic Information Segment Reporting Disclosure [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Subsequent Event [Table] Subsequent Event [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Technology And Revenue Milestones Technology And Revenue Milestones [Member] Technology And Revenue Milestones [Member] Eximo Medical, Ltd. Eximo Medical, Ltd. [Member] Eximo Medical, Ltd. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Divestitures Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Product technologies Product Technologies [Member] Product technologies. Trademarks Licenses License Agreement Terms [Member] Gross carrying value, finite intangible items Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Legal Legal Costs [Member] Legal Costs [Member] Mergers and acquisitions Mergers and Acquisitions [Member] Mergers and Acquisitions [Member] Transition service agreement Transition service agreement [Member] Transition service agreement [Member] Divestiture Divestiture [Member] Divestiture [Member] Restructuring Restructuring Charges [Member] Other Other Expense [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Recently Issued Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Biolitec Bankruptcy Biolitec Bankruptcy [Member] Biolitec Bankruptcy [Member] Proceeds from Legal Settlements Proceeds from Legal Settlements Restructuring charges Restructuring Charges Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventories Estimated federal statutory income tax rate Effective Income Tax Rate Reconciliation Before Discreet Items, Percent Effective Income Tax Rate Reconciliation Before Discreet Items, Percent Cover page. Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Preferred Stock Purchase Rights Preferred Stock Purchase Rights [Member] Preferred Stock Purchase Rights [Member] Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date No Trading Symbol Flag No Trading Symbol Flag Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Acculis Inventory Acculis Inventory [Member] Acculis Inventory [Member] Inventory [Line Items] Inventory [Line Items] Inventory valuation reserves Inventory Valuation Reserves Inventory write-down Inventory Write-down Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Contingent Consideration Contingent Consideration Earn Out Liability [Member] Contingent consideration earn out liability. Revenue based payments Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount rate Measurement Input, Discount Rate [Member] Probability of payment Measurement Input, Probability of Payment [Member] Measurement Input, Probability of Payment [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Discounted cash flow Valuation Technique, Discounted Cash Flow [Member] Estimated probability Valuation Technique, Estimated Probability [Member] Valuation Technique, Estimated Probability [Member] Contingent consideration, liability, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated other comprehensive income (loss) Foreign currency translation loss Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Other comprehensive loss before reclassifications, net of tax OCI, before Reclassifications, before Tax, Attributable to Parent Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Net other comprehensive loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] The 2004 Plan and Employee Stock Purchase Plan The 2004 Plan and Employee Stock Purchase Plan [Member] The 2004 Plan and Employee Stock Purchase Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Amount of shares issuable through two stock-based compensation plans Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Charges against income for share-based payment arrangements Allocated Share-based Compensation Expense Unrecognized compensation expenses related to share-based payment arrangements Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Recognition period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Earnings Per Share Earnings Per Share [Text Block] Income Statement [Abstract] Cost of sales (exclusive of intangible amortization) Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense Sales and marketing Selling and Marketing Expense General and administrative General and Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Other (expenses) income: Other Nonoperating Income (Expense) [Abstract] Interest expense, net Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Total other expenses, net Nonoperating Income (Expense) Loss from continuing operations before income tax benefit Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income from discontinued operations, net of income tax Net loss Loss per share continuing operations - basic (usd per share) Income (Loss) from Continuing Operations, Per Basic Share Loss per share continuing operations - diluted (usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Income per share discontinued operations - basic (usd per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Income per share discontinued operations - diluted (usd per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Loss per share Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Basic weighted average shares outstanding (in shares) Diluted weighted average shares outstanding (in shares) Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Medline Medline [Member] Medline [Member] Consideration received Disposal Group, Including Discontinued Operation, Consideration Gain on divestiture Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Working capital adjustments Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Working Capital Adjustment Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Working Capital Adjustment Service period duration (months) Transition Services Agreement, Terms, Service Period Transition Services Agreement, Terms, Service Period Revenue from Contracts with Customers Revenue from Contract with Customer [Policy Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] EX-101.PRE 11 ango-20190831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 angologoa23.gif ANGOLOGOA23 begin 644 angologoa23.gif M1TE&.#EA(@2A /< TB/S E/P\E1 \G2!8K1Q$J31LO2ATD01TR3Q,M4QXU M5RH]5B4\7"$W53DH1!TY8AL[:Q<^>1D]=B4^8T,H1%(L1UHS3VRI(=S!/?S-0?#5&7TE9;E=">4=2:FU! M=EAF>GA!5:4>-JH>.+(>/+@>/J0G/84[598[5:HK0KXF1K4I1+ Y3J(^6JLT M4(DZ:*D_9^D83LHI3L0H2M,L4]HL5MXM6<@U5]4P6-LT7= X6\\O6N4E5ND@ M5.HF6.,J6>$G6.$R7LHY8MPT9.(O8)U#7K9'6[A%6J5!6HY&;;M6 M:*U+<NE9?>I'<<%D=,AM?=-@>AA"A!=&CQ],D"E/C"A+ MBRQ1BC)4B2!-D251EBU4D#19D3-JZ2LMYBD MN,R C=*.FM>.;JMVAK=VJL_>HO/"CMHNBQYFNSI.GQK.Z MPZBYU:ZWQ..XP.^QP_BWQ[;%W,+(S]'5V^C'S?G%T^[5V?O4WNW)T<71X]/< MZM7:X>'CY_3CYOSBZ>+H\?#Q\_SQ\_#S^ M M M M M M "'Y! $ *D + B!*$ C^ %,)'$BPH,&# M"!,J7'CPE*5#6ISHF$AQHI8[ARR18LBQH\>/($.*'$FRI,F3*%.J7,FRI[?P(,+'TZ\>,U-O)-_]6V\N?/G MT*-+%WW*J_+K%9E/W\Z]N_?OX)O^;L9.ON+G\.C3JU_/OGTJY.7C3SSRV+W] M^_CSZQ>M1;Y_'5ELLM^ !!9HX(%;P?>??WB AN"#$$8HX80I];?@?T<@0N&& M'';H(8*=7"BB%K!]:.*)**;HW&HBBGB(BC#&*..,I)W2XHU9D$7CCCSVZ"-< MNMUXHX8_%FGDD4@V59>0-Y*8Y)-01BGE2:0PR>01EDRIY99<;HF(E58VV.68 M9)8YHX5@"IFCF6RVZ2:$-J9I)7UOUFGGG>M9(F>:8N+IYY^ %C?>GE9F46*@ MB":JZ&A+$CJG@(M&*NFDAL7I:)I$4JKIIIRNI>>E]?$B"BKI]?3+'&N^&(<]*XAPJ*NRKGK:^-XL'*">%K'2<1\C02>Y;^^DQ@SUVW<*SW[/KO4TDR M=];@@?+)\Y\\XLCTU%\"_?,>?8H=#[XN@E+A*[0MI^_(PU1\R7(8=W[)QY,]KW.N'(X_ WD!2AIW R6 EA9 !"Z1&.L^Y;R5R MZQD:\D:<]7FL?0]T"M]Z%H?A%><2CM#?_D:(,SG,@0Y/( ^K7M %EA2.!3)K M8 9?\HFK86P-%*Q@ZF8XE4?$SV/^3@AY_M;(=7C HJ'C&'+?HAA\-!!1^.R,8CDB$#.5@" M[^YB.U9IXB6M$T:T%*<\$9DO MF7 B"C'^9)*QWKF>=G:3GQ(2X3P'>D0T\ &-*SE%%:AXI4,!]#O^?.B)"$I1 M1,8A9"X9Q R">:%+2I0[$?VHA^1Y!C68]*1CJ*@1U^ ((:)D$2W@Z(+N(%+P MA+2F&ZKE&J"MTZ*I8 R7R#%W=JV0E2U8S5%0. M1B.L%U9Y(R;XL;&X82QH!Y3(#TSVM*A-0 A2.D^0L:0.^13^T1GM;27PBN' 9KF^G9]S,2N5ZT$.N:"E3BN@M-[=, MJ9_]ENL(X^J6*<[C;G-34C])7%> ?:DN<6\+W)P\C[N.:.]'$ED U-KWM *8 M !G.(,^QK800L5V0$0Q1F'K]:X1QR!=R;7()/PA4@G)PQ#]C4@HR+A5G:U!P M0G@;0.>*)+R?^"X$'3$'3_:,BY=8,$U \0@MABW!DO#P= U2OT=8+R?5M;&( M3U)A.9BX9#!6,4OLYV,$:]@G/=Y?A'>,$%1<@@\7QEF08?()271X)D3^LX:LI^$/^)# Q38.8 A-P_L,?W%""#MSWJPDP@QC" ML&=;=G EBPCP?X:0-L" @@]:'J$<,(J33R"ZC09E,DO&6.;]D;,@CO!D'"9L MD$=<> V,5@DH_!!E$I)3R"P9=:G[Y@BCS7@@I>C8Q=#@!U2;Y!(/!O5**&W1 MS^/.:')C]"3CE(.F1Z#R<:Y USHKF$7#V#.$B MJ>$\@^X2P:.5FPN)^<0+/SF#?-QC."S(WB0^E*?+";+!(X[@IW^HT%V6$(,*3#;>F ]; M^@"-[P7QH-!N 06X/PGWCXS<8V*'-D'G-^30S_,1'MGVN^;^H'2]M_;TW3\\ M+!6"NJ&M/B7;7'PJ.CDTC!I>GG&H^T) 87U04O\C6\-PWD@F>]7%7IZ>9W=S M@WTTMWR(%( >P7\#A0:#57Y&='L 8&XF875@L00PX "1%58,P%^?! DL0787 M@@2GY!:BP($5U7P<@0K+@PJ@H'T&%W(*X7;BQWT=,3=H4!+TQU0HB!(Y*'[' MI!#/5S+WQQ++=&(%D7HEHS$RV'\X&'S,!Q*A-T$].%#Z@H2N=WX+X8 E5!*7 MX(06A6I#IU)>I()L) ( D (J08%W400VX'MY)0 ?8()L= :A\(&"UBR%X!96 M.%#JIQ"^(4HL8=,-7P&\\9&;= 2BO!6\5$$,O!96N�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end XML 13 R70.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition, Restructuring and Other Items, Net - Summary (Detail) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net $ 1,500 $ 4,422
Legal    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net 669 2,880
Mergers and acquisitions    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net 246 1,318
Transition service agreement    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net (737) 0
Divestiture    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net 758 0
Restructuring    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net 26 130
Other    
Restructuring Cost and Reserve [Line Items]    
Acquisition, restructuring and other items, net $ 538 $ 94
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Financial Statements
3 Months Ended
Aug. 31, 2019
Accounting Policies [Abstract]  
Consolidated Financial Statements CONSOLIDATED FINANCIAL STATEMENTS
The Consolidated Balance Sheet as of August 31, 2019, the Consolidated Statements of Operations, Consolidated Statements of Comprehensive Loss, Consolidated Statements of Cash Flows, and the Consolidated Statements of Stockholders’ Equity for the three months ended August 31, 2019 and 2018, have been prepared by us and are unaudited. The Consolidated Balance Sheet as of May 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended August 31, 2019 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three months ended August 31, 2019 and 2018 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.”  Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Balance Sheets - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Current assets    
Cash and cash equivalents $ 83,649 $ 227,641
Accounts receivable, net of allowances of $1,434 and $1,906 respectively 32,540 43,577
Inventories 45,229 40,071
Prepaid expenses and other 4,939 4,003
Total current assets 166,357 315,292
Property, plant and equipment, net 25,334 24,258
Other assets 9,352 3,835
Intangible assets, net 141,655 145,387
Goodwill 347,666 347,666
Total assets 690,364 836,438
Current liabilities    
Accounts payable 16,870 22,829
Accrued liabilities 22,693 38,338
Current portion of long-term debt 0 7,500
Current portion of contingent consideration 878 4,635
Other current liabilities 6,731 0
Total current liabilities 47,172 73,302
Long-term debt, net of current portion 0 124,407
Deferred income taxes 14,367 14,542
Contingent consideration, net of current portion 10,952 8,851
Other long-term liabilities 3,800 521
Total liabilities 76,291 221,623
Commitments and contingencies (Note 15)
Stockholders' equity    
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,359,875 and 37,984,382 shares issued and 37,989,875 and 37,614,382 shares outstanding at August 31, 2019 and May 31, 2019, respectively 373 372
Additional paid-in capital 555,723 555,040
Retained earnings 65,194 66,469
Treasury stock, 370,000 shares at August 31, 2019 and May 31, 2019, respectively (5,714) (5,714)
Accumulated other comprehensive loss (1,503) (1,352)
Total Stockholders’ Equity 614,073 614,815
Total Liabilities and Stockholders' Equity $ 690,364 $ 836,438
XML 16 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Other Liabilities Disclosure [Abstract]    
Payroll and related expenses $ 5,970 $ 14,987
Royalties 1,439 2,088
Accrued severance 616 504
Sales and franchise taxes 3,417 807
Outside services 1,781 3,514
Litigation matters 0 2,700
Indemnification holdback 4,866 4,807
Other 4,604 8,931
Total $ 22,693 $ 38,338
XML 17 R57.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) - shares
shares in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Earnings Per Share [Abstract]    
Basic (shares) 37,783 37,323
Effect of dilutive securities (shares) 0 0
Diluted (shares) 37,783 37,323
Securities excluded as their inclusion would be anti-dilutive (shares) 2,503 2,309
XML 18 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value (Tables)
3 Months Ended
Aug. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2019 and May 31, 2019:
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at August 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
11,830

 
$
11,830

Total Financial Liabilities
$

 
$

 
$
11,830

 
$
11,830

 
 
 
 
 
 
 
 
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at May 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
13,486

 
$
13,486

Total Financial Liabilities
$

 
$

 
$
13,486

 
$
13,486



Fair Value Measurements Using Significant Unobservable Inputs
The table below presents the changes in fair value components of Level 3 instruments in the three months ended August 31, 2019:

Three Months Ended August 31, 2019
(in thousands)
Fair Value Measurements
Using Significant
Unobservable Inputs
(Level 3)
Balance, May 31, 2019
$
13,486

Total gains or losses (realized/unrealized):


Change in present value of contingent consideration (1)
(448
)
Contingent consideration payments
(1,208
)
Balance, August 31, 2019
$
11,830


(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability
The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2019:
(in thousands)
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
Revenue based payments
$
8,533

 
Discounted cash flow
 
Discount rate
 
4% - 5%
 
 
 
 
 
Probability of payment
 
66% - 100%
 
 
 
 
 
Projected fiscal year of payment
 
2023
Technical milestones
$
3,297

 
Estimated probability
 
Estimated probability
 
90%
 
 
 
 
 
Projected year of payment
 
2020 - 2022
Total
$
11,830

 
 
 
 
 
 


XML 19 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Intangible Assets (Tables)
3 Months Ended
Aug. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Intangible assets consisted of the following:
 
Aug 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,968

 
$
(77,967
)
 
$
105,001

Customer relationships
60,147

 
(26,995
)
 
33,152

Trademarks
9,300

 
(6,470
)
 
2,830

Licenses
5,887

 
(5,215
)
 
672

 
$
258,302

 
$
(116,647
)
 
$
141,655

 
May 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,971

 
$
(75,412
)
 
$
107,559

Customer relationships
60,166

 
(25,950
)
 
34,216

Trademarks
9,300

 
(6,404
)
 
2,896

Licenses
5,752

 
(5,036
)
 
716

 
$
258,189

 
$
(112,802
)
 
$
145,387


Schedule of Future Amortization Expense
Expected future amortization expense related to the intangible assets is as follows:
(in thousands)

Remainder of 2020
$
11,308

2021
14,022

2022
13,406

2023
13,369

2024
11,813

2025 and thereafter
77,737


$
141,655


XML 20 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Segment and Geographic Information
3 Months Ended
Aug. 31, 2019
Segment Reporting [Abstract]  
Segment and Geographic Information SEGMENT AND GEOGRAPHIC INFORMATION

The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
The table below summarizes net sales by Global Business Unit: 
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
Vascular Interventions & Therapies 
$
28,913

 
$
28,598

Vascular Access
23,159

 
23,790

Oncology
13,970

 
11,555

Total
$
66,042

 
$
63,943


The table below presents net sales by geographic area based on external customer location:
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
United States
$
52,937

 
$
51,496

International
13,105

 
12,447

Total
$
66,042

 
$
63,943


XML 21 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from Contracts with Customers
3 Months Ended
Aug. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three months ended August 31, 2019 and 2018:
 
Three months ended August 31, 2019
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,676

 
$
3,237

 
$
28,913

Vascular Access
19,284

 
3,875

 
23,159

Oncology
7,977

 
5,993

 
13,970

Total
$
52,937

 
$
13,105

 
$
66,042

 
Three months ended August 31, 2018
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,851

 
$
2,747

 
$
28,598

Vascular Access
20,447

 
3,343

 
23,790

Oncology
5,198

 
6,357

 
11,555

Total
$
51,496

 
$
12,447

 
$
63,943

Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the three months ended August 31, 2019, such product returns were not material.
Contract Balances with Customers
A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Receivables
$
32,540

 
$
43,577

Contract assets
$

 
$

Contract liabilities
$
607

 
$
681


During the three months ended August 31, 2019, the Company recognized $0.2 million in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of $0.1 million.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
XML 22 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Long Term Debt
3 Months Ended
Aug. 31, 2019
Debt Disclosure [Abstract]  
Long Term Debt LONG TERM DEBT

On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.
The Credit Agreement provides for a $125.0 million secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million.  The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries.
The Credit Agreement has a five year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. After default, the interest rate may be increased by 2.0%. The facility will also carry a commitment fee of 0.20% to 0.25% per annum on the unused portion.
The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.

The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: 
maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00).
fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00.
* The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019.
The Company was in compliance with the Credit Agreement covenants as of August 31, 2019.
As of August 31, 2019, there was no outstanding balance on the Revolving Facility. As of May 31, 2019 the carrying value of long-term debt approximates its fair market value.
XML 23 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition, Restructuring and Other Items, Net
3 Months Ended
Aug. 31, 2019
Restructuring and Related Activities [Abstract]  
Acquisition, Restructuring and Other Items, Net ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET

Acquisition, Restructuring and Other Items
For the three months ended August 31, 2019 and 2018 acquisition, restructuring and other items, net consisted of:
 
Three months ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Legal (1)
$
669

 
$
2,880

Mergers and acquisitions (2)
246

 
1,318

Transition service agreement (3)
(737
)
 

Divestiture (4)
758

 

Restructuring
26

 
130

Other
538

 
94

Total
$
1,500

 
$
4,422


(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.
(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.
(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.

Included in the $0.7 million in legal for the three months ended August 31, 2019 is a $0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.
Restructuring

The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations.
Operational Consolidation
On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate its manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan were completed in the fourth quarter of fiscal year 2018 with immaterial regulatory filing costs to be incurred.
The Company recorded restructuring charges related to the plan during the three months ended August 31, 2019 and 2018 of less than $0.1 million and $0.1 million, respectively. Total restructuring charges recorded to date are $6.3 million. The Company’s remaining restructuring liability is comprised of regulatory expenses which are expected to be paid in the next twelve months and are included in "accrued liabilities" on the Consolidated Balance Sheet.
XML 24 ango-083119x10q_htm.xml IDEA: XBRL DOCUMENT 0001275187 2019-06-01 2019-08-31 0001275187 2019-10-02 0001275187 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 ango:PreferredStockPurchaseRightsMember 2019-06-01 2019-08-31 0001275187 2018-06-01 2018-08-31 0001275187 2019-08-31 0001275187 2019-05-31 0001275187 2018-08-31 0001275187 2018-05-31 0001275187 us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 us-gaap:TreasuryStockMember 2019-05-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2019-06-01 2019-08-31 0001275187 us-gaap:CommonStockMember 2019-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-01 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0001275187 us-gaap:RetainedEarningsMember 2019-05-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-05-31 0001275187 us-gaap:RetainedEarningsMember 2019-08-31 0001275187 us-gaap:CommonStockMember 2019-08-31 0001275187 us-gaap:TreasuryStockMember 2019-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2019-06-01 2019-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2019-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-05-31 0001275187 us-gaap:RetainedEarningsMember 2019-06-01 2019-08-31 0001275187 ango:RadiaDyneMember 2018-09-21 0001275187 ango:RadiaDyneMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember 2019-08-31 0001275187 ango:RadiaDyneMember ango:TechnicalMilestonesMember 2018-09-21 0001275187 ango:BioSentryMember 2018-08-14 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2018-09-21 2018-09-21 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember 2018-06-01 2019-05-31 0001275187 ango:BioSentryMember 2018-06-01 2019-05-31 0001275187 ango:RadiaDyneMember ango:RevenueBasedPaymentMember 2018-09-21 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-08-14 2018-08-14 0001275187 ango:BioSentryMember 2018-08-14 2018-08-14 0001275187 ango:RadiaDyneMember ango:RadiaDyneTrademarkMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:RadiaDyneTechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:RadiaDyneMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:OarTracTechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 ango:RadiaDyneMember ango:OarTracTrademarkMember 2019-05-31 0001275187 ango:BioSentryMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2019-05-31 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-08-14 2018-08-14 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-06-01 2019-08-31 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-03-01 2019-05-31 0001275187 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember ango:NAMICFluidManagementBusinessMember 2019-05-31 0001275187 ango:MedlineMember 2019-03-01 2019-05-31 0001275187 ango:OncologyMember country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:OncologyMember 2018-06-01 2018-08-31 0001275187 us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember 2018-06-01 2018-08-31 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 ango:OncologyMember us-gaap:NonUsMember 2018-06-01 2018-08-31 0001275187 country:US 2018-06-01 2018-08-31 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2018-06-01 2018-08-31 0001275187 srt:MaximumMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember country:US 2019-06-01 2019-08-31 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 ango:OncologyMember 2019-06-01 2019-08-31 0001275187 country:US 2019-06-01 2019-08-31 0001275187 ango:VascularAccessMember 2019-06-01 2019-08-31 0001275187 us-gaap:NonUsMember 2019-06-01 2019-08-31 0001275187 srt:MinimumMember 2019-06-01 2019-08-31 0001275187 ango:AcculisInventoryMember 2019-08-31 0001275187 2018-12-31 2018-12-31 0001275187 us-gaap:TrademarksMember 2019-05-31 0001275187 us-gaap:LicenseAgreementTermsMember 2019-05-31 0001275187 us-gaap:CustomerRelationshipsMember 2019-05-31 0001275187 ango:ProductTechnologiesMember 2019-05-31 0001275187 ango:ProductTechnologiesMember 2019-08-31 0001275187 us-gaap:LicenseAgreementTermsMember 2019-08-31 0001275187 us-gaap:TrademarksMember 2019-08-31 0001275187 us-gaap:CustomerRelationshipsMember 2019-08-31 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-08-31 0001275187 ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-06-03 2019-06-03 0001275187 srt:MinimumMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 0001275187 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2019-06-03 2019-06-03 0001275187 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-06-03 2019-06-03 0001275187 srt:MaximumMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2019-06-03 2019-06-03 0001275187 ango:The2004PlanandEmployeeStockPurchasePlanMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2019-05-31 0001275187 ango:ClinicalDevicesBvMember 2019-06-01 2019-08-31 0001275187 srt:MaximumMember 2019-08-31 0001275187 srt:MinimumMember 2019-08-31 0001275187 ango:TechnicalMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:ValuationTechniqueEstimatedProbabilityMember 2019-08-31 0001275187 ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 us-gaap:FairValueInputsLevel3Member ango:ContingentConsiderationEarnOutLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-08-31 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-08-31 0001275187 us-gaap:BuildingMember ango:TwoYearBuildingLeaseMember 2019-08-31 0001275187 us-gaap:BuildingMember ango:SevenYearBuildingLeaseMember 2019-08-31 0001275187 us-gaap:AccountingStandardsUpdate201602Member 2019-06-01 0001275187 us-gaap:GeneralAndAdministrativeExpenseMember 2019-06-01 2019-08-31 0001275187 us-gaap:CostOfSalesMember 2019-06-01 2019-08-31 0001275187 ango:TheUtahActionMember 2012-01-11 2012-01-11 0001275187 ango:TheUtahActionMember 2016-03-24 2016-03-24 0001275187 ango:TheUtahActionMember 2016-03-29 2016-03-29 0001275187 ango:TheUtahActionMember 2016-03-11 0001275187 ango:CrBardIncMember 2012-01-11 2012-01-11 0001275187 ango:TheUtahActionMember us-gaap:PendingLitigationMember ango:C.R.BardInc.Member 2016-03-30 2017-01-31 0001275187 ango:TheDelawareActionMember 2019-03-07 2019-03-07 0001275187 ango:TheUtahActionMember 2016-03-24 0001275187 ango:ConstructionIssuesMember 2019-08-31 0001275187 ango:TheDelawareActionMember 2015-06-01 2015-06-01 0001275187 ango:TheUtahActionMember 2016-03-11 2016-03-11 0001275187 ango:TheUtahActionMember 2012-01-11 0001275187 us-gaap:RestructuringChargesMember 2019-06-01 2019-08-31 0001275187 us-gaap:OtherExpenseMember 2018-06-01 2018-08-31 0001275187 ango:DivestitureMember 2018-06-01 2018-08-31 0001275187 us-gaap:OtherExpenseMember 2019-06-01 2019-08-31 0001275187 ango:MergersandAcquisitionsMember 2019-06-01 2019-08-31 0001275187 ango:MergersandAcquisitionsMember 2018-06-01 2018-08-31 0001275187 ango:LegalCostsMember 2018-06-01 2018-08-31 0001275187 ango:TransitionserviceagreementMember 2019-06-01 2019-08-31 0001275187 ango:TransitionserviceagreementMember 2018-06-01 2018-08-31 0001275187 ango:LegalCostsMember 2019-06-01 2019-08-31 0001275187 us-gaap:RestructuringChargesMember 2018-06-01 2018-08-31 0001275187 ango:DivestitureMember 2019-06-01 2019-08-31 0001275187 2017-02-01 2019-08-31 0001275187 ango:BiolitecBankruptcyMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-01 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-08-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2019-05-31 0001275187 ango:EximoMedicalLtd.Member us-gaap:SubsequentEventMember 2019-10-02 2019-10-02 0001275187 ango:EximoMedicalLtd.Member ango:TechnologyAndRevenueMilestonesMember us-gaap:SubsequentEventMember 2019-10-02 ango:covenant pure ango:segment ango:motion ango:Petition iso4217:USD shares iso4217:USD ango:reexamination_appeal ango:patent shares ango:claim P30D false --05-31 Q1 2020 0001275187 true 1906000 1434000 1.00 0.05 0.66 0.04 0.01 0.01 75000000 75000000 37984382 38359875 37614382 37989875 P5Y P15Y P7Y P5Y P2Y 5600000 0.01 0.01 5000000 5000000 0 0 0 0 370000 370000 10-Q true 2019-08-31 false 0-50761 AngioDynamics, Inc. DE 11-3146460 14 Plaza Drive Latham NY 12110 518 795-1400 Common stock, par value $.01 ANGO NASDAQ Preferred Stock Purchase Rights NASDAQ Yes Yes Large Accelerated Filer false false false 37619875 66042000 63943000 27825000 27990000 38217000 35953000 6292000 7374000 19380000 18405000 8453000 8435000 3868000 3434000 -448000 12000 1500000 4422000 39045000 42082000 -828000 -6129000 465000 917000 -98000 114000 -563000 -803000 -1391000 -6932000 -116000 -1228000 -1275000 -5704000 0 5235000 -1275000 -469000 -0.03 -0.15 -0.03 -0.15 0.00 0.14 0.00 0.14 -0.03 -0.01 -0.03 -0.01 37783000 37323000 37783000 37323000 -1275000 -469000 0 33000 -151000 -125000 -151000 -92000 0 0 -151000 -92000 -1426000 -561000 83649000 227641000 32540000 43577000 45229000 40071000 4939000 4003000 166357000 315292000 25334000 24258000 9352000 3835000 141655000 145387000 347666000 347666000 690364000 836438000 16870000 22829000 22693000 38338000 0 7500000 878000 4635000 6731000 0 47172000 73302000 0 124407000 10952000 8851000 14367000 14542000 3800000 521000 76291000 221623000 0 0 373000 372000 555723000 555040000 65194000 66469000 5714000 5714000 -1503000 -1352000 614073000 614815000 690364000 836438000 -1275000 -469000 5207000 5599000 1984000 2150000 -448000 12000 -175000 -10000 -453000 -228000 99000 0 593000 0 8000 -25000 -11474000 562000 5153000 761000 746000 1200000 -17633000 -13429000 -6534000 -8873000 1391000 682000 150000 0 0 37000000 -1541000 -37682000 132500000 1250000 741000 0 1208000 2100000 -1300000 705000 -135749000 -2645000 -168000 -134000 -143992000 -49334000 227641000 74096000 83649000 24762000 477000 38000 37984382 372000 555040000 66469000 -1352000 370000 -5714000 614815000 -1275000 -1275000 48136 1000 530000 531000 287087 -2459000 -2459000 40270 628000 628000 1984000 1984000 -151000 -151000 38359875 373000 555723000 65194000 -1503000 370000 -5714000 614073000 CONSOLIDATED FINANCIAL STATEMENTS<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Consolidated Statements of Operations, Consolidated Statements of Comprehensive Loss, Consolidated Statements of Cash Flows, and the Consolidated Statements of Stockholders’ Equity for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, have been prepared by us and are unaudited. The Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:10pt;">May 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (and for all periods presented) have been made.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 31, 2019, the Company completed the sale of the Fluid Management business and all of the assets used primarily in connection with the Fluid Management business (Note 3). As the disposal of this business represents a strategic shift with a major effect on the Company's operations, for all periods presented in our Consolidated Statements of Operations and Comprehensive Loss, all sales, costs, expenses, gains and income taxes attributable to Fluid Management have been reported under the captions, “Income from Discontinued Operations, Net of Income Tax.”  Cash flows used in or provided by Fluid Management have been reported in the Consolidated Statements of Cash Flows under operating and investing activities.</span></div> ACQUISITIONS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RadiaDyne Acquisition</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> included an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$47.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, contingent consideration with an estimated fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, an indemnification holdback of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a purchase price holdback of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in contingent consideration is comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$16.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the revenue milestones and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the technical milestones. The </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> indemnification holdback is recorded in accrued liabilities at August 31, 2019 and the </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> purchase price holdback was initially recorded in accrued liabilities, and was paid during the third quarter of fiscal year 2019. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Final allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne trademark</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OARtrac trademark</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne legacy product technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OARtrac product technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,445</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities assumed</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>458</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>seven years</span></span><span style="font-family:inherit;font-size:10pt;"> and the product technologies are deemed to have a useful life of </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. Both are amortized on a straight-line basis over their useful life.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over </span><span style="font-family:inherit;font-size:10pt;"><span>fifteen years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BioSentry Acquisition</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$39.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which </span><span style="font-family:inherit;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid on August 14, 2018 and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes. </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal year 2019. The following </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Final allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    BioSentry trademark</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    BioSentry product technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen year useful life and are amortized on a straight-line basis over their useful life. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div>The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations. 75000000.0 47900000 22300000 4600000 200000 22300000 16500000 5800000 4600000 200000 1600000 900000 732000 98000 133000 400000 200000 1500000 18900000 4600000 47982000 75445000 352000 106000 458000 74987000 P7Y P10Y P15Y 39800000 37000000.0 2800000 1000000.0 The following <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Final allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    BioSentry trademark</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    BioSentry product technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div>The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:<div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Final allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>732</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne trademark</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OARtrac trademark</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne legacy product technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OARtrac product technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RadiaDyne customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,445</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities assumed</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities assumed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>458</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 50000 10000 2500000 20900000 2600000 13740000 39800000 P10Y DIVESTITURES    <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fluid Management</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was </span><span style="font-family:inherit;font-size:10pt;"><span>$169.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and resulted in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$46.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> after working capital adjustments of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The gain was recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>24 months</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying Consolidated Statements of Operations as “Income from discontinued operations, net of income tax” for the </span><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">three months ended August 31, 2018. The following table summarizes the financial results of our discontinued operations: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales (exclusive of amortization)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with accounting principles generally accepted in the United States (“GAAP”), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating and investing cash flows of discontinued operations for the three months ended August 31, 2018 is comprised of the following, which excludes the effect of income taxes:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 169200000 46600000 600000 P24M The following table summarizes the financial results of our discontinued operations: <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales (exclusive of amortization)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,882</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,515</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of intangibles</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,060</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,220</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from discontinued operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating and investing cash flows of discontinued operations for the three months ended August 31, 2018 is comprised of the following, which excludes the effect of income taxes:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 21397000 12882000 8515000 288000 1028000 62000 682000 2060000 6455000 6455000 1220000 5235000 524000 224000 REVENUE FROM CONTRACTS WITH CUSTOMERS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has one primary revenue stream which is the sales of its products.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-bottom:20px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018:</span></div><div style="line-height:120%;padding-bottom:20px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,937</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Product Revenue</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contracts and Performance Obligations</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction Price and Allocation to Performance Obligations</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>90 days</span></span><span style="font-family:inherit;font-size:10pt;"> from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates and Allowances:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product Returns: The Company generally offers customers a limited right of return. Product returns after </span><span style="font-family:inherit;font-size:10pt;"><span>30 days</span></span><span style="font-family:inherit;font-size:10pt;"> must be pre-approved by the Company and customers may be subject to a </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least </span><span style="font-family:inherit;font-size:10pt;"><span>twelve months</span></span><span style="font-family:inherit;font-size:10pt;"> remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, such product returns were not material. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract Balances with Customers</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs to Obtain or Fulfill a Customer Contract </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.<div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>90 days</span></span><span style="font-family:inherit;font-size:10pt;"> from invoicing, the Company does not provide any significant financing to its customers.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates and Allowances:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations. </span></div><span style="font-family:inherit;font-size:10pt;">Product Returns: The Company generally offers customers a limited right of return. Product returns after </span><span style="font-family:inherit;font-size:10pt;"><span>30 days</span></span><span style="font-family:inherit;font-size:10pt;"> must be pre-approved by the Company and customers may be subject to a </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;"> restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least </span><span style="font-family:inherit;font-size:10pt;"><span>twelve months</span></span> remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.<div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs to Obtain or Fulfill a Customer Contract </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.</span></div> <div style="line-height:120%;padding-bottom:20px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018:</span></div><div style="line-height:120%;padding-bottom:20px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,937</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 25676000 3237000 28913000 19284000 3875000 23159000 7977000 5993000 13970000 52937000 13105000 66042000 25851000 2747000 28598000 20447000 3343000 23790000 5198000 6357000 11555000 51496000 12447000 63943000 P90D P30D 0.20 P12M <div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,540</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 32540000 43577000 0 0 607000 681000 200000 100000 INVENTORIES<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,786</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,071</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and May 31, 2019 was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Of the </span><span style="font-family:inherit;font-size:10pt;"><span>$4.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> reserve as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> reserve as of May 31, 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017 and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span> relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018. <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,786</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,247</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,071</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17443000 16045000 8539000 6786000 19247000 17240000 45229000 40071000 4100000 4200000 4100000 4200000 400000 700000 GOODWILL AND INTANGIBLE ASSETS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>eighteen years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. </span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's annual testing for impairment of goodwill was completed as of December 31, 2018. The Company operates as a single operating segment with </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even though the Company determined that there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairment as of December 31, 2018, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2019. There were no adjustments to goodwill for the three months ended August 31, 2019. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,967</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26,995</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,950</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,896</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>716</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected future amortization expense related to the intangible assets is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,308</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,369</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,813</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P18Y 1 0 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,968</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77,967</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26,995</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,830</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product technologies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182,971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107,559</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25,950</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trademarks</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,300</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,896</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,752</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>716</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 182968000 77967000 105001000 60147000 26995000 33152000 9300000 6470000 2830000 5887000 5215000 672000 258302000 116647000 141655000 182971000 75412000 107559000 60166000 25950000 34216000 9300000 6404000 2896000 5752000 5036000 716000 258189000 112802000 145387000 3900000 3400000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected future amortization expense related to the intangible assets is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,308</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,369</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,813</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11308000 14022000 13406000 13369000 11813000 77737000 141655000 ACCRUED LIABILITIES<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,987</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued severance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and franchise taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation matters</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indemnification holdback</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,338</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,987</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,088</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued severance</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>616</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and franchise taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation matters</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indemnification holdback</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,866</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,338</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div> 5970000 14987000 1439000 2088000 616000 504000 3417000 807000 1781000 3514000 0 2700000 4866000 4807000 4604000 8931000 22693000 38338000 LONG TERM DEBT<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 3, 2019 and in connection with the completion of the Fluid Management divestiture, the Company repaid all amounts outstanding under its existing Credit Agreement and entered into a new Credit Agreement with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and Bank of America, N.A. and KeyBank National Association, as co-syndication agents.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement provides for a </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> secured revolving credit facility (the “Revolving Facility”), which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.  The proceeds may be used to refinance certain existing indebtedness of the Company and its subsidiaries, to finance the working capital needs, and for general corporate purposes (including permitted acquisitions), of the Company and its subsidiaries. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement has a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> year maturity. Interest on the facility will be based, at the Company’s option, on a base rate of LIBOR plus an applicable margin tied to the Company’s total leverage ratio and having ranges between </span><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span><span style="font-family:inherit;font-size:10pt;"> for base rate loans and between </span><span style="font-family:inherit;font-size:10pt;"><span>1.25%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> for LIBOR loans. After default, the interest rate may be increased by </span><span style="font-family:inherit;font-size:10pt;"><span>2.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The facility will also carry a commitment fee of </span><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.25%</span></span><span style="font-family:inherit;font-size:10pt;"> per annum on the unused portion. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's obligations under the Revolving Facility are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Revolving Facility are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> quarterly financial covenants as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than </span><span style="font-family:inherit;font-size:10pt;"><span>3.00</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">1.00</span><span style="font-family:inherit;font-size:10pt;"> (during certain periods following material acquisitions the ratio shall be increased to </span><span style="font-family:inherit;font-size:10pt;"><span>3.50</span></span><span style="font-family:inherit;font-size:10pt;"> to 1.00). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than </span><span style="font-family:inherit;font-size:10pt;"><span>1.25</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">1.00</span><span style="font-family:inherit;font-size:10pt;">. </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">* The definitions of consolidated total indebtedness and consolidated EBITDA are maintained in the credit agreement included as an exhibit to Form 8-k filed on June 6, 2019. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was in compliance with the Credit Agreement covenants as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding balance on the Revolving Facility. As of </span><span style="font-family:inherit;font-size:10pt;">May 31, 2019</span> the carrying value of long-term debt approximates its fair market value. 125000000.0 75000000.0 0.0025 0.0075 0.0125 0.0175 0.020 0.0020 0.0025 2 3.00 3.50 1.25 0 INCOME TAXES<div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was </span><span style="font-family:inherit;font-size:10pt;"><span>8.3%</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of fiscal </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;"><span>17.8%</span></span><span style="font-family:inherit;font-size:10pt;"> for the same period in fiscal </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. In fiscal </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation). </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&amp;D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.</span></div> 0.083 0.178 SHARE-BASED COMPENSATION<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has two stock-based compensation plans that provide for the issuance of up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, share-based compensation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$16.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span>. The Company has sufficient shares to satisfy expected share-based payment arrangements. 11300000 1900000 2200000 16600000 P4Y EARNINGS PER SHARE<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reconciles basic to diluted weighted-average shares outstanding for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:78%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,323</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities excluded as their inclusion would be anti-dilutive</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table reconciles basic to diluted weighted-average shares outstanding for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:78%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,323</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,783</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,323</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities excluded as their inclusion would be anti-dilutive</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 37783000 37323000 0 0 37783000 37323000 2503000 2309000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes net sales by Global Business Unit:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies  <br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents net sales by geographic area based on external customer location:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The table below summarizes net sales by Global Business Unit:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Interventions &amp; Therapies  <br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,913</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vascular Access</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Oncology</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 28913000 28598000 23159000 23790000 13970000 11555000 66042000 63943000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents net sales by geographic area based on external customer location:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:79%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 52937000 51496000 13105000 12447000 66042000 63943000 FAIR VALUE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures, </span><span style="font-family:inherit;font-size:10pt;">establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements using</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">inputs considered as:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value at August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration for acquisition earn outs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Financial Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements using</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">inputs considered as:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value at May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration for acquisition earn outs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Financial Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, 2 and 3 for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the changes in fair value components of Level 3 instruments in the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements<br/>Using Significant<br/>Unobservable Inputs<br/>(Level 3) </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gains or losses (realized/unrealized):</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in present value of contingent consideration </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, August 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. </span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration for Acquisition Earn Outs</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. </span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Range</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Revenue based payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4% - 5%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 100% </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected fiscal year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Technical milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Estimated probability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated probability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2022</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the range of estimated potential undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to $</span><span style="font-family:inherit;font-size:10pt;"><span>34.0 million</span></span>. The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2020 to 2023 in order for the associated consideration to be paid. <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements using</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">inputs considered as:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value at August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration for acquisition earn outs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Financial Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements using</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">inputs considered as:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value at May 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Financial Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration for acquisition earn outs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Financial Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div> 0 0 11830000 11830000 0 0 11830000 11830000 0 0 13486000 13486000 0 0 13486000 13486000 <div style="line-height:120%;padding-left:0px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the changes in fair value components of Level 3 instruments in the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value Measurements<br/>Using Significant<br/>Unobservable Inputs<br/>(Level 3) </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,486</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gains or losses (realized/unrealized):</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in present value of contingent consideration </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, August 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. 13486000 -448000 -1208000 11830000 <div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Unobservable Input</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Range</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Revenue based payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,533</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted cash flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4% - 5%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66% - 100% </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected fiscal year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Technical milestones</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,297</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Estimated probability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated probability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected year of payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2022</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,830</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8533000 3297000 0.90 11830000 14000000.0 34000000.0 LEASES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Topic 842)</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets. </span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&amp;D, manufacturing and warehousing.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our leases:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:57%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of the lease liabilities:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Current portion of lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of operating lease expense during the three months ended August 31, 2019, which includes immaterial short-term leases. Within the accompanying Consolidated Statements of Operations, $</span><span style="font-family:inherit;font-size:10pt;"><span>0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> is classified in cost of sales and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> is classified as general and administrative. </span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the total lease obligations presented in the table above, we have a </span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;">-year building operating lease with undiscounted payment obligations of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>2</span></span><span style="font-family:inherit;font-size:10pt;">-year building operating lease with undiscounted payment obligations of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> that are expected to commence during fiscal year 2020. </span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,749</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow and other information related to our leases:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>563</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5600000 <div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our leases:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:57%;"/><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease ROU asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The following table presents the weighted average remaining lease term and discount rate:<div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5104000 1606000 3489000 5095000 P3Y8M12D 0.043 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of the lease liabilities:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,251</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Current portion of lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term lease obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1142000 1251000 1118000 1138000 576000 0 5225000 130000 5095000 1606000 3489000 700000 300000 400000 P7Y 6500000 P2Y 400000 <div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">May 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,920</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,338</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,749</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2920000 2338000 2133000 2131000 3227000 12749000 <div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow and other information related to our leases:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>563</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets obtained in exchange for lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 563000 0 COMMITMENTS AND CONTINGENCIES    <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">C.R. Bard, Inc. v. AngioDynamics, Inc.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> patents asserted by Bard in the litigation. The Company's petitions were granted and </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> of Bard's </span><span style="font-family:inherit;font-size:10pt;"><span>41</span></span><span style="font-family:inherit;font-size:10pt;"> patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reexaminations which were decided as follows: In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> claims under reexamination were affirmed, but were reversed on </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> claims under reexamination were affirmed but the rejections of the other </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947,022) the rejections of all </span><span style="font-family:inherit;font-size:10pt;"><span>twenty</span></span><span style="font-family:inherit;font-size:10pt;"> claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions.  </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company filed Cross-Appeals for the ‘302 and the ‘615 reexams and completed briefing.  Medcomp also filed an Amicus Brief in support of the Company on November 22, 2017.  An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 6-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent (confirming validity of claims 1-10) on June 10, 2019, and for the ‘022 patent (confirming validity of claims 1-20) on July 2, 2019, and for the ‘615 patent on August 26, 2019.   The Company has since filed a Motion to Unstay the Utah Case; that motion is fully briefed and awaiting decision by the Utah Court. Meanwhile, on July 12, 2017, Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as Co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action.  The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding claim construction issues prior to trial. A Report and Recommendation was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case (Plaintiff), Judge Bataillon granted judgment as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was served on September 27, 2019 and the Company's answering brief is currently due on November 6, 2019. We maintain our belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AngioDynamics, Inc. v. C.R. Bard, Inc. </span></div><div style="line-height:120%;text-align:left;text-indent:64px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  The parties are currently engaged in discovery, which is set to close in February 2020.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merz North America Settlement</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of </span><span style="font-family:inherit;font-size:10pt;">$2.5 million</span><span style="font-family:inherit;font-size:10pt;"> to Merz in return for dismissal of the case with prejudice during the first quarter.  Merz filed a stipulation of dismissal with the Court on July 23, 2019.</span></div> 3 3 40 41 40 3 6 10 4 8 10 2 20 3 3 2 2 ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition, Restructuring and Other Items</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 acquisition, restructuring and other items, net consisted of:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mergers and acquisitions</span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transition service agreement </span><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Divestiture </span><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>758</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1) Legal expenses related to litigation that is outside the normal course of business. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in legal for the three months ended August 31, 2019 is a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restructuring</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operational Consolidation </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 1, 2017, the Company announced to employees an operational consolidation plan (the “plan”) to consolidate its manufacturing facilities in Manchester, GA and Denmead, UK into the Glens Falls and Queensbury, NY facilities. This plan will streamline and optimize the manufacturing functions into one centralized location increasing the utilization of the Glens Falls and Queensbury facilities, optimizing inventory and reducing cost of goods sold through savings in overhead expenses and direct labor. The restructuring activities associated with the plan were completed in the fourth quarter of fiscal year 2018 with immaterial regulatory filing costs to be incurred. </span></div><span style="font-family:inherit;font-size:10pt;">The Company recorded restructuring charges related to the plan during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 of less than </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Total restructuring charges recorded to date are </span><span style="font-family:inherit;font-size:10pt;"><span>$6.3 million</span></span>. The Company’s remaining restructuring liability is comprised of regulatory expenses which are expected to be paid in the next twelve months and are included in "accrued liabilities" on the Consolidated Balance Sheet. <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 acquisition, restructuring and other items, net consisted of:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Aug 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Mergers and acquisitions</span><span style="font-family:inherit;font-size:6pt;"> </span><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transition service agreement </span><span style="font-family:inherit;font-size:9pt;">(3)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Divestiture </span><span style="font-family:inherit;font-size:9pt;">(4)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>758</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1) Legal expenses related to litigation that is outside the normal course of business. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in the </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in legal for the three months ended August 31, 2019 is a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.</span></div> 669000 2880000 246000 1318000 -737000 0 758000 0 26000 130000 538000 94000 1500000 4422000 700000 400000 100000 100000 6300000 ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign currency translation loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at August 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three months ended August 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign currency translation loss</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss before reclassifications, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at August 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1352000 -151000 0 -151000 -1503000 RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: </span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Adopted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 14, Leases, for the required disclosures related to adopting this standard. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: </span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Adopted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 14, Leases, for the required disclosures related to adopting this standard. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements: </span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Date Adopted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Note 14, Leases, for the required disclosures related to adopting this standard. </span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:22%;"/><td style="width:34%;"/><td style="width:11%;"/><td style="width:33%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Standard</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect on the Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820)</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June 1, 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is currently assessing the impact of this standard on the consolidated financial statements.<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> SUBSEQUENT EVENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology, for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> with up to </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span> of potential future contingent consideration related to technical and revenue milestones. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease. 45800000 20000000.0 XML 25 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Recently Issued Accounting Pronouncements (Policies)
3 Months Ended
Aug. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Revenue from Contracts with Customers

Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls.
Costs to Obtain or Fulfill a Customer Contract
Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
Recently Issued Accounting Pronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
Recently Issued Accounting Pronouncements - Adopted
Standard
Description
Date Adopted
Effect on the Consolidated Financial Statements
ASU 2016-02, Leases (Topic 842)
This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.
June 1, 2019
Refer to Note 14, Leases, for the required disclosures related to adopting this standard.



Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
Standard
Description
Effective Date
Effect on the Consolidated Financial Statements
ASU 2018-13, Fair Value Measurement (Topic 820)

This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.





XML 26 R69.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Coontingencies - Additional Information (Detail)
10 Months Ended
Mar. 07, 2019
patent
Mar. 29, 2016
claim
Mar. 24, 2016
claim
Mar. 11, 2016
claim
Jun. 01, 2015
motion
Jan. 11, 2012
Petition
reexamination_appeal
claim
Jan. 31, 2017
reexamination_appeal
Aug. 31, 2019
claim
C.R. Bard, Inc.                
Loss Contingencies [Line Items]                
Number of petitions filed for reexamination of patents | Petition           3    
The Utah Action                
Loss Contingencies [Line Items]                
Number of claims dismissed   20 8 6   40    
Number of reexaminations | reexamination_appeal           3    
Number of pending claims     10 10   41    
Number of claims reversed     2 4        
The Utah Action | C.R. Bard, Inc. | Pending Litigation                
Loss Contingencies [Line Items]                
Number of reexaminations | reexamination_appeal             3  
The Delaware Action                
Loss Contingencies [Line Items]                
Number of patents allegedly infringed upon 3       2      
Construction Issues                
Loss Contingencies [Line Items]                
Number of pending claims               2
XML 27 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail)
$ in Thousands
3 Months Ended
Aug. 31, 2019
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Financial liabilities, begining balance $ 13,486
Change in present value of contingent consideration (448)
Financial liabilities, ending balance 11,830
Clinical Devices Bv  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Contingent consideration payments $ 1,208
XML 28 R65.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Supplemental Balance Sheet Information (Details)
$ in Thousands
Aug. 31, 2019
USD ($)
Leases [Abstract]  
Operating lease ROU asset $ 5,104
Less: Current portion of lease obligations 1,606
Long-term lease obligations 3,489
Total lease obligations $ 5,095
Weighted average remaining term (in years) 3 years 8 months 12 days
Weighted average discount rate (percent) 4.30%
XML 29 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from Contracts with Customers - Narrative (Details)
$ in Millions
3 Months Ended
Aug. 31, 2019
USD ($)
Disaggregation of Revenue [Line Items]  
Days after purchase after which pre-approval is required for product return 30 days
Restocking charge (as percent) 20.00%
Minimum remaining period prior to product expiration 12 months
Revenue recognized from contract liability balances in respective periods $ 0.2
Additions to contract liabilities $ 0.1
Minimum  
Disaggregation of Revenue [Line Items]  
Payment term 30 days
Maximum  
Disaggregation of Revenue [Line Items]  
Payment term 90 days
XML 30 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Details) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Assets acquired    
Goodwill $ 347,666 $ 347,666
RadiaDyne    
Assets acquired    
Receivables   900
Inventory   732
Prepaid and other current assets   98
Property, plant and equipment   133
Goodwill   47,982
Total assets acquired   75,445
Liabilities assumed    
Accounts payable   352
Accrued expenses   106
Total liabilities assumed   458
Net assets acquired   74,987
RadiaDyne | RadiaDyne trademark    
Assets acquired    
Intangible assets   400
RadiaDyne | OarTrac trademark    
Assets acquired    
Intangible assets   200
RadiaDyne | RadiaDyne legacy product technology    
Assets acquired    
Intangible assets   1,500
RadiaDyne | OarTrac product technology    
Assets acquired    
Intangible assets   18,900
RadiaDyne | Customer relationships    
Assets acquired    
Intangible assets   4,600
BioSentry    
Assets acquired    
Inventory   50
Property, plant and equipment   10
Goodwill   13,740
Liabilities assumed    
Net assets acquired   39,800
BioSentry | Trademark    
Assets acquired    
Intangible assets   2,500
BioSentry | Product technology    
Assets acquired    
Intangible assets   20,900
BioSentry | Customer relationships    
Assets acquired    
Intangible assets   $ 2,600
XML 31 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies
3 Months Ended
Aug. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES    

Legal Proceedings

The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
 
C.R. Bard, Inc. v. AngioDynamics, Inc.

On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard’s complaint sought unspecified damages and other relief. The Company filed petitions for reexamination in the US Patent and Trademark Office ("USPTO") seeking to invalidate all three patents asserted by Bard in the litigation. The Company's petitions were granted and 40 of Bard's 41 patent claims were rejected and, following further proceedings, the Patent Office issued a Final Rejection of all 40 claims subject to reexamination. Thereafter, Bard filed appeals to the USPTO Board of Appeals and Interferences for all three reexaminations which were decided as follows: In one (issued on March 11, 2016 for US Patent No. 7,785,302), the rejections of six of the ten claims under reexamination were affirmed, but were reversed on four of the ten claims. In the second (issued on March 24, 2016 for U.S. Patent No. 7,959,615), the rejections of eight of the ten claims under reexamination were affirmed but the rejections of the other two of the ten claims were reversed. In the third (issued on March 29 for U.S. Patent No. 7,947,022) the rejections of all twenty claims under reexamination were affirmed. Thereafter, Bard sought Rehearing in all three appeals and the Company sought Rehearing in the ‘302 and ‘615 appeals. The PTO denied all three Rehearing Requests, but modified its characterization of one prior art reference for the ‘302 and ‘022 decisions. 

Bard filed appeals to the Federal Circuit Court of Appeals in all three reexams and the Company filed Cross-Appeals for the ‘302 and the ‘615 reexams and completed briefing.  Medcomp also filed an Amicus Brief in support of the Company on November 22, 2017.  An oral hearing was held on September 5, 2018 and the Court rendered its decision on September 28, 2018, affirming that claims 1-5 and 10 of the ‘615 patent were invalid, but that claims 6-7 of the 615 patent and 1-4 of the 302 patent were valid over the prior art references considered in the Reexamination proceedings.  The Federal Circuit also reversed the PTAB’s claim construction ruling and remanded for consideration of obviousness for the remaining claims under the new claim construction ruling and for further findings with respect to whether one of the asserted references qualified as a printed publication.  On January 28, 2019, on remand, the USPTO reversed the rejections of the ‘302 claims 1-10, ‘022 claims 1-20 and ‘615 claims 6-9.  The USPTO has since issued Inter Partes Reexamination Certificates for the ‘302 Patent (confirming validity of claims 1-10) on June 10, 2019, and for the ‘022 patent (confirming validity of claims 1-20) on July 2, 2019, and for the ‘615 patent on August 26, 2019.   The Company has since filed a Motion to Unstay the Utah Case; that motion is fully briefed and awaiting decision by the Utah Court. Meanwhile, on July 12, 2017, Bard assigned the asserted patents to Bard Peripheral Vascular, Inc. (“BPV”) which was added as Co-Appellant before the Federal Circuit and as a co-Plaintiff in the Utah action.  The Company believes these claims are without merit and intends to defend them vigorously.  The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

On March 10, 2015, Bard and BPV filed suit in the United States District Court for the District of Delaware (the “Delaware Action") claiming certain of the Company's implantable port products infringe on three other U.S. patents held by Bard, which are different from those asserted in the Utah action. Bard's complaint seeks unspecified damages and other relief. On June 1, 2015, the Company filed two motions in response to Bard’s Complaint - one sought transfer to the District of Utah where the Utah Action is currently pending, and the other sought dismissal of the entire complaint on grounds that none of the claims in the asserted patents is directed to patent eligible subject matter under Section 101 of the Patent Statute and in light of recent authority from the U. S. Supreme Court.

On January 12, 2016, the Court issued a decision denying both motions. A Markman hearing was held on March 10, 2017 and the Court issued its Claim Construction Order on May 19, 2017. On May 19, 2017, Bard served its Final Infringement Contentions and on June 2, 2017, the Company served its Final Invalidity Contentions.

On October 20, 2017, the scheduling order for the case was amended to, among other things, set a trial date commencing July 23, 2018. The parties completed Expert Discovery in January 2018 and completed briefing on their respective case
dispositive motions on April 27, 2018. On June 26, 2018, the Court denied all case dispositive motions, ruling that issues of material fact remained in dispute. On July 9, 2018, the Court continued the trial until March 2019. On January 9, 2019 the Court held a further claim construction hearing to resolve two outstanding claim construction issues prior to trial. A Report and Recommendation was issued on February 11, 2019 and entered by the Court on February 28, 2019. Jury selection was held on Friday March 1, 2019 and trial began on March 4, 2019.  On day four of the jury trial, at the close of C.R. Bard’s case (Plaintiff), Judge Bataillon granted judgment as a matter of law under rule 50(a) in favor of AngioDynamics, dismissing Bard’s suit.  On April 5, 2019, Bard filed a precautionary Notice of Appeal to the Federal Circuit. On April 26, 2019, the District Court issued a Memorandum and Order confirming the grant of judgment in the Company’s favor of patent ineligibility, non-infringement, patent invalidity and no willful infringement. Meanwhile, on May 10, 2019, the Company filed a Motion for Attorney fees and non-taxable expenses under 35 USC Sec. 285. On May 21, 2019, the Court issued a Memorandum and Order which, inter alia, stayed proceedings on the Company’s fee Motion and the Company’s equitable claims pending appeal; and entered Final Judgment on May 21, 2019 as well. Bard filed a second Notice of Appeal on May 23, 2019. Both appeals have since been consolidated and Bard’s opening brief was served on September 27, 2019 and the Company's answering brief is currently due on November 6, 2019. We maintain our belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

AngioDynamics, Inc. v. C.R. Bard, Inc.

On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”).  In this action, the Company alleges that Bard has illegally tied the sales of its tip location systems to the sales of its PICCs.  The Company alleges that this practice violates the federal antitrust laws and has had, and continues to have, an anti-competitive effect in the market for PICCs.  The Company seeks both monetary damages and injunctive relief. Bard moved to dismiss on September 8, 2017. On August 6, 2018 the court denied Bard’s motion in its entirety.  The parties are currently engaged in discovery, which is set to close in February 2020.
Merz North America Settlement

On May 16, 2019, Merz North America, Inc. (“Merz”) commenced an action in the United States District Court for the Southern District of New York entitled Merz North America, Inc. v. AngioDynamics, Inc.  In this action, Merz alleged breach of contract against AngioDynamics based on a March 1, 2016 Distribution Agreement.  On June 28, 2019, AngioDynamics reached a settlement with Merz. AngioDynamics made a lump-sum payment of $2.5 million to Merz in return for dismissal of the case with prejudice during the first quarter.  Merz filed a stipulation of dismissal with the Court on July 23, 2019.
XML 33 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Events
3 Months Ended
Aug. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS

On October 2, 2019, the Company acquired Eximo Medical, Ltd., a pre-commercial stage medical device company and its proprietary 355nm B Laser Atherectomy technology, for an aggregate purchase price of $45.8 million with up to $20.0 million of potential future contingent consideration related to technical and revenue milestones. This acquisition expands and complements the Company’s Vascular Interventions and Therapies product portfolio by adding the 355nm B Laser Atherectomy technology which treats Peripheral Artery Disease.
XML 34 R60.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Financial Liabilities    
Contingent consideration for acquisition earn outs $ 11,830 $ 13,486
Recurring    
Financial Liabilities    
Total Financial Liabilities 11,830 13,486
Level 1 | Recurring    
Financial Liabilities    
Contingent consideration for acquisition earn outs 0 0
Total Financial Liabilities 0 0
Level 2 | Recurring    
Financial Liabilities    
Contingent consideration for acquisition earn outs 0 0
Total Financial Liabilities 0 0
Level 3 | Recurring    
Financial Liabilities    
Contingent consideration for acquisition earn outs 11,830 13,486
Total Financial Liabilities $ 11,830 $ 13,486
XML 35 R64.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Details) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Jun. 01, 2019
Lessee, Lease, Description [Line Items]    
Operating lease ROU asset $ 5,104  
Total lease liabilities 5,095  
Lease expense $ 700  
Building | Seven Year Building Lease    
Lessee, Lease, Description [Line Items]    
Lease term (years) 7 years  
Lease payments $ 6,500  
Building | Two Year Building Lease    
Lessee, Lease, Description [Line Items]    
Lease term (years) 2 years  
Lease payments $ 400  
Accounting Standards Update 2016-02    
Lessee, Lease, Description [Line Items]    
Operating lease ROU asset   $ 5,600
Total lease liabilities   $ 5,600
Cost of Sales    
Lessee, Lease, Description [Line Items]    
Lease expense 300  
General and Administrative Expense    
Lessee, Lease, Description [Line Items]    
Lease expense $ 400  
XML 36 R68.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Supplemental Cash Flow Information (Details)
$ in Thousands
3 Months Ended
Aug. 31, 2019
USD ($)
Leases [Abstract]  
Operating cash flows from operating leases $ 563
Operating leases $ 0
XML 37 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from Contracts with Customers - Contract Balances with Customers (Details) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Revenue from Contract with Customer [Abstract]    
Receivables $ 32,540 $ 43,577
Contract assets 0 0
Contract liabilities $ 607 $ 681
XML 38 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Divestitures (Details)
$ in Millions
3 Months Ended
May 31, 2019
USD ($)
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Consideration received $ 169.2
Gain on divestiture 46.6
Working capital adjustments $ 0.6
Medline  
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Service period duration (months) 24 months
XML 39 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
3 Months Ended
Aug. 31, 2019
Oct. 02, 2019
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001275187  
Current Fiscal Year End Date --05-31  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Aug. 31, 2019  
Document Transition Report false  
Entity File Number 0-50761  
Entity Registrant Name AngioDynamics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 11-3146460  
Entity Address, Address Line One 14 Plaza Drive  
Entity Address, City or Town Latham  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 12110  
City Area Code 518  
Local Phone Number 795-1400  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   37,619,875
Common Stock    
Title of 12(b) Security Common stock, par value $.01  
Trading Symbol ANGO  
Security Exchange Name NASDAQ  
Preferred Stock Purchase Rights    
No Trading Symbol Flag true  
Title of 12(b) Security Preferred Stock Purchase Rights  
Security Exchange Name NASDAQ  
XML 40 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Statement of Financial Position [Abstract]    
Accounts receivable, allowances $ 1,434 $ 1,906
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 38,359,875 37,984,382
Common stock, shares outstanding (in shares) 37,989,875 37,614,382
Treasury stock, shares (in shares) 370,000 370,000
XML 41 R71.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition, Restructuring and Other Items, Net - Narrative (Detail) - USD ($)
$ in Thousands
3 Months Ended 31 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Aug. 31, 2019
Restructuring Cost and Reserve [Line Items]      
Acquisition, restructuring and other items, net $ 1,500 $ 4,422  
Restructuring charges 100 100 $ 6,300
Legal      
Restructuring Cost and Reserve [Line Items]      
Acquisition, restructuring and other items, net 669 $ 2,880  
Biolitec Bankruptcy      
Restructuring Cost and Reserve [Line Items]      
Proceeds from Legal Settlements $ 400    
XML 42 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions
3 Months Ended
Aug. 31, 2019
Business Combinations [Abstract]  
Acquisitions ACQUISITIONS

RadiaDyne Acquisition

On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of $22.3 million in contingent consideration is comprised of $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The $4.6 million indemnification holdback is recorded in accrued liabilities at August 31, 2019 and the $0.2 million purchase price holdback was initially recorded in accrued liabilities, and was paid during the third quarter of fiscal year 2019.
This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.
The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately $1.6 million in fiscal year 2019. The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:
(in thousands)
Final allocation
Accounts receivable
$
900

Inventory
732

Prepaid and other current assets
98

Property, plant and equipment
133

Intangible assets:
 
RadiaDyne trademark
400

OARtrac trademark
200

RadiaDyne legacy product technology
1,500

OARtrac product technology
18,900

RadiaDyne customer relationships
4,600

Goodwill
47,982

Total assets acquired
$
75,445

Liabilities assumed
 
Accounts payable
$
352

Accrued expenses
106

Total liabilities assumed
$
458

Net assets acquired
$
74,987


The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.
The values assigned to the RadiaDyne and OARtrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five to seven years and the product technologies are deemed to have a useful life of seven to ten years. Both are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
BioSentry Acquisition
On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and was paid in the fourth quarter of fiscal year 2019 upon fulfillment of hydrogel orders by SSC.
The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in "acquisition, restructuring and other expenses, net" in the accompanying Consolidated Statements of Operations, were approximately $1.0 million in fiscal year 2019. The following
table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:
(in thousands)
Final allocation
Inventory
$
50

Property, plant and equipment
10

Intangible assets:

    BioSentry trademark
2,500

    BioSentry product technology
20,900

    Customer relationships
2,600

Goodwill
13,740

Net assets acquired
$
39,800


The Company finalized the allocation of the purchase price to the assets acquired and liabilities assumed in the fourth quarter of FY19.
The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen year useful life and are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 155 368 1 false 71 0 false 11 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.angiodynamics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Operations Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.angiodynamics.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 2101100 - Disclosure - Consolidated Financial Statements Sheet http://www.angiodynamics.com/role/ConsolidatedFinancialStatements Consolidated Financial Statements Notes 8 false false R9.htm 2102100 - Disclosure - Acquisitions Sheet http://www.angiodynamics.com/role/Acquisitions Acquisitions Notes 9 false false R10.htm 2104100 - Disclosure - Divestitures Divestitures Sheet http://www.angiodynamics.com/role/DivestituresDivestitures Divestitures Divestitures Notes 10 false false R11.htm 2105100 - Disclosure - Revenue from Contracts with Customers Sheet http://www.angiodynamics.com/role/RevenueFromContractsWithCustomers Revenue from Contracts with Customers Notes 11 false false R12.htm 2106100 - Disclosure - Inventories Sheet http://www.angiodynamics.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.angiodynamics.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 2108100 - Disclosure - Accrued Liabilities Sheet http://www.angiodynamics.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2110100 - Disclosure - Long Term Debt Sheet http://www.angiodynamics.com/role/LongTermDebt Long Term Debt Notes 15 false false R16.htm 2111100 - Disclosure - Income Taxes Sheet http://www.angiodynamics.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2112100 - Disclosure - Share-Based Compensation Sheet http://www.angiodynamics.com/role/ShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 2113100 - Disclosure - Earnings Per Share Sheet http://www.angiodynamics.com/role/EarningsPerShare Earnings Per Share Notes 18 false false R19.htm 2114100 - Disclosure - Segment and Geographic Information Sheet http://www.angiodynamics.com/role/SegmentAndGeographicInformation Segment and Geographic Information Notes 19 false false R20.htm 2115100 - Disclosure - Fair Value Sheet http://www.angiodynamics.com/role/FairValue Fair Value Notes 20 false false R21.htm 2116100 - Disclosure - Leases Leases Sheet http://www.angiodynamics.com/role/LeasesLeases Leases Leases Notes 21 false false R22.htm 2118100 - Disclosure - Commitments and Contingencies Sheet http://www.angiodynamics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 2119100 - Disclosure - Acquisition, Restructuring and Other Items, Net Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNet Acquisition, Restructuring and Other Items, Net Notes 23 false false R24.htm 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 24 false false R25.htm 2121100 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 25 false false R26.htm 2122100 - Disclosure - Subsequent Events Sheet http://www.angiodynamics.com/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 2221201 - Disclosure - Recently Issued Accounting Pronouncements (Policies) Sheet http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies Recently Issued Accounting Pronouncements (Policies) Policies http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements 27 false false R28.htm 2302301 - Disclosure - Acquisitions (Tables) Sheet http://www.angiodynamics.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.angiodynamics.com/role/Acquisitions 28 false false R29.htm 2304301 - Disclosure - Divestitures (Tables) Sheet http://www.angiodynamics.com/role/DivestituresTables Divestitures (Tables) Tables http://www.angiodynamics.com/role/DivestituresDivestitures 29 false false R30.htm 2305301 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.angiodynamics.com/role/RevenueFromContractsWithCustomers 30 false false R31.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://www.angiodynamics.com/role/InventoriesTables Inventories (Tables) Tables http://www.angiodynamics.com/role/Inventories 31 false false R32.htm 2307301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.angiodynamics.com/role/GoodwillAndIntangibleAssets 32 false false R33.htm 2308301 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.angiodynamics.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.angiodynamics.com/role/AccruedLiabilities 33 false false R34.htm 2313301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.angiodynamics.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.angiodynamics.com/role/EarningsPerShare 34 false false R35.htm 2314301 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.angiodynamics.com/role/SegmentAndGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.angiodynamics.com/role/SegmentAndGeographicInformation 35 false false R36.htm 2315301 - Disclosure - Fair Value (Tables) Sheet http://www.angiodynamics.com/role/FairValueTables Fair Value (Tables) Tables http://www.angiodynamics.com/role/FairValue 36 false false R37.htm 2316301 - Disclosure - Leases (Tables) Sheet http://www.angiodynamics.com/role/LeasesTables Leases (Tables) Tables http://www.angiodynamics.com/role/LeasesLeases 37 false false R38.htm 2319301 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables) Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetTables Acquisition, Restructuring and Other Items, Net (Tables) Tables http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNet 38 false false R39.htm 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss 39 false false R40.htm 2321302 - Disclosure - Recently Issued Accounting Pronouncements (Tables) Sheet http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsTables Recently Issued Accounting Pronouncements (Tables) Tables http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements 40 false false R41.htm 2402402 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 41 false false R42.htm 2402403 - Disclosure - Acquisitions (Details) Sheet http://www.angiodynamics.com/role/AcquisitionsDetails Acquisitions (Details) Details http://www.angiodynamics.com/role/AcquisitionsTables 42 false false R43.htm 2404402 - Disclosure - Divestitures (Details) Sheet http://www.angiodynamics.com/role/DivestituresDetails Divestitures (Details) Details http://www.angiodynamics.com/role/DivestituresTables 43 false false R44.htm 2404403 - Disclosure - Divestitures - Results of Discontinued Operations (Details) Sheet http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails Divestitures - Results of Discontinued Operations (Details) Details 44 false false R45.htm 2405402 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details) Sheet http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails Revenue from Contracts with Customers - Disaggregation of Revenue (Details) Details 45 false false R46.htm 2405403 - Disclosure - Revenue from Contracts with Customers - Narrative (Details) Sheet http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails Revenue from Contracts with Customers - Narrative (Details) Details 46 false false R47.htm 2405404 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details) Sheet http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersContractBalancesWithCustomersDetails Revenue from Contracts with Customers - Contract Balances with Customers (Details) Details 47 false false R48.htm 2406402 - Disclosure - Inventories - Schedule of Inventories (Detail) Sheet http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail Inventories - Schedule of Inventories (Detail) Details 48 false false R49.htm 2406403 - Disclosure - Inventories - Narrative (Detail) Sheet http://www.angiodynamics.com/role/InventoriesNarrativeDetail Inventories - Narrative (Detail) Details 49 false false R50.htm 2407402 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail) Sheet http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail Goodwill and Intangible Assets - Narrative (Detail) Details 50 false false R51.htm 2407403 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail) Sheet http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail Goodwill and Intangible Assets - Intangible Assets (Detail) Details 51 false false R52.htm 2407404 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail) Sheet http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail) Details 52 false false R53.htm 2408402 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) Sheet http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail Accrued Liabilities - Summary of Accrued Liabilities (Detail) Details 53 false false R54.htm 2410401 - Disclosure - Long Term Debt - Narrative (Detail) Sheet http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail Long Term Debt - Narrative (Detail) Details 54 false false R55.htm 2411401 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.angiodynamics.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 55 false false R56.htm 2412401 - Disclosure - Share-Based Compensation - Narrative (Detail) Sheet http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail Share-Based Compensation - Narrative (Detail) Details 56 false false R57.htm 2413402 - Disclosure - Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) Sheet http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail) Details 57 false false R58.htm 2414402 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) Sheet http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) Details 58 false false R59.htm 2414403 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) Sheet http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) Details 59 false false R60.htm 2415402 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) Sheet http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) Details 60 false false R61.htm 2415403 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) Sheet http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) Details 61 false false R62.htm 2415404 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) Sheet http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) Details 62 false false R63.htm 2415405 - Disclosure - Fair Value - Additional Information (Detail) Sheet http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail Fair Value - Additional Information (Detail) Details 63 false false R64.htm 2416402 - Disclosure - Leases (Details) Sheet http://www.angiodynamics.com/role/LeasesDetails Leases (Details) Details http://www.angiodynamics.com/role/LeasesTables 64 false false R65.htm 2416403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 65 false false R66.htm 2416404 - Disclosure - Leases - Liability Maturity Schedule (Details) Sheet http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails Leases - Liability Maturity Schedule (Details) Details 66 false false R67.htm 2416405 - Disclosure - Leases - Non-Cancelable Payments Schedule (Details) Sheet http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails Leases - Non-Cancelable Payments Schedule (Details) Details 67 false false R68.htm 2416406 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 68 false false R69.htm 2418401 - Disclosure - Commitments and Coontingencies - Additional Information (Detail) Sheet http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail Commitments and Coontingencies - Additional Information (Detail) Details 69 false false R70.htm 2419402 - Disclosure - Acquisition, Restructuring and Other Items, Net - Summary (Detail) Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail Acquisition, Restructuring and Other Items, Net - Summary (Detail) Details http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetTables 70 false false R71.htm 2419403 - Disclosure - Acquisition, Restructuring and Other Items, Net - Narrative (Detail) Sheet http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail Acquisition, Restructuring and Other Items, Net - Narrative (Detail) Details 71 false false R72.htm 2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Schedule (Detail) Sheet http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail Accumulated Other Comprehensive Income (Loss) - Schedule (Detail) Details http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables 72 false false R73.htm 2422401 - Disclosure - Subsequent Events (Details) Sheet http://www.angiodynamics.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.angiodynamics.com/role/SubsequentEvents 73 false false All Reports Book All Reports ango-083119x10q.htm a083119-exx3111.htm a083119-exx3121.htm a083119-exx3211.htm a083119-exx3221.htm ango-20190831.xsd ango-20190831_cal.xml ango-20190831_def.xml ango-20190831_lab.xml ango-20190831_pre.xml ex2183119.htm angologoa23.gif http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 44 0001275187-19-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001275187-19-000026-xbrl.zip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

K^152 M&TH 'P-SO;36;I<2B?+TO\'.Z;V=TT5>[(RVZ_2N[9%PWF" #0;8L?'J$#'K M2<3LR/ARR'P96&/(?.E3YLN1<>&0^=)":V]0KT/F2Y\6NBN:;]!#C5A#Q[#4 M[^!,_ M$;;O>2 MXC!Z*O!;@-QLXA^E_JWO3Q]3X5,6IY0:'#%1U]R:)_$D9@$'OZ?>2E-L*-%SWV M8?W7T-U75NA *=FAK.OK6"&UC3(?<5%:\&BV?5Y^9T,MR4?* $O6\, 1\ M#5K,KV* P2YX<[N@;:PP^ 4]7/3!&'PS8W"?K&!&WMA/''*>_D_^&=[J8 M5'_DR@_^RWNZE6WNO"::6))PY*=_/']9&-PG H M[S:Y>9IZSS14,9+C8LS5 MV2OX;^TJO'+[OM!QU6N8V4+-+&)38ZU@@;*V?LX#1RBDV6;$?\X"/(A9@V(V ML'E#VSIXAVV=!Q \9KCNP,.M1Z'=GCMSO#GGC@. S2H[!R!)=W=Y[XONSVZ=RXO!K0<$##;J#A5HP^@.004>X3 M2 Z!Y@$D!Y!L""3;C'$#./4:'+HBEJNGER=NL'SCZ=YU$HZ^?IE%([FRLNTXQ")?[3*9&:_N1.<19OJM9F:[?O1W=S+SC*?%KW\3 MT^L*8I\^>=^\Y<(3BS[GP726Q&D'] Q$2X_\[+GRIF$Y T[D_3'S@M%3]?-* M/>,K;S2+(F'0'!<[;3>5!=BLF>C:=%#L!\$U369I-(\]F?>'$2!HO+7H[()RGE94UF M*9ESLL3C"DI7V^PX\1\%4HV_1.&M>UO*,&H[ R]2J#8MV'3C!V<2 M?N\F2-4N\P!2+0&I^O8Z'NT"2NT77#[Y&:P_*Q=<(S6V&P67LV3QK2':VW[9 M7EWBW,O?98V/$7/:+N);GVKIHZ%2ZI.^?B5Y_'F'7 D41TG[9_0=-!6#V2Q.@WEWN!CF@/T#]K?T MTZ-(BFW* :4,J>_A/SPW,F:^(#"X3WL^@S:Q4N+5R9,LHY#HP=C^8^9/Y6-* M*J+(:9T_YSBP+&7,RLG),XMJ9Z2U1?>#+6KY<-S\# M9[Z ,XN"[D5FA#[^URQ.TJEWPNC"^ZZ/4O4@Z!23$XA?1R6^77QKT>E:#&CL M1N/X]^G833PQ9@K0<3!@OJX[34'!#EO-P:&XI)SKOX=3'.?!*'ST!)U).A.? MPI&[.,F1]_FK%PB+<2*D2!\_^H$?)]*:_>;9/Z;RXN#CXHDU!!<S[HWL-[T-_)9A@H0 M&5;\("LNBRR>(;+MBC_KWN2*\V'%#[CB?+<5YPVM^'EIQ0=4/XA)GRX@;/ B M[>V4LAD9PH\1UDT'ENX9+7U1QMIO6 @J!F=BM3'\Y]CS__G)NW+8<*O@B:)*QFT6?XV M,6\?GLU;SEQ/WN1EZ7]%T5 M38?S7/$9T+9=]F?=&[1R!D_F<%9.X9@TF112:^&$XB71+*7T/(YGQQ)Y6F_J MU!!UA'L4$GS5=(_"V^AI#.C;*/JJN\4-GW5O,*HP^)B'-+.V=U:>=6] WR(A MZ4.D^$! _Z/107OM/E33V8?=H&U-T-XU7R#L0,;#=F8&_*#"GH6_XW(4&^D)\N,4**_RND]84)7J(N M!D3HJ'K8A1FR\PI"AT:Q&XQ+]5:[9#ID&>3U5/:%-796%@-K]$6%[,P:Z1Z. MS,3J'#L\IZPO++"SXKB)W" 3%B^2M;C=^\CSBJ,XW6&)390."F1@D7:PR/&A MR*!(^HP20_1RL#*&@-6! U9O?9!!\L#!5O&EDZ2= ?3F@1QY\&?=%I[AAQ,_ M\4:&&WR-9M-D="27-*S=QZLCJ@_24061"PB1IVB3)S-\G(:!5W%T=/8XFXBN MX]06G,,[STNP#U[26:PYW:^# !$?"! W> M%CC7(&B[FP+M'_YC^-D;RPN0/B7C_,3"@G]FMW%:&BBQOXD?*Y4QGK4?%Z.L MOV:P>F;6\<,N/%H]KP5W5D[LP?08!,+XW5Z/+75_??::Y-[+4=(,!YMA,!(3 M,"\ =N7'7XTGPPM&#X]N]+44IY15G,))>/^D!^.L*ECMK6^#4.Q'*#8M5?G" MM@UKU5$Q7=(92U+W ITQ"_RYR(U",7;QY3*+/LX+KLUG/.^0/RAO+!XMG[7R MW&#VG/'S+V8#%+_N^,ALVFI'FK7O^-3'4')<[4/GS3L^\XN7^&N?FG?8\;FS M>/S%BZX?W,@K/WKL?Q,P4.85^8V+V:,L?1B6&;]XDQ^'!$'MP^_7UNH@_M?2 M,)8?5'J#Y07AHQ_4OB/C=CG<>--+GCTK;UJ0MFE>JJ9Z+8UK'QAYW@\W'8Y8 MI'^ZTZGG3FH7LZKSCN^;"J6YAK/GS;N*2SKO]1)8MRYK'SJ:N/YC/5;(UDU/ M?.__$%,6A[-HY,7S/Q\\=RPP\M?W8KD__IK^<..H&.SSZXXU[._&4\$Z1Q4NEN_+K>_F(,G$E$F^C]Z6_ M:ZF=NF-YVO0L":<#G'AWR0>0CS ;C_R[3%(01H_N9(DH*/N(,2;I M[(V\R21K_$R-LCWL_F _/G25A M_D&4#BC]Y+L_3AY$;S'=MV$DF/AL%$XF[C3V/N2_E.==/BH=L6#V9*R(+G)2 M_G(")1\G8_DC6K1F RZ]8DVO;UZ42,,L>]%MF"3A8SZF^5\?X/2'$H<3?ZS\ M":3_^65I!9"8S?+TEO_.GE#^:#X+\I/L+>F2K+SB9&G)A3$1W4W"[Q\>_+%8 MYE^RQ56;Y+V%[,SE9C%A[U,^69&G5\A/,0"T\Y#3;Z1_?I^_\S: M, U3.J>VC:#6#=R"]&# Y5Q>?59R&N8_A6D7A$'J/_BCU* ;JX@RKE*/('SV M_>N9XXZ2,Y.KFH%U4]6QJ5K,I([-J*W9U&#$Q%P[40)71D5D^1 K',T>,W=< M",36.XYE:O+6L=G>N2[$^7WP!^%8T_Y?%WSU?5: M05476H$XCDHI8AK&%G> 93)D":];=ZCJ.)J-JK3";S,W$F@Y>;KRIF&4U"L( MY4XR6?*7$U^0&WLC(>7AY-:=3,+D-OPA98-KA/Y2IPQ69>:(%JH"$%"UQOKM M=_WJQK[Z] _EROYR>76C?/G]ZOIW_>)&N;E4A"]P(PQ^!6+E\DJ!ZD_CGY5+ M1[GYFZV4W(2%BZ";-[(9Q-!Y(4Q6&3IAI"0/GO)'SFS*/-JN> +/QLKN M!D/=BWY=?=#W!S_QSB38>8(OOT?N]&2]0-%"H*#)(&'"H+*)+62+JZIJ9F:6 MJ@L3K$J@OJ24V?-MO>W$Z8,LU_XH.CZ,W:5/6JJDX6[);KZKLH?&Q,5:?$ MC+U1.$]?^# 3D!K).5BS']+4SP:5I9*$PY2\UG[(@($:['+M&X91+ F1@$A8U%X(YF.4_RS=P7#FMK*.VB%3@$"X\V6+AV1X)L:8.J MB!? 18!E:\PA-C(=C3*L60:UF6G;5"5(K0"N*^\^O5LJ2"Y$RPNV$FHV'/7@ MW@^M)_$Z?Q2?*K*@^09<:V8[X/7H^)/]0TQE.E$R%25:3)#BQDH\]48RS72L M^('B)[$R>DBC'S^_A@H9NWB\5^)H-+^YAR["[^[]NQ/%G205GV8/SYY+ M)2[/)96@3"3>BT>^>E([[#P/L-E2V-S1"ZQ^^&LY?N=![&C '+5ITE#T"6^4 M'\+KPT^XOHFPED6F]JBMMK /:,D^H!QPP8#80A93;0BH:0O'Q@20.X;%X*I] M($_P1]/,?4V/E9GR9M+HR0S'6T;"TW!5++\ZC<)O\@4R%)X7(V\@8I7!YB%@ M<9]8V%\.U0H.18(-.12,:=FZ81(#:YQ)#E41T323JJL<>N/^.,]._\RK2VST MPZ&\T(500L'VS+>U\C[T0K%=UXG5F+VI<"MAI(2R;JCRKUGDQV,_+20N[.!: MU7:(L?EE$$J'&-V[@?_O].^?!ZCH#A.>O[MZ=_U.L1^GD_!)'B-[0ZY;1A7E M(GQ7Q6JOS1(Z4,1L6ZQ?"]2T%"/539USX@@WRG9L0H".-<:0HQ+H,$OC]BI0 MZ^-Q)$]5SO_Y)$8(7Q$LA43Y,G'_[2I6Y'_S]AXS/=T^DDPA6LR2RC'7#<"! M02@E&'$#(C%+Q.8J1C?A]^ 5<_3)31[+R6^> M0E1B+V*8JLDQM T+*]\,;S1*!1>)CH32$ ^T&8^7?_E21"08[! C? M:)/XI^TY$!=)ZX1Q8!N2#86M;D#(@,.%O6X+S]*BPM),O#V'P^HU# MC:MGD(#>"6*Q>?%__L00U'Z)E<2;>%,YJ=D&\*DBY',RDP*EN(+W4F%LO2Q> M"R@1/7T!(O/]!R_RQLIT%L4SN1&1A(KH(:W2N8< T4^W/TLTDDD>^BCY, 0B M=PE$JIL#D; ^VHCJFR!YT=?*;^M\W.'&3^9GOCUW]*",)FXQ2 ME,.%S6CKJH&186+;UBG5# L2:3-""T,+Z=J2!9W9!4\0W::X66LSKE8_-"6R M7MY=)^'HZU*I+IDX)[=VQ.=YF:[Y1V(2Q&>GRM2-E&_N9.8I?WXG2WL.^S4] MWZ_10(E[$26<(HZX8W);MYA. 4,.UAR=4]-9RCC*E,%UJ@OVQ+KZQ5\O!Q8= M6!06+*HR$QDZ=S!SD*ECE=K"/[\IG-_KJ)4UN67:?"XIH,]O\W"$2]NG%#LV$R:2A1V+6P:QR%PI65#3D*[N4REM"TD'4E&M MV3Q?*BGX$!51T'OO[#;RW*]G[IW@G@_NY+O[%,L(W4,TE%L\UHCY_0LCYF]$ MX$48[+!O<9!MT$7H-D68'78X2]2^--^ZT:3OX]OY&(XY'/LQAY<"3<:#S MY/- %K)//.7V21D]>,+OD*7F%7^.C*7#3WZLN,IWP;AG7X/PNWB)Y\8"DL:B M(9[)?58W5L;>G1_,ST9=S03?$Z#F&%O"9P&W[^K.+/_#BW\H+:01KU'] M6&80SZL_% ; \7/D1=AC_OC^X*59Z\M,\D'Y"?X\GP_AW*3\,5;W.0YKW]WXU5&3[^<$?+S:9IL]A,J47LKW#31Z?9? MTC$37TK[BV_*H60/D]YAG(XD':D;)PH'\R>,A8=3*Q,OYMTM?&1>Y)8A'5F0 M&+H)D88QL0Q= ]36@08)475JK68WFC/AT0;)O)B.W&H0/O L7I-9]0]O4V"M M72C=;K0@1XT6BI0:(3"/?I((.4LC&E$82,-U\J1XPG)\4LZEZR!X4Z9Y6F[B M*LY_/-;2#8#M*B5A1P, MN*,YAB7>RG15%[UL'1*+J5RSM:ISB(N)E_.>"?H@V8-D;R/9J?,RD5>-*^Y( M>-_R(A\A&U(8I.<25'XJ[,O@;*5!V@*N$@N'7_X1Y9I&,.*CH.'IG; -O/3U MJ3.4%MM*$\5EABH"O]0,(FV%OYSFW>HZI&H^ZU,[AKQO[H9!='N&UM;4DV? M5P=\<9!_LTHJI>Y3 YN:Z6#L:)JC8XLB67V?,P9-#I!!JVM^1:80T?LP>MKA M$-+\DKM4JD?9M^6&RJ=J9&CWON\>EJV5^X:-UQ:M]*Z[MXRMVN3> Y5Z(:YS M4C.9[2J]/1+.YR;OV^O(-]J\6*X8/9 ]D-U!LKMF_%Y4^:Z#7NJJ7FJ#.GJ3 M93PN-KV>AVSF9"[B-O,_L^!-=XGOAXQNCCIP A91!TW3.$2J;:J<0)NH#*=9 MZ4RGFFI25E&P-V4A8Q;[@1>OV=EJ_+Z(GEJ^ ZD#J0.I ZD#J8-;U@"AME"S M]W*K[CX*OR9))K/N6GBG,#M0DK M]8EK:]*TU^(R!.4SXB9&U+)59#"@4U-E#C)D6IK-5*I1SBN\<4G+J_%X>\VS M&@-LI-3?D%6><;%DN.SF.,%^\8,;>;$2SI(X<0,YC$7)HXPYS]/#+XOJ@VGY M,B_-]QHMU=!QX_P;$_&:.%&F:3+C*,UQDC<%O]M^1E;I[5_V54ON#CGJ(E[K M[J8T6U2'K]YP?]$\M,R,>-MUOBQ!VQRC+D=)*.$/Y5>4O\ G/^Y"#EGUL^OJ MZF=M8YJWVYUY(Z'84\4.)U7(8MV?F8>T, \IMW5;F"\&X91CS=0-*LQ#S:8& MYS;3*C9K2F6?KE-;HB1OR^;B>6HM(B%]Z$29!?[\T[D!C>'4545U^FF1X&N9[>Q/_;=R/?BU_K4>R?B1C<^VYO&0;8 MTN:H454+*\32B 8P0;J.;=50569"32>46[:J6:JF-Z(7O[A1HIQ_4!P_<(.1 MC*"?!W/'3CAK%39*'\"D5=(SY/4,I.Z1D]\@XZ4QF_X\\1ZS,DGOVJ ;]J8) MF(ZY W15-3!7F*B>U+1(T*( !%0=2CXJ3 M.^4(O [L"VSGNFIH!L<&@(YJ6%37=)V:R%8=ABUDFR^9)3,,4O:5SM5 M@,T M;B*L JH2@S&*<.44&'W.Z:N.D[#2D FC4;>@Q?$LI;DIS#NES+8/-MD M4 8#J=TDM56L:TC$Q M %;MW1+/MO #W/A!<<2B]$L);)YE.BB!@=1NDMHJ3AZ40 4\$2Y/_@)* 754 MRU89L36HFAP2W>":K3:L!-(3(@_A9.Q%<7:85+'_F/G)4Z^4PN99UP:E,)#: M35);Q+%\I*F)>U0 ME0?4*TVP>:KYH D&4KM):E\R1E&W,T:IC1@U '),XJC8!H9IJ@1JB")&@ -( M([/YV0W<^U1!+(K06'X\FL6Q/,LNCPCJ@3MYBOW4SRCTBE WX_1RLK3/E1?/ M)L^3DUJ4>+H_/;-QC1 ;%,U :C=)[8NBP=U6-+K!*6'0TAR#J4QS&.;$,IF! M3 =I2.>-S.9O\AY;7W@C,EU)Z@SQP23_6ZJ<21C/9+4T_3:<)V5*)S$J0[Y$H4C;RS51A^4Q.;YQ<.F=[^0LT>DMHJ3.[6_</;94!NC39(T M .5 ZN X]+LV!C>P3E550[8!55,H",(,0$P.L&U1[24;XQ6S^H79O:(U-ZH![W;^D'3L:D"B]B:057;YIRKN@6 ^%4%*H=: M(],IMQH46:<]C'JA&C9/*AYRI/J%ESTBM2^JH>,Y4H[FF-BVB6-@2R6(&-R$ MCC!T3: STU2;T0R_!_,KZ+Q('KQP)_,+NK+S%=?>:"8>XWOS'8G?X[1"?.9F M]$*1;%X# @9%,I#:35+[HD@ZG@,%-8Y5"FUL4:9R@^@.AIK&;%4WL6&C%QS8 MJYA-R[MSYWFR@= ;@1]&)?71!U6Q>98'5=$S_.P1J=U7%4K',YPL;&K M$S3 MU+@T=9G.F, M\8-H.M9?4.BU8B(_^X$GW(P[3W@7I<38/NB'S?,[Z(>>@6:/ M2.V^?IB3KG9;23"3#? M^JVZ_&=O6F'SA!)8J15J+FVNN[IW-4UZF< M;H#=&0S0,U%(?[[HCN8M;B(< M[FC>UT)62.@7_>I&@>\4Y_Q"OS#/]4_*^85S>?59OSF_O*BXHSM;QBVN$5M: MQEJ:RA+-FM!<:S%=$EI1D^A=/:%;W*FS.Z'[NJSZI.9J]3<=5,6"=.(:N:ZS^;G7XHJ;&'_CJ=[7*\W]+'_@M+DX_,/T+UM=.#C\7M7Y.,U?&"Z-6 M&,R>\EE\^A KMD"K<=M/]74]Y',H=L9OP,X[./)-,;@^N\^RC."I@@#DP[*W M8-FSMZ2&S\HK#LX3[,4AT5MW]/4^"F?!6)I38?3A3Z.1Y]W='6VL],)+E%CF M(;_$&#CD9!R[6JB=K#VO^/D,SI\7\(QRIP(G>45@^5 ML9ZQBM)T#T]%Y.S[US-Y".O,QH A4Z:1FXPS#DR3$&IK-C4T; !'/5$"]U&\ M>Q:?W;ON],.5]\T+9EXLW# 9^?N17,D8HV,A@,!O\!\WUHDR"_SYI[-X?**, MO9$O_+OX+R=G$F[%;'HI\,YW5/]RXO\0+N#L<1PF6<^3CY2> H)^?;],0Q'V M:6[%]LY?%?&J 3X&^#AN^"!X 1\<4(-A;-L4V% EA@8 FL,'=6S+T;>'#\A_ M@[\U Q_XE!/<:?CH]AZU&<:)C(^FMI?RD_=C-)FEUR^+S_P@<8-[7\8%W<=0 MD/SO-"WGYYY[,JA-\9B#@A$MP A"CFT+6=@A%C8PMBC5YF!D8@?8QG,PDGQV M>??7,!S'>C"^]J)O_LB+KP43[M.Z0=HI0VJ3\+1A;5MKY P"V 4!9&@A@( # M8#+#P0:QF$5T4];-G L@@ 9:L09V$<#F[ ,A@)R#/@A@DW$;M:T&Q,G'OT9A M'"O3*+SSD\'7V@\^-3I)K0 N"K0%M@GOR[8K#BK9B!8^ =<=$R,56:8T22@T M5)9)-K<))SM)=G,V"%9/N=IHC.*E+/"RY6R'Y7*L 8[L\J[@7O%^3+T@]N(/ M/7>?-NW$=H#6KM/7F[5L=#>>;'G1J.'-'-Y['WS)N%49I,/1MH+ MC;3N>5"\\*!,F]L:,DV,'6!I@)M4WA&?AGZ@18"SNA$TYRX]&%L%;]ES=;C7 MS>53Q(>]Y4$:.R>-&BR\'HL!1].I89LZ1$(L*8-ZYO50X&#V2FELS@_23K%& M.BV-+_%DVFL4S,MR2HO@,;TY4KR^Y];N)J Y7CPAL(BB.+:E800QL1VJ<<,2 MR))I=THP6,D2N_8F$T&3@)//.9L<0+5#?HI9DQL[K57A@P =@P!14$JS-!C5 M+8NJ@.@F1AK%^5:]^A]]+]Z@1>YDU0AN^-' M/_#C)$KO>A[\@L$OR&"(J0L8PH9F"OBQ+5W#3-55 K&=^04Z $A;V0V9\Y> M(7V)NPZ@S 44-;M!TCK/8)#'7LHC \7I"Z(QRV86H@XT@,F8;ND@,PL,0*V5 MA*F=Y;$YVT#((VXT:[%U\M@M3UTO94)$%\06R,&PS%1$3 M$F(31&W;P3#3])!S:R7OH5K)"MQ5AAI,)Q+*NLMU\-'[[>:#8 U/ MZ&3ESO4CY9L[F:6GFR2'B*%X02)_C?UQFB=4JCH\> _=]QY^6@]06G'@B2 + M:1:S#0.J2->99B*>*7FF,AWD "68+?PPY[GSP!$<]W?)<)=WYH+=S#*W70:O M]^QC,3'BL[6H14B3>G_C6A?,^YK%;@H"7G)B<9#I8Y7I]2+-"Y%6=8<;P+$) MLVQ@J,S2F9V?8=0M&SDN_7*SCJZL%.#DO1!-OD#D0:9HP)&,+4XOG^/[>0 MKBVA4HF_KLKG(*GJJ@%T<\!U'L@RCB(BA!.#2HIE$, M+ <#H!%97GYN\YO"ZH<-B6)SM@$Y):A1\Z"MHMB3T]8W8>).E'#E"-/@SPR' M-YO NE)!%XL2G5@0:P:CC-@< CL_5(!-!_'G =C%N;IL/W2_^Q;\%)!#UG$Y MLB.<@_"W3?C;(=^E>C'<9-C0+*0)$;Z]'A2>@MX;^/%21Y@'C:CCSOM M=I,5QXOM9@0AMHB-N:99PG93=8IS*PYJ)EJQXG)6.<"Q-$*;#/D.CM8@90>5 M,EA.ZC =3;>$D"&5J186_]/RPV>:P=G*F?2-4M9<[)4W6O7V>*2L)^GO)D.].1PP&TF*5A@SH.P#RO>&5 :M"5P(]D MP8LP")<#0$U9$-O$@/@A0[I#=OR T>+ QM@@!8P8#!H$!OID')&@84M2Z=Y M_-=AHW;MA;[D-27&I79.':8> 1:^WF2$ORG\!9$%#MPQH M:9Q S$V39^6_A,M%R$I XVT-$Y4>\F:"[A@@@^!V?[,9P4*J,=%5C&VHFJ9! M5*@ZG(-]AR9J#U4CUL.+=DPUGF02AW4?B85228R:RYC'?#(%9N M/<%H7A[!2=P?XI/ &ZY?>SF<=B[)?Q..XE*UKE@4"/ESWF_&_>'%W_V@U ,]BF/8>O!>/DI]A\ST?S9 M2QY"T?)-=)$5T ^3W =/,8>MK830/E >$&5 E I$40M$,0Q&,50YM4W3HY5BZ M8^H:-&VL84ZIC8A*Y94PIFXAS5X)AB_0+7-+C3FS',8&@K27._Z#V'5"[# H MGVJD&J)4,S'@#&"'Z]KB\B75HN#%8K<'0P&>HD9/%AV/X/6D6L.%EZ3''==$ M>_NU%X=B-'R1?, 31+X=,5#S*6E:#F'=? MS$M%NDW=%)\3W;8-J .$,#2M3,RAQ<"&[:5&Q;RYA&3U%#5[P==12GK/PD*# MR_=2AL:"9\?A3$CIZY"OG44=_[R/^=G(.6W7$!O<8H(*2Q!:0D7(_QH6$]:@ MHR%32_?>+%WES%HYCR8$\L EQ1H/A;UZ^8_<11Z LQ7 V3]L; O\D0+^A'%, M@ XU1B!4$70XH#G\(=.F]H[PMX< (*'[J[^V=_ [EA!@6PW@NI1WX8TI\8,; M>30>?'LM7\N?S!)OW$\W[O# ?ISX?40P38LC)(9IJ9I#J64Z MD$%@#QP-.#3AU?#A5.F%J48,22\.$8&X0 MFT%&LPO\# =;<$.^XXMPJCL&Y?'@5$^K(&59XN5-H9ID\2'J\+(]ABY/0F\) M'U:_6W[V2W>8CGT5!^OU&*W7]<8K54LY2L#@.I9'%U7&,;>)K6-JFP[5=4W5 M^$HLM#)O?XO4_CRS?R][1NO];G!(>W8XG3, T0!$VP*15APGPH[&H$:PK-7D MF(A;D*(,B##&ULHEU'L&HI=YV.L=Z_W=== F(.I)RM'+-UXZ:_$/6^W]V&K? M .J\J(L!N*,2B'3',BBAMN4X#(A_ &8$8(>MY!PU .K[V.!ID7W9OCML!K@; MX*['<*=!;0%W%'"@4E5#EI,>A->H;G X9UK([M/;$[1Y.^@Q6:"^MT T)21HKO&[(5*0Z%@0V%0ZO;5JF;6;G MSCG3\(K7;;M1(*B*<\,PE;$N)T=V((M]P+L![_J,=PR4HHQ(I;E,;:808!*#\PE%@ KY2+2+7JOII7O4ZN,.J$7/4DNV,X5/$JQ&ET$EH"1;2HVP<-:JJ44=-1$:80JBKG M64$HHCHZW!**RBFS940Z-B7?OMS804A[*J1,70BI#AUL0%/%FLVX;ME"9',[ M7%>AOG*.\]5"VFZ+H7U"FIH2[].K]1:?IS]+PYGX@7?V,(]"0@3^8XD5(16, M5QKPR!,+$C4QY)L'3W%'H_!1?/%)O$X)PL2+%9F)+I[DB]?<1^Y$F;I1>BEM M\N#%GN2']-XC5X9([_S #4:^Z"08)O$>Q=#B=\N3D/Z8S\USLE>).ED_+0W0 MC)\M4?KS(>[7,_=.C.B#._GN/L7B3>\?HHP8-Q7'V&: 6ERH M1A50E1B,4X8IH4S'CJFKCB._XR[-PG:DL3EE[G9DI;V5AT@*XI]B QF:06V. M@%#1#%$#6-BTN*E1;&J69>\T8_.!W$C.E"<8>*]>SV]@?^V[D>_$*L[ZI3%8085Y>7%]^ M.K?T&]M2KF_$/Y_MBYMKY=)1S,O/7Z[LO]D7U^=_MY5/E]?7RO;D'&;T/\T" M=S;V!5;\W+JA^8& M' 6"Y:()8./P\G$C>(=!EIZ"=IY6*C6QMD- DN]ETP: MD+.H'PA[;/YW^7&!5,N39;8&51^)&=^&GL?\E]^>:Z@3Q;N^,+P MXR?USOK\11KZCU].5@R'>1M\6=,+O[;/EVV.570G&-AU^A;,K;W!A=BU)O(* M"+-=2<],"6&F>'/R/XNFAWC^NRWPJ2H&-3!V=^C;?AMX#XR]0V2U*5;79_?S MZ<#P5)%.\[#L+5CVE]W?NR^>8$/.56Z+#U?#'P8>CNQ@U1&?FZ*<<^BII8R) M'M[.?OSGH ;T&=#G>-&'H/Y>CG[\V-.MU-#+1#0H:G)=ZK< M>H(K/"5Q?WP8O*2NT]IU^GJSEDUZJFI;7=63C[\'D2>>^&]OK-R[?J ('?OH M1E^]^19)[(UFXFLK^XB]MQU[F9XSM[HHX NKR[9UB#C4*7 TAU#3X,C.[BK3 M#+[J\Z5*TBSKR+D15G#AW\*)I/JO@A>E97897"]84(_\6#19XL_@_HL8?S@V M4M5ZX_YXM?]8-MS^[47AV(T?) LP!-$OG4[@&<2XGV*,2A5OL&4ZMHT)M%4A MRI@0+;O!6KM!'MYNWE2+S1)'\(-XGB*8)O*"T9.2 M1&X03])RQ7TO([L1JPZY=W[0@ ]5BPM>-&Z; ,(;&!S@U)AA&39^[JA88-L MBUEI9>PYMYD9L]U(7IN_7P_&-P7GZ>-_S>)$9H$V9WAL%;A6]U?"H9X_VA]! M&J2^%U)?NM9))4*^J8%U2+DC? U#93B3>MU!<"7,>S"IWT/ &*+]79U\S%+? MD\.+VP24!W>N1^[N8$:DKD3=+CEDFH^(GWF)Y6 M"BO,'S_]ZN (=M817(][I#@63I!C !WI%H,:Q"HT!?IE%HYE &LGW%N/>/!X MMI8V+'QK=Y@&Z>R"=-*B3*X*#(=CW20&-"W,;08=EDDGMBR\D_^QLW2^8L>H ME]+9^W!*X,W+/PSAE'V!6A>=,%8X89QI%G(LT^%$LW4#&IIJ+H+2<+>@].(N MUFY%6U[+(.UWT@:@&("B"BA8*5W.5)%I&D@U$./ !,Q6'2.SBRC2S*W3Y5X, M%*T/UG0?)[I]X?--F+B3YJVL#F#D#GP_7 QS%,!.0'$O#+8,J*NZY2"*54@A M,WCN\#KP6FYWA^H).P!-'A5IB>YA0='HI>5ICBV''J950?%L1H&<2( MBKEFZ38SF+]&'G39'X7H2+ W&UX[*7O M+QFP+:PB^^A&]WXP'YX[2\+\@[GAD7Z2%4D%X'4E9ME)?5 J*S%+7U3:E1^R MC"P8RLBVNRQAK9T[5*,[0VI,\1=.-']*(S$C^XOTQ\[^YDZ48TW[9 M^]653?BNA/.7;](5F?IJO 1HAKIK.HE@$K+K%_(:A _AMI %00 MT@2J'.20=\L/6QR+K:*/1F)RDUB)O)$GV.5VXBT2_=R)P"LW&'EIG/_/\)1@ MDMHUXE<.J/A*//7$ G_S)D^OS"K>:W+P'B65P:*:E6-R0@U*NNW-ZV/T:E*0(/RV5KEW@$=WG7IH:#(7-(=2+BM M8I,A&S-;M[B592Z9B'%+?YWT-*3>"#Y5-:T+TM,33_P\^";X(5S-B#B2(B1[ ME#U4R)X-J(61K3/54G5LVQ0#.Z] XC"D/I>]?%:?A,CM35,1]528NYVV)/OL MG_97\'!QF(PXD$-H4H-C"T#5$+HN+]K,3;9ZX\UZP6M*R8%3H TNW/&X<%\B M;^KZX[P43YRZ:&GMG6,N=+%'"50+"529XQ@:9!P3&ZNZ(1PW/3<[#6"NQ&RS MN;;G4ZT'X_1\YWRK?M^^&SGEN%&%V-9R%H-KUWT9U(JK"PBPL69@W0%(WO8& M'*'*,AE4'=U>*0/^(AEL2CF> M#H)01ME<&>W)V4'7;>)>&B=P8K+T256LPR MA:"J!'(3<0,2F%6%TE5".%Z)TAQ$,4)*3[':9%RF?2;KX"OV4/0TJ)7*Q*HZ M<+!F0J$3N"?3I7I MQ)4J3_B*,D-I*@]:ICM__=R+T' A:@ZS,:(.019#NF8 ;*)?F< M?I$S*NQ1.Y_/?<9'D7J*,>G"7L3@[AV_]*A%QHI#. -$ P0@2I&E"M,P4U0F MUS3P2NEI*E&%G"*5=4%Z^G Z)B_].?AG5;*G%;)'#15B;E(34 Y40""R\IK: MV(2D^D:UN:5X$0:C/?MI7'AIW385!R^MCP+(BZ+V5$=$,[%%3$QMBS*'ZVI> MU-ZFSDJ 9$L!;,I;.V6XT0O)6B> G?+5SH/$#>Y]6:)@KOEZ[)\Q6 B9#C3. MH,U,VU*!;E*^*-9L0 >CE5RQ8AXS2?,2^\=H,I-D_C4,Q]_]R61_P4D"3ZG: MI-2U5KOU28D=JQCAXHH'9FC8$3X98#K%G #BD.QH@6$0#:T4BWN9DNB!1 M3S$;<<;JJ($&+9F$%#90Q"DE=SU,#JB8*]ZS), MM%-*]U=U=H?E;:T2'%R\/DJM5JA5@(@04(*$5I?9%?V/JLE771T!V6[\"EZ@]Y#/B0A>KW""ZE:Z%-@XB/!=PPC#2D.1K5 MLJU)DP*$5RY-G%OJ>S,(* >GF#:Y"[EQS5JK^#N@WP?4Z YJ<%C*L*4(<:BJ M0/@0&M,M2&!^NQFE0#6V18V&#!*&Z2G!3>Z^MAEX3 MKP=F96_6LB=5%18U@Z;NDZR\,50@ZUH%,@A*Y2& AB&Q"54AU '3 '8<*]N& M(%K%^;R;Z9;92\$?T0S;[R#*]'1G!X(U&+W$9E8MS& M@ " = @TKJ,\9X @9_68X'P62_&:?>MK(6B4-WF&OK5JN0/:M_NRH^%"=H"M M4I-JQ 2,0,>!4,V2MW4'D]7;4W>0G::V\MDI;C1PWG)==/2N$SKA)$Z.'@=D"RUN*+!L4P;88YMW7!4:A&L(IQ7&J187SDXV*1D M-5: D#9ZA+?E&N[H'JKA1BMH']UYB\%_'&2X0H9YD54@C%FB,]/$4+,0 M0 M;4D110;-JQU:W%HY97Q /4JT4Z@U63&JM?JP3VKO:(4&E>Z-D!6P(8#(839! M)C.!D5]7QI#XPDN$IJG@*#[%H!-"TX>S,RMFP43@X>L-&X=;21XO# MI2K@AL$Q)08G0-.1R?,R4B;D&*TXM, Q;33>'F48KRZ@DV4O65M-"&Y:NIH@NG3&UR M3Z+EZN[8O4++N_,$0XP5/QB%CYZ2N#^&.ZQ7I!25I)01S"C7'=N"7(<.H69> MS11IU%R1TGR"S]/YO9'3FU\E6 K6'$+QD5-,NVVA#DYB+Z63:*6;KHE.#(>) M?Z&J&]BQK+PHHHXU!)N7SL;J#I^JI-N75G3*?YSGVQ1G+ Z7<7.T8DH+,15N M)6,$(,20@4WB:%C/*PX[NN6L7$C_!NH2G[)F<[_;>@/OX$;V0/98<7>387/3 M 9J*':X!#+BID7Q+$9N(K]0-?@-EJ*)#9K6U7"%VY.[K(27UQ=(KY',AO1Q2 M:D =&UC'-A$2MSBKJ#O^P ^8>4 M:E32'=Q;G(D2^O^=!$FG@+5GUM8>+'Q EI;"2]12_NB MD-BFPXEI,6Q1 $T$\JK7EDY7[F(L3;4>C,WR1&^GHG_$_H? GPC2HYE7*\UA M^BAAI7^L%>'!(^P1Q]*B>!,5[&L;"!*H:@XS$-9Y7B(-8$A6SB?NQ+%5ZF?? M'-N'O;KTS^4JQ]=#M?-=A+ZWA ^KWZTZ%U^B?-<^O>_@5)FZD?+-G47SI(X M$;\(FGJ:E*.6/#,-4$=G&M(A9)1HM@T)RT\M,7OU\M+%TJ38_'>Y)L>1\MW: MT,FQ0T\O)(84QJ6LF89TH!FJ RBW50N;3B8QED7L%7=H*XEIXV';E@<>CKZD MA?0ZPF"SBM/6ZCA9RE+EITQ34^V&M5/.R"EFJ$+UI8U+?2E*^-+4$XSVS9MLLLQ[E[>CECQ2VZ#4)"K3N&DA M+GQ5I&L9:!C07*V8,^>-?>C8YVD 6J,1T&'CXAC5FH34U"J^.V8C@.XB@W('4MG" ,]"[@BF^LK^WO%9'X1F/.9+(G> MWA2>JJJG6J/;?JW5;7U284/1R">BZ)I%0ZV!1JC /= M8M#A#C8 @'GI8$MX<2MG\?/)M;.YU4>CV>-LXB;>V/+N_)&_QQJ)ZBGDC=X< MWSI#BF/M"A4BG0,+!TXPH.S#)7;G-JY?66%O!)F"SU)B;!:30TXNE5< M>@& 4*K/Y35?@P,$/(7W!YM4EZL<^YH%:R9?JB:-<7 6CUW&-%#(& 6F QDW MB,8@0]R&6EZNQF",HY5]R&UDK"GOL*&\+G_X.(V\!R^(A0I4 M)F$\G(':6;11$4[5F*4QQR&84P,3%1CJ0GW:AKTJVJ4%24\SFN7EF!_]_R36 MY,)++N]NW!^OTZVQF!GQV?K3_JI*=!6SC6_&A1V,0:V P7<:&&ZSH-"%^\.**?TIREKVB^*O4UB M?U]+&VBE+"+3X:8E+ 5A&! "'$R!K>4FOT/XBEU0GNSY).\O# W)*6@VEZBM M90T&3WJ_4M?ZD\U:*;N(V"I3-<0QT[EJ 8:%5.8[10"O:N5M1+*I2+0020:; MO.1NH\8]XG/,'2E#4CHYG\:IEX_0K=.T.ZP\%HL[#F>W$^]U@O[:G8T7ROB? M]S$!&_FGY78&*U7JM;&A8U7\%YN$F0X JI8GHC@"U];=RJ('XT-:'1R<8MKH M[O>+U[FU]DB78P M+8\V_3$G(O^[8KI&XIM>]&PZ)W[@G3W,"R5 !/ZCB?E4G\UE^O,ARI\Q=>^] ML]O(<[^>N7=B1!_O\09<2XJ83%)C!-U334_Y^]-V]N6T?VAK\* MRW/G/CE52@8 0+(>6>JN,[U\R1Q)O:Y4_/7%"W1-N?(HH:4DG@^_=L 29%: M;,LR)6O!77(LB0N [O[U@D:W)+Y@#@\\ATF7$]>F'K)9&*I[XKE56&]JHIQ9 MO-ZT]-767:ZD[0^%1SSN.:$D2)W!(HZ' ML/I,\=V^=!$+YHQ5 78 ^G M_H\5?;KX^^7ZL]C-H-]-1_%TD )$_+)W0TM'@&39M !.*!1?#[+A,,Z+%PQT M>5BMJ^=,+52S23H"&['\W'[<2*G X3QKH=+4U-!N]9/AL/KUSV?H3'^&8?;K MSRN6XBJ]!Q#_DORPOF7W\9)A^B,=3.[@3YA'I=GZ:@'&1?*Q_N/713UV-@LK MS.)EXNSQH$/Y"L[^^.O9DG:N7O_$3VBSV[;YLN<#*T<8$>7[M ^Q! CBI5.O MM!EHRL3Z#-_>%58(0CG8*(YVA.1^MJ+0%LC]@N!A5PS@3F_+Y:AS6D]\WV,_ MR+Z9C[4MGA"F,-W,^HR+.TOQ96'=Y-F]E8UU)S)5-4-E@>O0P$=3J\Q4JC/4 M/^[#(U^2R1/IKKM+0N]J/IL$DKO R*8*E7N= Z"9G;B' &Y3[6?^X"KI-ER.\R\W[K6:];4RW$SVJ M8I!AOY"AE63'J4N1B[F@&#."(XF<&AF('SI+51B>008L_X;_UBTR='N^]'!P MX52.UPS^-2VJ5@63S,H38*E^.DQTYW9E;*AOU=]]Y86,\^Q[.D@&UO6#<4., M&V+&J-_=82;U./856$_*AK(!GOX33%D,N9&+I$'9.0W+41\CW/\1W; MJ\20"U"6FXIA=]J0]##KM,?[WHGA<;EQ_ET\NDVL=&3=Q&G=#B*[:9I53G2> M<3K089ZC]NR>CMVTO1HOUD;:SS4-IE_G\AQ/,-1[B80CBDW+(<2.'S(VD MAZ*0BB!$'A.!*ZH>S[[M!DU?I"[DL#L5B;NL2++G:O#@O<6@;@N8Z@TW:Q+_ M7#RJ)LR0#O5E<;9/%)!9HT@8]5?T/8X8K!6V/6H M&]1!']NG>"DMX<6"O(5$!;P3Y_-PY/A8O55U6G:JTA7RI)^DW_41K7@(&!&/ M^J]6T KB*ECDJR*)*)E=Z/XS0O4__4!8.T&&<% ML-$IVL9/"W@KN8<19$>>3Y$JC4DBGX0D* 5 M#%Q%@.(J\Y) +WHRN+C9YA9IIVD*^[SVW[_# MFY+WVTB_92)VR*S=1JAV4;>JL3FM['OZ&B?$BCU5NGQ9;TH@M]B0! MKU(XU \RWP[])E4 MISNE[02R/B =2.(NU< 'U:KZ"2=!4O[W?%2O^+?9@N\F61#W*#=GS8P5?(CB M^8SW*D6K*A'WN(>8:XN $.ISX7MU$@.Q)>Y&/CL\B.UTVNKS\%W9#4SG/5:O MYZ/OR6B2+;<*.*J0[M/BB5'K] OW"$,A_!M($0J7!MRO@KJ>'R)G*<]^63Y; M2[K=$B/89/8=O1-SS%+7/MWB.,P7OL-81'C@NS*J4PP\2DF$7BEUW:E#[N"3 ME+D3\3:_YLDX3@=64H8:R_!19O9D5@MPNY2)QR,:*1GV AX%/F9>?6A4$!LM MI1(L"W"U]/5QERK8ZXX&S;;I5O4IIXXQ=(VW:N0:HU:. PG5Z6^7N+[DMJL: MO^%ZLY43+OUMR76'!\-[!)GC:T?LPLXBQ./X045#>NH86SZM4O/+U+_6#M!K M!7Z7;:%V*_?@!SPPE)[4?50IIP+T>;U;ZW)/+M5$>CQ,];6DBJH=6)*E MU75U1Z?0>X[=I:>\+@OL/Q 83_HT!+MUQL9CR*441-UE$2(^DK[C5@K==0A; MP]/>3+"W<2K=[E'2Z>F;HQ'L$ZFP_Z4NGC\M=#&9E87SMXP+Q^@!8$J:T)Q' M0S<4?H!<0B(7_HRJ4[>^='Q[Z5 >T$1U5?M:M3/P'GXK5/&*BYHR[HPP.]'^ M3H_9G>XJOY8=]A\\C.-O8&$U+#@-+#@NMYG/:1BYD@:1#&3 *SO"V0A8TO>$--WT*+9Y)+%/<82$ M# G&I(H;^(SZ:*ELW=?X09<_N5YPB3B_IJ MDWR/=;5BK4*K:U6THRFJ=<*IJ?#?)L3ZFB'$X;!4H^TB'+W3-B)QJQPS:)B.\)1!W&L3K#3"M=Z2/L MR:5Z QN(G2GV<9+.J8XYZ7Q3H*@5-^K/E(EAQSP4 M4;NR7DF PN=]46]:I*,$A+'XDDPN;A0=JE\&G>K$TZI)9SS+8Q7-9XQ4F[2, M5,=UD&-'H#(I"23VW;#>+A;(\9XW4E\DF]WYEC;O(9,G>LSNY5*RR*HMGCU, M(JN>J:Y8?N"^( !MM#.CKAUB%D5.%$@_D*[OR/J$,Q5DW9WA\YHZ.TX8P3U& M.PT9;R.I;#.>,'[O?N2&'"T*. T*@R9ZEH]&M0 M8 OY(6 .=!QM/@T8Z-1SWU-38HWLD9MT%(_ZW6:/'+/[=+(3-]0_+B?C6S(N M'5JU@S7,U/B2_!Y4T?5K$TP..#Y 25/_R,78I=*/$/:HAP+;P?5!<4^"8;!4 M-'NVH$793.(*EC. U=SJWI5->JS38,#A^/S&CC\.D:.-R(6(!B%R"=CG3#@1 MP31TZ_XMB 1LUZSE=V,:][-B4EC NIWJR6,,L%.G*944 MADXD(A!;G_MA2*CKUN$UW_.%6"KP^74FRTJ&SXMBJIJY^FKMMUM.Q>1=&B_G M)(3W&=D5+=EECFN#M+K2X])U!5,M3*L:^") CZ:2K"6[>YI$LG_[U,?E<7YM M_,U6!HF5)\-XD@PTE\"(U!7P9Y$.]'D[N.!T;6.&&HE$C@1M"I*(0*=&''F- M-J61VZ22Q*/;K!;'BQM_MJA^>TVW>Y*!H-/L)FP\TN.0.M)(GO.+24]?*)QH!-Q2[_F&0QX4%COLNED&#\4OY0;.,G/ M).^G1:+4:C')^K];V;@\1Z@/#=Z/A]E#DE0_C:=Y_RZ&B]6Q0E-7X.70P)J" M@XZM#B7AB :$2Q10RA"O]XVC$"_5)ZH)& '5:@/YXN;R+LZ3XK<1+.4Y? &X M\5T5*M)?>T"I@9_=JSJ$&D#4&:8"+AM.U?I<*I)>E,3>4<*)W6WBV?&7(C"^ M]&GZTHRW*@Z'-' YLTG(&'6%'5'7FT6UN;_43V['0-%AR7%D>M$=CCN^E&6Z M*A5D#_/+]L44D(V$^Y+A*/1I,MNDK4'=R(NNN'%)-02,Y9$$D?!-RO3XU02M;-%EU+U+?1+;;G MT$Z5M$D6?6F,88\+E(5(7XU?QA6V9#H.HVZ6JB_PFBRP6(OA-U8 -3N2=GE4;3#D5H3)C@.>90M><3( MQ6[D"4=&JIIHP*BL52^SY5(R^NOD<0NJE\J>W:GV/1QQ/)&< /\QC6K%$^LZ MN4U'(Q7.!W]^K-G0&.,OWZ!A$L.&:^ M'=@\LJET650=\Q288;GD86\JU:(3J>:T!TASTD)]7+OP3ZKP1+4%?5IYOX"X M-A!WD$VOA\EV]M^[6I+_VN9,]Q^;6',>UI$.!?\C\IB,$ ?OPV&XRBOP([S< MTWA#;%*Q@ ZP2=A@<&POBV %4??6L#@"^\$ R[$!"^?-;J,+WX:V4&>'?(>2 M*'*J;06/!=Q9VFWR6N]@E8GC=N]L%UN2M+2A$$5^[*C=GK MLD,[7!"S"(8K.O"(]M0ATA_G*]9=3L?C8:(.UL5#:Y 6_6%63'-]W@FTP7OM M-[4*Y(X&6ZEI=^P6W1',[V1H>5!& N9&'>Q\0.@ (N@/]55O ;37%D"D[MD\SCJT40S#B98(4GK=)6@ M!/GP_YA(3#R/VCRJF^@(WQ%+1RZRD3(*+_*O<3ZI/K0Z]GU)U)?WV2B9Q/E# MV>BJ[MOQ*8VOTZ$V&.&'Z7TRP-LLE4(Y/X8F6"=@6QIXV"]XL)L2+8)Q&KI> MX*JCU9$=(C+K]TP\=SEOJ,+8URB9@.\0Y?*VZ[DR2 MVQP,BS$PB@HW@ U1)+HXF=HBUT7+JE #7%1,X M= ^_#_"+H?\JU69SV\J3. MGEZ6#N;L+)!(_WN7U\\8Q[?)^^L\B7]_']_ B#[&PQ_Q0P%O^M-=7DTFUM)8 M4$D\)T2.@YR(!2$3-%2)%!)3UY,\9.J>>&X5UIN:*&<6KS%^D@C?.E$_YO+9,K)N%??+F\ M^'0>N%=A8%U>P7\^AU^N+JV+"#Y=^/_O?RX^!>&W2UT/DO]JA7_[[?SJ'^O/ M:C>3>#<=Q5/P39+!+WLWM'0$R)9-"^",0O'Y(!L.XQSX)?G93\83JU E1BS MN_AMQ[Y2Q:R)EN3%;R2/VH0O ^C6U7-V(JH%*!V!_5I^;C]NI.R"X;S0H=( MT[K4ZB?#8?7KG\_0F?X,P^S7GU=,\RJ]!_7V)?EA?TKUAA7"0?ZS]^730CSF4[R#LC[^>+1DN]?N?^*WKG^@. MW^7L\%U/K6_7/\FN'RB.=*'X6G>M'=T_ K=ZAAG./A426E)8XJ53+V_PLWOP M(RU=?NLTPR;M$'R>_>@F(7W+&]E=4=^%-RJ?/1X^:CYLX:VZ27LZVN4KJ_C[ M:@Y8F^J&VP^:V[\EDQBLUX&5Q+DZ=/;(H6[# L?+ FZ_/[V?ZF+^NX2?; +? M[Q3OLOMQGMPEHR+]GNSRQ<.L.'6Q.DH[\4J="9_F#\92-,E;QS/1;9>,> ,- M5]9@-@)Z#+1T[[/IZ)$6?L=.2S._PYZ?P=4CI*7!54/+/:/E5;8ZKM=I>:5M MYQC+E\Y=KMXG]^*AZL2AZC)\CA\L&_SUU@GXW110WVB1GLG5X[84*.$. M:TJJ(4&(1P1A+F@6JRMIBJ5^H%U0,E&:PNE/3/ZM)_7M;I5^I\ M\N1!-4/)1OJ0\L^TF%U5[LAH-_MS1[ D41E=*1/$ 2/E7@87O46PK9U[EL&D0NJY!Z!^@Q]]R.8_>H!RMO0,* MA+&FC#6U$A!Y4Y/=E8R'KB^B*/"9:PNO 41?!G)7@?ZG\?#5=A/K<=QIXT8# MB082#20>$B0^C8BR040:,K 8B;0%8&. A!W93NU?(IL'FR)B%Y$O3'L"=]KP M_K!"7_M8&GI#KOR23*P=GH#:NI!M&*SBR_6AQ:AC*,)1A*,-0Q\=0 M:[C:TFGV9045OI#<]AW!*8LBZ=O$B9#-'">R;=]>JNR93,I]A$]@)CQ:MW>G MN[+K[5$0WJ6)NI%+O8=>LQ%7@_\&_XV;8YC(H))A*,-0;VB58F0W9BD.?$;4 M_WJ!$,2../&Y$_HN#EPF1>!L9I8:B_+U%N7QGTL]^TOX,\G[::$KDA3>*BG:[$'NQ*8,2:$UD181S;5$8"A%.(P M;?CH+!\V58M9GC4- M=,^@K[I=4)G#HG^\*!>ZIL#BD=2-7N[CFO7U0J*952ET#_YZM_A,-9\F=U8>5),\K2O M^@:7.S>**XXFGWT=:92--%+;]2."71)%,B1(AHY-J^0^(BA;2NY[>GM&_>O% M((,J0I.,"KWFSX=WW!]Q/KAZ&"<+*7\UG?1+?U-4^G;Y6QG.V8N]'2)X#PE^ M#.W!37K$GLNUR;M3]E?"!S0&*=>7^=YOT[ MX,A"A=S[.OPZ"[O]P7T(QMMV$V*ACA^@@&,OE"$6CHT1( MZX6AK'/^PTC*U;W/.G,IC1MX2GG_FB_>7ZO-,+7O,-L-,YD0^XG^IP3RAJ$, M0QT_0ZUA'##4%(^2"#E@#R"72RXP13:15?$H;@M?+AT(= ?_FA83%1DNKK)' MXK]Z"_1Z,2'B6_+O:5JDD^0RR;^G_:2T*KXE_>QVI)^B#8Q#"4WCGA1=-@ZMYS(Z>X6W#VX:W#6\;WC:\;7C; M\+;A[35ZP7<]0.)0XY)Y-, !W4GBRBRZ5()*^WT^&V?I^D@]R69 M7-Q #^? MJ,HTO&UX^Z"3SI\Q][C=[*>XA(>>[;LR$EYD"UPZFN1T_>E'HE]VG0T'\ 0O'JKR]%8\L=SI[;286#;N601AN:,-WPK9 MU17+L+X/.Z2\=8Y$.@@% >74Q2)R);<)C4J)=FT)%F0W/-2 MBY(TM>C:3/=%IM_#-"/O6:OD(M.^>B&@W>/Q?KYCC0:,.;^P(E9E.(NGY M+O$"&3(OI&Z%.IR[?'7E\SO ]R0O2C39.O9LFH9A<]M CH$< SG[ #FMMCP. M)IY GLU#28D?\-"/<.6ZV$[$T(X@9]M'6!AC/4X,!!D(,A"T#Q D< -!KN\Q M(5#DV)[T0B1XB/PJ&U4P*:(=0="W9!*GHV00QOD(EK/HKK(;ZV'990JJ@1X# M/09Z-H[<"INVS!\4!,*7+O*P4&GQ+K$K['&IOYP)ORWSYTWVY'L,=6D1;13E M?4L).-&N47N"8CL5>=I4G67"=6R'^2[\-V0,84Y$Y?%P'')G4>2O\B0NIOF# M%OW+*O3:@#5 MT1DOXF()J[9DGCP-5:\V1%B/XR[](X-7!J\,7NTJDB,;N/(CZ0< 5=26E*+( M=A#84U4D)Z)R=8_W->"JBR ,ICUT GM0.H7E3Y/X>IC,OM?_MH8S3$?)^[LR M.P03],>I-[96I _J)LG-&,P8S!C,&,P8S!C,&,P8S!C,&,P8S!C,&,P8 MS!C,&,P8#GT,]=>+8UH>PMG38^Y@A'PA"$4YP'B]T>FKK;MTA_GSZ^YH]LT M"QY&<%^_Z%GGH_X'*QX-K,OI=9$.TCA/DV)]OF]'WK$S_KFC2?@77RXO/IT' M[E486)=7\)_/X9>K2^LB@D\7_O_[GXM/0?CM\K__( CFOUKAWWX[O_J']5X' MQ=/1-!F\J62OF-"[Z2B>#M)),OAE[X:6CJS)738M@$L*Q?.#;#B,<^"=Y&<_ M&4\LG6)A#>))_+9CWPIHM^Z?VTE#-:^GHP'?E Y4:AWE2P M^LEP6/VJ,U'49QAXO_Z\8MY7Z7U26%^2']:W[#Y>VE:\C_/;=%0.+YY.LOJ+ M6;JETRH72Y@O7CKU\H;RF*>E-^%/,P&E40EG5I[]*/]^;9F>+9>'Z(KZ MS8F[1PV/+;QU',-*I:-=OK)?'B5WVXRTJJTUW6NT%RD_;3 MR8GFWITR,[1.V^P2B#)ULF>GR-<^1;3+%ZM^#2B6C \AB;$>!3H+5[GTU'D].DM9G?8<_/X/()TMK@LJ'UD='Z*EL=@5RO MX/ A-W18Y+VJ+2[7(;]/*)XR@7S.P?V M[=)^AV>AGZ7Z_HHN,C)K9+8+F3TRL=RVY#%J][A#NIR5$3 C8$; 9@+6PV23 M]B!&O(QX&?%Z=C[O).M4>2WSW6LF:;I;[EP8CR>>\6Y6A?*-V?O0RKJ=+.^; MX,5;4;C90;*3=2?JQ2SBCI, M^1D5O[\J_OAS:\_^$OY,\GY:Z))NA3J3:65C5=1ADR,$G:[$MGF7XYYM.R8U MX53P\Z"8$QN^-'RYAWSIH,6ZIX8S#Y8SGSTY=<2+<+(3-]0WU-^U5MJS13C9 MB1O9-]0_/HNTTV._)F_D]20Y+XJI.I[])U_].QS&NN=K=F/E23')T_XD&52A M)M63=5>U*K;NLE/9HW23@-+>>D''!'IFJ^3@YW?H6R6;'&4XE*V24V(_ R4' M/S]#R^.9G\EL.9[Y&;D\GOD9=TMID;[R>+%^G>?\N+A+=\+Y?-OBMLS4&26Z%EU^_'DG*!D4]1C=) M:-_;R,1XYF?D M\GCF=^#FUT&YAJ>0TJ&;QK^_CHM$\=;].!D5.JMCG\)F>R:")SMQ$S(WU#^V MD#GI8=9I0XR]#1:TPMYJA>-/E="? M?B3Z9=?9< !/\.*AKG@13RQW>CLM)I:->Q9!N-/ZJ9NLS9LV)K9Y3SBXAS9* M]CFPWL2G''SM'()-3_&W%]U-E)2162.S1F;?2F89=7H.[K0,E9%;([=&;K=] M5+KG;%00T4BMD5HCM6\EM>_ L:5T&S-^48CG+>F]R:[ R4KY\81UWMD<]>!% MAO<-[QL-=\0:CO4X-AK.2+F1\B.6$, MTU'R_J[P7I[T\J;.M$V)Q,U;_>Y?7SQC'M\G[ZSR)?W\?W\"(/L;#'_%# M 6_ZTUU>32:VTL&?SPHGX)[GVTPBSV',<05B ;>6X7UIB;* MF<7K34M?;=WER,3CGA-*@GS*!'$\%-A^('WNV#X/@O!%*U8.Y$K) MBB*_#S\H^LX6,%Z2H,<(O33;+;#SBAUY=W2;9L'#".[K%SWK?-3_ (P]L"ZG MUT4Z2.,\38K]DLD5D_AR<15>6E<7EG_QY?+BTWG@7H6!%9U_<;_XY^XGZ_(* MOO@X1+%GD^ M]DA %Z5H??)L8TKX@V7]?^G/CZ-L]&5Z#S?U%1ZJY?RF!# *""+H;_@?5\&9 M!6P'[YD6[V_C>/SQ(K^-1^E_=#4-?P:A\,$=#;[F *RCB?YX<1/5F'HY@]0@ M+?K#K)CFR16\RAMF_=_/]/*ICY?),.FK6]\'+)1(,% M#O8X?X_>__C]?13W)^]1Y+B<8LD09M+&PF>>5U[J20"-\$S/*QU-DX$[>?%[ M\)F5%/UXK# ^GR9G?UF#=^=6=4%5PF_5<,H>,QM,'3^C6MKL(VKA3D=@3D\^ MVJ0+=BKUK=]6GW7*T.5=DDRL6%>$K6?^XJ>724>EX5YE'LF-']93VGY^L T[ MJF%>C)-<$P. ]8G+_+GC49_T\:BG+H^+.RL"5P8N4TC]S"!TN9H[$,TD+W2U M8_ZK%?Y[FDX>K)LLUW=OO (3T*G)QG=;]_#-76$EP$&#/:&I7M&-[VXGLFW M3G3JQ!!M8VV-Q@:O>'TP%8W<.A-9AA?6'E"3!SM53*4)\J M#+R%%80;TO$0KKA-1B"'PZ'^/1FKUZ4CS?B_C=*9P.@%J@?7T&.+!OX#MRH&^4W-)"_UBN'2D&GL-863]:9ZK[UK7_F*- MDGY2%''^8$VR'0+ TRK(M@+TIR4TJR8 M9/ZD):Q =I_T5,OSZ;!$@VP&2>7U"DM46*2H.$9]6<,"7)IF@_T2SW?U !4) MR@$62EJ4;0 V5$N$[N-!LNQFO;ENFXFP]AWS]'X-.3 XO4\X/4.B214:F%:: M]C%7*H6??X#,@H1G/T:PA$7+M^JI''UMH7U/A@^E2:$$FZ!?_3+HH#_A7\&J M=H'G-==4X0CKNL3\4I8G>3PJXGXIW(T<),/T'IA**8W]DH:+D05JIDX E[4U M5J8ON*RR21/02GK M: U;PJ>BD5KQ?K M>U(: 4H,OX/V3A8C?7]:<-/F'7WD1QR[/J9>0!@+N1LP$D3882(B,HK$?CGZ M9&-'WZLD!OCR6F$3+,2:[KN#A;3MT'5Y( 4GU(X(KGU8U[%ERWWGL(*"1#AD MGAUR<.8QY>6EDC@R$$^Z[\^^9\E]=_V__79^>7YU#F[\:SWU==[^FL&3[<>0 M7QC,[WQ[8P6_?HM!YX)^3BRW#R9S:5V_X1 WWO&H=L3@(3^71C6GJ5%GFOI2 M^4WWUP!YI#JP-:^OXW[EAQ=KU 9TZ4$BD MO2NSNUMGMPJ]VM<=1M2 MX^TK0V-^9_?E9-7W_5>%C5%>&F5:S@>,.%S:-+$EGR%5X-B4.4&VS]: 3Z6T0->5:O-*68(W20[TJ("BQN1 65I_(T!-@O]9/>Z?]>-: M4N'^3(M_@M.9_7-&S\^:_&>Z3;5^UK08G %M^F!9#8L_G[V'80(@JD5RSBS= MVQJ *?TY^3B:W@^R277EV5\X^X!J@*S7!GR,=#ALB^.&2U]2KK+0!VJ+;CH& M P.H/XX?2BYX15AD'<)2A&>$=2105%(O#)'O4AR$'JXBR!(%*$2+A/U:CK&X MRMQ2GFK2),5?<[#:]H^8E'^06R-FKU)RMXIN_3:'5]8T>#> (O>EYQRGN?4] M'DZ3'9"8S4@L4!@ /<,(">HB&MJV@RK9!3.5\?5DMYKDG!1_2N/K=)A.'N:I M?KX'5"?D@[U%JNN-]4%R/TIO0%_H]51)9AK]6Z-"W*?8-4A4ZV3F="9G1F$DA@GK=O!=0$?W5/-0BKCKC.&P(?/(U?*>U5^\>?9$G?&(^R# MV#Z+3.H)M)BD4B#;91.["?8YKA#$=HEO^S)B\',4R4IEA)0Z>%-3+3HO@YA' M::8]:F2G:B^CKY*3=50\+HTB:]BLUW(%'SE+1MDRT:DQ[EY)]\<,X(J*T5/H(F, MSNZ"]1@^O"\F\6W24[M50(YDHA)#+MQO$Z#Z?_\!5)/'P_2>]!(ZOG MZ!$MQD''PWBB>$I3)M.EM^_C_/=D\GZ8Q'H,63V^(AM.JQVV,EA6$^^\R#YE MU9O_='Y_GUVGL\_E2-3#77C3M&A_>PT\D^DN[9I#_C,7EUW>!]M/BK?CV7I? M/YEEPY2S;-%0+T6+/9J-SO:W]\GD+M-6=2LW23URQB#]QE!16A,P"J0.KJJ3 M =3FK IK5Q'V]M:V$CZU['T= (-K)CK!!,8Q+(\JZ$0P?6DZT@R6Y7I4<&D= M."NJ[7)P]/*D&)>)""W'KRA3S9*?*FFIWEI?#)A_KV;^6#1._=8:S&RS0$U@ M!C/P]VV6#7X R,$Z_+7Z4^DB^'4*XU*[SFKIFCUI-9 Q"$%Q((C2\!>LGLYJ MJS+9JCR'^%ZQB%JQVNQ6P@8P,8+QEGE >LM>7='L9@%AU?H4%G!4?X[]>BH5 M3?VN-0TL7*EQ]"_723^>%DEU8J5\:+%:N^J MO<^385PF^17JJ461P?7JBUG&13/^N0'_N$O[=WH8LR ^\.[9W#7 J),<9ERJ MG ;LF@0&8+:S>C]_[O3.FMFZ/Q)UOF<,*_=3,_3P80=;0I0V6T($2^PX8>1Z M=@"6++(]&M1N#]BZLC9ME/GQL;7PW]I+XXX&VLX]AUD67Y)%T[; MRLK!V[5N5Q@>:VR^A]@/A1\ACU'N((=2-W"JW7.N_GB/GMQ\?_9V7"+!30;( MK8V&,I^FF-ZK%*7_)*6%,.9*.%C$?UN?W&,K][ M_IVH/'%>RG(_&0ZK7_]\IN "/@/!^O7G%:2_ M.^L+XD/ZQOV7V\=#X=H.$V M'97#BZ>3K/ZB/.ZNO_F1#B9W<#6L1G6N6&66QN,B^5C_L63FG,U*$,\J1>O3 M9(\4*"Y?(>@??ZTO6OP-/_'3>K?M:0,D\5+(*F]XIXV0;%HHU_&1(@GK-V0K MR5K;K4LGQK>\(DMRM.&:1*4J*S76ZL;9:S/!GM3'WEBCN77^.+A!2?I=H<=; M%Y38^IQW735B[<(0F^?QE?-YRKAGJ E6NW[(7>&P$(E0N-2QPU ($DD73'*! MD;/&GL8W\)K!0_M/,CA7*@I<-<4ZKC;XJMRA 9C_K5 G_#:]3P95Q+.\\MN, MZ8KEL+?R#;IV#.R98V _Z1A(M)PBMN 0F"Y_>P1CYZ/OP%19_K#/;2BV*MZX M20D+7$;\2,@0@V4L./R?YRKQ]I"+.(K(-L5[1HC]DF=N+V]G;"[/^R^VAVZ6 M?%7GC]-!*[96[8Y6,857BOG;]);=JOS;C?S[E$>A%TG$@]!V?9MS)$OYMRD* M@ZW*_YQZKZ@8EF'1.AI8_K9?^""7TQ2,NM]G>% 'WR8//;7EJ$!![5( HXQ5 M,/UD30#60(#M.3)B.. 25#\-"=CUM(0 Y#K$B[8) 35QOBK2P!5A39C]$GDP MCHQ)<$ FP?EH IR@-V%+&^#C:Z-9QUK^#AXEPY,NH! _.(R27#I@?,W@T)LB,1?2YJ\6[N_-@ M>\R8)H=IFG2.)D=HH[ &9J*(!C8BS+$I">T0;!2O\G2$3P)OJQO6^P8SM8VR M*Y 1/;,9?K#&2W]:P#@2=;9B6.:6WZ7CU^Z>'2ZD\ 92G"!2 7+FLB!4QWJ9 M1-79/=\!B#F5X,GLK'#%*-_:?-)="*7G&$OEH*+M]?$G8Y8L8DBK;AI#''F> MI [S_"#T77"#*@SA+@6+91%#ZD7=KXTPRGM2=)D>,U MN\K;?=.>89OD[NZLL=LV<8>WZM8$B$6!'T2" M3CE41;8?NLII"B RXOH<])((2.0+S&UFHRIT1Y' 6_6SJV34]@\5-WTMF6F_ MU)C-3)+ZX:@I#4VZ*%%=]L'XRHLXP)N:FA)Q CXR#CF6(48!=YUJIY!B%C7Q M-EU08D,0B%<:K"65JB3T/;-<,5HN0&$<[_T5^=+Q'JYKCAKG^SB<;X$:@X;: M+H^8]'PBN!]YGN>XO 0RC#%9JR#HQ@9-ZYO]PC'*.CU 8]SOO7*_ORS7\MF< MJM7<;"#L()NJ=/[7E(]X=*T/#RF?79_7U" X (PE#<;:$<*NAPCQ>1A@Y/D( M5467>>1&9)W"W.M@;+T?LQ)KE^N5O764D_:DX-W#[ 8,M\< _2== 6GV_;,U MMW91>''5@%>5.GMTD L"_285(W4!."5/95'#6?6<1VIR5F7@%BMNJI.:*\SG MNE;B33;-)W?MVKW1/W39O(,HKED6+%5S@E?-2N$M5&[52[!T1$%_NY05J%9( MEX*L&U@KQ+FMZN(/T^3FO6I>^3[/'N*A7LZJW&M3"[:J5:I+2<;].U5,5945 MKCZJXJ:Z866K(&M3]+6(OZ>J[*=NB%968)[57%>-9/.R8;-J"3MW,D\UF[5^ M9--A=7;_1PI>-@1N&>EIW23JFU%=>U37)];+> <8=%M6 M[5050]O]5:U4?U %30>Z<&C9X5:OD&**0KVS*C-:,6-94%;7)U1%^MZK.J[E MB!YF4U;U/P$O^].RBJB:=:+62U=RK'@U!\*EJC"J!:IFE-VG?9C+S6QX2ZNB M6\FI-J-E75^U%F5'U9)O]+!*7IEQ13F009+0,\ MM7E]2QC/*\N1+C3OG#<':%-GW>W98]$M2GS_'/]'YZOY!GM;/DK-EYE%E&5LM,>%\D M_8^#:?X#=#)PT]E?"B4^FE.+1_N ;DKSNL3^2J3:*J_J6>TML[)F<]X.?<<) M24@8BT*.J.UYO+9=@T@N-0\Z.F9=+S'Y*0Z>;(M_/UB6ETW*\L[QO2I&KNP9 M4#EENVRE,-XKB\*ZC@M0C75=\31OL_&!5)(OBY^W;9'5R<"Z"/JR?7$_!0W] MONS]75=?GQ4"?ZF9T11[GS2UW&=/NTU&JO*UHD1=R'T(HYE5>Z_'75DB"7#; MI*S77EL"K8+WJK+VG*HMK&*JAE"_;5GO^JO7Y05,TDEQ[J$B< MR $ER1T2B:IK%<V!AV'(?5U!P/@WK0TJE5W^T4A MT?W75&'\89S?JO;(($@%4"\O];BJIE.:M*40ZO#$7+OENVR<%&57B+LT40T; MU&O*5A(U@C0^7]4MHJZ\WQ3RKXMZ9;/2]QTO\S:BH5Z:7<*@\X?-VGB_%7=< MC.J&29@^V4%;?=G,L;;T-($OI\ AJJ+]Y3A1_1?*/CR?/OG6.]54AJ!?+R]] M_1?^]9>>=IM@E&_;Z%KPQC;S0NI$KA<%@1\*EWN^+ZK&CI(36Z[9S&W=1M?B M;QA6'*\9,)PM>6?=#6RYS>YK@ MEKXPM4Z\YLN-QP=T(^Y%@?B0)#CGW*S

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�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end XML 45 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]    
Remainder of 2020 $ 11,308  
2020 14,022  
2021 13,406  
2022 13,369  
2023 11,813  
2025 and thereafter 77,737  
Net carrying value, finite intangible items $ 141,655 $ 145,387

XML 46 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Narrative (Detail) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Charges against income for share-based payment arrangements $ 1.9 $ 2.2
Unrecognized compensation expenses related to share-based payment arrangements $ 16.6  
Recognition period 4 years  
The 2004 Plan and Employee Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Amount of shares issuable through two stock-based compensation plans 11.3  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Leases (Tables)
3 Months Ended
Aug. 31, 2019
Leases [Abstract]  
Supplemental balance sheet information
The following table presents supplemental balance sheet information related to our leases:
(in thousands)
Balance Sheet Location
 
Aug 31, 2019
Assets
 
 
 
Operating lease ROU asset
Other assets
 
$
5,104

Liabilities
 
 
 
Current operating lease liabilities
Other current liabilities
 
1,606

Non-current operating lease liabilities
Other long-term liabilities
 
3,489

Total lease liabilities
 
 
$
5,095


The following table presents the weighted average remaining lease term and discount rate:
 
Aug 31, 2019
Weighted average remaining term (in years)
3.7

Weighted average discount rate
4.3
%

Lease liability schedule
The following table presents the maturities of the lease liabilities:
(in thousands)
Aug 31, 2019
Remainder of 2020
$
1,142

2021
1,251

2022
1,118

2023
1,138

2024
576

2025 and thereafter

Total lease payments
$
5,225

Less: Imputed Interest
130

Total lease obligations
$
5,095

Less: Current portion of lease obligations
1,606

Long-term lease obligations
$
3,489


Lease liability schedule as of prior year end
Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:
(in thousands)
May 31, 2019
2020
$
2,920

2021
2,338

2022
2,133

2023
2,131

2024 and thereafter
3,227

Total lease payments
$
12,749


Supplemental cash flow information
The following table presents supplemental cash flow and other information related to our leases:
 
Three Months Ended August 31, 2019
(in thousands)
Aug 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
563

ROU assets obtained in exchange for lease liabilities
 
Operating leases


XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Liabilities (Tables)
3 Months Ended
Aug. 31, 2019
Payables and Accruals [Abstract]  
Accrued Liabilities
Accrued liabilities consisted of the following: 
(in thousands)
Aug 31, 2019
 
May 31, 2019
Payroll and related expenses
$
5,970

 
$
14,987

Royalties
1,439

 
2,088

Accrued severance
616

 
504

Sales and franchise taxes
3,417

 
807

Outside services
1,781

 
3,514

Litigation matters

 
2,700

Indemnification holdback
4,866

 
4,807

Other
4,604

 
8,931

 
$
22,693

 
$
38,338



XML 49 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Divestitures Divestitures
3 Months Ended
Aug. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Divestitures DIVESTITURES    

Fluid Management
On May 31, 2019, the Company completed the sale of the NAMIC Fluid Management business (the “Divestiture”) and all of the assets used primarily in connection with the Fluid Management business to Medline Industries, Inc. (“Medline”) pursuant to an asset purchase agreement dated April 17, 2019 (the “Asset Purchase Agreement”). Total consideration received by the Company for the Divestiture in the fourth quarter of fiscal year 2019 was $169.2 million in cash and resulted in a gain of $46.6 million after working capital adjustments of $0.6 million. The gain was recorded in discontinued operations. On June 3, 2019, a portion of the net proceeds were used to retire the outstanding balance on the Term Loan and Revolving Facility and the remaining net proceeds will continue to be invested in the business.
Pursuant to a transition services agreement entered into and effective on the closing of the transaction, the Company will supply certain services to Medline. Medline will receive certain legal, human resource, tax, accounting and information technology services from the Company for a period generally not to exceed 24 months.
As a result of the Divestiture, the results of operations from the Fluid Management business are reported in the accompanying Consolidated Statements of Operations as “Income from discontinued operations, net of income tax” for the
three months ended August 31, 2018. The following table summarizes the financial results of our discontinued operations:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net sales
$
21,397

Cost of sales (exclusive of amortization)
12,882

Gross profit
8,515

Operating expenses
 
Research and development
288

Sales and marketing
1,028

General and administrative
62

Amortization of intangibles
682

Total operating expenses
2,060

Operating income
6,455

 
 
Income from discontinued operations before income taxes
6,455

Income tax expense
1,220

Income from discontinued operations
$
5,235


In accordance with accounting principles generally accepted in the United States (“GAAP”), only expenses specifically identifiable and related to a business to be disposed may be allocated to discontinued operations. As such, the selling and marketing, research and development and general and administrative expenses recorded in discontinued operations include corporate costs incurred directly in support of the Fluid Management portfolio.
Total operating and investing cash flows of discontinued operations for the three months ended August 31, 2018 is comprised of the following, which excludes the effect of income taxes:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net cash provided by operating activities
$
524

Net cash provided by investing activities
224


XML 50 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Accrued Liabilities
3 Months Ended
Aug. 31, 2019
Payables and Accruals [Abstract]  
Accrued Liabilities ACCRUED LIABILITIES
Accrued liabilities consisted of the following: 
(in thousands)
Aug 31, 2019
 
May 31, 2019
Payroll and related expenses
$
5,970

 
$
14,987

Royalties
1,439

 
2,088

Accrued severance
616

 
504

Sales and franchise taxes
3,417

 
807

Outside services
1,781

 
3,514

Litigation matters

 
2,700

Indemnification holdback
4,866

 
4,807

Other
4,604

 
8,931

 
$
22,693

 
$
38,338


XML 51 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share
3 Months Ended
Aug. 31, 2019
Earnings Per Share [Abstract]  
Earnings Per Share EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
The following table reconciles basic to diluted weighted-average shares outstanding for the three months ended August 31, 2019 and 2018 (in thousands):
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Basic
37,783

 
37,323

Effect of dilutive securities

 

Diluted
37,783

 
37,323

 
 
 
 
Securities excluded as their inclusion would be anti-dilutive
2,503

 
2,309


XML 52 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Tables)
3 Months Ended
Aug. 31, 2019
Business Combinations [Abstract]  
Preliminary Aggregate Purchase Price The following
table summarizes the preliminary and revised final purchase price allocated to the net assets acquired:
(in thousands)
Final allocation
Inventory
$
50

Property, plant and equipment
10

Intangible assets:

    BioSentry trademark
2,500

    BioSentry product technology
20,900

    Customer relationships
2,600

Goodwill
13,740

Net assets acquired
$
39,800


The following table summarizes the preliminary and final aggregate purchase price allocated to the net assets acquired:
(in thousands)
Final allocation
Accounts receivable
$
900

Inventory
732

Prepaid and other current assets
98

Property, plant and equipment
133

Intangible assets:
 
RadiaDyne trademark
400

OARtrac trademark
200

RadiaDyne legacy product technology
1,500

OARtrac product technology
18,900

RadiaDyne customer relationships
4,600

Goodwill
47,982

Total assets acquired
$
75,445

Liabilities assumed
 
Accounts payable
$
352

Accrued expenses
106

Total liabilities assumed
$
458

Net assets acquired
$
74,987


JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ango-083119x10q.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 155, "dts": { "calculationLink": { "local": [ "ango-20190831_cal.xml" ] }, "definitionLink": { "local": [ "ango-20190831_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "ango-083119x10q.htm" ] }, "labelLink": { "local": [ "ango-20190831_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ango-20190831_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml" ] }, "schema": { "local": [ "ango-20190831.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 515, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 30, "http://www.angiodynamics.com/20190831": 1, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 37 }, "keyCustom": 33, "keyStandard": 335, "memberCustom": 36, "memberStandard": 34, "nsprefix": "ango", "nsuri": "http://www.angiodynamics.com/20190831", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.angiodynamics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Divestitures Divestitures", "role": "http://www.angiodynamics.com/role/DivestituresDivestitures", "shortName": "Divestitures Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Revenue from Contracts with Customers", "role": "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomers", "shortName": "Revenue from Contracts with Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Inventories", "role": "http://www.angiodynamics.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Accrued Liabilities", "role": "http://www.angiodynamics.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Long Term Debt", "role": "http://www.angiodynamics.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Income Taxes", "role": "http://www.angiodynamics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Share-Based Compensation", "role": "http://www.angiodynamics.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Earnings Per Share", "role": "http://www.angiodynamics.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Segment and Geographic Information", "role": "http://www.angiodynamics.com/role/SegmentAndGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Operations", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Fair Value", "role": "http://www.angiodynamics.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Leases Leases", "role": "http://www.angiodynamics.com/role/LeasesLeases", "shortName": "Leases Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Commitments and Contingencies", "role": "http://www.angiodynamics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Acquisition, Restructuring and Other Items, Net", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNet", "shortName": "Acquisition, Restructuring and Other Items, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Recently Issued Accounting Pronouncements", "role": "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements", "shortName": "Recently Issued Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Subsequent Events", "role": "http://www.angiodynamics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2221201 - Disclosure - Recently Issued Accounting Pronouncements (Policies)", "role": "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies", "shortName": "Recently Issued Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Acquisitions (Tables)", "role": "http://www.angiodynamics.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Divestitures (Tables)", "role": "http://www.angiodynamics.com/role/DivestituresTables", "shortName": "Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Revenue from Contracts with Customers (Tables)", "role": "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersTables", "shortName": "Revenue from Contracts with Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Inventories (Tables)", "role": "http://www.angiodynamics.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.angiodynamics.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Segment and Geographic Information (Tables)", "role": "http://www.angiodynamics.com/role/SegmentAndGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Fair Value (Tables)", "role": "http://www.angiodynamics.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Leases (Tables)", "role": "http://www.angiodynamics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Acquisition, Restructuring and Other Items, Net (Tables)", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetTables", "shortName": "Acquisition, Restructuring and Other Items, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:NewAccountingPronouncementsPolicyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321302 - Disclosure - Recently Issued Accounting Pronouncements (Tables)", "role": "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsTables", "shortName": "Recently Issued Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:NewAccountingPronouncementsPolicyTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Acquisitions - Narrative (Details)", "role": "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2019Q2Sep21_us-gaap_BusinessAcquisitionAxis_ango_RadiaDyneMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Acquisitions (Details)", "role": "http://www.angiodynamics.com/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4_us-gaap_BusinessAcquisitionAxis_ango_RadiaDyneMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ango_NAMICFluidManagementBusinessMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Divestitures (Details)", "role": "http://www.angiodynamics.com/role/DivestituresDetails", "shortName": "Divestitures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ango_NAMICFluidManagementBusinessMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Divestitures - Results of Discontinued Operations (Details)", "role": "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails", "shortName": "Divestitures - Results of Discontinued Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ango_NAMICFluidManagementBusinessMember", "decimals": "-3", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Revenue from Contracts with Customers - Disaggregation of Revenue (Details)", "role": "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "shortName": "Revenue from Contracts with Customers - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1QTD_srt_ProductOrServiceAxis_ango_VascularInterventionsandTherapiesMember_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Revenue from Contracts with Customers - Narrative (Details)", "role": "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails", "shortName": "Revenue from Contracts with Customers - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "ango:ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Revenue from Contracts with Customers - Contract Balances with Customers (Details)", "role": "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersContractBalancesWithCustomersDetails", "shortName": "Revenue from Contracts with Customers - Contract Balances with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Inventories - Schedule of Inventories (Detail)", "role": "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail", "shortName": "Inventories - Schedule of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Inventories - Narrative (Detail)", "role": "http://www.angiodynamics.com/role/InventoriesNarrativeDetail", "shortName": "Inventories - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Goodwill and Intangible Assets - Narrative (Detail)", "role": "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail", "shortName": "Goodwill and Intangible Assets - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Detail)", "role": "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail)", "role": "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail", "shortName": "Goodwill and Intangible Assets - Expected Future Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail)", "role": "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail", "shortName": "Accrued Liabilities - Summary of Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2020Q1Jun3_us-gaap_LineOfCreditFacilityAxis_ango_JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "ango:DebtInstrumentDebtDefaultInterestRateIncrease", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - Long Term Debt - Narrative (Detail)", "role": "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail", "shortName": "Long Term Debt - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2020Q1Jun3_us-gaap_LineOfCreditFacilityAxis_ango_JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember_us-gaap_LongtermDebtTypeAxis_us-gaap_LineOfCreditMember", "decimals": "INF", "first": true, "lang": null, "name": "ango:DebtInstrumentDebtDefaultInterestRateIncrease", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "ango:EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.angiodynamics.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "ango:EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Share-Based Compensation - Narrative (Detail)", "role": "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail", "shortName": "Share-Based Compensation - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail)", "role": "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail", "shortName": "Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Product Category (Detail)", "role": "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail", "shortName": "Segment and Geographic Information - Summary of Net Sales by Product Category (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:ScheduleOfNetRevenueByProductGroupTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail)", "role": "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail", "shortName": "Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail)", "role": "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "shortName": "Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail)", "role": "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail", "shortName": "Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail)", "role": "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "shortName": "Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1_us-gaap_ContingentConsiderationByTypeAxis_ango_RevenueBasedPaymentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1_srt_RangeAxis_srt_MinimumMember", "decimals": "-5", "first": true, "lang": null, "name": "ango:UndiscountedContingentConsiderationDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Fair Value - Additional Information (Detail)", "role": "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail", "shortName": "Fair Value - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1_srt_RangeAxis_srt_MinimumMember", "decimals": "-5", "first": true, "lang": null, "name": "ango:UndiscountedContingentConsiderationDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Leases (Details)", "role": "http://www.angiodynamics.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ango:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - Leases - Liability Maturity Schedule (Details)", "role": "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "shortName": "Leases - Liability Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416405 - Disclosure - Leases - Non-Cancelable Payments Schedule (Details)", "role": "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails", "shortName": "Leases - Non-Cancelable Payments Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2012Q3Jan11_srt_LitigationCaseAxis_ango_CrBardIncMember", "decimals": "INF", "first": true, "lang": null, "name": "ango:NumberOfPatentsAssertedForReexamination", "reportCount": 1, "unique": true, "unitRef": "Petition", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418401 - Disclosure - Commitments and Coontingencies - Additional Information (Detail)", "role": "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail", "shortName": "Commitments and Coontingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2012Q3Jan11_srt_LitigationCaseAxis_ango_CrBardIncMember", "decimals": "INF", "first": true, "lang": null, "name": "ango:NumberOfPatentsAssertedForReexamination", "reportCount": 1, "unique": true, "unitRef": "Petition", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "ango:AcquisitionRestructuringAndOtherItemsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Acquisition, Restructuring and Other Items, Net - Summary (Detail)", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail", "shortName": "Acquisition, Restructuring and Other Items, Net - Summary (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_ango_MergersandAcquisitionsMember", "decimals": "-3", "lang": null, "name": "ango:AcquisitionRestructuringAndOtherItemsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "ango:AcquisitionRestructuringAndOtherItemsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Acquisition, Restructuring and Other Items, Net - Narrative (Detail)", "role": "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "shortName": "Acquisition, Restructuring and Other Items, Net - Narrative (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Schedule (Detail)", "role": "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "shortName": "Accumulated Other Comprehensive Income (Loss) - Schedule (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422401 - Disclosure - Subsequent Events (Details)", "role": "http://www.angiodynamics.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "D2020Q2_us-gaap_BusinessAcquisitionAxis_ango_EximoMedicalLtd.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Consolidated Financial Statements", "role": "http://www.angiodynamics.com/role/ConsolidatedFinancialStatements", "shortName": "Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Acquisitions", "role": "http://www.angiodynamics.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ango-083119x10q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "ango_AccruedLitigation": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Litigation", "label": "Accrued Litigation", "terseLabel": "Litigation matters" } } }, "localname": "AccruedLitigation", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ango_AccruedRecallLiability": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Recall Liability", "label": "Accrued Recall Liability", "terseLabel": "Indemnification holdback" } } }, "localname": "AccruedRecallLiability", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "ango_AcculisInventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acculis Inventory [Member]", "label": "Acculis Inventory [Member]", "terseLabel": "Acculis Inventory" } } }, "localname": "AcculisInventoryMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "domainItemType" }, "ango_AcquisitionRestructuringAndOtherItemsNet": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Acquisition Restructuring And Other Items Net.", "label": "Acquisition Restructuring and Other Items Net", "terseLabel": "Acquisition, restructuring and other items, net" } } }, "localname": "AcquisitionRestructuringAndOtherItemsNet", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ango_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental balance sheet information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ango_BioSentryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioSentry [Member]", "label": "BioSentry [Member]", "terseLabel": "BioSentry" } } }, "localname": "BioSentryMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ango_BiolitecBankruptcyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biolitec Bankruptcy [Member]", "label": "Biolitec Bankruptcy [Member]", "terseLabel": "Biolitec Bankruptcy" } } }, "localname": "BiolitecBankruptcyMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail" ], "xbrltype": "domainItemType" }, "ango_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses", "terseLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ango_C.R.BardInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "C.R. Bard, Inc. [Member]", "label": "C.R. Bard, Inc. [Member]", "terseLabel": "C.R. Bard, Inc." } } }, "localname": "C.R.BardInc.Member", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ango_ChangeInFairValueOfContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The expense charged against earnings in the period resulting from remeasurement to fair value of contingent earn out liabilities related to acquisitions.", "label": "Change in Fair Value of Contingent Consideration", "terseLabel": "Change in present value of contingent consideration" } } }, "localname": "ChangeInFairValueOfContingentConsideration", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail" ], "xbrltype": "monetaryItemType" }, "ango_ChangeInFairValueOfContingentConsiderationOne": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Change In Fair Value Of Contingent Consideration", "label": "Change In Fair Value Of Contingent Consideration One", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "ChangeInFairValueOfContingentConsiderationOne", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "ango_ClinicalDevicesBvMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Devices B.V. [Member]", "label": "Clinical Devices Bv [Member]", "terseLabel": "Clinical Devices Bv" } } }, "localname": "ClinicalDevicesBvMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail" ], "xbrltype": "domainItemType" }, "ango_ConstructionIssuesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Construction Issues [Member]", "label": "Construction Issues [Member]", "terseLabel": "Construction Issues" } } }, "localname": "ConstructionIssuesMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ango_ContingentConsiderationEarnOutLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration earn out liability.", "label": "Contingent Consideration Earn Out Liability [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationEarnOutLiabilityMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "ango_ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return", "label": "Contract with Customer, Right of Return, Minimum Remaining Product Life Prior to Return", "terseLabel": "Minimum remaining period prior to product expiration" } } }, "localname": "ContractwithCustomerRightofReturnMinimumRemainingProductLifePriortoReturn", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval", "label": "Contract with Customer, Right of Return, Product Return Period After Purchase Date Requiring Pre-Approval", "terseLabel": "Days after purchase after which pre-approval is required for product return" } } }, "localname": "ContractwithCustomerRightofReturnProductReturnPeriodAfterPurchaseDateRequiringPreApproval", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_ContractwithCustomerRightofReturnRestockingCharge": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract with Customer, Right of Return, Restocking Charge", "label": "Contract with Customer, Right of Return, Restocking Charge", "terseLabel": "Restocking charge (as percent)" } } }, "localname": "ContractwithCustomerRightofReturnRestockingCharge", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "percentItemType" }, "ango_CrBardIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "C.R. Bard, Inc. [Member]", "label": "Cr Bard Inc [Member]", "terseLabel": "C.R. Bard, Inc." } } }, "localname": "CrBardIncMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio", "terseLabel": "Maximum total leverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatio", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions", "label": "Debt Instrument, Covenant Terms, Maximum Total Leverage Ratio, Subsequent To Material Acquisitions", "terseLabel": "Maximum total leverage ratio subsequent to material acquisitions" } } }, "localname": "DebtInstrumentCovenantTermsMaximumTotalLeverageRatioSubsequentToMaterialAcquisitions", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio", "label": "Debt Instrument, Covenant Terms, Minimum Fixed Charge Coverage Ratio", "terseLabel": "Minimum fixed charge coverage ratio" } } }, "localname": "DebtInstrumentCovenantTermsMinimumFixedChargeCoverageRatio", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "pureItemType" }, "ango_DebtInstrumentDebtDefaultInterestRateIncrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Debt Default, Interest Rate Increase", "label": "Debt Instrument, Debt Default, Interest Rate Increase", "terseLabel": "Debt default interest rate increase (percentage)" } } }, "localname": "DebtInstrumentDebtDefaultInterestRateIncrease", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "percentItemType" }, "ango_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationWorkingCapitalAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Working Capital Adjustment", "label": "Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Working Capital Adjustment", "terseLabel": "Working capital adjustments" } } }, "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationWorkingCapitalAdjustment", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "ango_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Research And Development Expense", "label": "Disposal Group, Including Discontinued Operation, Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ango_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Sales And Marketing Expense", "label": "Disposal Group, Including Discontinued Operation, Sales And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ango_DivestitureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divestiture [Member]", "label": "Divestiture [Member]", "terseLabel": "Divestiture" } } }, "localname": "DivestitureMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "ango_EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Before Discreet Items, Percent", "label": "Effective Income Tax Rate Reconciliation Before Discreet Items, Percent", "terseLabel": "Estimated federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBeforeDiscreetItemsPercent", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ango_EximoMedicalLtd.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eximo Medical, Ltd. [Member]", "label": "Eximo Medical, Ltd. [Member]", "terseLabel": "Eximo Medical, Ltd." } } }, "localname": "EximoMedicalLtd.Member", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ango_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetContingentConsiderationLiabilitiesPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Contingent Consideration, Liabilities, Payments", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Contingent Consideration, Liabilities, Payments", "negatedLabel": "Contingent consideration payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetContingentConsiderationLiabilitiesPayments", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail" ], "xbrltype": "monetaryItemType" }, "ango_JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]", "label": "JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association [Member]", "terseLabel": "JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association" } } }, "localname": "JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "ango_LeaseArrangementsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Arrangements [Axis]", "label": "Lease Arrangements [Axis]", "terseLabel": "Lease Arrangements [Axis]" } } }, "localname": "LeaseArrangementsAxis", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "ango_LeaseArrangementsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Lease Arrangements [Axis]", "label": "Lease Arrangements [Domain]", "terseLabel": "Lease Arrangements [Domain]" } } }, "localname": "LeaseArrangementsDomain", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ango_LegalCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal Costs [Member]", "label": "Legal Costs [Member]", "terseLabel": "Legal" } } }, "localname": "LegalCostsMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "ango_LesseeOperatingLeaseLeaseNoteYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Note Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Note Yet Commenced, Undiscounted Amount", "terseLabel": "Lease payments" } } }, "localname": "LesseeOperatingLeaseLeaseNoteYetCommencedUndiscountedAmount", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "ango_LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Accordian Feature", "terseLabel": "Line of credit accordion feature" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityAccordianFeature", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "ango_LineOfCreditFacilityNumberOfCovenants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Number Of Covenants", "label": "Line Of Credit Facility, Number Of Covenants", "terseLabel": "Number of covenants" } } }, "localname": "LineOfCreditFacilityNumberOfCovenants", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "integerItemType" }, "ango_LossContingencyClaimsReversedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Claims Reversed, Number", "label": "Loss Contingency, Claims Reversed, Number", "terseLabel": "Number of claims reversed" } } }, "localname": "LossContingencyClaimsReversedNumber", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "ango_LossContingencyReexaminationsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Reexaminations, Number", "label": "Loss Contingency, Reexaminations, Number", "terseLabel": "Number of reexaminations" } } }, "localname": "LossContingencyReexaminationsNumber", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "ango_MeasurementInputProbabilityofPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement Input, Probability of Payment [Member]", "label": "Measurement Input, Probability of Payment [Member]", "terseLabel": "Probability of payment" } } }, "localname": "MeasurementInputProbabilityofPaymentMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "ango_MedlineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medline [Member]", "label": "Medline [Member]", "terseLabel": "Medline" } } }, "localname": "MedlineMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "domainItemType" }, "ango_MergersandAcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mergers and Acquisitions [Member]", "label": "Mergers and Acquisitions [Member]", "terseLabel": "Mergers and acquisitions" } } }, "localname": "MergersandAcquisitionsMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "ango_NAMICFluidManagementBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NAMIC Fluid Management Business [Member]", "label": "NAMIC Fluid Management Business [Member]", "terseLabel": "NAMIC Fluid Management Business" } } }, "localname": "NAMICFluidManagementBusinessMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "ango_NewAccountingPronouncementsPolicyTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Accounting Pronouncements, Policy [Table Text Block]", "label": "New Accounting Pronouncements, Policy [Table Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyTableTextBlock", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "ango_NumberOfPatentsAssertedForReexamination": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of patents asserted for reexamination.", "label": "Number of Patents Asserted for Reexamination", "terseLabel": "Number of petitions filed for reexamination of patents" } } }, "localname": "NumberOfPatentsAssertedForReexamination", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "ango_OarTracTechnologyBasedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "OarTrac Technology-Based Intangible Assets [Member]", "label": "OarTrac Technology-Based Intangible Assets [Member]", "terseLabel": "OarTrac product technology" } } }, "localname": "OarTracTechnologyBasedIntangibleAssetsMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ango_OarTracTrademarkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "OarTrac Trademark [Member]", "label": "OarTrac Trademark [Member]", "terseLabel": "OarTrac trademark" } } }, "localname": "OarTracTrademarkMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ango_OncologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Oncology [Member]", "label": "Oncology [Member]", "terseLabel": "Oncology" } } }, "localname": "OncologyMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "domainItemType" }, "ango_OperatingLeasesFutureMinimumPaymentsDueAfterFourYears": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Leases, Future Minimum Payments, Due After Four Years", "label": "Operating Leases, Future Minimum Payments, Due After Four Years", "terseLabel": "2024 and thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAfterFourYears", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "ango_PaymentOfContingentConsideration": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment Of Contingent Consideration", "label": "Payment Of Contingent Consideration", "negatedLabel": "Payment of acquisition related contingent consideration" } } }, "localname": "PaymentOfContingentConsideration", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ango_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred Stock Purchase Rights [Member]", "label": "Preferred Stock Purchase Rights [Member]", "terseLabel": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ango_ProductTechnologiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product technologies.", "label": "Product Technologies [Member]", "terseLabel": "Product technologies" } } }, "localname": "ProductTechnologiesMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "ango_RadiaDyneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RadiaDyne [Member]", "label": "RadiaDyne [Member]", "terseLabel": "RadiaDyne" } } }, "localname": "RadiaDyneMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ango_RadiaDyneTechnologyBasedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RadiaDyne Technology-Based Intangible Assets [Member]", "label": "RadiaDyne Technology-Based Intangible Assets [Member]", "terseLabel": "RadiaDyne legacy product technology" } } }, "localname": "RadiaDyneTechnologyBasedIntangibleAssetsMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ango_RadiaDyneTrademarkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RadiaDyne Trademark [Member]", "label": "RadiaDyne Trademark [Member]", "terseLabel": "RadiaDyne trademark" } } }, "localname": "RadiaDyneTrademarkMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ango_RevenueBasedPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Based Payment [Member]", "label": "Revenue Based Payment [Member]", "terseLabel": "Revenue based payments", "verboseLabel": "Revenue milestones" } } }, "localname": "RevenueBasedPaymentMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "ango_RevenuePerformanceObligationPaymentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue, Performance Obligation, Payment Term", "label": "Revenue, Performance Obligation, Payment Term", "terseLabel": "Payment term" } } }, "localname": "RevenuePerformanceObligationPaymentTerm", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "durationItemType" }, "ango_ScheduleOfIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of intangible assets.", "label": "Schedule of Intangible Assets [Table Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ango_ScheduleOfNetRevenueByProductGroupTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of net revenue by product group.", "label": "Schedule of Net Revenue by Product Group [Table Text Block]", "terseLabel": "Summary of Net Sales by Product Category" } } }, "localname": "ScheduleOfNetRevenueByProductGroupTableTextBlock", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "ango_SevenYearBuildingLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Seven Year Building Lease [Member]", "label": "Seven Year Building Lease [Member]", "terseLabel": "Seven Year Building Lease" } } }, "localname": "SevenYearBuildingLeaseMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ango_TechnicalMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technical Milestones [Member]", "label": "Technical Milestones [Member]", "terseLabel": "Technical milestones" } } }, "localname": "TechnicalMilestonesMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "ango_TechnologyAndRevenueMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Technology And Revenue Milestones [Member]", "label": "Technology And Revenue Milestones [Member]", "terseLabel": "Technology And Revenue Milestones" } } }, "localname": "TechnologyAndRevenueMilestonesMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ango_The2004PlanandEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2004 Plan and Employee Stock Purchase Plan [Member]", "label": "The 2004 Plan and Employee Stock Purchase Plan [Member]", "terseLabel": "The 2004 Plan and Employee Stock Purchase Plan" } } }, "localname": "The2004PlanandEmployeeStockPurchasePlanMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "ango_TheDelawareActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Delaware Action", "label": "The Delaware Action [Member]", "terseLabel": "The Delaware Action" } } }, "localname": "TheDelawareActionMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ango_TheUtahActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Utah Action", "label": "The Utah Action [Member]", "terseLabel": "The Utah Action" } } }, "localname": "TheUtahActionMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ango_TransitionServicesAgreementTermsServicePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transition Services Agreement, Terms, Service Period", "label": "Transition Services Agreement, Terms, Service Period", "terseLabel": "Service period duration (months)" } } }, "localname": "TransitionServicesAgreementTermsServicePeriod", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "durationItemType" }, "ango_TransitionserviceagreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transition service agreement [Member]", "label": "Transition service agreement [Member]", "terseLabel": "Transition service agreement" } } }, "localname": "TransitionserviceagreementMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "ango_TwoYearBuildingLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Year Building Lease [Member]", "label": "Two Year Building Lease [Member]", "terseLabel": "Two Year Building Lease" } } }, "localname": "TwoYearBuildingLeaseMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "ango_UndiscountedContingentConsiderationDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Undiscounted Contingent Consideration Disclosure", "label": "Undiscounted Contingent Consideration Disclosure", "terseLabel": "Potential amount of undiscounted future contingent consideration" } } }, "localname": "UndiscountedContingentConsiderationDisclosure", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ango_ValuationTechniqueEstimatedProbabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation Technique, Estimated Probability [Member]", "label": "Valuation Technique, Estimated Probability [Member]", "terseLabel": "Estimated probability" } } }, "localname": "ValuationTechniqueEstimatedProbabilityMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "ango_VascularAccessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vascular access.", "label": "Vascular Access [Member]", "terseLabel": "Vascular Access" } } }, "localname": "VascularAccessMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "domainItemType" }, "ango_VascularInterventionsandTherapiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vascular Interventions and Therapies [Member]", "label": "Vascular Interventions and Therapies [Member]", "terseLabel": "Vascular Interventions & Therapies" } } }, "localname": "VascularInterventionsandTherapiesMember", "nsuri": "http://www.angiodynamics.com/20190831", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag", "terseLabel": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r360" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r71", "r122" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r151", "r228", "r231", "r355" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail", "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r152", "r228", "r232", "r357", "r358" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r39", "r229" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowances of $1,434 and $1,906 respectively", "verboseLabel": "Receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersContractBalancesWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r336", "r350" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees", "terseLabel": "Outside services" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r29", "r30", "r58" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r77", "r78" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r75", "r78", "r79", "r284" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss", "verboseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r73", "r78", "r79", "r284" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation loss" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r40" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r237", "r239", "r251", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r239", "r246", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Charges against income for share-based payment arrangements" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r65", "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Accounts receivable, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r114", "r170", "r176" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded as their inclusion would be anti-dilutive (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r147", "r333", "r345" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r26", "r27", "r70" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r241", "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail", "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail", "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r272", "r273", "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r271", "r274", "r278" ], "calculation": { "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration for acquisition earn outs", "verboseLabel": "Contingent consideration, liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail", "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r271", "r275" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, liability, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r271", "r275" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "verboseLabel": "Assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "verboseLabel": "Prepaid and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "verboseLabel": "Receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r266", "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r266", "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r266", "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r267" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r24", "r50", "r116" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r15", "r110" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash provided by investing activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r15", "r110" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash provided by operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r62", "r200", "r337", "r349" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r38" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r38", "r213" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r38" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $.01 per share, 75,000,000 shares authorized; 38,359,875 and 37,984,382 shares issued and 37,989,875 and 37,614,382 shares outstanding at August 31, 2019 and May 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r82", "r84", "r85" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss, net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r140", "r141", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r140", "r141", "r298", "r299", "r356" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Contract Balances with Customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r222", "r224", "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Net", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersContractBalancesWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r222", "r223", "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersContractBalancesWithCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Additions to contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized from contract liability balances in respective periods" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r98" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales (exclusive of intangible amortization)" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percentage)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r60", "r123", "r214", "r215", "r216", "r217", "r304", "r305", "r307", "r343" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term (years)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r114", "r121", "r258", "r259" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Gain on contingent consideration for IPR&D Write-off" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Deferred Income Taxes and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r114", "r181" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r221", "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r2", "r4", "r6" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax", "terseLabel": "Gain on divestiture" } } }, "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r13", "r91", "r352" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Income from discontinued operations before income taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Income per share discontinued operations - basic (usd per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Income per share discontinued operations - diluted (usd per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r3", "r4", "r5", "r6", "r13", "r18", "r257", "r261" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Income tax expense" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales (exclusive of amortization)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "terseLabel": "Amortization of intangibles" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r14" ], "calculation": { "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Net sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r22", "r188" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Divestitures" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDivestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r93", "r128", "r132", "r133", "r134", "r135", "r138", "r341", "r354" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r93", "r128", "r132", "r133", "r134", "r135", "r138", "r341", "r354" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r301" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized compensation expenses related to share-based payment arrangements" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail", "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r287", "r288", "r289", "r290", "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail", "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r234", "r235", "r236", "r289", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r294", "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r234", "r235", "r236", "r289", "r329" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r234", "r235", "r236", "r289", "r330" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r234", "r235", "r236", "r289", "r331" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r287", "r288", "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r293", "r296" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r293", "r296" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r293", "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value Measurements Using Significant Unobservable Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r287", "r294" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Financial liabilities, ending balance", "periodStartLabel": "Financial liabilities, begining balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueMeasurementsUsingSignificantUnobservableInputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r287", "r294" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful life", "verboseLabel": "Estimated useful life of intangible assets other than goodwill" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r175" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "2025 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r177" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r177" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r177" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r177" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r171", "r172", "r175", "r178", "r332" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r175", "r332" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross carrying value, finite intangible items" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r171", "r174" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r175" ], "calculation": { "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying value, finite intangible items" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsExpectedFutureAmortizationExpenseDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r163", "r165" ], "calculation": { "http://www.angiodynamics.com/role/AcquisitionsDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r114", "r164", "r166", "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r96" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r114", "r180" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Fixed and intangible asset impairments and disposals" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r97", "r115", "r135", "r280" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r124" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from continuing operations before income tax benefit" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r88", "r93", "r132", "r133", "r134", "r338", "r339", "r341", "r351" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Loss per share continuing operations - basic (usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r88", "r93", "r132", "r133", "r134", "r135", "r341", "r351", "r354" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Loss per share continuing operations - diluted (usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r2", "r3", "r4", "r5", "r6", "r13", "r18", "r281" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from discontinued operations, net of income tax", "totalLabel": "Income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r7", "r8", "r9", "r10", "r11", "r12", "r16", "r19", "r20", "r21", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresDetails", "http://www.angiodynamics.com/role/DivestituresResultsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail", "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail", "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r146", "r260" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r113" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r113" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r113" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r169", "r173" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r89", "r145", "r303", "r306", "r342" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r66" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r25", "r69", "r159" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r68" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r69", "r125", "r159", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r67" ], "calculation": { "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r99", "r157", "r158", "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lease term (years)" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lease liability schedule" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2025 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r323" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r57" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r44", "r335", "r347" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r288" ], "calculation": { "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total Financial Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r255", "r256" ], "lang": { "en-US": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "Licenses" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r35", "r334", "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r55", "r123" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee (percentage)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r60" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r60", "r211" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualPayments": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow reducing loss contingency liability.", "label": "Loss Contingency Accrual, Payments", "terseLabel": "Payment of final settlements" } } }, "localname": "LossContingencyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Number of claims dismissed" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "terseLabel": "Number of patents allegedly infringed upon" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r110" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r110", "r112", "r115" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r80", "r83", "r92", "r115", "r137", "r340", "r353" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "auth_ref": [ "r117", "r118", "r119" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "terseLabel": "Accrual for capital expenditures incurred during the period" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract]", "terseLabel": "Liabilities assumed" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive loss before reclassifications, net of tax" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r313" ], "calculation": { "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails", "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Less: Current portion of lease obligations" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r313" ], "calculation": { "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease obligations" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesLiabilityMaturityScheduleDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r315", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails", "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r321", "r324" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r320", "r324" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r308", "r309" ], "calculation": { "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesNonCancelablePaymentsScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r23", "r285" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Consolidated Financial Statements" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r29", "r30", "r31", "r58" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r114", "r184" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Write-off of other assets" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive loss, before tax:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r281", "r282", "r283" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive loss, before tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r72", "r76", "r300", "r302" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r81", "r84", "r86", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r81", "r84", "r281", "r282", "r283" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Net other comprehensive loss", "totalLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r281", "r282", "r283" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Income tax expense related to items of other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r74", "r76", "r156" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "terseLabel": "Unrealized gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r28", "r29", "r58" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r115" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expenses) income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r109" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Deferred financing costs on long-term debt" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r105", "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r105" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangibles" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r106" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CommitmentsAndCoontingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r241", "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r37" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r37" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r26", "r48", "r49" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r107", "r249" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.", "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options", "terseLabel": "Proceeds (outlays) from exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "terseLabel": "Proceeds from Legal Settlements" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r51", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r33", "r34", "r183", "r348" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r33", "r182" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r101", "r225" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.", "label": "Provision for Doubtful Accounts", "terseLabel": "Change in accounts receivable allowances" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r78", "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Amounts reclassified from accumulated other comprehensive loss" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r108" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r254", "r359" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Acquisition, Restructuring and Other Items, Net" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r114", "r189", "r193", "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r190", "r193", "r197" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r189", "r195" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Accrued severance" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r41", "r218", "r346" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r120", "r233" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RecentlyIssuedAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r126", "r233" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r95", "r143", "r144", "r150" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/RevenueFromContractsWithCustomersDisaggregationOfRevenueDetails", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail", "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r319", "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r30", "r53" ], "calculation": { "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Sales and franchise taxes" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Preliminary Aggregate Purchase Price" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r0", "r7", "r8", "r9", "r10", "r11", "r12", "r16", "r19", "r20", "r21", "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Results of Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/DivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value of Assets and Liabilities Measured on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r171", "r174" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Lease liability schedule as of prior year end" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r32", "r45", "r46", "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r191", "r192", "r194" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetNarrativeDetail", "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetSummaryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r191", "r192", "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionRestructuringAndOtherItemsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r95", "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Summary of Net Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r87", "r90", "r152" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByGeographicAreaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r142", "r147", "r148", "r149", "r167" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r241", "r248" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SegmentAndGeographicInformationSummaryOfNetSalesByProductCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r113" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Amount of shares issuable through two stock-based compensation plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ShareBasedCompensationNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r238", "r243" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r36", "r37", "r38", "r213" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r64", "r213" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.angiodynamics.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r37", "r38", "r213", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Purchase of common stock under ESPP, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r37", "r38", "r213", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance/Cancellation of performance share units and restricted stock units, net, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r37", "r38", "r213", "r218", "r244" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r37", "r38", "r213", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Purchases of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r37", "r38", "r218", "r240", "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance/Cancellation of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r64", "r213", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r38", "r42", "r43", "r155" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleDetail", "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Product technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks", "verboseLabel": "Trademark" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/AcquisitionsDetails", "http://www.angiodynamics.com/role/AcquisitionsNarrativeDetails", "http://www.angiodynamics.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r63", "r219" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r63", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Ending Balance,Treasury Shares", "negatedPeriodStartLabel": "Beginning Balance,Treasury Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.angiodynamics.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r63", "r219", "r220" ], "calculation": { "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, 370,000 shares at August 31, 2019 and May 31, 2019, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted cash flow" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/FairValueSummaryShowingRecurringFairValueMeasurementsOfContingentConsiderationLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/LongTermDebtNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r135" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive securities (shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r135" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average shares outstanding (in shares)", "totalLabel": "Diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r135" ], "calculation": { "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Basic weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.angiodynamics.com/role/ConsolidatedStatementsOfOperations", "http://www.angiodynamics.com/role/EarningsPerShareReconciliationOfBasicToDilutedWeightedAverageSharesOutstandingDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.5)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=SL66093879-108312" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=SL66093883-108312" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4542-108314" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77904769&loc=SL2265659-115463" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r22": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130534-203044" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r23": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5227-128473" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=82918529&loc=d3e30304-110892" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r362": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r363": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r364": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r365": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" } }, "version": "2.1" } XML 54 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value
3 Months Ended
Aug. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value FAIR VALUE

On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Level 3 - Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to the immediate or short-term maturities. The Company's recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2019 and May 31, 2019:
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at August 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
11,830

 
$
11,830

Total Financial Liabilities
$

 
$

 
$
11,830

 
$
11,830

 
 
 
 
 
 
 
 
 
Fair Value Measurements using
inputs considered as:
 
Fair Value at May 31, 2019
(in thousands)
Level 1
 
Level 2
 
Level 3
 
 
Financial Liabilities
 
 
 
 
 
 
 
Contingent consideration for acquisition earn outs
$

 
$

 
$
13,486

 
$
13,486

Total Financial Liabilities
$

 
$

 
$
13,486

 
$
13,486



There were no transfers between Level 1, 2 and 3 for the three months ended August 31, 2019.

The table below presents the changes in fair value components of Level 3 instruments in the three months ended August 31, 2019:

Three Months Ended August 31, 2019
(in thousands)
Fair Value Measurements
Using Significant
Unobservable Inputs
(Level 3)
Balance, May 31, 2019
$
13,486

Total gains or losses (realized/unrealized):


Change in present value of contingent consideration (1)
(448
)
Contingent consideration payments
(1,208
)
Balance, August 31, 2019
$
11,830


(1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Contingent Consideration for Acquisition Earn Outs
Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations.

The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. The fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on the Company's internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.

The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of August 31, 2019:
(in thousands)
Fair Value
 
Valuation Technique
 
Unobservable Input
 
Range
Revenue based payments
$
8,533

 
Discounted cash flow
 
Discount rate
 
4% - 5%
 
 
 
 
 
Probability of payment
 
66% - 100%
 
 
 
 
 
Projected fiscal year of payment
 
2023
Technical milestones
$
3,297

 
Estimated probability
 
Estimated probability
 
90%
 
 
 
 
 
Projected year of payment
 
2020 - 2022
Total
$
11,830

 
 
 
 
 
 


At August 31, 2019, the range of estimated potential undiscounted future contingent consideration that the Company expects to pay as a result of all completed acquisitions is $14.0 million to $34.0 million. The milestones, including revenue projections and technical milestones, associated with the contingent consideration must be reached in future periods ranging from fiscal years 2020 to 2023 in order for the associated consideration to be paid.
XML 56 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Accumulated Other Comprehensive Income (Loss)
3 Months Ended
Aug. 31, 2019
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) ACCUMULATED OTHER COMPREHENSIVE LOSS

Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three months ended August 31, 2019:
 
Three months ended August 31, 2019
(in thousands)
Foreign currency translation loss
Balance at May 31, 2019
$
(1,352
)
Other comprehensive loss before reclassifications, net of tax
(151
)
Amounts reclassified from accumulated other comprehensive loss

Net other comprehensive loss
$
(151
)
Balance at August 31, 2019
$
(1,503
)

XML 57 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Disaggregation of Revenue [Line Items]    
Net sales $ 66,042 $ 63,943
United States    
Disaggregation of Revenue [Line Items]    
Net sales 52,937 51,496
International    
Disaggregation of Revenue [Line Items]    
Net sales 13,105 12,447
Vascular Interventions & Therapies    
Disaggregation of Revenue [Line Items]    
Net sales 28,913 28,598
Vascular Interventions & Therapies | United States    
Disaggregation of Revenue [Line Items]    
Net sales 25,676 25,851
Vascular Interventions & Therapies | International    
Disaggregation of Revenue [Line Items]    
Net sales 3,237 2,747
Vascular Access    
Disaggregation of Revenue [Line Items]    
Net sales 23,159 23,790
Vascular Access | United States    
Disaggregation of Revenue [Line Items]    
Net sales 19,284 20,447
Vascular Access | International    
Disaggregation of Revenue [Line Items]    
Net sales 3,875 3,343
Oncology    
Disaggregation of Revenue [Line Items]    
Net sales 13,970 11,555
Oncology | United States    
Disaggregation of Revenue [Line Items]    
Net sales 7,977 5,198
Oncology | International    
Disaggregation of Revenue [Line Items]    
Net sales $ 5,993 $ 6,357
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 21, 2018
Aug. 14, 2018
Aug. 31, 2019
Aug. 31, 2018
May 31, 2019
Business Acquisition [Line Items]          
Contingent consideration, liabilities     $ 11,830   $ 13,486
Other long-term liabilities     3,800   521
Accrued liabilities     22,693   38,338
Acquisition, restructuring and other items, net     $ 1,500 $ 4,422  
Minimum          
Business Acquisition [Line Items]          
Useful life     2 years    
Maximum          
Business Acquisition [Line Items]          
Useful life     18 years    
RadiaDyne          
Business Acquisition [Line Items]          
Aggregate purchase price $ 75,000        
Payments to acquire business 47,900        
Contingent consideration, liabilities 22,300        
Other long-term liabilities 4,600   $ 4,600    
Accrued liabilities $ 200        
Acquisition, restructuring and other items, net         1,600
RadiaDyne | Customer relationships          
Business Acquisition [Line Items]          
Useful life 15 years        
RadiaDyne | Minimum | Trademark          
Business Acquisition [Line Items]          
Useful life 5 years        
RadiaDyne | Minimum | Product technology          
Business Acquisition [Line Items]          
Useful life 7 years        
RadiaDyne | Maximum | Trademark          
Business Acquisition [Line Items]          
Useful life 7 years        
RadiaDyne | Maximum | Product technology          
Business Acquisition [Line Items]          
Useful life 10 years        
RadiaDyne | Revenue milestones          
Business Acquisition [Line Items]          
Contingent consideration, liabilities $ 16,500        
RadiaDyne | Technical milestones          
Business Acquisition [Line Items]          
Contingent consideration, liabilities $ 5,800        
BioSentry          
Business Acquisition [Line Items]          
Aggregate purchase price   $ 39,800      
Payments to acquire business   37,000      
Contingent consideration, liabilities   $ 2,800      
Acquisition related costs         $ 1,000
BioSentry | Trademark          
Business Acquisition [Line Items]          
Useful life   15 years      
BioSentry | Customer relationships          
Business Acquisition [Line Items]          
Useful life   10 years      
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Inventories - Narrative (Detail) - USD ($)
$ in Millions
3 Months Ended
Aug. 31, 2019
May 31, 2019
Inventory [Line Items]    
Inventory valuation reserves $ 4.1 $ 4.2
Inventory write-down 0.7  
Acculis Inventory    
Inventory [Line Items]    
Inventory valuation reserves $ 0.4  
XML 60 R62.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail)
$ in Thousands
Aug. 31, 2019
USD ($)
May 31, 2019
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities $ 11,830 $ 13,486
Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Liabilities 11,830 13,486
Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities 11,830 13,486
Total Financial Liabilities 11,830 $ 13,486
Revenue based payments | Discounted cash flow | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities 8,533  
Technical milestones | Estimated probability | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liabilities $ 3,297  
Contingent consideration, liability, measurement input 0.90  
Minimum | Revenue based payments | Discount rate | Discounted cash flow | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 0.04  
Minimum | Revenue based payments | Probability of payment | Discounted cash flow | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 0.66  
Maximum | Revenue based payments | Discount rate | Discounted cash flow | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 0.05  
Maximum | Revenue based payments | Probability of payment | Discounted cash flow | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, liability, measurement input 1.00  
Contingent Consideration | Level 3 | Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Liabilities $ 11,830  
XML 61 R66.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Liability Maturity Schedule (Details)
$ in Thousands
Aug. 31, 2019
USD ($)
Leases [Abstract]  
Remainder of 2020 $ 1,142
2021 1,251
2022 1,118
2023 1,138
2024 576
2025 and thereafter 0
Total lease payments 5,225
Less: Imputed Interest 130
Total lease obligations 5,095
Less: Current portion of lease obligations 1,606
Long-term lease obligations $ 3,489
XML 62 R58.htm IDEA: XBRL DOCUMENT v3.19.3
Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Segment Reporting Information [Line Items]    
Net sales $ 66,042 $ 63,943
Vascular Interventions & Therapies    
Segment Reporting Information [Line Items]    
Net sales 28,913 28,598
Vascular Access    
Segment Reporting Information [Line Items]    
Net sales 23,159 23,790
Oncology    
Segment Reporting Information [Line Items]    
Net sales $ 13,970 $ 11,555
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Intangible Assets - Narrative (Detail)
3 Months Ended
Dec. 31, 2018
USD ($)
Aug. 31, 2019
USD ($)
segment
Aug. 31, 2018
USD ($)
Finite-Lived Intangible Assets [Line Items]      
Number of reporting units | segment   1  
Goodwill impairment $ 0    
Amortization of intangibles   $ 3,868,000 $ 3,434,000
Minimum      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets other than goodwill   2 years  
Maximum      
Finite-Lived Intangible Assets [Line Items]      
Estimated useful life of intangible assets other than goodwill   18 years  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.19.3
Long Term Debt - Narrative (Detail) - Credit Facility - JPMorgan Chase Bank, N.A., Bank of America, N.A., Keybank National Association
Jun. 03, 2019
USD ($)
covenant
Aug. 31, 2019
USD ($)
Debt Instrument [Line Items]    
Debt default interest rate increase (percentage) 2.00%  
Maximum total leverage ratio 3.00  
Maximum total leverage ratio subsequent to material acquisitions 3.50  
Minimum fixed charge coverage ratio 1.25  
Revolving Credit Facility    
Debt Instrument [Line Items]    
Line of credit $ 125,000,000.0  
Line of credit accordion feature $ 75,000,000.0  
Debt instrument term (years) 5 years  
Number of covenants | covenant 2  
Borrowings outstanding   $ 0
Minimum    
Debt Instrument [Line Items]    
Commitment fee (percentage) 0.20%  
Minimum | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate (percentage) 0.25%  
Minimum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate (percentage) 1.25%  
Maximum    
Debt Instrument [Line Items]    
Commitment fee (percentage) 0.25%  
Maximum | Base Rate | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate (percentage) 0.75%  
Maximum | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility    
Debt Instrument [Line Items]    
Basis spread on variable rate (percentage) 1.75%  
XML 65 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Statement of Comprehensive Income [Abstract]    
Net loss $ (1,275) $ (469)
Other comprehensive loss, before tax:    
Unrealized gain on marketable securities 0 33
Foreign currency translation (151) (125)
Other comprehensive loss, before tax (151) (92)
Income tax expense related to items of other comprehensive income 0 0
Other comprehensive loss, net of tax (151) (92)
Total comprehensive loss, net of tax $ (1,426) $ (561)
XML 66 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Stockholders' Equity - 3 months ended Aug. 31, 2019 - USD ($)
$ in Thousands
Total
Restricted stock units
Common Stock
Common Stock
Restricted stock units
Additional paid in capital
Additional paid in capital
Restricted stock units
Retained earnings
Accumulated other comprehensive loss
Treasury Stock
Beginning Balance at May. 31, 2019 $ 614,815   $ 372   $ 555,040   $ 66,469 $ (1,352) $ (5,714)
Beginning Balance, Shares at May. 31, 2019     37,984,382            
Beginning Balance,Treasury Shares at May. 31, 2019 (370,000)               (370,000)
Net loss $ (1,275)           (1,275)    
Exercise of stock options 531   $ 1   530        
Exercise of stock options, Shares     48,136            
Issuance/Cancellation of restricted stock units   $ (2,459)       $ (2,459)      
Issuance/Cancellation of performance share units and restricted stock units, net, Shares       287,087          
Purchases of common stock under ESPP 628       628        
Purchase of common stock under ESPP, Shares     40,270            
Stock-based compensation 1,984       1,984        
Other comprehensive income, net of tax (151)             (151)  
Ending Balance at Aug. 31, 2019 $ 614,073   $ 373   $ 555,723   $ 65,194 $ (1,503) $ (5,714)
Ending Balance, Shares at Aug. 31, 2019     38,359,875            
Ending Balance,Treasury Shares at Aug. 31, 2019 (370,000)               (370,000)
XML 67 R73.htm IDEA: XBRL DOCUMENT v3.19.3
Subsequent Events (Details) - USD ($)
$ in Thousands
Oct. 02, 2019
Aug. 31, 2019
May 31, 2019
Subsequent Event [Line Items]      
Contingent consideration for acquisition earn outs   $ 11,830 $ 13,486
Eximo Medical, Ltd. | Subsequent Event      
Subsequent Event [Line Items]      
Aggregate purchase price $ 45,800    
Technology And Revenue Milestones | Eximo Medical, Ltd. | Subsequent Event      
Subsequent Event [Line Items]      
Contingent consideration for acquisition earn outs $ 20,000    
XML 68 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Inventories
3 Months Ended
Aug. 31, 2019
Inventory Disclosure [Abstract]  
Inventories INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Raw materials
$
17,443

 
$
16,045

Work in process
8,539

 
6,786

Finished goods
19,247

 
17,240

Inventories
$
45,229

 
$
40,071



The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at August 31, 2019 and May 31, 2019 was $4.1 million and $4.2 million, respectively. Of the $4.1 million reserve as of August 31, 2019 and the $4.2 million reserve as of May 31, 2019, $0.4 million relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017 and $0.7 million relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018.
XML 69 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
3 Months Ended
Aug. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 8.3% in the first quarter of fiscal 2020, as compared to 17.8% for the same period in fiscal 2019. In fiscal 2020, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible stock based compensation).

The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence that the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.

Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of August 31, 2019. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.
XML 71 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Segment and Geographic Information (Tables)
3 Months Ended
Aug. 31, 2019
Segment Reporting [Abstract]  
Summary of Net Sales by Product Category
The table below summarizes net sales by Global Business Unit: 
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
Vascular Interventions & Therapies 
$
28,913

 
$
28,598

Vascular Access
23,159

 
23,790

Oncology
13,970

 
11,555

Total
$
66,042

 
$
63,943


Summary of Net Sales by Geographic Area
The table below presents net sales by geographic area based on external customer location:
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Net sales
 
 
 
United States
$
52,937

 
$
51,496

International
13,105

 
12,447

Total
$
66,042

 
$
63,943


XML 72 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Inventories (Tables)
3 Months Ended
Aug. 31, 2019
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Raw materials
$
17,443

 
$
16,045

Work in process
8,539

 
6,786

Finished goods
19,247

 
17,240

Inventories
$
45,229

 
$
40,071



XML 73 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Accumulated Other Comprehensive Income (Loss) (Tables)
3 Months Ended
Aug. 31, 2019
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in each component of accumulated other comprehensive loss, net of tax, are as follows for the three months ended August 31, 2019:
 
Three months ended August 31, 2019
(in thousands)
Foreign currency translation loss
Balance at May 31, 2019
$
(1,352
)
Other comprehensive loss before reclassifications, net of tax
(151
)
Amounts reclassified from accumulated other comprehensive loss

Net other comprehensive loss
$
(151
)
Balance at August 31, 2019
$
(1,503
)

XML 74 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Intangible Assets - Intangible Assets (Detail) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items $ 258,302 $ 258,189
Accumulated amortization (116,647) (112,802)
Net carrying value, finite intangible items 141,655 145,387
Product technologies    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 182,968 182,971
Accumulated amortization (77,967) (75,412)
Net carrying value, finite intangible items 105,001 107,559
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 60,147 60,166
Accumulated amortization (26,995) (25,950)
Net carrying value, finite intangible items 33,152 34,216
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 9,300 9,300
Accumulated amortization (6,470) (6,404)
Net carrying value, finite intangible items 2,830 2,896
Licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross carrying value, finite intangible items 5,887 5,752
Accumulated amortization (5,215) (5,036)
Net carrying value, finite intangible items $ 672 $ 716
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Additional Information (Detail)
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Income Tax Disclosure [Abstract]    
Estimated federal statutory income tax rate 8.30% 17.80%
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.19.3
Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales $ 66,042 $ 63,943
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales 52,937 51,496
International    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Net sales $ 13,105 $ 12,447
XML 77 R72.htm IDEA: XBRL DOCUMENT v3.19.3
Accumulated Other Comprehensive Income (Loss) - Schedule (Detail) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning Balance $ 614,815  
Net other comprehensive loss (151) $ (92)
Ending Balance 614,073  
Accumulated other comprehensive income (loss)    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning Balance (1,352)  
Ending Balance (1,503)  
Foreign currency translation loss    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning Balance (1,352)  
Other comprehensive loss before reclassifications, net of tax (151)  
Amounts reclassified from accumulated other comprehensive loss 0  
Net other comprehensive loss (151)  
Ending Balance $ (1,503)  
XML 78 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Income Statement [Abstract]    
Net sales $ 66,042 $ 63,943
Cost of sales (exclusive of intangible amortization) 27,825 27,990
Gross profit 38,217 35,953
Operating expenses:    
Research and development 6,292 7,374
Sales and marketing 19,380 18,405
General and administrative 8,453 8,435
Amortization of intangibles 3,868 3,434
Change in fair value of contingent consideration (448) 12
Acquisition, restructuring and other items, net 1,500 4,422
Total operating expenses 39,045 42,082
Operating loss (828) (6,129)
Other (expenses) income:    
Interest expense, net (465) (917)
Other income (expense), net (98) 114
Total other expenses, net (563) (803)
Loss from continuing operations before income tax benefit (1,391) (6,932)
Income tax benefit (116) (1,228)
Net loss from continuing operations (1,275) (5,704)
Income from discontinued operations, net of income tax 0 5,235
Net loss $ (1,275) $ (469)
Loss per share continuing operations - basic (usd per share) $ (0.03) $ (0.15)
Loss per share continuing operations - diluted (usd per share) (0.03) (0.15)
Income per share discontinued operations - basic (usd per share) 0.00 0.14
Income per share discontinued operations - diluted (usd per share) 0.00 0.14
Loss per share    
Basic (in usd per share) (0.03) (0.01)
Diluted (in usd per share) $ (0.03) $ (0.01)
Basic weighted average shares outstanding (in shares) 37,783 37,323
Diluted weighted average shares outstanding (in shares) 37,783 37,323
EXCEL 79 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +=\1$\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ MWQ$3R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " "W?$1/4\4+P>\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/3L,P#(=?!>7>NEG+)**N%Q GD)"8!.(6)=X6K?FCQ*C=VY.6 MK1."!^ 8^Y?/GR6W*@CE([Y$'S"2P70SVMXEH<*&'8B" $CJ@%:F,B=<;NY\ MM)+R,^XA2'64>X155:W!(DDM2<($+,)"9%VKE5 1)?EXQFNUX,-G[&>85H ] M6G24@)<<6#=-#*>Q;^$*F&"$T:;O NJ%.%?_Q,X=8.?DF,R2&H:A'.HYEW?@ M\/[\]#JO6QB72#J%^5B:3XF MUQ]^5V'KM=F9?VQ\$>Q:^'47W1=02P,$% @ MWQ$3YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " "W?$1/JF8D$UD# "I$ & 'AL+W=O,C]:>[I.DVQYU771W MYJ0;=V9OVKJP[K ])-VIU<7.%]55(M-TDM1%V<2KA6][;%<+<[95V>C'-NK. M=5VTO]>Z,I=E+.+WAJ?R<+1]0[):G(J#_J;M]]-CZXZ2L9==6>NF*TT3M7J_ MC!_$_49-^@*O^%'J2W>S'_53>3;FI3_XO%O&:3\B7>FM[;LHW.95;W15]3VY M[L<1G/XFBG]\6YLD_F\DD/$\KC M:)C]%_VJ*R?O1^(\MJ;J_&^T/7?6U$,O;BAU\7;=EHW?7JYGLFPHPP5R*)!C M@9+_+5!#@1H+A'=(KB/S4_U0V&*U:,TE:J]IG8K^IA#WREW,;=_HKYT_YV;; MN=;75;I(7OMN!L7ZJI W"C$J$M?W:""1P5J2D#3<:D+S'[DG*=A>DC#9.^Q.Q+\'8/ MTT<:S@6S+RG76?AJ01KF:2DQ^Y)RG85O%Z#A3##ZDF*=D5N,:C@33+ZD5&?A M*PQH.!,,OJ109\%MO!DTF=J MPF@K\,8.<4 :YF&H,-J*8IN'#T.D81Z&BOEN!Y_ES)>4PM@JBF0>WH9 PWVO M*8RM DB29(&&<\'<*L DN>9 $U[SY&;A5^OVX-?(7;0UY\8OT&]:QW7X@U]I M)G_EUT7\UZ(]E$T7/1OKEI]^D;@WQFHWE/3.3?BHB]UX4.F][7>G;K^]+IZO M!]:&PO M=V]R:W-H965T&ULE9C;;N,V$(9?1="](W(HB53@&(A5%"W0 M L$6VUXK-GW 2J(KR?'V[:M3O,K,L$%O8HGYA_,/#Q]MKF^N^=:>K.V"[U59 MMT_AJ>LNCU'4[DZV*MH'=[%U_Y^#:ZJBZU^;8]1>&EOLQZ"JC$"(-*J*\.7\_'4#0W19GTICO8/VWV] MO#3]6W3O97^N;-V>71TT]O 4/LO'7*DA8%3\>;:W=O$<#*6\.O=M>/EU_Q2* MP9$M[:X;NBCZCS>;V[(<>NI]_#UW&MYS#H'+Y_?>?QZ+[XMY+5J;N_*O\[X[ M/84F#/;V4%S+[HN[_6+G@I(PF*O_S;[9LIVX]]@=VT[5\V]]%:J MXOOT>:['S]O<_WL8'P!S -P#^MS_%:#F /4C(!Z+GYR-I?Y4=,5FW;A;T$RS M=2F&12$?53^8NZ%Q'+OQ?WVU;=_ZMDFR=?0V]#-+MI,$%A)Y5T1]Y_<,P&78 M @F'CPERJD@%GT&Q-:@Q/EG&>QS&;'P\QJME/+*XG23I**DG22IB7 BC4EFL M>"\)ZR6A7A3R,DGB11;0!A+DA5-EF6=<4]9+2KW$R$M*LB@#4B,OC"K)$L^X M:-:+IG.<\/&&C3>TEA358HC+%#(\Q52DE8YY)QGK)*-.T'AM,Y)$9LH(9(51 MF5AX1D4*?OL+ZL;@_2]((A,G:%7FK$KYW'A@)*D;0B/)+#GL.>=4L?+,DV3! M]2R!N-$"NP&29Q7'Q U52?!XX1$G%?4BL1=%LR0"KQI&%&I,3PE!>,J(Z-+15+Z1H:GIZ3XU!B? MDI)QE>!C-.=41G@.)>#Q"12?&N,3*!A74F5H]^:<+,V49R, #U"@ -48H$#1 MN)(RQ78X%2SVRT<[/$&!$A2?8EM@""H!K_:!8/\!0%2E&#*0J4CQBA MC"0!WU$'/$*!(M1@A +]/LD.#2.+4P^R@"L\9\YH>5>?WP0 8*9(.!#!2U9.5HXJ6WXEO$/(V!TMA@&@,% M+;%B_H\5'L:0D8/.>(X6Q0-448 :#-!9\]D\>V2>7X**!ZBB #48H+/FLWW@ MD?G\\ 15E* 9)JBB:%1:X^V;LS(%G@-/>7YJ4X+BDVRK*!Y9/YR,^HD6-QF5 M;8[CI4\;[-RU[H9+@T7K_6+I&8:;$-2^E8_Y=#WTHYOIMNKWHCF>ZS9X=5WG MJO$VY.!<9WN7XJ%?W"=;[.\OI3UTPZ/NGYOIEFAZZ=QEO@&+[M=PFW\!4$L# M!!0 ( +=\1$_QK=4T80( -P' 8 >&PO=V]R:W-H965T&ULC55=;YLP%/TKB/<6S#<1B=1DFC9IDZ).VYX=]I!*]^<*&NP MD%MV]GC' !\UJ2%>X/N)U^"Z=3>%CNW9IJ 70>H6]LSAEZ;![.\6".W7+G)? M H_UN1(JX&V*#I_A!XB?W9[)G3=E.=8-M+RFKX<- M7ZO#ZD^!5J$\S%(%]=GI=](ME]'K)@\*[ZKRC)#M EF$#0A/)E\JA#8*FR# M!=THL%LB$M]>(;1Z"#4_GGL([?S(RH\T/YSQ,_,,!DBB(:V&W*$@C0TC%E24 MY'8IL55*O+02V?F)E9\LK.2&R.T B68B?.,_4*B)=BD@,$>FBQ!V* MD:'#!@IBNY+,JB1;*DD-)=E'E%A LVOR1DAN%9(OA62&D/R_W^4]Q!L-R+?? M=7^I(C^IAGFWG?,SG7+G0,5LF/KOGJB5( 4 MZ=_+6UW)43MM")R$6J9RS89Y,VP$[<99ZDT#??,/4$L#!!0 ( +=\1$]" M7C>91 0 )D4 8 >&PO=V]R:W-H965T&ULA9AAC^(V M$(;_"N+[73(SMI.L6*1"5;52*ZVN:OLY"V9!EQ":9)?KOZ\3LAS,C/>^0!)> MC]]Q[,>#%^>F_=KMO>]GW^KJV#W.]WU_>DB2;K/W==E];D[^&'[9-6U=]N&V M?4FZ4^O+[=BHKA),4Y?4Y>$X7R[&9T_M) L%Z?RQ?_I^[].3VVX2ZY1MH?:'[M#UF2& M!J/B[X,_=S?7LR&5YZ;Y.MS\MGV;7_NJ&B(%'_].0>?7 M/H>&M]?OT7\9DP_)/)>=7S?5/X=MOW^@,?F+LS'5G\N^7"[:YCQK+V_K5 Z3 AXH#.9F>#B.W?A;R+8+3]^6 MD,(B>1L"39K518,W&KQ7K*4"TN^:)#BXVD#5!HX![%T T@.0&H#& '07P+ \ M+AHW:HZC)B=G"I:+5"%FSH#NQJANC.+&,C<7C;GIA]":E+F1*D,VRW0S5C5C M%3..F;&R&XO(AT91I6D6&1FGFG&*F8R9<;*;@K@7193&IDRF6LD4*SFSDHE> MP+GP I@9*2.P6$260*[:R14[+.E5+OI!2\3F^5I1&;2Y;J90S132#+"IN2I$ M-P593@8IHIRL;@52'5&I8D8P*I5ORH"SEI-*TUG*(RL*(M0$Q1)R2R!S-YES MCEOZH>[>DDY00,42<4LHNG)%&B#(+4G=@$J*S"'0F0PDJ0XF$D('*2@D!4Y2 MD) $EV<A(26;3-.)%)RHH2 6.5)"PS+.-(@$T)HWP%'6>HL)3 MY#Q%R4DPY/A>K,JLB0U/I!Y5:(J1JB..DE1(2DOQU]D>2>R,Z1%&!*'%PH<0C97RW4T6Q M5:E3%!6*%(U>40*55(!RHI0"6.KTET>S*A%N^*3BW>DYLSHN'0[H^R M?3D1R_\!4$L#!!0 ( +=\1$]V+I)P<0( -D( 8 >&PO=V]R:W-H M965T&ULC9;=CMHP$(5?)&S D MVB1.;4.V;U_;R;+$F87E@MC.F3/?)-8XBXZ+9UDPIKR7NFKDTB^4:N=!(/<% MJZF<\98U^LZ1BYHJ/16G0+:"T8,-JJL@1"@):EHV_FIAU[9BM>!G594-VPI/ MGNN:BG]K5O%NZ6/_=>&I/!7*+ 2K14M/["=3O]JMT+/@ZG(H:];(DC>>8,>E M_PG/-S@T 5;QNV2=O!E[II0=Y\]F\NVP])$A8A7;*V-!]>7"-JRJC)/F^#N8 M^M><)O!V_.K^Q1:OB]E1R3:\^E,>5+'T,]\[L",]5^J)=U_94%#L>T/UW]F% M55IN2'2./:^D_??V9ZEX/;AHE)J^]->RL=>NOY/D0Q@<$ X!X34 1W<#R!! MW@*(+;XGLZ5^IHJN%H)WGNC?5DO-IL!SHA_FWBS:9V?OZ6JE7KVL,$D7P<48 M#9IUKPEO-.%8L9DJ,'K3!)K@BA&"&*$UB$<8&6Q 0 -B#TUTDR5& M]N?0/-:-@!(0* & G,VT3B:)7)1[BA%$"D*D 1Q(-*'$/<4(X@,A,@ "&V)9KI[%/H[XSJIV%&98:K'HC]L^XGB M[? A$5R_9E;_ 5!+ P04 " "W?$1/;8"^"E4$ "\% & 'AL+W=O MX^KODR .;X^]]K^8;R\5?7WYNA<._M1%N=F M-3^V[>4I")KMT95Y\ZFZN'/WGWU5EWG;W=:'H+G4+M\-CZNPL>47:GTIV;4W6>U6Z_FC^KITR;OL&@^//D;LWD>M:G\EI5W_N;7W>K M>=@[C\T6??<'K]'OW+D'R7S&O>N*PJ_CKM MVN-JGLQG.[?/KT7[M;K]XL:$XOELS/XW]^:*3MX[Z?K85D4S_)UMKTU;E6.4 MSDJ9_[C_GL[#[VV,_]X,-Z"Q 3T:='W_5P,]-M _&T1#\G=G0ZJ?\S9?+^OJ M-JOOHW7)^TFAGG17S&W_<*C=\+\NVZ9[^K964;H,WOI HV9SU]!4\U $7?1' M%X2ZV)!H3A\[R*3"A+@'#9/00_MX:C#V!(A@@&@(H"807(>) M% M-F:9 %5D4FPEAE9BD(NGW 8&,"(7%?-D[IIH8C.FT+)<@"A./;E8:,4"*YI9 ML:(7E281LR)%Y!WA!%I)A!4;,B>)Z&0110ES(D6*L(\4^DA!25BVFU0:46*F M(9&G(BK$2S\$7F*^]D-0%3Z(&5(1)1X['A(I8,=P.TITE*;!8AF36>,BM,"\5 ";'\D9) M&"YL9+@=H%+=[L[C!T-326JJ24JC'\!-98T6!4(Z'9%O"F%^*@!0PU]O"L#1 MQ%I,(2!+$JNQ(<(4I5 N"^,+@"? MX2\&DFA;3-_)HYW_#4#" "0 0,.7*$FX"2. D=J&O@5!F($D-XK*\ 4ZBEAE M(C%20*:M?ZPP4@GL%XWGQ4N8@@0H:/@W &\*4UQ* J-A.3;K!$&(0$0BOT: M2<19664I\EG!#"3 0,L92(AM%/*7,)*1\LY!3$ "!+2<@(2VAUH.EI39T+,M MT)A_&NPB+=_D:[ _5#JV_%,S0T(RD<\2YJD&/.7[AXU&/#5\Q*!J\B+Y: ?C M5 .<\NW\1B.<1CI-^;3,IW3U83@>:V;;ZGIN^].5R=/'$=PS]6=&[/E&/67W@[2?8>[G>K_G]>%T M;F:O5=M6Y7!NM*^JUG46PT]=I8XNWSUN"K=O^TO;7=?W\[3[35M=QK/"X'%@ MN?X74$L#!!0 ( +=\1$_DUFCP=@, &4. 8 >&PO=V]R:W-H965T M&ULC5==>#,)H?DC7_G]8_#TOY.Z)! VA1?Q,^:FZN+>:5%Z%>&\&Z^W4=AM'/..;N@F1R,N1+WB6 M-9&DC]\JJ-UK-L3+^\_HJS9YFU_:_-1U2)74:25//G37=.BO9Y4_$\:3O 4P>L) MA(P2J"+0GN#148*O"/Y989S %('U!,I&"8$B!&=+X2@A5(2P)_CQ*"%2A.B< M0S1*B!4A/NV/AB$Z9H%A/!VS-#$,2-UC8:B.66$8 M7\<\8!BF8QX1# 66UQ@&:#UA6D&/<>3\]T7P\")X;02J10A!$3I,T&**%A,0 M/R(@J:4)HR%(:F5B&&.N#VKQB"@&?A"#&3)1-X0R(/F$H%A(?'R6*#Y+%)FE M"*3?87PM_3CRZ<5:U*1\7,I'I$#B<]^0NJ&A*_] ZM=QFB.&.V*&([B]Y@RI MA!?"5<],.QI*,Q/@9@)S>F+8- )#AU'0-):!X1@@5EB4@8D+<:\AXA7Z" T5 MN;/HP!Z.<)T(T0$56D1FA3R?@87U< VEN8EQ-S'B!O31^]C(VHM"]Z+Q:$+- M28,>("XB!5KD7($NM0(/[-W5%9#N9N@X(X@;V",52*NWZX4#ZXH,-&V"=.TX M@(E[AA2)X6FUNH;2_0RT1X+TQQB>(L1LD#>$@?VPOH;2_0ST4((TT3B"?GSL M6'-#"DMFXB@$K1"0/-A"#^ >,5%F+-HU I.SX()H3QAL^&PC _V=F V>Q#&< M!;-YTXBR.!KJWV2@@1.S@WOPX)H3L_GB)]Q_ #M7SL5K:?,!]BTIW]*BLEY% M+=]QV]?0G1 UET'=6YGK7G[S]8.,[^KF-I3W9??ATPUJ<5 ?=4[_93G[!U!+ M P04 " "W?$1/:D(1P[,! #2 P & 'AL+W=OO&C5N9RVWO<'QES9@A;NRO30X4UMK!8> M3=LPUUL0501IQ7B2?&!:R(X66?2=;)&9P2O9P"'A-&MSB14"I[L,G8)1'/,<8KAJYCW"(;L2PJ^E>+(_X+S;7BZJ3"-\.O?%/Z#8+]) ML(\$Z7]+W(I)_TC"5CW58)LX38Z49NCB)*^\R\#>\O@F[^'3M#\(V\C.D;/Q M^+*Q_[4Q'E!*JVF3-NG4:>MG+G$25 @9D$OW[V=(FF9; MM"^ C=_SLS'9:.R+:P$\>=6J^/C+FR!2WFAPYO:6"T\FK9AKK<@ MJ@C2BO$DN65:R(X66?2=;9&9P2O9P=D2-V@M[*\3*#/F=$??'$^R:7UPL"+K M10/?P'_OSQ8MMK!44D/GI.F(A3JG][OC:1_B8\ /":-;G4FHY&+,2S ^5SE- M@B!04/K ('"[P@,H%8A0QL^9DRXI W!]?F/_&&O'6B["P8-1S[+R;4[O**F@ M%H/R3V;\!',]!TKFXK_ %12&!R68HS3*Q964@_-&SRPH18O7:9==W,?I)DUG MV#: SP"^ .YB'C8EBLH?A1=%9LU([-3[7H0GWATY]J8,SMB*>(?B'7JO!4_V M&;L&HCGF-,7P5>9>!O>?Q3=[#IVG_*FPC.TX 0 T@, !D !X;"]W;W)K&UL;5/; M;MP@$/T5Q <$F]U-MBO;4C91U$JMM$K5Y)FUQS8*%Q?P.OW[ G8<)_$+,,.< M,V>&(1NT>;$M@$.O4BB;X]:Y[D"(+5N0S%[I#I2_J;61S'G3-,1V!E@505(0 MFB371#*N<)%%W\D4F>Z=X I.!ME>2F;^'4'H(<(2E.5:(0-UCF_3PW$;XF/ $X?!+LXH5'+6^B48/ZH<)T$0""A= M8&!^N\ ="!&(O(R_$R>>4P;@\OS&_A!K][6"F2O8X[5W$?QIO=;H*M ^@$ MH#-@'_.0,5%4?L\<*S*C!V3&WGA:BB/] J?K\,VJPDV$[SXHW*\3;%<)MI%@\X'@VZ<2 M5V+2Y%,2LNBI!-/$:;*HU+V*D[SPS@-[2^.;O(>/T_Z+F88KB\[:^9>-_:^U M=N"E)%>^U-9_L-D04+MPO/%G,X[9:#C=33^(S-^X^ ]02P,$% @ MWQ$ M3SED\2:T 0 T@, !D !X;"]W;W)K&UL?5/; M;MP@$/T5Q >$-;NY:&5;RB:J6JF55JG:/+/V^*( XP!>IW]?P([CI&Y>@!GF MG#DS#.F YLDV (Z\**EM1AOGNCUCMFA "7N!'6A_4Z%1PGG3U,QV!D0904HR MOME<,25:3?,T^HXF3[%WLM5P-,3V2@GSYP 2AXPF]-7QT-:-"PZ6IYVHX2>X M7]W1>(O-+&6K0-L6-3%09?0VV1]V(3X&_&YAL(LS"96<$)^"\:W,Z"8( @F% M"PS";V>X RD#D9?Q/''2.64 +L^O[%]B[;Z6D[!PA_*Q+5V3T1M*2JA$+]T# M#E]AJN>2DJGX[W &Z<.#$I^C0&GC2HK>.E03BY>BQ,NXMSKNPWBSNYY@ZP ^ M ?@,N(EYV)@H*K\73N2IP8&8L?>="$^<[+GO31&9*D[!R( MIIC#&,,7,6\1S+//*?A:B@/_!\[7X=M5A=L(OWRG\#\$NU6"7238?EKB6LSV M0Q*VZ*D"4\=ILJ3 7L=)7GCG@;WE\4W>PL=I_R%,W6I+3NC\R\;^5X@.O)3- MA2^U\1]L-B14+ARO_=F,8S8:#KOI!['Y&^=_ 5!+ P04 " "W?$1/1\Y@ M_[4! #2 P &0 'AL+W=O& M;$3S8EL 1UZUZFQ.6^?Z(V.V;$$+>X,]=/ZF1J.%\Z9IF.T-B"J2M&(\26Z9 M%K*C119]9U-D.#@E.S@;8@>MA?ES H5C3E/ZYGB63>N"@Q59+QKX#NY'?S;> M8HM*)35T5F)'#-0YO4^/IWW 1\!/":-=G4FHY(+X$HPO54Z3D! H*%U0$'Z[ MP@,H%81\&K]G3;J$#,3U^4W],=;N:[D("P^H?LG*M3F]HZ2"6@S*/>/X!',] M!TKFXK_"%92'ATQ\C!*5C2LI!^M0SRH^%2U>IUUV<1^GFQV?:=L$/A/X0KB+ M<=@4*&;^63A19 9'8J;>]R(\<7KDOC=E<,96Q#N?O/7>:Y$FMQF[!J$9E^6V"_*;"/ KO_EO@1P]/#/T'8 MJJ<:3!.GR9(2ARY.\LJ[#.Q]?$3V#I^F_9LPC>PLN:#S+QO[7R,Z\*DD-[[4 MUG^PQ5!0NW#\Y,]F&K/)<-C//X@MW[CX"U!+ P04 " "W?$1/7?4X(+4! M #2 P &0 'AL+W=O/*J5>LRVGC?'1ES10-:N!O308LWE;%:>#1MS5QG0901I!7CF\TMTT*V M-$^C[VSSU/1>R1;.EKA>:V'?3J#,D-&$?CB>9-WXX&!YVHD:GL%_[\X6+3:S ME%)#ZZ1IB84JH_?)\;0+\3'@AX3!+?Y@_QQKQUHNPL+]EZ9N,'B@IH1*]\D]F^ )3/7M* MIN*_P144A@Y*DU [%C[SL1GC@YW*;L&HBFF-,8PQ---/XC-WSA_!U!+ P04 " "W?$1/XRQ$H;0! #2 M P &0 'AL+W=O).^8%K*G91Y] M9UOF9O1*]G"VQ(U:"_OG!,I,!4WIB^-1MIT/#E;F@VCA._@?P]FBQ5:56FKH MG30]L= 4]#X]G@X!'P$_)4QN-.D:,A"WYQ?U3[%VK.4B'#P8]4O6OBOH'24U-&)4_M%,GV&IYY:2I?BO M< 6%\) )QJB,B\T8L*IJ+%\[S+/N[3?)-E"VV?P!<"7PEW,0Z; \7, M/PHORMR:B=BY]X,(3YP>.?:F"L[8BGB'R3OT7DN>?LC9-0@MF-.,X1M,NB(8 MJJ\A^%Z($W]%Y_OT;#?#+-)OMW2>[ L<=@4.42![L\0=#/^_2+;IJ0;;QFER MI#)C'R=YXUT']I['-_D'GZ?]F["M[!VY&(\O&_O?&.,!4TENL-0./]AJ*&A\ M.+['LYW';#:\&98?Q-9O7/X%4$L#!!0 ( +=\1$\2@ ^+M $ -(# 9 M >&PO=V]R:W-H965TD%@ M&V@Z#!NP 4&+K<^*3=M"=7$E.>[^OI3L>MYF[$42*9[#0XK*!NM>? L0R)M6 MQN>T#:$[,.;+%K3P5[8#@S>U=5H$-%W#?.= 5 FD%>.;S0W30AI:9,EW(/SH3@XM-K-44H/QTAKB MH,[I_?9PW,?X%/!3PN 79Q(K.5O[$HVO54XW41 H*$-D$+A=X &4BD0HXW7B MI'/*"%R>/]@_I]JQEK/P\LZQ"F],[2BJH1:_"HQV^P%3/-253\=_@ @K# MHQ+,45KETTK*W@>K)Q:4HL7;N$N3]F&\X;<3;!W )P"? 76?1!!% MYNQ W-C[3L0GWAXX]J:,SM2*=(?B/7HO!><\8Y=(-,4U 0 T@, !D !X M;"]W;W)K&UL?5/;;MP@$/T5Q >$7;R;1"O;4C91 ME$JMM$K4]IFUQQ<%& ?P.OW[ '98J]DZV& MDR&V5TJ87T>0.&1T2S\=SVW=N.!@>=J)&E[ ?>].QEML9BE;!=JVJ(F!*J-W MV\-Q%^)CP(\6!KLXDU#)&?$U&%_*C&Z"()!0N, @_':!>Y R$'D9;Q,GG5,& MX/+\R?X8:_>UG(6%>Y0_V](U&;VEI(1*]-(]X_ $4SU[2J;BO\(%I \/2GR. M J6-*REZZU!-+%Z*$N_CWNJX#^--DDRP=0"? 'P&W,8\;$P4E3\()_+4X$#, MV/M.A"?>'KCO31&I66W)&YU\V]K]"=."E;*Y\J8W_8+,AH7+A>.//9ARS MT7#833^(S=\X_P!02P,$% @ MWQ$3QO>_$NV 0 T@, !D !X;"]W M;W)K&UL?5-A;]L@$/TKB!]0')*N661;:CI-J]1* M4:=MGXE]ME'!>(#C]M_OP*[GM=:^ '?<>_?N.-+!V&?7 'CRHE7K,MIXWQT8 MR>6IZKV0+)TM< MK[6PKT=09LCHAKXYGF3=^.!@>=J)&KZ#_]&=+%IL9BFEAM9)TQ(+549O-X?C M+L3'@)\2!K M=-,/8O,WSO\ 4$L#!!0 ( +=\1$_8> ( L@$ -(# 9 >&PO=V]R M:W-H965T=6JM1EMG.OVC-FB M 2WL%7;0^IL*C1;.FZ9FMC,@R@C2BO'-YA/30K8T3Z/O:/(4>Z=D"T=#;*^U M,+\/H'#(Z)9>'(^R;EQPL#SM1 T_P#UU1^,M-K.44D-K);;$0)71N^W^L OQ M,>!9PF 79Q(J.2&^!.-;F=%-$ 0*"A<8A-_.< ]*!2(OX]?$2>>4 ;@\7]B_ MQ-I]+2=AX1[53UFZ)J.WE)10B5ZY1QR^PE3/-253\0]P!N7#@Q*?HT!EXTJ* MWCK4$XN7HL7KN,LV[L-XDUQ@ZP ^ ?@,N(T -B:*RC\+)_+4X$#,V/M.A"?> M[KGO31&;)-V3D033&',88O8MXBF&>?4_"U% ?^'YROPY-5 MA4F$7_^E\!V"W2K!+A(D'Y:X%I/\DX0M>JK!U'&:+"FP;^,D+[SSP-[Q^"9O MX>.T?Q>FEJTE)W3^96/_*T0'7LKFRI?:^ \V&PHJ%XXW_FS&,1L-A]WT@]C\ MC?,_4$L#!!0 ( +=\1$_ILF!IM0$ -(# 9 >&PO=V]R:W-H965T M[^?I3LNMYF[$42*9[#0XI*!V/?7 /@R;N2VF6T\;X[,.:*!I1P5Z8# MC3>5L4IX-&W-7&=!E!&D)..;S353HM4T3Z/O9//4]%ZV&DZ6N%XI87\=09HA MHUOZX7AJZ\8'!\O33M3P _QS=[)HL9FE;!5HUQI-+%09O=L>CKL0'P->6AC< MXDQ")6=CWH+QK%"".0HC75Q)T3MOU,2" M4I1X'_=6QWT8;Y+]!%L'\ G 9\!MS,/&1%'Y@_ B3ZT9B!U[WXGPQ-L#Q]X4 MP1E;$>]0O$/O)>?)+F670#3%',<8OHC9SA$,V><4?"W%D?\#Y^OP9%5A$N'[ M/Q3NUPEVJP2[2)#\M\2UF.N_DK!%3Q78.DZ3(X7I=9SDA7<>V#L>W^0S?)SV M[\+6K7;D;#R^;.Q_98P'E+*YPE(;_&"S(:'RX7B#9SN.V6AXTTT_B,W?./\- M4$L#!!0 ( +=\1$^&@5$[M0$ -(# 9 >&PO=V]R:W-H965T=&JM1EMG.L.C-FB 2WL%7;0^IL* MC1;.FZ9FMC,@R@C2BO'-YA/30K8T3Z/O9/(4>Z=D"R=#;*^U,*]'4#AD=$O? M'$^R;EQPL#SM1 W?P?WH3L9;;&8II8;62FR)@2JCM]O#<1?B8\!/"8-=G$FH MY(SX'(S[,J.;( @4%"XP"+]=X Z4"D1>QN^)D\XI W!Y?F/_&FOWM9R%A3M4 MOV3IFHSN*2FA$KUR3SA\@ZF>:TJFXA_@ LJ'!R4^1X'*QI44O76H)Q8O18N7 M<9=MW(?Q)ME-L'4 GP!\!NQC'C8FBLJ_""?RU.! S-C[3H0GWAZX[TT1G+$5 M\<4?"W%D7^ \W5XLJHPB?#K?Q3N MUPEVJP2[2)#\M\2UF,_ODK!%3S68.DZ3)07V;9SDA7<>V%L>W^1O^#CMC\+4 MLK7DC,Z_;.Q_A>C 2]E<^5(;_\%F0T'EPO'&G\TX9J/AL)M^$)N_&PO=V]R:W-H965T?2=3)GKP0FNX&20':1DYNT(0H\%WN!WQQ-O M.Q<E/@ ?M^S\,2; _6]J8(SMB+>>?'6 M>R\EW64YN02BA#E.&+K ;&8$\>QS"KJ6XDC_":?KX=M5A=L8?OU!X7_R[U8) M=I%@^X& ?BIQ#;/]E(0L>BK!M'&:+*KTH.(D+[SSP-[0^"9_X=.T/S+39NQ%$BF>PT.*2@=CWUP#X,F[DMIEM/&^.S#FB@:4<%>F XTWE;%*>#1M MS5QG0901I"3CF\TU4Z+5-$^C[V3SU/1>MAI.EKA>*6%_'4&:(:-;^N%X:NO& M!P?+TT[4\ /\R:+&9I6P5:-<:32Q4&;W;'HY)B(\!+RT,;G$FH9*S,6_! M^%9F=!,$@83"!P:!VP7N0\EYDJ3L$HBFF.,8PQ;ZKR1LT5,%MH[3Y$AA>ATG>>&=!_8N/B+[#!^G_;NP=:L=.1N/ M+QO[7QGC :5LKK#4!C_8;$BH?#C>X-F.8S8:WG33#V+S-\Y_ U!+ P04 M" "W?$1/S4E3];4! #2 P &0 'AL+W=OU MUKX =]Q[]^XXT@'-LVT ''G1JK49;9SK#HS9H@$M[!5VT/J;"HT6SINF9K8S M(,H(THKQS>83TT*V-$^C[V3R%'NG9 LG0VROM3"O1U X9'1+WQQ/LFY<<+ \ M[40-W\']Z$[&6VQF*:6&UDILB8$JH[?;PS$)\3'@IX3!+LXD5')&? [&?9G1 M31 $"@H7&(3?+G '2@4B+^/WQ$GGE &X/+^Q?XVU^UK.PL(=JE^R=$U&]Y24 M4(E>N2<-*BMXZU!.+EZ+%R[C+-N[#>)/L M)]@Z@$\ /@/V,0\;$T7E7X03>6IP(&;L?2?"$V\/W/>F",[8BGCGQ5OOO>0\ MN4G9)1!-,<J8N]DJ^%DB.V5$N;U"!*'C&[HN^.QK1L7'"Q/.U'# M$[COW$.Y<^V=$U&;R@IH1*] M=(\X?(&IGCTE4_'?X +2AP!TL:5%+UUJ"86+T6)EW%O==R'\69W/<'6 M 7P"\!EP$_.P,5%4?B^&PO=V]R:W-H965T':326*M+\%VFN7O&3O9$"#BQ?:,YYPY M,Q[GHW7/O@,(Y$4KXPO:A="?&/-5!UKX.]N#P9O&.BT"FJYEOG<@Z@32BO'= M[@W30AI:YLEW<65NAZ"D@8LC?M!:N)]G4'8LZ)Z^.IYDVX7H8&7>BQ:^0/C: M7QQ:;&&II0;CI37$05/0A_WI?(SQ*>";A-&OSB164U)#(P85GNSX M >9Z,DKFXC_!#12&1R68H[+*IY54@P]6SRPH18N7:9-TD_$9M@W@,X O M@/N4ATV)DO)W(H@R=W8D;NI]+^(3[T\<>U-%9VI%ND/Q'KVWDF>'G-TBT1QS MGF+X*F:_1#!D7U+PK11G_@^<;\,/FPH/"9[]H?"X37#<)#@F@L-_2]R*R?Y* MPE8]U>#:-$V>5'8P:9)7WF5@'](CLM_AT[1_%JZ5QI.K#?BRJ?^-M0%0RNX. M2^WP@RV&@B;$XUL\NVG,)B/8?OY!;/G&Y2]02P,$% @ MWQ$3\&XFDJU M 0 T@, !D !X;"]W;W)K&UL?5-A;]L@$/TK MB!]0$I*T661;:CI-G;1)4:>UGXE]ME'!N(#C[M_OP*[KK5:_ '?<>_?N.)+> MV&=7 WCRJE7C4EI[WQX8)!5[8.#94DK*O@%_G=[LFBQ MB:60&AHG34,LE"F]71^.VQ ? QXE]&YV)J&2LS'/P?A>I'05!(&"W <&@=L% M[D"I0(0R7D9..J4,P/GYC?U;K!UK.0L'=T8]R<+7*=U34D I.N4?3'\/8ST[ M2L;B?\ %%(8')9@C-\K%E>2=\T:/+"A%B]=AETW<^^&&?QEARP ^ O@$V,<\ M;$@4E7\57F2)-3VQ0^];$9YX?>#8FSPX8ROB'8IWZ+UD?'>=L$L@&F..0PR? MQ:RG"(;L4PJ^E.+(/\#Y,GRSJ' 3X;M_%-XL$VP7";:18/-IB4LQ^_^2L%E/ M-=@J3I,CN>F:.,DS[S2PMSR^R7OX,.T_A:UDX\C9>'S9V/_2& \H976%I=;X MP29#0>G#\0;/=ABSP?"F'7\0F[YQ]A=02P,$% @ MWQ$3_:O4&UL;53M;J0@%'T5P@,4 MQ;'M3M2DTTVSF[3)I)OM_F;T^I&"6,"Q??L%M*X[Y8_ Y=QSS@6NV235JVX! M#'H7O-8W\-1V1596:I. M0*\[V2,%=8[OXOTA=7@/>.E@TILYY?0#EGI2C);B M'^$,W,*=$ZM12J[]%Y6C-E(L+-:*8._SV/5^G.:=-%G2P@ET2:!KPJW7(;.0 M=_Z=&59D2DY(S6<_,'?%\9[:LRE=T!^%W[/FM8V>"YI^R\C9$2V8PXRA&TR\ M(HAE7R5H2.) OZ33<'H2=)CX]/0_A[LPP2Y(L/,$R98@CB]*#&"NH[!(&A1) MOQ*DR85(")->B)#-Q0E0C7^R&I5R['V[;*)K5]Q1?_'_X'-+/3'5=+U&)VGL M\_&77$MIP%J)KJR7UG;QNN!0&S>]L7,UO^5Y8>2PM"E9_Q7%7U!+ P04 M" "W?$1/C]4N";8! #2 P &0 'AL+W=O=6JLSEMG>N/C-FR!2WL#?;0^9L:C1;.FZ9AMC<@ MJDC2BO$DN65:R(X66?2=39'AX)3LX&R(';06YL\)%(XYW=$WQY-L6A<X@O+PD(F/4:*R<27E8!WJ6<6GHL7KM,LN[N-TD][- MM&T"GPE\(=S'.&P*%#/_))PH,H,C,5/O>Q&>>'?DOC=E<,96Q#N?O/7>:\%O M=QF[!J$9.?/9AJSR7#8SS^(+=^X^ M02P,$% @ MMWQ$3]M]]F*W 0 T@, !D !X;"]W;W)K&UL M;5/M;ML@%'T5Q ,4A\19%-F6FDY5)ZU2U&GK;V)?VZA\>(#C]NT'V'7=SG^ M>SGGW \NV:#-BVT!''J50MD"*S@;9'LIF7D[@=!#CC?XW?'$F]8%!RFRCC7P M"]SO[FR\16:5BDM0EFN%#-0YOMT<3[N CX _' :[.*-0R47KEV#\J'*Y B"#DT_@[:>(Y9" NS^_J][%V7\N%6;C3XIE7KLWQ :,*:M8+ M]Z2'!YCJ23&:BO\)5Q >'C+Q,4HM;%Q1V5NGY:3B4Y'L==RYBOLPWJ3I1%LG MT(E 9\(AQB%CH)CY=^98D1D](#/VOF/AB3='ZGM3!F=L1;SSR5OOO19TO\O( M-0A-F-.(H0O,9D80KSZ'H&LA3O0_.EVG;UBK!-'&:+"IUK^(D+[SSP-[2^"8?\'':'YEIN++HHIU_V=C_ M6FL'/I7DQI?:^@\V&P)J%X[?_-F,8S8:3G?3#R+S-R[^ 5!+ P04 " "W M?$1/PN1<><8! W! &0 'AL+W=OC>?K:AE*7L#_:] M/N?<#_N2#DJ_F ; HCDTL#*0 MI" TBFZ)9+S%>1I\)YVGJK>"MW#2R/12,OWG"$(-&8[QN^.1UXWU#I*G':OA M%]C?W4D[B\PJ)9?0&JY:I*'*\%U\."8>'P!/' :SV"-?R5FI%V]\+S,<^81 M0&&] G/+!>Y!""_DTGB=-/$++=3;1U M IT(=";L0QPR!@J9?V66Y:E6 ])C[SOFKS@^4->;PCM#*\*92]XX[R6GM[N4 M7+S0A#F.&+K Q#."./4Y!%T+<:2?Z'2=OEG-_T=@NRJP#0*;?TK< M7Y6XAOFR'B19#9)\%MA%5T'6,->=)(N+DZ#K\&0-*E3?AG%9>.>IN*/AXC_@ MXTC]9+KFK4%G9=WS"9=<*67!I1+=N%P:-\6S(:"R?KMS>SV^Y=&PJIO&E,S_ MBOPO4$L#!!0 ( +=\1$_7"D<-M0$ -(# 9 >&PO=V]R:W-H965T M7+2R+6535:W42JM4;9Y9>VRC M@'$ K]._[X =QTG] LQPSID+0S8:^^Q: $]>M>I<3EOO^P-CKFQ!"W=E>NCP MIC96"X^F;9CK+8@JDK1B?+>[85K(CA99])ULD9G!*]G!R1(W:"WLWR,H,^8T MH6^.1]FT/CA8D?6B@5_@?_:-G%4Q% MB]=IEUW]"$^<'#CVI@S. MV(IXA\D[]%X*?LLS=@E",^8X8?@*DRP(ANI+"+X5XLC_H_-M>KJ981KIUVMZ MLM\6V&\*[*- ^J'$]%.)6YC/0=BJIQIL$Z?)D=(,79SDE7<9V/OXB.P=/DW[ M3V$;V3ER-AY?-O:_-L8#IK*[PE);_&"+H:#VX7B+9SN-V61XT\\_B"W?N/@' M4$L#!!0 ( +=\1$^NB&$ Q $ #<$ 9 >&PO=V]R:W-H965T$"CR"$%W)I_)XU\6+IB>OYA_KG4+NKYVS?$>HPIJ-@C[K,8O,->38C07_PTN(!S<9^(\2B5,^*)R,%;)6<6E(MGK M-/(NC..TDVYG6IQ 9P)="/O@0R:CD/DG9EF1:34B/9U]S_P5)P?JSJ;TP7 4 M8<\E;UST4M!=FI&+%YHQQPE#5YAD01"GOEC0F,61_D.G+(&E6KH0KNL MHDM7/-!P\7_@4TL],=WPSJ"SLN[YA$NNE;+@4MG&PO M=V]R:W-H965T#2SZA>;8=@",O6O6VH)USPXDQ M6W6@A;W# 7I_TZ#1PGG3M,P.!D0=25HQGB3OF!:RIV4>?1=3YC@Z)7NX&&)' MK87Y4?V2M>L*>J2DAD:,RCWA]!F6>NXI68K_"C=0'AXR\3$J5#:N MI!JM0[VH^%2T>)EWV<=]FF^R;*'M$_A"X"OA&..P.5#,_*-PHLP-3L3,O1]$ M>.+TQ'UOJN",K8AW/GGKO;>2'Y.?4U!-\+<>;_T?D^ M/=O-,(OT^RV=)_L"AUV!0Q3(M@+IASW\V\YC- MAL-A^4%L_<;E7U!+ P04 " "W?$1/,)I;U+8! #2 P &0 'AL+W=O MUL4IX-&W#7&]!5)&D)..[W0>F1*=ID47?V1:9&;SL-)PM<8-2 MPOXZ@31C3A/ZYGCNFM8'!RNR7C3P%?RW_FS18HM*U2G0KC.:6*AS>I\<3_N MCX#O'8QN=2:ADHLQ+\'X5.5T%Q("":4/"@*W*SR E$$(T_@Y:](E9""NSV_J MC[%VK.4B'#P8^:.K?)O3 R45U&*0_MF,3S#7,@$8Y1&NKB2 MJ%D%4U'B==H['?=QNKE+9MHV@<\$OA .,0Z; L7,/PHOBLR:D=BI][T( M3YP<.?:F#,[8BGB'R3OT7@M^X!F[!J$9&UL;53K;ML@%'X5Q .4A,1M%MF6FD[3)FU2U&G= M;V(?VZAQA\#A^]R#G"G""*S@;9 ^"9MYT+ 5+F/6OA.[@?_=GX%5E4:BY!6:X5,M 4^'%[/&4!'P$O M'$:[FJ-0R47KU[#X4A=X$Q(" 94+"LP/5W@"(8*03^/7K(D7RT!,758-U M6LXJ/A7)WJ:1JSB.T\Y^/]/2!#H3Z$(X1!\R&<7,/S+'RMSH$9GI['L6KGA[ MI/YLJA",1Q'W?/+61Z\E/60YN0:A&7.:,'2%V2X(XM47"YJR.-'_Z#1-WR4S MW$5ZMJ;OLK3 /BFPCP*[?TJ\ORDQA7E(FV1)DRPA<+@Q26$^W)B0U<5),&U\ MLA95>E"Q75;1I2L>:;SXO_"II;XQTW)ET44[_WSB)3=:._"I;.Y\+IWOXF4A MH'%A^N#G9GK+T\+I?FY3LOPKRC]02P,$% @ MWQ$3R^85,W. 0 G 0 M !D !X;"]W;W)K&UL=51M;YLP$/XK%C^@!A-8 M%P%2TVK:I$V*.JW[[,#QHMJ8V29T_WZV(8PQ]TOL.YZ7.\?G;!+R5;4 &KUQ MUJL\:+4>CABKL@5.U9T8H#=?:B$YU2:4#5:#!%HY$F>8A&&*.>WZH,A<[BR+ M3(R:=3V<)5(CYU3^/@$34QY$P2WQW#6MM@E<9 -MX#OH'\-9F@BO*E7'H5>= MZ)&$.@\>HN,IM7@'>.E@4IL]LIU"-[>#@VS<7"A4BK%W,[G)KJ/W0-SM^@N?Y_8;E4W7 M*W01VMQ1=Y-J(3284L([TW!KGHHU8%!KN_U@]G(>F#G08EC> KP^2,4?4$L# M!!0 ( +=\1$^ P 0IX0$ $% 9 >&PO=V]R:W-H965T(#+ ZCX^Q$37:V:=JD32;;=/N;T>,E"V(!Q^W; M%]"UUF7_".?P7NC,2B4DI]J$ MLL:JET!+1^(,DS \8$[;+LA3E[O(/!6#9FT'%XG4P#F5?\[ Q)@%N^ M\=36 MC;8)G*<]K>$'Z)_]19H(+RIERZ%3K>B0A"H+'G:G[Z>5*%3P*]JLM M=9,%QP"54-&!Z2^I_<6[$S%[4]BDVPJW M9HI7)GO+R7V2XIL5FC'G"4-6F-V"P$9]L2 ^BS-Y1R=^^MY;X=[1XS4]^L _ M\@I$3F#_7XO'38L^S+W?)/::Q.\$]F&X,?%A/NCDX#4Y> 3(QL2'V?M-$J]) MXA&(-B8^3+PQP:LCR$'6[O(I5(BA&UL;5/M;ILP%'T5RP]0$Y(T401(3:MJDS8IZK3MMP,7L.H/9IO0O?VN#66L MXX_M>WW.N1^^S@9C7UT+X,F;DMKEM/6^.S'FRA84=W>F XTWM;&*>S1MPUQG M@5>1I"1+D^2>*2XT+;+HN]@B,[V70L/%$MWO,T@SY'1#WQTOHFE]<+ B MZW@#W\!_[RX6+3:K5$*!=L)H8J'.ZH?)O3(R45 MU+R7_L4,GV"J9T_)5/P7N(%$>,@$8Y1&NKB2LG?>J$D%4U'\;=R%COLPWNP/ M$VV=D$Z$="8<8QPV!HJ9/W'/B\R:@=BQ]QT/3[PYI=B;,CAC*^(=)N_0>RNV MR7W&;D%HPIQ'3+K ;&8$0_4Y1+H6XIS^1T_7Z=O5#+>1OE_2=\=U@=VJP"X* M;/\I\?"AQ#7,QR!LT5,%MHG3Y$AI>ATG>>&=!_8AC6_R%SY.^U=N&Z$=N1J/ M+QO[7QOC 5-)[K#4%C_8;$BH?3@>\&S',1L-;[KI!['Y&Q=_ %!+ P04 M" "W?$1/)@,.L;"KC5; M^P>XEW/._>"2C<8^NQ; DQ>M.I?3UOO^Q)@K6]#"W9D>.KRIC=7"HVD;YGH+ MHHHDK1A/DG=,"]G1(HN^BRTR,W@E.[A8X@:MA?U]!F7&G*;TU?$HF]8'!RNR M7C3P'?R/_F+18HM*)35T3IJ.6*AS>I^>SON CX G":-;G4FHY&K,!V@P=0*@AA&K]F3;J$#,3U^57]4ZP=:[D*!P]&_925;W-ZI*2" M6@S*/YKQ,\SU'"B9B_\*-U (#YE@C-(H%U=2#LX;/:M@*EJ\3+OLXCY.-X?C M3-LF\)G %\(QQF%3H)CY1^%%D5DS$COUOA?AB=,3Q]Z4P1E;$>\P>8?>6[%+ M/F3L%H1FS'G"\!4F71 ,U9<0?"O$F?]#Y]OTW6:&NT@_K.F'_\3?;PKLH\!N M76*:O"EQ"_,V"%OU5(-MXC0Y4IJABY.\\BX#>\_CF_R%3]/^3=A&=HY7 MC?VOC?& J21W6&J+'VPQ%-0^'-_CV4YC-AG>]/,/8LLW+OX 4$L#!!0 ( M +=\1$_TRUCBN $ -(# 9 >&PO=V]R:W-H965T;:.5;2F;*&JE5EJE:OO,VF,;!8P+>)W^?0?L.&[B M%V"&<\Y<&++1V&?7 GCRHE7G))-ZX.#%5DO M&O@!_F=_MFBQ1:62&CHG34,L$8I5$NKJ0 ML6L0FC&G"<-7F&1!,%1?0O"M$"?^@EFAFFD'];TPWY;8+\IL(\"Z7\" MZ;L2/V+2)'T7A*UZJL$V<9H<*>9>!O8N/R-[@T[1_%[:1G2,7X_%E M8_]K8SQ@*KL;++7%#[88"FH?CI_Q;*4;%_\ 4$L#!!0 ( M +=\1$]Y&PO=V]R:W-H965T4F FVW]?WB8+ M^+@+7Y) SKV^!_OQ!=;WO/A67K6NG.]IDI4;]UI5MR?/*T]7G4;EI_RFL_J? M2UZD454?%J]>>2MT=&Z#TL3COJ^\-(HS=[MNSST7VW7^5B5QII\+IWQ+TZCX M=Z>3_+YQF?MQXFO\>JV:$]YV?8M>]1^Z^O/V7-1'WB/+.4YU5L9YYA3ZLG$_ MLZ>CI":@5?P5ZWLY^.TT5E[R_%MS\.MYX_I-13K1IZI)$=5?[WJODZ3)5-?Q M3Y_4?8S9! Y_?V0_MN9K,R]1J?=Y\G=\KJX;-W2=L[Y$;TGU-;__HGM#TG5Z M][_I=YW4\J:2>HQ3GI3MIW-Z*ZL\[;/4I:31]^X[SMKO>_>/^@C# ;P/X(\ M)OXW@/H FAL@^@ Q-T#V 7)N@.H#U(^ =H*][F*U5_\05=%V7>1WI^@6T"UJ MUBE[4O7\GIJ3[72V_]434-9GW[?$Q-I[;Q+UFEVGX2.-'&OV2*/&FH.IX6/% M%U.A_+'D:$J8_R.-5YM]..;0,6\3R%&E 4Y , &U"6B4()Q8[32JU61=E2RD MJ1>@(A$J7(R Q0BC&,8G\W?H-&(P#(7^M!93)#G#E4A8B30K,5: - ;A7*UH M4HJIHI HQ,4H6(PRB@G8I!9E7GPYO2I?3)$0W++< EA) %;+"B<(88)P_GI= MP00KLP(^\7E &LOL,Q]O)#Y(8;E2S+(7L?E6&8:;\1EFH8@LX^ ]@(%-8,#= M. 4FEXD%;C%RS&2.N)SNWM)8PT&]T'W+2)@G9@)%7$U'4@:X(EA91\*\, 1, M.!TI !L)64?"8+'PYWOGKA>-/*GI-G'H5#,64F@\8&NNM%PX&X;1R. M0>4FJ-.]\=AKAJZ9U0_'-',&EHQE?7-+JU[0JSD&E2-0)].W@R)+O^&89FXV M8N*6?9YCFKE+#L[ +S(&B!74Y(5M MH'%1M$ ++%(T^:VUZ;40270E[CIY^^@61ZLY3.P_UFTX9X[(CZ2UOMCF7-U_>FM)=-*,+O-SX4SR?7WXBVZW/^ M;/XU[K_S8]-=1=?GW[/_,9COS#SEK=G9 M\E-Q<*=-F(7!P1SSE])]L)<_S61(A\'D_F_S:LHNO*^DT]C;LAU^@_U+ZVPU M9>E*J?(OX[&HA^-E?**RJ1EN(*<&\MI J)\VH*D!_6A @_FQLL'J[[G+M^O& M7H)F[*USW@\*\4#=R]SW-X=W-SSKW+;=W=+ 6 MP%"V5!*\:[2:=>!;)4RN0.BN/"DPNP+!NQQ&4]"\6-*^EX*A%(!*'2]U%._F MV,.^P.P*#73$4D?S;M:>,2LPX@(PKMEPXI"G:I6E'B7,N0"@:]_8QQ2+[/89 M36!(!:!4+^NQ@:B:#QT" Q#3*]PRZF08)%C=OEJYK( MO"NTQ-!( (WT^"7, \5W[,XP#P36(^:7^'JD$I]=PM00H(8\TRIYMI)TAUT, M!(&5AFV,B*\TVF<60T, &K9M(0"-3P8C0QP9OFTAOLX(2I5/"9-%B"S/9H(P M683(8L5RLFB5>8<:)HO0IM&30F&RU!UD*4R6NH4LQ!_B/-/WGS7-1M\&2=L]7P$>!HK3-=QOA=5_/)Y(?K16F.KC]-N_-F_#@R M7CA[GC[\1->O3]MO4$L#!!0 ( +=\1$_?(0NP"P( ,X% 9 >&PO M=V]R:W-H965T8A#R1;4 .GICE*MMW&K= M;Q!250N,J)GH@9LWC9",:'.41Z1Z":1V28PBG"0Y8J3C<5FXV%Z6A3AIVG'8 MRTB=&"/R[PZH&+;Q/+X$GKMCJVT E45/CO 3]*]^+\T)32QUQX"K3O!(0K.- M'^:;W3RQ"0[QNX-!7>TC6\I!B!=[^%9OX\0Z @J5MA3$+&=X!$HMD_'Q.I+& MDZ9-O-Y?V)]<\::8 U'P*.B?KM;M-E[%40T-.5']+(:O,!:4Q=%8_71_Y(63L!C IX2L$M 7L@Y_T(T*0LI MADCZYO?$?N/Y!IO>5#;H6N'>&?/*1,]EFJT+=+9$(V;G,?@*,Y\0R+!/$C@D ML<.?TM,\"1.D08^I(T@_$-QQL @2+!Q!]H$ APFR($$6<)#>=,ECU@[#?9?R M]>R.3!Z4R0,RBQL9CS$7X5UGD<_RL,PR*+,,R&0W,LM/U23W1%9!D55 Y [! M.DBP_O^/9KL1^K>3@(?E[<\= JUN=-#5=6(@CVZ0J*@2)^ZFV%5T&E8/V%W' M=[B?=#^(/'9<10>AS:5V5Z\10H/QDLQ,M:T9KM.!0J/M=FGVTD\8?]"B'Z&ULE59M;YLP$/XKB!]0L,U;JB12DVG:I$VJ.FW[["9. M@@J882?I_OUL0RCU'=/V)=C.W?/<';Z'6UYE]Z).0NC@M:X:M0I/6K?W4:1V M)U%S=2=;T9A_#K*KN3;;[ABIMA-\[YSJ*J)QG$4U+YMPO71GC]UZ*<^Z*AOQ MV 7J7->\^[T1E;RN0A+>#I[*XTG;@VB];/E1?!/Z>_O8F5TTHNS+6C2JE$W0 MB<,J?"#W6QI;!V?QHQ17-5D'-I5G*5_LYO-^%<8V(E&)G;80W#PN8BNJRB*9 M.'X-H.'(:1VGZQOZ1Y>\2>:9*[&5U<]RKT^KL B#O3CP.>UP'_YH8[T,&!C@Z&^V\. M;'!@;PZ)2[Z/S*7Z@6N^7G;R&G3]VVJYO13DGIEB[NRAJYW[SV2KS.EES;+% M,KI8H,%FT]O0B0T9+2*#/E)0C&)#@3M]3["%%EF,,S T">;\TW=)4!P@00$2 M!\"F 'GL5:&WR9Q-XVP\BRVT2"E+\3A2-(X4QI'-U#I# ;)_KT2. N0@@LQ[ M6YO>))FD20E;Y#A+@;(42+V)1U, &D*+8B:9!4JS@,DD'LL"L!0IF7EG),9; M*(8TF=]",2Q:42C@F;MF!&]9PB + MT!T&6>8N ,$;F\#.SOW[/-B\>S?QG 1O'$)TKF0*(7Y).G<9<,;G&0($?.) MLO\APH6 0"5@N=\]!&H!H72N=+@6$$P,?/$E4 WFM97@:D"@'+ \]8F@(*0T MP7DHK@<4Z@'+?4$8C*8?"PIXHLE7O!;=T0T\*MC)&ULE5CMCJLV$'T5Q -<\ P&>Y5$VJ2J M6JF55K=J^YM-G 1=P"DXF]NWK_G87!:/N^3/@ITSXYF#CSVSJYMNOK5GI4SP MO2KK=AV>C;D\15&[/ZLJ;[_HBZKM+T?=5+FQP^84M9=&Y8?>J"HCB.,TJO*B M#C>K?NZEV:STU91%K5Z:H+U65=[\NU6EOJU#%KY/?"U.9]--1)O5)3^I/Y3Y M\_+2V%%T]W(H*E6WA:Z#1AW7X3-[VF'6&?2(OPIU:R?O09?*J];?NL&OAW48 M=Q&I4NU-YR*WCS>U4V79>;)Q_#,Z#>]K=H;3]W?O/_?)VV1>\U;M=/EW<3#G M=2C"X*".^;4T7_7M%S4FQ,-@S/XW]:9*"^\BL6OL==GV?X/]M36Z&KW84*K\ M^_ LZOYY&_V_F]$&,!K W<"N_7\&.!K@#X.D3WZ(K$_UI]SDFU6C;T$S?*U+ MWFT*]H26S'TWV7/7_V:S;>WLVP:S;!6]=8Y&S'; P 3#[HC(>K\O =026W#, MX>,".Q>1QO0*2":!O3W_D(2@'22D@Z1W@-, 9C%N!TC:0^H!DL;)/!,"A3)! M.A9.QL*=6#"3M(.4=) N9R,C'62?LS% DDF>'"3.-LZ.0+%$IG0L@HQ%N&P( MS]Z0I .YG T6TQ*)/^=CQ$Q3913)2DL\,'F"% MUAS#!:R@DRX(R7#."@7CTA%S0RF/\ 59H[;%T 2NIFRY/LW3. M"@43W/>A:2DS5\LH/,<1HQ7(Q .LT!ID<@$KTDD7P3E1"!1D/OT K6=P]8PB M\;B@)0AL.2= 2Q#@@BXKPM6/ MR.87$(5"7WT"M)K!5;-=R5.OT1+$>#DG2$L0W5O0X63$?+R591;/2*%@C'// MYD=:S^CJ&84O)4\9^T =B[0$<4$E.V*FZ69R7O3O"!1GOCL9:34C4RO\#%WO-IO?VA9Y:&A_N!GZZ]_SYE34;?"JC>T,^_[MJ+51-LCXB^7J;%OZ M^Z!41].]9O:]&?K:86#T9>S9H_L_#C;_ 5!+ P04 " "W?$1/,D!,13<" M !#!P &0 'AL+W=OT>9;<5-\[*&H_34K:J8_'4 +MJ=3_SWC>?R6FB[$63;AEWA&^CO MS5&:53"PG,L*:E6*VI-PV?E[LCF0I35PB)<26C6:>S:4DQ"O=O'YO/-#ZQ%P MR+6E8&:XPQ-P;IF,'S][4G_0M(;C^3O[1Q>\">;$%#P)_J,\ZV+G)[YWA@N[ MQ:E MX3:X6Z(><^@P=(0A R(P[(,$Q20.=&8>I0\((M3'R!&LQ@1Q@A,L48*E(XC^ M\H!.@L0P$2ZR0D56",%R(H)A5KC(&A59(P3KB0B&B7&1&!6)$8)D(M)A4H>I M'29<4%PD04421"2=B"2(R(,_)T5%TKD(27$"$N+Y$?[[ST<>I!B9>;$,9SDV M!SW\_PB:9WM"YQ3TP9L0/-/(?Z0:P7.-S!,)B18#35\V&-6P"N3556_EY>)6 MN]8QVATZQ)ZZ&O@'WK67KTQ>RUIY)Z%-)77U[B*$!N-+N##1%J:C#0L.%VVG ML9G+KJQW"RV:OF4%0]_,?@-02P,$% @ MWQ$3RF;-+K@ 0 XP0 !D M !X;"]W;W)K&UL?531;ILP%/T5Y ^H 9NDB@!I MS31UTB9%G;8^.W )J#:FMA.ZOY]M"*6$]07[7LXY/L<8I[U4+[H&,,&;X*W. M4&U,M\-8%S4(IN]D!ZU]4TDEF+&E.F'=*6"E)PF.XS#<8,&:%N6I[QU4GLJS MX4T+!Q7HLQ!,_7T +OL,1>C:>&I.M7$-G*<=.\$O,+^[@[(5GE3*1D"K&]D& M"JH,?8EV^\3A/>!/ [V>S0.7Y"CEBRN^EQD*G2'@4!BGP.QP@3UP[H2LC==1 M$TU+.N)\?E7_YK/;+$>F82_Y! 5C^!]P 6[A MSHE=HY!<^V=0G+618E2Q5@1[&\:F]6,_ZE]IZX1X),03(:*?$LA((.\$XL,/ MSGS4K\RP/%6R#]3PL3KFSD2T(W8S"]?T>^??V;3:=B\Y#>,47YS0B'D8,/$, MLT#L;Q'13 5;!Y.->-5&[ 62^1+1?P3(J@#Q F0F0"A=Y!@P&X]I!TR'3?W^_]DZM2T.CA*8T^N/U^5E :L7GAG!6M[XTP%A\JXZ=;.U?#? M#861W7BEX.E>R_\!4$L#!!0 ( +=\1$]/)9U+ @( 'H% 9 >&PO M=V]R:W-H965T6\LZF?NU4OT> M(7FJH:7RCO?0Z96*BY8J/107)'L!]&R+6H9P$"2HI4WG%YF=.X@BXU?%F@X. MPI/7MJ7B[R,P/N1^Z+]//#>76ID)5&0]O6+?F\)_AQLP+3H\39](^O=-5*MY.+AJEI6]CVW2V'<:5%$]E[@(\%>"Y("3_+8BF@NBC(++A M1S(;]8DJ6F2"#YX87U9/S3<1[B-]F""A+$&;H9HTGS.&KP M0H,_*\JM(@P^-$@3S!C8B8&M0;S<(B1N@\AI$%F#Z%..9)5CU"16TXV4*2'1 M*HM#E00D=L,0)PQQP*0KF%%#%MOLXNA^Q;(5)>DN<:/$3I38@;);H<2;7<)[ M3%; I4.58A*X81(G3+*!"3Z+\3H8!XKWTTV'YNNV^ =02P,$ M% @ MWQ$3RK;D5@& @ F 4 !D !X;"]W;W)K&ULC539;MLP$/P501]@ZK LQY %Q J*%F@!(T739UI>'0@IJB1EI7]? M'HJBV&R0%Y-=;C&GZ"_-4?N3JAF>7<4NA$RSJ/0[7W[\-=L=5X WAJ812+O:>= MG!A[UH=OY[T?Z(* 0"DU U;+!0H@1!.I,OY,G/XLJ1.7^U?V+\:[\G+" @I& M?K=GV>S]K>^=H<(#D8]L_ J3G\3W)O/?X0)$P74E2J-D1)A?KQR$9'1B4:50 M_&+7MC/K:&^2=$IS)T130C0G*.V/$N(I(7Y+B(UY6YFQ^H ESC/.1H_;/ZO' M^IL(=[%J9JF#IG?F3KD5*GK)U\%=ABZ::,(<+"9:8,(9@13[+!&Y) [137KT M7J"X181!Y):(G2YB0Y L782!FV#M)%@;@O@=07C5!HNY,YC.8E97F,*%^8^3 MQ%E(XBCDJET'BPF#A4JP2MTJ&Z?*QJ$2NPE2)T'Z^89OG03;3S1\>]/,8+6^ M$D&+#YT"K\U,$%[)AL[,HT5T'COWD7DH;W [LWY@7K>=\$Y,JN=F'D7%F 15 M2K!25ALU)N<#@4KJ;:KVW X+>Y"LG^8@FH=Q_@]02P,$% @ MWQ$3_C. MI[,C @ R08 !D !X;"]W;W)K&ULC57K;ILP M%'X5Q /4& ,A$4%:$U6;M$E1IVV_G>0DH!I,;2=T;S_;4 ;$K?(G^/+=SG$P M6WGF5W;B3SC%\7*&G;"DY>JHN+O(S#>KGWLOR\\E^="F0649PT]PT]0 MOYJ=T#,TJ!S+"FI9\MH3<%K[7_!JBRW!(GZ7T,K1V#.E[#E_,9-OQ[4?F$3 MX*",!-6/*VR ,:.D<[SVHO[@:8CC\;OZDRU>%[.G$C:<_2F/JEC[J>\=X40O M3#WS]BOT!<6^UU?_':[ --PDT1X'SJ3]]0X7J7C5J^@H%7WKGF5MGVVWDY"> MYB:$/2$<""'^E$!Z OE/2#\E1#TAFCF@KA3;FRU5-,\$;SW1'6]#S;\(KR+= M_8-9M,VV>[H]4J]>\PA'&;H:H1[SV&'""2:>8C8N3#+%;%V8Q8!!.N<0-G2& M#:U /!%(W0+$*4"L )D(+&>5=)C(8FJ+P6Z+R&D1W5J$P:RA'289601NB]AI M$=]8)/,BXAL'DB9I$,R2;!VXB$1CW"1/XLR3W.0AHZY.!!9.@<7]YYHZ!5)' MT_&L);<8$GYPLDNGR=(A$+H%<.!^V8+["\4?O*_XCE(=(!*2F0\:71'FDO]! MQ;FLI;?G2M\V]DXX<:Y "P8/.G*AORO#A,%)F>%"CT5WN783Q9O^PX&&KU?^ M#U!+ P04 " "W?$1/><8J;1H# #.#0 &0 'AL+W=OSN*CFL3U(J8.GJJS;97C0^G@;1>WF(*N\ MO5%'69M_=JJIKA3KILJCE?1.T MIZK*FS]WLE2790CA\\2W8G_0W42T6ASSO?PN]8_C?6-&T37+MJADW1:J#AJY M6X;OX79->1=@%3\+>6E'YT%7RH-2C]W@\W89DLZ1+.5&=RER\E:N5?FKV.K#,DS#8"MW^:G4W]3EDQP*XF$P M5/]%GF5IY)T3+X074T]2TP1PUQ MQ!!W#/')A2 &P1W9&I-QEB:X'8':$8@=@2=(T 3)_(9)T03IC(9)IY6F-!.I MLR"X+ '<3H;:R68T3#9MA"3)A-LOF(S'X&D7(#@7R(R&&42O*B><$'#Q@.D2 MSCV/%'A0!8@E3];%PF/ \"X*B!.:P!!")4 M9)G[;*,ZGG'BL83#!N;0!J8<80SXY-6"R&(*OC7"<0,8;WSW'0<.O($X@",' MYC 'IC3)&"'NJOQ']=H.CAR8PQQ :&)>41,_J(S$N"&*,X?.80Z=LH2:E[CC M!U5EGJ:A.&\HQAL/LJAG6_,&WE"<-W0.;^@4)#Q-7=Q@JH3[]FDX;>@SJ1N*1!1,F$,]%H8]U]Z7S-FWU1M\&#TF:/ M;G?2.Z6T- G)C4EX,!]7UT$I=[H[3UNFS 4AF\%<0$UQGPE(DA-JFF3-BGJM.ZWDYP$5(.9[83N[F<; M0BFX^Q/[F/>\SSF.,7G'Q:LL 93W5K-&;OQ2J7:-D#R64%/YP%MH]),S%S55 M.A07)%L!]&23:H;"($A03:O&+W*[MA=%SJ^*50WLA2>O=4W%WRTPWFU\[-\7 MGJM+J[U9&;P4O%71R,O=, M)P?.7TWP[;3Q U,0,#@JXT#U<(,=,&:,=!E_!D]_1)K$Z?SN_L7VKGLY4 D[ MSGY7)U5N_,SW3G"F5Z:>>?<5AGYBWQN:_PXW8%IN*M&,(V?2_GK'JU2\'EQT M*35]Z\>JL6,W^-_3W GAD!"."3CZ;P(9$LA[ K'-]Y795I^HHD4N>.>)_L]J MJ3D3>$WT9A[-HMT[^TQW*_7JK8A(D*.;,1HTVUX33C3A1\5NJ<#!NP;I"L8R M0F<9H36(IPB>8U?*<13B)9[*=2Q:3;%X.FKS* MYFK]0<6E:J1WX$K?"O;=/7.N0%L&#_I8E/HV'P,&9V6FJ9Z+_D[K \7;X;I& MXS>C^ =02P,$% @ MWQ$3_@,#@QO @ ,0@ !D !X;"]W;W)K&UL?99OKYL@%,:_BO$#7$%0\:9MLKHL6[(ES5UV]YJV MM)JKXH"V=]]^@-;; MV;"OBQO4M4D*0)YTM.GCU<*.;<1JP4^J;7JV$9$\ M=1T5?]>LY9=E#./KP$MSK)492%:+@1[93Z9^#1NA>\GLLF\ZULN&]Y%@AV7\ M"3Y7T 98Q6O#+O*F'9E2MIR_F,!=6/,ZM8VQHGS?%G,HWG MG";PMGUU_V*+U\5LJ605;W\W>U4O8Q)'>W:@IU:]\,M7-A64Q=%4_7=V9JV6 M&Q*=8\=;:7^CW4DJWDTN&J6C[^.SZ>WS,OE?P\(!Z120S@$0_S< 30'H(P#9 MXDP[7:W4H^<51ODB.1NC2;,> M->F-)KU75+X"@@]-H@EFC#2(D5J#[ ZC"!N@H &R!NC.@#AUC)K<:GJKR%DQR=YF$1(]F!X+P@00\ M&)BY.WD2W27* 79/)5]%2@0?X#PX'Z&/XZZ$]22Z/332-"^1R^/+$$'(W=#) MS=EM+M,?5!R;7D9;KO0U8 _K ^>*:4OPI#=FK>_ON=.R@S+-0K?%>(F-'<6' MZ8).YG\)JW]02P,$% @ MWQ$3Y&ULE5?;CILP%/P5Q <$;'/+*HG4356U4BNM6K5] M]B9.@A8P-4ZR_?L:P]($QJLD#\$VI7IJ#$-I[+8NJ6?H'K>N' M(&@V!U'R9B9K49D[.ZE*KDU7[8.F5H)O;5!9!#0,DZ#D>>6O%G;L2:T6\JB+ MO!)/RFN.936(NB M:)E,'G]Z4G_0; ,OVV_LGVSQIIAGWHBU+'[G6WU8^IGO;<6.'PO]79X_B[Z@ MV/?ZZK^*DR@,O,W$:&QDT=A_;W-LM"Q[%I-*R5^[:U[9Z[GG?PO# ;0/H$, MG;\;P/H ]C^@*[[+S);ZD6N^6BAY]E3WM&K>+@KRP,QD;MI!.W?VGJFV,:.G M513%B^#4$O68QPY#KS#)-68]Q; Y&3"!R6%(A,)$J"6(KT123, @ ;,$[(H@ M&U6",',L$D&1:$H0AR.1#A-93-5-!9:(H40,),A(HL-DEQ*S&(LD4"0!(G0D MDDQ$R(PZ5%*HD@(5QUQDD""[?5',(<$<9!"-ZNPPR66=- [M#TN1$%LI!&(3 M+X43M?1],8=O"1!+QF)3$&,N'6Q+0H%..M:ADR5/'2K8NP08,\[&6PR;3)VK M%FQ>,G4O(P[[$VQ.$M^^(@FV'D'>FX]G%( 25[78? 2X+W%LR03;C]SA/X(- M2( #D_%. T&.C8)B\U%@OB1R4&!+47)[M=3Q$@-NF50+08Y]E6*_T*E?&'58 MCF(ST.B.:K$9*'I5C5=;2L^^^-8/CH6?T#4$L#!!0 ( +=\ M1$]>2,X9U0$ &($ 9 >&PO=V]R:W-H965TV;JQSL#SM>0T_ MP?[JSQHMMJB4K83.M*HC&JJ,/H2'4^+P'O"[A=&L]L159Z[BF9B_\.5Q (=YE@C$()X[^D&(Q5IUJ-1$^7U7/W)L)#C,TLG-/WSI]A MM0:]USS9!RF[.J$9$E7<9 ME(?(7>V-_X@#-+WW-YEI^GYP7;>=(1=E\>'XZZV4LH I!G?8I@8'?C$$5-9M M][C7T[.?#*OZ>:+9\EO)_P%02P,$% @ MWQ$3YLK(](? @ %@8 !D M !X;"]W;W)K&ULC57;CILP$/T5Q =@+H&$B"!M MLJI:J96BK=H^.V02T-J8VD[8_GU](2PA;K4OL3V<.>?,@"=%S_BKJ &D]T9) M*S9^+66W1DA4-5 L M9!JYZ<&*=8JB,_(]%QP$>31 F*PS!#%#>M7Q8FMN=E MP2Z2-"WLN20&T]HN!/FLD$=,',1N(ZG32.HPLIP921^-9$'F5LF<*IE#9353 M<6%RM\C2*;)\)%C]XZVNG 2KC[_5W$F0.QQ$LS(M)@JGW8R"9":#)M>) C^; MR2.\BEU:J3_<270<;D^QOHZS^%8-/3NCWFGLQ/R&^;EIA7=@4EUVCRAXDZX8IC,:_@O(O4$L#!!0 ( +=\1$_/ M/!62& ( ,& 9 >&PO=V]R:W-H965T'(DS MA*,H19PV;5CF+K:392[.FC4M[&2@SIQ3^6<#3/1%N JO@>?F5&L;0&7>T1-\ M!_VCVTES0I/*H>'0JD:T@81C$3ZLUMO,XAW@9P.]FNT#6\E>B!=[^'(HPL@: M @:5M@K4+!?8 F-6R-CX/6J&4TI+G.^OZD^N=E/+GBK8"O:K.>BZ"._#X !' M>F;Z6?2?8:PG"8.Q^*]P 6;@UHG)40FFW#.HSDH+/JH8*YR^#FO3NK4?]:\T M/P&/!#P13.Z/"&0DD#="[(H?G+E2'ZFF92Y%'\CA8W74_A.K-3'-K&S0](O0*Q$R#OND 671@PL<.T#D.R;(G:^E $$[^9Q&LF\9B)%V:2FS31 MPLA'B',^G"3':3!B?1THL'1*)/"RMH M=G&PO=V]R:W-H965TUK&\(1XO32 M/\%>9F=G)]B;=I2]\@) 6&]UU?"E70C1+AR'YP74A#_1%AKYYD!9383&PH=6O MAG-_!?TLP)WI#@C0FR]K\2\)" WQ-\W7RO3+?ZB0B2I8QV%NO_K9:H MCP(ML#0S5T'MG7XGN^4R>L[\.$J=LR(:,.L>XTTP:$0XDGTLX9E*K+V;=.^Z MP.86$;KF"MC8!-;YP543L9G -Q+XF@!/!N6%"!TRBXXA9>>I. MG,77:O3HN_*=II];WPD[E@VW=E3(&U??BP=*!4B5[I-TJY"C&ULC57M;ILP%'T5Q /4@/D(%4%J,DV; MM$E1IW6_'7(34&W,;"=T;S_;$,J(N_9/;%_./?><2WPI>BZ>90V@O!=&6[GV M:Z6Z>X1D50,C\HYWT.HG1RX84?HH3DAV LC!)C&*HB!($2--ZY>%C>U$6?"S MHDT+.^'),V-$_-D Y?W:#_UKX+$YU&J@E[.]9ZSL.7\VAZ^'M1\814"A4H:"Z.4"6Z#4,&D= MOT=2?ZII$N?[*_MG:UZ;V1,)6TY_-0=5K_V5[QW@2,Y4/?+^"XR&$M\;W7^# M"U --TITC8I3:7^]ZBP59R.+EL+(R[ VK5W[D?^:YDZ(QH1H2M"U_Y> QP3\ MFA!;\X,R:_434:0L!.\],;RMCI@_17B/=3,K$[2]L\^T6ZFCES)>Y06Z&*(1 MLQDPT0P33@BDV:<2D:O$)KI)C_XML+U%I(&[ G::P#8_F9O(WR"(G02Q)8[>6Q*DEN=&"L]Q-D#H)TH]W(W,29.]W8X#$ M,Y])E.-LT0T'*HSSU*UEY=2RNNW&Z@TSN9,@_W@W]#AR7I'@_7Z,F/F+#W$8 M)(N&N&!1'&<+/6AV>QF(DQUTTJOXN57FGLRBTS!]B,SM7\0W9LC:J?!*,TSH M[T2Z[T;+$3X,BY JTRN-/=JO5'83I0."JSS?1>#)-Q."C>C5,?39^> M\B]02P,$% @ MWQ$3^,4YO=D @ M0D !D !X;"]W;W)K&ULE5;M;ILP%'T5Q ,4S%=(19#63-,F;5+4:=MO)W$"JL', M=D+W]K.-0T-RH?0/_N#'E?L)/:Y1 MJ@,,XG=)6G'5=W0J6\9>].#;?N7Z6A&A9"UFLW-1U]N2 3U0^L_8KL0G%KF.S_T[.A"JX5J*^ ML6-4F*>S.PG)*LNBI%3XM6O+VK2MY;^$P0&!#0CZ !1-!H0V('P+"$WRG3*3 MZF,I!;V, )01&()X(&.$( 0)0D,0#@C"FSPZ3&(P=:<2I:%_DPN M"J,T@<5$H)@($!/!!#%($,\O1P(2)(""^*8<'29ZIQP :KP<"U#, A S0I"" M!.G\E_(%&0H!+8]B@$AZ0@%;'R4?&!= M8+LBR*]WZ[*8M7M L/'M \'V1^F<]4EG[>X0#!#D79V?^D+S _-C60MGRZ0Z MBLV!>6!,$D7I/ZAB%^H.U0\H.4C=7:@^[RX2W4"RQEZ2O/ZFEO\'4$L#!!0 M ( +=\1$],^&9'! ( (L% 9 >&PO=V]R:W-H965T:N3B5;8 *GACM)>;L%5J6",DFQ88D0]\@%[_.7+!B-*A M."$Y"" '6\0HPE&4(T:Z/JPKF]N)NN)G1;L>=B*09\:(^+T%RL=-&(?7Q'-W M:I5)H+H:R F^@WH9=D)':&8Y= QZV?$^$'#EL:O 7\Z&"4BWU@G.PY M?S7!E\,FC$Q#0*%1AH'HY0)/0*DATFW\FCC#6=(4+O=7]D_6N_:R)Q*>./W9 M'52["8LP.,"1G*EZYN-GF/QD83"9_PH7H!IN.M$:#:?2?H/F+!5G$XMNA9$W MMW:]7<>)_UKF+\!3 9X+L//BA&SG'XDB=27X& AW]@,Q5QROL3Z;QB3M4=A_ MNGFILY'A-+D"T(LBCR M$Z1>@M02)/\0Q#@E*3P?9C='R_M9P='N<:/$8 M&(B3'0,R:/BYMR-HD9TGS2.VC^DOW(VI;T2Z[TD[0/Y\BY MU+]*"] MMGHRS@&%HS+;E=X+-Q]!;&U06 M$1"21"7/JW"UL'./S6HACZK(*_'8!.VQ+'GSYT$4\KP,:7B9>,KW!V4FHM6B MYGOQ7:@?]6.C1U'/LLU+4;6YK()&[);A!WJ_9F "+.)G+L[MX#XPI3Q+^6(& M7[;+D!A%HA ;92BXOIS$6A2%8=(Z?CO2L,]I H?W%_9/MGA=S#-OQ5H6O_*M M.BS#- RV8L>/A7J2Y\_"%12'@:O^JSB)0L.-$IUC(XO6_@:;8ZMDZ5BTE)*_ M=M>\LM>SX[^$X0'@ J / /K? .8"V+\ FR'JE-E2/W+%5XM&GH.F>UHU-R\% MO6>ZF1LS:7MG_]/5MGKVM(I)LHA.ALAA'CH,## LHV\Q:P23D!X3:0V]$$"% M@"6(WPB9XP0,)6"6@ T5T/2JD@Z36$QE,92FC%S5@J#8+$UP,3-4S&PD9I;- M<((8)8BGMR-!"1)$07S5C@XS>Z<=",K?CCDJ9HZ(27&"%"5(I[-B! MAFU)8\8\B7![TK$_8Y)Y*'"#TAL<2G&+TK%'D7*3T>-ED/D2X?:C8__%E%PG MZD#I(!&Y\_4$=RE-D3S40X'[E&;3VPJXN6!LKG&U#O2V6N+Y1 -N&D!,0\%# MX5GU;C -X*:!L6F0X8=D"W \P7KB02;[S9YU4;/$NE]])VQ[N34@E-2>ZTZ(,^!/6#0NR4 MN9WK^Z8["70#)6MWRHGZH];J+U!+ P04 " "W?$1/QO%0UL8! " ! M&0 'AL+W=O\,!CU:AXY)T0.8$L"63R,A7RG7^E MAE:%DF.DIKT?J/O$\8[8O:G=HM\*_\XVK^WJI4KCK, 7!YHU^TE#5IKD(5XT MV/*7(B18A'A L@;$#V% $@0D'I#^UV4>!FR#@.U-!VE\_\'FI,F\IO>:>!NN MD09KI+TK@( ,X* 9 >&PO=V]R:W-H965TN?E%R!=UY%Q'KU59JT5\U+JY1TAMC[QBZDXTO#9O]D)63)NM/"#5 M2,YV+J@J$4F2'%6LJ./EW)T]RN591FASJ675'Q6A6BCB3?+^('?+\FJ0UPB.>"7U1O'=E2 M-D*\V,W7W2).;$:\Y%MM*9AYG/F:EZ5E,GG\]J1QIVD#^^LW]L^N>%/,ABF^ M%N6O8J>/BW@:1SN^9Z=2/XG+%^X+RN+(5_^-GWEIX#83H[$5I7*?T?:DM*@\ MBTFE8J_MLZC=\]*^28D/@P.(#R!=@-'^5P#U ?0]P'43M9FY4C\QS99S*2Z1 M;+^MAMD?!;ZGIIE;>^AZY]Z9:I4Y/2\S/)NCLR7RF%6+(3T,[A#(L'<2!))8 MD5$XN198CQ$926 )"E9!'4%V11#(,04)4D= KP@&6:Y:3.XPM6]5DL(J&:B2 M 2ITH-)BTKY*,LM@E1Q4R0&5=*"2CVJ9)(&.3T"1"2 2R'(*$DQO_\IF(,$, MR" ?E#G&4$I@$9S _D@ F5P)[AD">&5YU'M2_46FH6@(; MBQ"@VE"JL+'(!_ZB".P9 GEF5.TMGD&]Z:#B\N &*15MQ:EV4USOM!O6'MS\ M@M[A[:3WGJ/9KALMN4?*_M43?"+O\"4$L#!!0 ( +=\1$^T1=(;[ $ %<% 9 >&PO=V]R M:W-H965T^W $- :3&TG;-^^/K ($?<&>^Q__F_&R"YFQM]$!R"]]X&.HO0[*:P+*YM(/_8^%E_[:2;V JF(B5_@)\M=TYBI"JTO3#S"*GHT>A[;T/X7' M4Z[U1O#:PRPV@2JXK48R: M46&^7GT3D@V+BRIE(.]V[$$O":@!/3BP69RC\32:J"L]GC M]NPGHG]Q>,3J;&J]:(["[*GBA5J]5TF$"W371HOF9#5XHXD.X:I!RG^%8"<$ M&X-D8X#C_QA$3H/(&$3;*O&^2JM)C6:TFC"(W93828D?*5&THUA-O*&$:9"Z M*8F3DC@H\8Z2/%"B.#^X*:F3DCHHR8Z2/IY8<$C]=M(-FT/&-H?4NK?U!+ P04 " "W?$1/NF6_1T " !?!P &0 M 'AL+W=OG&3&A[A.,ZBAM9M6!9N["C+ M0MPUKUMVE(&Z-PV5_PZ,BWX?HO!]X*6^5=H.1&71T1O[R?2O[BA-+YI4+G7# M6E6+-I#LN@\_H=T!)7:"B_A=LU[-VH&UF=%'2=*XB!Y6:(PY M##%X%I-LT103&?T)@D$(=@)D)H#3%8$$%$B<0#(32!.TR'*(R5Q,ZV(02C%, M24%*"E#P@C+$I',*)BM>"$@A "594(A/02B'*1E(R0!*NJ!D "59H6Q RL:C MD'2Y+QN/0C89#,E!2 Y8(0M([D%B&+$%$5O QW+GM[X/C E,03%\V&* L]S[ M,>C#MB0K;M#*H48^QUNR,>B#H7B[9@@^V @#(,\0]@UE\SJ[;- MC6G+H>0/'2VZ\3J+ICNU_ ]02P,$% @ MWQ$3^+Q@3/S 0 6 4 !D M !X;"]W;W)K&UL=93;;IPP$(9?!?$ \6*.60%2 M-U752JVT2M7TV@O#@F(PM;U+^O;U@2 *S@WVF'_^;^R1G4^,OXH60'IO/1U$ MX;=2CD>$1-5"3\0#&V%0?QK&>R)5R*](C!Q(;9)ZBO#AD*">=(-?YF;MS,N< MW23M!CAS3]SZGO"_)Z!L*OS ?U]X[JZMU NHS$=RA9\@?XUGKB*TN-1=#X/H MV.!Q: K_4W \95IO!"\=3&(U]_1.+HR]ZN!;7?@'71!0J*1V(&JXPQ-0JHU4 M&7]F3W]!ZL3U_-W]B]F[VLN%"'AB]'=7R[;P,]^KH2$W*I_9]!7F_<2^-V_^ M.]R!*KFN1#$J1H7Y>M5-2-;/+JJ4GKS9L1O,.-D_23JGN1/PG("7!&PXR(), MY9^))&7.V>1Q>_8CT2T.CEB=3:47S5&8?ZIXH5;O91Q%.;IKHUESLAJ\TH3) M8=$@Y;] L!."C4&\,L!1X#8(G0:A,0A7!NFF1JM(C&*PB$?\09&1DQ'M&%&( M-Q2KB=:4,,S4.(HW ME'1'"3%.W93,2;\(/S:#<*[,*GNE[D%#6,2 ME./A036A5<_<$E!HI)ZF:L[M9;>!9./\CJ'E,2W_ 5!+ P04 " "W?$1/ MZ*ITELX! W! &0 'AL+W=O^DRIS.1K6"S@II$?.J?IS!":G N_PF^.I;SOC'*3,!]K"#S _ MAY.R%EE8ZIZ#T+T42$%3X(?=X9@ZO <\]S#IU1ZY2LY2OCCC:UW@R"4$#"KC M&*A=+O (C#DBF\;OF1,ODBYPO7]C_^QKM[6D*?(=1#0T=F7F2 MTQ>8ZTDQFHO_!A=@%NXRL1J59-I_435J(_G,8E/A]#6LO?#K%$ZR^SEL.R"> M ^(E( ZU!"&?^2=J:)DK.2$5[GZ@KL6[0VSOIG).?Q7^S":OK?=2IOLL)Q=' M-&.. 1.O,+L%02S[(A%O21SC=^')_0<$R6:.B2=(5P3Q_@."_2;!WA,D_Q5Y M>U5DP&0>(P(F2[9%TDV1=$/D[DHD?2<274F05>,XJ-8_68TJ.0H_+BOO,A4/ ML6_\/W@8J>]4M;W0Z"R-?3Z^R8V4!FPBT8W-I+-3O!@,&N.VMW:OPEL.AI'# M/*9D^5>4?P%02P,$% @ MWQ$3Q&ULE59M;YLP$/XKB!]0,.]42:0U:=-(FU1UVO;9 M39P$%3"SG:3[][.-BX(Y6OHEV.9YGKLS=Y>;72A[Y4="A/-6E36?NT4%K MAY']W/V&;C"UWT\GQ H+O)@Q>G%8F],-5J6#;G.97I>1%'^ MO-ON@@/P@@,M$/8$,E@@! 5"+1#W!')8( (%HJ$'B?7YUBTFTIA:8T+81 R: MB $3"!9(0(%D>I I*) "'EBYM4P'00;6/:R&D,Q*T"'"2IGU$!'Y<"@9&$H& MA&*5P#J;^KURT$0.F+ J:)4/3"#KMNX_AZR'D&@D,9 /-R@?\#6V.XL__+1V M8QE"HA%'1CHE AQ)1B3@7H""Z6F.X&Z PL^SX]& )J0'@EL&@GK&2-M#<$M M\1=BA9L"2@ OK'J\,R X5O-_,80$(X[ S05!W64L%KBH4?:%ZX"+%DVHV@T: M%IP=JW4D&DG'\C'3[**;K;E&0OU#*5:]:. MDNU&T,:,R5XWJR_^ U!+ P04 " "W?$1/.AGJ';L" #!"@ &0 'AL M+W=O,74C&EZ;)SLA*Z;-4NXCU4C.MJZH*B,QFH8U4Q^7?%2W%>A"B\;#P4^X.V&]%RWK ]_\GU8W,OS2KJ6;9% MQ6M5B#J0?+<([]#M&F-;X!"_"GY6@_O 2GD2XMDNOFT786P[XB7?:$O!S.7$ MU[PL+9/IXT]'&O9GVL+A_87]BQ-OQ#PQQ=>B_%UL]6$1YF&PY3MV+/6#.'_E MG2 :!IWZ[_S$2P.WG9@S-J)4[C?8')465<=B6JG82WLM:G<]=_R7,K@ =P6X M+S!G_Z^ = 7DM2!QXMO.G-3/3+/E7(IS(-M_JV'VI4"WQ)BYL9O.._?,J%5F M][2D63R/3I:HPZQ:#!Y@4(^(#'M_!(:.6&&O'+\]8.TCTA@^@8 BB*NG;T1, MM)B !(DC( ."07VKHH6D#E*W)M!XY-3:!R4)QG G%.R$>IW0;((@!0G2Z[W( M0(+L?2]:2#*0F::SD14^!N?YQ+^:@XWD@!4$)IB!!+/KK4 QG([X?3,ZS!NE M23IR P A@O*)9B:BB@!#D@D*,(IW"'_ $CAKB%QA"?'4?LI(-O;$1TV\'PA. M+?)C2S,Z00''#=$/& ('#J57&))Z4C.:C_WP05-^P,E%?G1IEDY0P)E#^0?\ M@%.'9E?X,?,SXT7&QR R80B&XXO]^"(Z$3H,APZCZPW!<.@P?M^0#C/\&ULC57;CMHP%/R5*!^PN5] 6D)JEJIE=!6W3Z;<"#1.G%J M&[+]^]I."+D8R@NQG9GQG#'Q21I"/U@.P(W/$E=L9>:"M..9<+UCJIT0E^ O]5[ZB86;W*H2BA8@6I# K'E?GJ++>.(BC$ M>P$-&XP-6D \Y^798F;9T!!@R+B60>%P@!8REDO#QIQ,U^STE<3B^JG]1 MQ8MB]HA!2O#OXL#SE1F;Q@&.Z(SY&VF^0E=08!I=]=_A EC I1.Q1T8P4[]& M=F:&LD_T7.TA?I9W)1A:W>B7B86+VL@RA*K(L4ZC";%N,. M,,X8L9TC@BCN,99PT-MP=38V[DS '6^1SA&A/7'Q2&3DP=-&X2EZ,"K"T0OX M6@%?"7@#@6@2U*:%A I2M5$&]J2.= [R??=.*8'623!S$D2+B946XP^MS)P\ M@=D&,[>A-P"-W(9:MZ'&[9UR(ZU ]/S)Q5J!^/\G%\^B",-)I&D\B\*-XSM1 M++1&%O,H[@DXMOZ#MI\/P[ES)S@:%],\.M#H7SH[=FMP#95 3^J*9T9&SA67 M7^I@M6\CKZZ\QB;K&V>9MLW@)M/VIA^(GHJ*&7O"Q26IKK(C(1R$1_M%I)"+ M=MA/,!RY'$9B3-N>T$XXJ;M^9_5-=_T/4$L#!!0 ( +=\1$\%17V,A@( M !D) 9 >&PO=V]R:W-H965T(%;#-SSLR8XW'<4/;. M,T*$\5$6%=^8F1#UVK)XFI$2\V=:DTI^.5%68B&G[&SQFA%\U$YE83FV'5@E MSBLSB?7:"TMB>A%%7I$79O!+66+V;T<*VFQ,9-X67O-S)M2"E<0U/I-?1+S5 M+TS.K![EF)>DXCFM#$9.&W.+UGL4*@=M\3LG#1^,#97*@=)W-?E^W)BVBH@4 M)!4* LO7E>Q)42@D&3KZ-3*?Z!0NHM+(G>4S@0Q7 D01@) $023"*))A$(C.VPYG*AB!/"/"$,$ $ D3+]W8% JP6 M[.T*J+GKSQ04V;"2[ 4E[8Q&NVO/)(1F-(L IF@& M3D%CG+RXI@T2%W06$[ MHZ65A=6)('FNQDS>8]W<$\'R1( ^5_:8:"K0F<,*P=)#D/;&IP":BN]!.K#V M$"2^R1\93H\2X(^T!@VE).RL>R\W4GJIA#JZ!ZM]?]\ZJB&-UG>J[^M&]0G3 M7AI^8G;.*VXE$Z6"R"CM9UGT3-Y3^DE!3D(-0SEF;;-N)X+6W47$ MZF]#R7]02P,$% @ MWQ$3Z98B*4' @ ^@4 !D !X;"]W;W)K&ULC53;CILP%/P5Q >LN0P\U6M'EJ?T(DC3P9%9_-*VF/W> M :%#9KOVV\)ST+:F\%_@"D3"E1-Y1D$)U[]6 M<>&"MI.*M-+BUW%L.CT.X\XFG&AF@C<1O)G@!O\D^!/!?Y003(3@G>#K:HU1 M=&T.6. \972PV'B[/59_(G<;R.H7:E$76^_)\G"Y>LW#Q$W150E-F-V(\188 M_Q:Q7R.\6\1AC7"==PR2'F>CGM&HIP7"&Z-_$?"- KX6\!<"07*?8\1$&M.- M+MW8=^ZR&%!^$$=F,X'13+ R$R[,W B$1H'P\7)$1H%HY<#WPKN+CU9!@S!V M'/,Q&^,Q&T/0P"P0&P7BQX,F1H'D__>^2U9!9>-&POAX]%WT99$OJW__[G&]7OWP_??5[#%=)%6G6*5+^.6^*!?)&OXL'[ZO5F6: MS*O'-%TO\N_[W>[X^T62+;_[P[]5V1_^;?V'T^)S6D97R4,:'4758U*FU;]] MO_[#OWV//_,C@^A#L5P_5M'9;!XZT: 71_UN[[C^X^5LW8FZ_?"/ M)XMT.8?_KZ.W>?)0__4^R:NT_N6;8K;A-[)JEN31SVE21F_AR\:B^]U^=]?; M5VF9%?/P^W_NU;\Y6ZZS]7-T"@.4\/(Y .-+]!_I<_VY;K?;ZT]&O>FD_LOI MIBSKBP>81F^2=6.G1T?=T=&@L0BSA=OG5>.=7O?HSZTO_'F3E.NTS)^CZW15 ME.OZ@^MRTPYN@53;8A4'_H__];]"!VT772;+*EMGQ;)E$0+CMUF>1A>;Q5U: M-J![-.I.QFV'?+W)'I39I\;O]9'.\6_8'>WQ=.R M_NS[9/V8+':-8 !T51:?L^6L,>7%S[N&N"JJ-=R*_RM;!:';Z_=Z#;#0PD^ MP@5?@3O8V$U!%_^Q6+8AV.1X=-0;=MM.0.\PXV^V?*"M-^G'STTZ:E +KF$R M6\.YX&5*=,@M=P'P#L#[4)0-8O,^*8%RG\QF*3P%S\SY^9:Q;A9)GD>O-Q5@ M3=6VOK-%6C[@QMZ5Q=/Z$2"[6"7+QLPZY&,*0VY_!GY= ,[?K(O9)T 58C+1 MY68-Y[VK_]VFZV!-A3W4:]_<'<8W:2S30ESM Q1\90K(+2?DWR3 M1J\ZW0;M *HTIX-\7MP5>8-F7+R[K'^GLT9G7V:/R1).($1M+DYNWIPT"/)5 MF=ZG<.!SWE]TM2EAC"J-KK.'QW7C4"Z*R%]?D%F>%LNJR+,Y80#=1:2W%<+I M1,=O#H41A]ER^CVL=A4< QP 5]Y?V_C\XUKA>1RD=J9H_\\ MN4,Z/%O_WXT-I>NH2O+F]3B%^X\+IA^C@_3++ =$_4R'G2T!51ZR.SCZ9('W M[N^TIZ3 ( F7X!.:E*JQ_JCURG%?#DV6,$ (CFZ> MC$"@)WJI&M@[G=PV &,.]_Y M!%Z&?/MT+8/2"W,0)/D=N/;V%=H5HY(NH&WBX-YA(*80+0 XBNZ2*IM%!YMJ M;A]N7,8]QYIG^0;)UH[19-]VO);-[[NZ%XRWYPK]_=9_? A.V^P*1.;B"==-('[5BX>#(0T*'X^[ M8^2CJY3$^;PAAIXO/\-T11E &9 #5TDV-ZS(%<4\Z?TNS]$3LFEPO%6 MHG/%.X(:/LL666 #DU]:PU<%A8)6M<2YFXB$;#C:E,^*[ &$Q\> MOWBIL]EFL6%&&F*>(1&9$=M%L'_YW]-^;_)C=!9$,W[^O;T(M$8?0<-O;F.> M!U<)7M1'4#YG27[X=2+5VVP)8V9H$2O$+MLN4 5YI&6.+[A=NT7;QLN-"[!- M&&U[6V[$5[RYMQ0VOU ]0-GL+:+2_ M1$BOW-,KI =;DP395>F6-63[D_E?@5+PM" T Q87@/L@XBQ5"8=O\3,)BRNT M8\]AL7?/^PW_)@6Z 7>);A%9?1R[3I ]H9Z:SHGB +D)/O=.E) V820"A2$Z MO[K^EV2Q^O%-]!?03M*CXOZ^W7"4-&_QEDO\-OLB+"2KB811M@#B7EKV#>KS MJJB2O#&&69354,*RX65(^.65DZG2.09ZGZ9U!(SFB3?WNDO8C!% I6'B+.ZT MRS 7BBZ;BB2O(*KLPMX,E(1J-_8R4R4L76V3]K<8_7:9%PGQ42E!M$KL>[OW M'=K#KGW?,_?9ON]KT)*>E5]M%^*-!&P'GA45$IGECC>O[!3.KHV*O:\J $K8 M+$WG0 B!CN;)Y!_H2099LZO4_W*CPTV1W:EJF>T8K-,59]L M>:5M.D*9H]TR6"Z#7IY<7/Y_OS-R>W9F^CM^<7)Q>GYR?OHYA:^^'!V<7L# M]"J-VK5>D/L0NG65/R;RNI<+/-[V6--1L?UQH[?$A.$[%M%N," V@F^O'TL0 M ^K4O6'>0 <\;/HQ@57>I>D2Q$$0DDK6539\W?CR)1L@I^F\LQ]<7;-)] 3? MP5(!$G,68F0LDH#,,/<&1RJ[V;O-.IH7@ G+8HTW(]_,2<=P&#"*Y+!W67-B ML6@%['*6K="]_L >])Q^3U=K%G@03A^7F8$O8\0"5CI+.M$Y/U"LLJ70)*!& MR4/*5G!<0^)H@0.R@+P;I( [+.'<+5!/ZH2N$P@@--NR0D/ MR\,9+2!6A3K89U9UJ0*'ST9),7V&B F :9,S\CCN2",'L23-1T>2BV 1RQDM M^'.@3R(L^$F,ET@KV&0Z/W20:I',4T8<@T>H.\ KBSUPX&M06E$%WS-J*IYN M,VJ/55+X^0F "D=0/*$5L=K<@7">)>AN ?##+VKW8Q*!D.]W?Y1@)?JK]V,G M.@%0T,YF_ /HY3G[>^A:HR3(I( 'PT'SE#QU M\"T&MQ"'@,]O\TV&QDI%4+@X')C%-QA6)0^*NDLR/UR0!6P0]IR166"9TM*B MIVS]N&-4-JD/#F''%3VJ*CO/DU7VT3(5G("U1!2X N+,#)AZ=K_FJ1) D+_" M(:>B7"S=3?^^\J(16O&--.9-N1_M)JB$:#0.34%#,>M[L1/>@5[<2@P8UBT" MC!"$$:!39/Z ^]P FCWHD@+]8%TL0> N0225G0E&N3$9;]PP I?S7+!L(,_> M)E\Z@H&1HQ@;.T+I6:#V65^VW,6"'$L;;\:Q5A"$FCI\(S[V9(M50 ,+\93N M\'+0L6VQ*)_^^>/YS?GM.<@%T74"-Q=N.48S6A4?(:]PSUY3/-YM$CG:"<'E$\>EH D@,P2XY7-TD@O_OH1)*1Y M6F4/@C02 X;F(8#&$OE:1>0L0Z&" +D W %Q*\U M&Q8V:SSUB@EJ\O!0I@_(0:RR7^(ZT+\\&76ZT2++<]R^D$2T1D6;%> 7NN:L ML>+5<-(Y-@_'[69"OK) M6#G"Z;:7@#9JWZ_,W &2G#J>;I8VHAEY%YW"2H7 M.&]G;)XF8E7?B?=TM],W3S,$MLV>;3%W HTB7IGA-2%O_+@S,F\JTRGAU.#Z MX?>PX6(IE/S5J#-M/$L'2*AAG^8U>IMLA49&UL6BG/,-3)K.Z38O%<[N@:8- MA"B*@3RSSD@8VC$;RZ+X"BG0COT!*'PYC_[&:0 (O'M.0WC&- 1<%6X;MN-: MP("0HO7 O6\BOH!\5A9/./8E$#2Z (9[H$@W)T7$7$GS%DR6/Q^!I/ UQ3M MF,"LURA579Y<(Y7XE__=FPQ_C# ,YPAP%4U5"C1/U#<=4RT'ZQSE M*4?,%KHTH(@;(<-\I10HYU7QOI!)OS\'??$N,W_3N"5DN#] M=X\"9(HXEC"1#)-:T20/3 K#% MA!\WL"SD\0@X)V 3U@&23_W 8&6DLXB>(B);LD#HLWF$Z0I9;<5C32-SR#(\ M80\8@(:35U&5D;[O1MXNF;N3K016Q>E:],M=.DM !,!Y*YVY(F4.UX5\B4C0 M<7GID35GHU$<0%J@NPJAJ;)C$#]C$+(SC(GFF%?F1X 6WR7[ M1!-[D;;?J9""*$T+QX?WU-R?4EA L@+ ?2%< 5KXJN>1Z"!%P[-'_Q;=50[C MVRQ0A/Y[RG0-Y$F6Y8O!*/W*CRBPA>(51,L/AR(^OJ."(4=.L.??@Z<&H'VD F8F\ZW7' M42-M M">ZLP\S?_JSHSM07WP!R8='4N=LP=O.8\=O&H>'4=._4%(2\YT&$K#Q+[X]0 MYSDJB^Q6.95)9^)Q))8SK*.8:6H M\9=L^FCZII\>B^BIV.1R9Y[0.$X:$_I.05.WZRW0O3M#=1*Y:\K>,*'S)*P0 M!!_+8O/ )')3I9Y:'F7T!S*/.1%I-D40A"BA!^<4DBZGS,=$9.,>3N\(&1*O MZ-ELF0+FDWPFL4FXZQ3A1:1-D*!,,9.7$C% 2BX6H-/DV;U97@,JXJ57H83\ MR*2(,\KPL@Q"\!KF:;K@9PE^"6[E?I.;B>XSAFJ%(*/554:X#6+3/H/R8(BW M9LQ.]+I8,P^2N I4 )9BG4! '^68"HFA_Y61*T"4<(9VKH=W.UK(D&L!M6B_ MV #B'*F-C84;(PN\%/NM++6VHI(9C0V@%)JF=44VQ09M;#M.16 MY&(5A*Q8I>S6VK, %;/B)J4TX)JI0M2\WG"KG0*_M$/H+:'EW6Q@?RC"W*PP MEBAGC>[]^]/H0$Q--S>G8C8Z%,/:65NSW7!ER[*H"GR[;ROKK8%VU6J.%O\GM8LMI*'I_G M90&8%.$\)2FI ,M=&IL]IV\:V_\O-;;&1?SGTMB"^/G_;8VM^ZMK;'#*9!!D MS>TWT=>L5O8J&G5WJ5S=D,9EC\K1K4AG:C(#1VOJ=TEK:F'&?5]7Z@WBR;#; MHJP,CN,I//S/H*R$8/5-0?FFH+@*2CM"!'4,5Q3U% X-E_BF5_SSZ!6.8MA, M:"8O)L=ANG\T'PPZ:FDS;]0S_@XNUFJ;#W/K#.<_G=W$WBBV 4_Z0SNF8SI?S#<;ZI1JKH:J+/&!6 LP% M PE9Y%T*#3 <)P&=AB=A,>,$5@<,;J*!+,XV3^A-$_IWHF_J3)U(4Y==!80M MK^Q?=T&O!-P!W@M4#[S=KWKC8\>OYX9*.\DQQS]J6/7H8I$%]A#^8E" MV"6^V U<8J?JN.94I=$\.1O^;JEJ0$$K?]K <0T4_1(W^U4%I96&M!.354Y8 MIFO53]R,(8F;T6"06PRW?U\D["*^3C\7.?*.Z&TR8\5/#4663_A3HD2CB\=I M[U*)4;"RA2)@!X_?8A-'[3"%PA31C*)Y#$:E5%J$XID*EMTHBH6*S?"XJ$U( M6-B:F8X& ?GWE-98890YW%F0"/$(S(3V4G3,[: 7!/7,&VA4S^/H<;-($"\K M0#,,^@2^&[NZ) =I&.7#E1+-G,:8XJ)SHD%A-J8.)0&4:;X@K*/^4&.T*#@H M$3S5[3M7(983"X6FF;FW1#:5:2-BY>6J!?*B0.C-_N50-/)F[S"UZ5Z*B=7H M7 !MRK:5_0"#XL1N?<6Z*@+K,(N(3/$D$.?[O7AP/(FVE4WR:B5%O7X\G?8C MMT92-(U'O5%D"_88GTA;*:2H/YU&@?I'42_N]J=1>]FC:-R/MI0ZBL;&Q],L M, 1J3G?<=98I)SF.AZ-1M <*-&OVX(SNVVYIC5X,F+77L* ,QOT!#D)87,Z) M_G&TS2\*:E6>^>[DY,K:^XHEO&B @B8<,B[@<)G4%^2$/N(TICY(XO'I.PW\ M2_'XGO%O3T=NY1@G+-HQ!:A28#U"DPP2D%$AC#;X]T,[+3'Y]]M/9Q<>SZ.WUY8?H]/+B]OKD]/8F^LOY[1^CTX\W MMY<%3J)H\/:8HO!GUKKA; M4Y0IXD-9D&0-@%K0L:*9DY1X9= Q27Y+M5&2AE6F]QBI7(EAP0O<(R2@L^=: MBGA19B:#.>5X<9O8Q^B'@5*-F1&_X4IB$B0*(KJWTMD^R0IEB2-)GC09-I8Z MN7F;&3F>AU ON PK8CD&=JX,(HE!E8_B[#P$:6Y5H0'N4&G8L\*!3O< L%#*WP1J-7X5T+AYIXQY8N?.SSH:&+X8?46+7WU$A/ M#F!8@TOF$ BE#A#ZL%OGM#$#J;HGFT;+-$U[>$'11ZC)/9OQ*PQ%70@V9951 M*HF481R]&K\[J/JJ/TFXM%Z4@ !460E(97Y07H!:;H*/&YZ."[ M=Z\_?G!QWA_W=^Y_^ M5^U_.NKAAW@RE/V/CJ>-_?>[\1!^'\2#X0#W/SGNVOV/XAZ\,HX'HTG4Z\4C M$,_,_GOQ\!CA"U+LD"88 X!@#%SKE:"=BZG6SV(<.^)3)LD8:,H<@TN1:&*: M$,>'QX#/XH%EFY:)%N=(<3&4W)&E_A[VPU![3)-\_3A#FB@LLF1)X+/N/J'= MQQ;%;6@XYRZO'DDT,B^ ?$%YUIJOL^&<:Q/1BM^;M5;I&CFQ[QS[?646C0NS MDJ?F&* MF#A<0GS C$&YK0 N>CH84-!+D'I+HX8#L\J@68+O+WIG)25*, ^5T867!&4\!Q'13DK/3"DSXS)7# BX=3N/" M9>:+6 @0:]#E[%8,KU#AQ=C;V"VN8B>B!XU&^;>$/VAX73+R+Y)J;=\E&5!M M*SX.FK#OVJKLBGS4O&<_*UUF5'8XFGU>>*F$[*9LX[IZJL8B D-J<#AFK^$) MD]^#%!I$#^6!:("L*KV4Y,W09?OB3(J&;"*>:L"YAV>*4C43M>GK+@T4-.)! MO#S(\&>@KP!#!"7@TV$G>JMNE/#$*ANJ&Y2$3!)#4#:Y3PWP, <*AS'Q'AE? M"U@?#DGWD_P(HC6F\S9X=KAHO\@]5^Q2I;AXXRN$X5H1LRXS52(=6ZJQ?EZ) M"FN14S8/?Z%VA\:]FER1H4\$4YO9+^$[_7T)VCNX/81G@21G&#B4Q8J?)$BS M8V6=D@P?$@X%6RN@$25KY;6*>]["/(>-W4KX71;+@4BB _'.]_&'%P.T4-,5 M'E,! SS//BOV+CGZ?4WM(75<3&AE>H?+Q&?6FW+I5*W4V W"F7/DL'J,]('S M\#"VXB%O$YEC(_J608@&0F"VCN>23P*9+(2=;:O6]TQV,BEJ#:=XNLG[2O\\54G.G)D&('E$Q5 8A985(Z17UT@KKV=;MR[6C2 AVZ_:BXZ/6T*&!8 MV4'623LQC[ .\* MZQ4U:WZH_*^8S38EI6ZA6P3X.-VM#-.RV>)%4@O%F:'W MDIA&W?1N)H8I-\@A.-*FRKA3QCQ%KROGDP>YQ3)!#[9B7^R?AUXN+$.#*UAE M(BEQ/KCYG7+B];CQ&0#/F@M8,(P1:1RHMC$[C** 7OPPY-P.IR]> (*/@QD<8,NKA,4G7GR;&M^%70_ M?7B;L@FB1D0DZ3I!9+8\D0B[9D,=MLK'&H@PG\<.<6:+MZ3$,Q;=I8])?B^Y MW[3N1;LPD0J&B\7*U]0[K@6?V?Y% M!:/NR6,H)B\KSMZEZZ?4)SBF.(%S-K<4'N@MR[O.&C@H 3THB)"0-LN3;&$? M4Z-^91PP%(>38]@)82V&B39J#!,!MOL[,?O[P;LN@G-6JK67A83V73 "L0)+ MP*#=G0(:G93T-F5 =^!&AJ+S420)-X13QA)'I@N,NM')8R@^1;"H@//8$&12 M.DEQ6 AF&+'9%:Z2>N;03@^F7[75XD$0DN)TY5MDR8_4)"(4=,!MHS4,)B7K MM3C2'?: Q\&>(H,XGXM\L]#Y?4<,A9BYR)PYM5I$;X%_'C NQE4 B_(A68IK MSQ'8K_F"^8AF]3W9DZ,.1AC92<(3L19" !S"U0%$\J0PB8%0U05:O.XH-O2( MXJ "D1VD9INIA(=7F[N_HE.%1/Q^]W<4%UO,./;B$9,/2-Z_2XW'+B84Q44X MR*?S;Y;)'",\*, J1C$N09,*!TER*!I<3-!=8,:G-/]L3'8[^)5Q#)40[$S-]O**;+R*ZRI3K+!KFY0A\K MF3B;UZ,O\KBD3J]7]T/IV& MUO,J&G?);S'MO9@N!,]O[IJP6@(AH<5/]. ] MQEE*=0\VE&"8$1P1^3F4T95U,7!\>&>@) MG>B/Q1,\4/H 0P*5BN+'A MUK9D4K9U38:.-@?=@V#V"__5'1T..$.2@*#8Z MY/FH*(YXR0JJ M:W(VBXQ])8DNL^ WAWF0P9$DTH2B;*TX#U)9O^*PXU MPP5P*R_B--*&P:9;W&=EM3[*@#7RIV*S%COX8<>;2'S&@0BMEW"4Y,D(;\@( M>I-X.!S@!_3ACZ*_%.4GR=LD)_DT'@V.HW$\F8XQ%8U/C$\:XP>&$QRA/^QZ M*\4Z%7&_?XP?NG%WTO.5>[IB8@[#A+GTB<_P#O/JBSO H+0"*B;N'>J'0)86 MDWBC(RV23YKCI57,[Q!\CFB%"3I:9](0 C]'-%,\Z("H8 TA5>J.O)^3A!>_ M3F-6EO0:5G!,P%<_<[RHF0VWLJ:@ O.EVF7VZ2?# ?Y#A[51@O308<1^RYE. M=,D[]EXR,P8KVIKR8.ZP_BM^Z@CPVJ'S8,Y0*GQ(FQ'P7+#S34Y2GOZ:-..^ M68^!Y2P!UK-T_Q3L"4.EVYGHJMJ:A]K;D2; UQ/:G]R,E[RXOW_SE_/W[ MZ.3B371^<7MR\>[\]?LSX'DW9[J*>& GY?'.X,,NGMP?8A)C"V40BQ(Q1/(I13^7%'])]EY6RS M0#OZC+[ A:Y%F"7&E)0E*1H>(6F9&6T=J)3=I2K,(2-@SV0@(=-_G4-SV5Y@ MXEEX'^HAL>2'[IBS1T23]&^D 3_6L^GK6]#\NV8./:W&3X['[1C.\F!K$X>JR"1"^7F $_#T:\]C4@E*O?5+@75!,1H;1-F9NIQIL$8:5:;C"_;!DY7Z8.@ ++4I6:ZX$]8[=Z8H;M.'[# ]26[#DI'#XN=C5-.)6=B;*I M)K4G,8P@X@'1^P34[0C)Z1$E'^FU;MW$[ZOZ:G! JR&0O<:[4)WHC"H'/9IL MZ,:^YV9B#&"F!5K@NQ05!S8JM$SH2.&AZ MVUU3+1FP?A((+K2>H^+!/C7.*"GN8\EL=V(HM&ZX$V%E:[5ZXQK;-Q.,+VOK M?)";[8P1/B.N+("GRW93+W-R7?A7;3\+3"<@'6Q3##Q-H*8EE5<".XT&W&QV,X^&D"P_TX^F@&[VGD@0P[RB>3N%]4#QZ M^/IXTJ=8X"F\A)\.>J#AC(>REF$O'H]&OCC]7PF=28^@,XJ'O;Y 9Q*/1L?; MH#,> W1&\?$(-S\8PC['8>ATAPR=X[$+G0D $Z#3'8SAUTEO+-#I38\9.O!" M5]8"VML 8.GER*GQY6O*Z9.B,G#J0Y-(/G 4A;JBMH=_MHV6UUP,H3O&O'M:=ZO;[^+F/H>[#[A@_4SC\ M8'R,GX?X_+0WP,\C595 /B9W(*#^A,/D&=G:F@>_;^_I=L7%(L57SIV>ME/8F>G]^\OK\_?DMFBH"/8I_'4L"+*XL1 _2DS#6-G/V^K:>)"\9@<':"")*.BRSD6HXKZ=16XLV%WG%@Q6;FYM7S[99=CY*NY)3 M#ALVI0XXB]U+:P?V^=1\SJPW1_)1<@3T,U^A=1%'?[KZ0*[\Z)2$^M?)\E,< M771..C&)+7ZP0/+ ?5667[Z)4>&T]E>]OELNO\+6+>REDEH#$EY]KR4'W+(1S8H$-M.V M%GV$Y?7&87D!##E*$R*5')5!),\[67(O2LN\M;$\.>OSFV!_C[N: MS^GHUG0%)4:4FFT7"6>5>27_1!'U\_G]+@(,2U-708,733$'#BJSY0@,EB&A MOH,-+QU]KQ[DY#==02.ZC(8/UXM8+'$!L4EJT81@F\BK9=Z0(AJO.DKN!'>W M)26F0^]>40L:/9((3OF'9+):X"E2H!3E.:65Z6AB,$4A$SA1&-J%H^@.H66]#O=WYEV#RX0@9T6++:13TXO (8>(:!@]? B M0(*WL:*(@>5FH2>R67*Q&M9/ZOJ_&\5MZR6%BH]0ARRC/Y&1Y&&3E)B%A ?\ M5XSZS271BB"?8_B!'U+T^\IFE;#;3EB$_#''IA^8/N;BI$>$WO&4!?>%XFHU MV)#(W4< S_%O^^KNG2IEO'MFAP(9BLJ.),Y1%>N2*1M(*$Z9F]L;"X(/.R$P":*A;O*YQO.'<16*DK8R(YB:F;+ ME 2AX*%\P#]%0?"![V/?KK:E-E233.F8KKK3=!YK[ZQ 4U/SV[Z>Y=/+#V?1 M[783#H/V*]"FE?)\Z3A,)FFU;$D$0TLBD"TO1:44J7>@:/3W&[1$.=XS MME:EZCU]IG!UD,U3H6YN<5?7Y6Y#=HR-[YDME%+6UZQ&#&F!11GKFYDS6Z<+ MCOZ9=@:_,_X_8B%-]Q_I\R+3+[@E)5Z=26?Z.[/A*EF8A=H"L()6Y\O:4"%I M*+#P><:!Q";]Y&/GID,! AOV?,KN)&!ZOC'%&R2R4_B98]K6L&S*V4ZSAR4C M@9M4@2VDG8K%**?C8.WXA.V1OW#Q:'ZF?Q M0HHHML$?COO;-OO6'OKWGTW)R-K8@IIR\K23DBH^1LZAUH _!+%6!3WAO!U3 M7]4&,C''K;^AMMO*,RS;CIS17S=S\IBT)BFU+(4I)[JSV-3-I!H)MXWY"*?L MBI+].9!J1$@ Z.PI>XE]JBSAZ$_VJN,:"XHAQ[ C-*/I M(\;67D^GHANKD7DFBIEJW%.>I?$HY90J%=NL%E,\T#)&<(A?F#PB'J@M4+VPZ3>ZJVN&Q%8-QF\W9*B9C.*44!<. ESR5?N$4[2VM2K?Q R;K MYDWV=@DA$B@;^5O92UM@XI[[TD0M]A4?,H1 MB3PB4[ K%9C;1:6;/YYQ.!T'1U=G%S@DT[&\G'J$)5+6W4)<"5 M<%&S&U4FR*2C/*Y[LR*4\*K&]WI.?\B*>YD7?H-W1K%^%ZW8Q! Y4DCC;#_Z2FM?"5@L-;!K3YA0M"\] M%N-%4;H#B(7?EK2IA>*B&>=1=!(92=9O8T( P%S5XH7>JYCW$\(C50VYTF[= MO]7?$HCWLJA[NQ27]-/!ZGD9K&!WC'^8?$B.LFE0CM1>M;5ZZ+,@3[8QK[PN M$&O1QZW'TQ'LYHGU9)&&D_O3K2C^.D_@(M[,, A$#9-'6A5@44'M MU2=A>+O#4[]UON M:;?6BPUIQVZ[G_@O*:1N_7X-']4XO!+IY0'QZ@Y<]'>$B.\ M'B5BM[$;\VDLQG1RT&"=_)]I*?T<&*#L)XNC^&CB=7Q. M\B;+-Z2V!Q:T=,IQSO$YDCE,7<[PD.K[E>R:'5Q " F;RH_U(C2(ZYNU50\% MIB3P6GA*\1X1DYZTHDUMH;>/S>0Q1/7E#'LVTV6>L=F")VD@?0 KOB:DPG?3 MO[#NZK%?A)5Q?C"))],!_C/H#Z(S@T<&M9Q#5$^Z_JMHZH]Q8U\P51P8REGI M($D8U-209@#_'70;QK<;B6Y$:+R3FHVP@W.;9]OVQK6)\=HB8YZ]^W!V<4O! MV>_.+M]=GUS]\?PT.K]X>WG]H2EM^I6P:N6-MX1FILL'RL86)'4J%,=.F1;6 MC+3K@ND=+]7T@H7]=M7P,X7[B!D]<%%,XD)U#Q;F>-T[2Y^#)%AQ1,4GS>RZ M FRFZ%D:^Y3>./L")T^'>(E:$1;$.3V[/(R=*%-6:>#&;RI=@N8!F3+(%:_0 MUNB019KAW:A,%2G/+DUU-DZ90\$+CT@[>2$U3$ORI[B%V?W*..XO-O*1MDA) M=*+CF_(4QFM\OUEJY:E;68[=M&YO58EF/*-4ISN)4C'= '"Z3^LL(S-<4\>2:I>W% M.[E>:;ULIY0JK57LE/JDIE!G'1(FIMR#PX.E+ #=Q+)_++964@E&#=;3RDB_ M%IC\NJA.R56I/>I72I4ZK%*.M&73=2KW%F.=?T*AMOT7QWVQ32E_>W)^'?UT M\O[C&48IH3D"@Y'9U0)(ZFLM4BS/*5AHW)M.1H?]TDL1]CHR\GE0\:2_;0J$ MET2%<]$P*K^%MT#-?IWH+_1%Z&%;FK&X0[E;/'P@-EBQP@Q4:Z:)\1-47$\- M-!3PF?UMPUY%4[C"+AWTT).;UY3B>ENL +^F_6X<.7#_P$ RP3CN0<2UTC$D M-1RQMAPB=7OGTV=(6N/<6"X<":2+IFPU(>B=,SI+S@@IPQW:"E&AJ9# M(R-;\80^5F-K(Y!'FON>K;@!#_I[6D8O M.H(+1DL.;-LGFO##VU;AACCKPCS[O>'$6, MRNP("X2AEQWO!\N/4I58K0HF0,3=X[/Z35TL0L;JPJZ93HJ5X.JBD<7_;(D< M5SW]T@Y"FRS1!]3H 33L,C5IX[:4A/.E!A=H*8FLO9NM!IL[U49?.BO'L-1F MMJIXY5(*SU&) M&RQ$0K'UF+!A/K"@$IYTOQ%^.:2V)8#\=X%I$ ^G8_OA*\!4'\'+0=(2$C9( M4S8*4"!T'+S$(-%4*[P$32>GUKD?:) IEAH@IW#U">F^"PB*W#LN0!O>2*6@ MV$>+VDD\4/U@J@A/H0L'FA#]/1I8^>/A#QBT+@ET7L])"=(*H\I![S Z& ZG MT6$[.IFHLH->W._BHV;5]5V;>X+CVO50V(R7Z=BZH%KM)6.%9/;D- QRSMF) M-1),MVLV+!\H[U\YQ*12#Z'3G271V@])K4L7^<8]<&H%S8X+L=/&!71:64=H M(J;B&W*QUDWZP1SJ5YL(:>>R>5].JWA0UD:-(RB[>5I@:V5=*Z.A[)H12 MS"!NRZH%&A?7Q9(5%;6;-*O/VQQ,6R]-_09SC2YNGK%; LVLVJQ2DAYG)L0# M%^['?)H%V(5Z(I4I!FG+/VJ!*)75R^#&UQCIN:XZ[??!K0RN47%;&L([&S18 MZ>[4Z26K >-;A@@LQ14)6A>#O6P3"J-1\Y7X0FP.C[FNSFN.3X4K:DF8@/%# M2DG8T+M;K[G&!.S1\+!6@46U>;;[9VM7(]26Z-Y#]L>@E,2LV[($UL KH[:Q M#S/9 #4'49.C:+!'B DLVJK<.C^B\2]'SI!4W4*YU; M@U$L0\!/=U[M,;[E\E/]+?:LF.^5BLQ-JX'F"_5RO99N94LQ2[G$E6+[L#E MQ:%E2?Y,[D:I'T_72[4JC5J2@LA*Y- [PZ'9%1<+US\H_^?9T?KDN#*\"D6N MR7?/6LJ%&LWZU2RE7%()2OH#E\(,G9[A6D1:^2@MXBBRM*D6NZZM*]E;T[&K M+NQ22\*B?2.7TA$[?C(PNU5C4?31'9D4Z^B:+K*6I_>\L2C\87&F =F&&CBK M7W*\Z?!WH*N/?H<8=6>NW[W!M_$8?^]UN[]S<,Z-!':>I1187C3^[' F:CAU M/(G.#,5;.=.%OSWVI@S,U86%40:NFC5%I#EI:CG2#U;[*%G":]DU4 \+K%V, MNA$SZ53EP]K#M2I%"862F2(>;K9#AM[XH9,&!R, M)QO&LF??,/XGY8?MZ2. MAE\[.[G!A."Y1&P@RMY\C"Z*#L5:'G7[L4P8'8A9;@"0Z& K<_ MD-M-OI@KPU^7A<; U/O%X_N9H3*DHF#0]G+V;&3-I#1#RN Y0N?6A@)+3$VM>J*CNE$ED7"A1,U$@VRDV,;(M$G/Q00Y$YKE&# MF:DZ63IGV4&B 6Q90NU-0D $SG97&X6!JZ7>9U;*-F,5=@H=A(Z1!])K9I:S MPD!=(),H@&I92M(X6)Z0##8.-;'>8L0@ #/2-QO9A.FJVO^@$[W%XF!;:U 6 MLC5M@\C+%3E,>UCT^JJ#HMI'&:@!%.(].B.+;8U DQOW*X;A"02M&NQ6\3%? ML[M278PY09\HC03!WY)8;V\SU6[3B M=Y1VN??'J3&4\:;MQ>7V(;)U"AI)5ZZ>:=N6U&-+G9AIGI*R6C=9/N?T/9O= M<4]E=] %#II/@CJZQ$_7_KS,#4W6BQP,AG M(\UVL/C LXXI0#>-V@S% 8J?/J%COHSXX)BV .YO*M?NRA734ZDOP.$3[@O> M/+0HKJM+&EI2 =+?(:V1JZ6,OK*QM8;*I%\P5J"J$V:G\"]/4BN/4AE*LCOB MSZYR1VUJ#!7/M:RPS[U<5N5$\6$@':^C(8QZ5;&C]]I8RO=.,T[5<1'03H@% ME\LC'').25V*C-;-(L4)73[$ M50\>4Z]:]!WZW9XXDWY=4_4\><0DLX2N&Q=*MTE,P=NMN0ARESNR_=:U9)7K M/%V[L'*WQ5='FG/P$!K(DB-BEL+=)39 A0%V#G'@MV:KY>GR84VM _>^(\'0 M3-O0PB53(O 9+:E6+.LO[:/0^WB?*$CU,!IT)LW'Y[X&UAE$O]N]=.M"\VF8 M@ZW;2_0$BQK%O6%?:AK%_5%/2AK%O=Y4*AK%O<&4"QJ-)N-@-2/U+KA7R-%$ ML=SO"#AP!VWL>&%3N M>XAB^\5@G807@QY*R^2A8(]0V7I*:W!1\:XQ,7EE>__G$&("95'F%=2@T5T5%=0"O6PY34-G*G(SA MH#MA0]^G5&7"271$JK[*3(T3(/';4]:-@=TO1O%JW!EY61<)AE+\6H.[,'-[ M2QD)7PFOHHI?>[C?10U$0O$HT=G<&%984!68(1=F2MZ0*Q5!;(6==:W:,A74 MT#@^/ZBE1B4\EY80AGY\#/\28>AC*2LF#'V@!@,F#/BQQX2A1@\&<.$G;=2@ MAYVWCU\@S%B[E9LTM%.D>;GGSZ.5I#Q060?RT4JYJWKT>"WB*"!WF&,SVY#T M[\:! K4;#ZS\5$E/"/&NN?>4U?%*R[X1+Y#ERAGQJ]&$%#'%K=B M7-F77&>2C=_EKM;41W##SP.(,+!6/4E&@XW%$V$">;4D'!5+729J"-1 @25B M7FX2E=4CV&@ 46ZT_M="PVO9VW['T> I80+M M^43&O:6VM/N88;UV#$##N'46$XO->B9N5WPBMV7ZU)7J.5=%2+6/=:+3SC7F M>9< G_/EK!-][D0GRX>L>/.\3!;9K)*OT6X).C;6]>GQC>_'C7=5D\:OC"K- M)4PPS3LSK@<_(O=-Q@DHL-$-=^W^N$X>N46BZQIM^):EN;R NES;)AL8NYV1 MZ7HIT@85CE@E:[JD)_GNT/>E=/7$"?"9K$5%B!&MX5U MO7(?.#>_LL2.8_<^$C$45NE:C-AX&K"L+XG1LA4T-]$5K9(&-!5))?8_.OCN MX\W5[>5WAU&5II\D5!]N?<)2#MG-Q;8I>T7:6"*T=;\RD8L$?GR9725%N6AF M)*YGV,53P&'@N6%/)N&CDL?+5/P/\'SL<*Q[MA[ZA @7(MN5#6+*,.$+QNCD M((&+\TV= K "FZHK@* WKJ=,.@>! M^)*ZD>V(Y^RH24JTWLC],5$]X46AC*R94%5GRW5]*]4S3K&;1.8P"[VX'L08 M^DV(\="G6(WZ2%]L6:#S%4+.'=%Z)N_*#*TX#YWH0SK'KSE]7G:PC$Z AX(, M]AH?X_I[7*"B5FOJO+8<']=/LU#^%VE-&], K:0V2.E<,N!JV]YG2Q;\I:LF%\*#*Z+>/[R%3DG'DCN:&L!QTSK341KKZY'. MOKG+Q??HR7J"(L=4^)2W'3O,TP-@DRX[%\J@5*\;NU??? ^J=U13XB8 ML#2."X,VY:[X/7=!)F951.$HU&6HD :V1KI5C8 M&M=FP0)+3)H7T>?LH2C)-]\\.76=<_!E:V%^1^4C%[6C\]VELX0R=]9:& !+ M;;$2FJ>\%G'AD@?7T0Y)&W45ZB4I*#7=F/+^+HT,RU=AI&>,U<*O?A++5>&VU"9IAGU0(H=F)*<"'BE:D#$1@/FW31 MK4&RM'18F=PU->'6"0@ZTRBL12)*F5P"]+B!A6J*;+H1WFN*,G9[.HOP@QLJ MZR2MK#"BT32LGY'X(N&RSVY5R@BPYF:S0LNF4D779,+4T/2[1;PWBJZAK""* MD]>".C?*88(0B+?M$W#>H!CHW<1)30:4*5 "/"4)X]25,"Y+% MSDO_"]5/,+^8 UE- %-I-Q/> 0S)''KA] MPBA#,G7;BF%+E9)[3Z"DBN%M5FA2:;RI)HCS.2N="E:\:FZTQ*7N]"(COP<) M+8_Z$UV-D@(1 *8N1CFJ7-N0L[#L?@,[!"$SXD1VP"O;U.P>W*=5 M<.X T+ ^' 6RZ>AZ>=^6V1RNFMQAMT@Z MV.4%8#)7%&3]O<4^X(RJPG+LL[8:&?Z0+D#97LXW',S U-$1XO%=4_W/P*6E ML[V!@[ BN$W$C,1_@J[*S"&@L7W.D$*.;J2BFMBXTWV\+G$3O>ZZF_2% Z,' M4/+6>EV4R_09VS)4)H9RG7SA8J[:L4>64'4'IDN$._%K^\&Y(D M/+&/":VI68*EJ))GCF W[JRB!9SDF%RK6SKT""9HLYPGLH*((V)&^M&[MLQW M_J2'6/B;0F1_ B7"MT:I,;2!?_KV0._G:^3?:KTB[PXK9>3C\0K0D,CLWH<" M5DTB -F+D%8(M_0--Y-:/V&W36;UQ.$_/(0GH2U6DTN(^-\\5EBW?XJ,3LSBZ,6GQM:R$/$\?-%Z4!L;S MS7+R*V.-[BQU,YT*[BV\SE:FD$]4\1+TT+T'K\Y/3QL52)T9:5T2J)^" EWD MIN25+:@,$"K1+@)\B6D:+O$Q$:>ORB>T +R0,1T4%DBCRHWKS*WVIY$*G,:% M9Q18(JMO(JDOTS5R)E>!RY9_I=I5GU.CQ1'H%L5G1G[AB/[%GCI"N%AZ1,YC MENZ*>=Z]5!,.%Z=FU6K][ NO>&DM+7 *ILU5B#515Q4)R!B20T)$Y@HV%(CS M(2W_SFBKC<%@%^LUAZ 8%<+PW>;C-6S$!XQAYY=>IQL@*GM$ MWF=410&?4E E+Q2Q-4HHMWWMC^4T_O7DOK$L]F[#@<,:%^M(_,84ZP]($PN# M,B= UF%<8&TK@-5SJA:^6:R.*F#03JKUJ[X3_05G3_LC6\)Z4RZU\I&OQ,], M"!@(:2 493,OT,_K)R%88]@I4(A-[M21U*%M^Q*5JEV-[+A11MO)1H^Y.NW& M303@0.9S)H$7::.'8/,-+:I]PI7_LZW982>G?_YX?G..A0QA]K.;V^N/I[SZ^C\]NS##4Q_=AOMO]ROJ:_LILI)!5)O>(D&8VA@(JS; MO5)CP+R9]BZXQL%)6!T!RZ4=4T3<=-K%4W](I0"UE\AWT#^,^L,QW( !O'Z+ M)B@.C-1:O;95SL'@,#K !J"'3I5,TW0Q.A@>1I/1U/SF@[4_IJ!9ANQH,(V. MAS8!,AYU,7AO& _[?5H\;\/(P8Z\XL@F6E.KD*:9Y,CA,"A7*4O#A4AV1R+:?4^E]>@Z@!%V5&)U!N5NO9 M;('UF1A3"^YZY]3E#/BCR?3P4)AB E0EV\<7@*?M71\;*[Q/=3CO MD N,H@BR3CZEQ%_2Y:/I)]EHM]A88<=&;*.2;[0HLF2Z9IJ0@(Z! MIS*[G4 J>=A!5Z:G@,@H^(614?P&9W08-23G]E>.;>"'O*OA#.H9/K2(JGO!H \31:4$<59:Z#A8 HFB[+>RK2H M*D^+5G:T:VLFB1':)8-8>3D()GFM>$S[:IV5QKH61@:L4JK%7TML=L11J!QA MCRW<*^X]#]<9'0= D3Z390 U4T"*1P"9O5.<=4+YK'ER5Y1:S,#C>I:+)]*@ M-G5*@S $4_5$I(X#!PUL\%2S'99$I&,O;AS&R4UP@F)!SM&M:?UB&]_I7FFC M)?OKYKY\]2!87N^+7-S=2P(E++*'@;M.$J'4_5RTKT=PS"C'@QR8B*UG108XN_[P-#(:UBKM_6A5SJ9LZEF<:Z# M'E4X;Z#+-3GM0'\X9_/D":>1(_Y>E06S!8K8#R"I/JC(@K?DK"PQ4[HH2PUV M:,//R(\7S1U?7EQ?P^?2,0_UO'T/)'=*]!EV$ MU:S,3$*U.B+M"E?>5B2L(VFV+=*&!O6T<<\J::MQ5B9EZH=H;T!&1UP5@_5T M3F-_XVS@#9((?>*LMB!G&;9(GY.YA:4MMM77^.>O?_%6\U5,\P9*=<-[]Y3F MG]-:\828TNYA:92&8%MJ RW&NO)L0K%X M"=224,">:ABXO#D\4_YRJHE(\L MK<=KY1Q:X-#QZIH MD@TP44!I]T;ZF'%3DBS^D S2TQ:\':\4J/NP)%HWJE,X"M]"Q5Y;13.B^5 MO1?JL)VGZ#H$5,8 #K> H2WC*+4>64^IM-(#R31:2=>]]+44Q&F$%_?/B#ATGHW?6>1*=R<$@'ST""G(D!70L!&+6='2>P1XQ3 MQU*)3N5I"D.M5R]W"_39QDPDSPOU$!GGT.R2^.!;0U:/KZ^.?OS1^S1=F/WU1TY?$-C(0UIKMF+J7Y*O9$V>NE69L1]E,!HM%]'K MZ#TP#/178^@9K&?QS+T ")5B::/LI//:YG2E.&A?#4>=J5%I.%.9NA"^ZG?; MJX7MSV .KI"= JT.2)U<9.Z:>2?V+=!4$LV*G^89Q0^5=N'>6V9+!R;1%SK*B>N ME@U5!#+J[S MN(NA2Y+0S0LBV[8+[WF1LKM?"\J3O]4I&BDT4G(?U\Z&.M$-EP^5PK#SN=O6 MFYN]8^$49CL48_"8Y/="FFG=UE=JNFS18J7";@?DN9+[#OMUD>4FR];TMMHR MH_6RNK8(*9.K SI1.07ZZK!1!,/P(5SP9UU'LT"ZZ2J-L2.R&=/E9&YZF)#J M'HM_CS[ D>&I;7*=.5$%!SW-3&->4N%/AT3>YSNMG34ZS0TQU8#&$[^WPSLPJ_L(FE*R^[P%"$*T,, MI58&T6MX8S/FJ:,)U0I:"&:8: "WB@,GZL]=GP^?7FOA%:\XEH,'04B*?X%O MD24_TCR34- !MRT.9_WJICRVPQ[P.$R@/2/.YR('V5C5++=*"T?&K7WASJBK M4J\4_L%H]96*'5G=B$ 5A^E,KOF"^8AFJX3+GBRBV6;>I0T]QR'LD')G(RD? M(E1U@3:Q.RH+HHR5 M&51],3R<:TXX56MQ"DY2++1UJW?1+%2@8(RV*C'8IC*-*A)V;#?L,"V07& M"!H?!OJNT!G3*"7"C(0HFLJ%C'O+>5YS"CD M#29#M^YD97UX]P+0HI0OL@X MR\9FT'""BCJ:-.$(1)/@2F;7U.J!%ZA"%5_)V1F=QHW\I':85D$_TQM.>XI9+BF8R+?FKG> M.=R3VD=%2VX6+J>1Y%4\VG/C%'T5C;I(X[7R3JZ-KY'YL(+5ZV+&:[+DS":> MZP>,5;A!'RZY@J1B2)]"6^PO>II6B<:TFF-XQE!6P@"$.IQ9!0.,X<=W@#QD M3>L-XLFP2[Z:VA:Q1-QQ/(6'=VWUI-DY"U[&-5@@3 9][(-*\1)6>%=Y3J8^ MGNZ"TV 0 M1U,L^2-\_+U '4$*:_/+G&J^^"#[ZU3Z..-@O"D".(]/W0 U," MLAUK%@;WT ?WQ/@DU$\'(Z\\J#4:\T:+&P7,CB>41^_]@6W7E>[ M\.2!45Y%P]&TY;0G0UC;I'Z[G(B@]FM[3?(=D25*GM+,(5N/[RLNK;6:E79X M#&2?NU/88)(7=A9UFXF^PC2!P?&$9!5;%?" M$5R6J+IP6%1"S?DI&7K=1T]I%3=67Q&[ MF&D[R+L@^"K\H]V8_O @UCO;MN(,MK<=AI^W@'&>[_>';<9+.H%37R8Z-;R] M[8+#K5:;K&";C+?'O:[LQ2966M=J6_HI1P??O7O]\;M#.GYM-/S\-9W@OR8: MPX])]YL),WY^3C+D+"/4JEA;.]<[-O>.X/QW"4]/)2-LXF_[-P$$F M$[@IQ\<#[>6L<:^F![*T.S8=CG?N?_I?M?_IJ$A"/)A.K9)MZY,WFB*>A M]0 DNP3/::\.')7QLBWRP0WG=A,;=9[?-A25;65C&]H5N G2/3LA*;\QI6+B MJ%'C<;!M^, V5:$LA:-L&PPLXBOZ"22J9E# "#,>V1,> Q)/I&.5IULQ8H\/+#[@+(_2'76^E*+P! M,\7 J&$W[DX:1V'$3"EWIW*R%*EO.YW&DUL>$,39!C0/2C4(LKAD&O/RJ;F1 M@YYU@!F>]^Q5711GP/2F0/K&4PP9FP"!'&-. 7S;'<7=;J]-%1IWXQY ^J _ M!F(Z@C<&2&K[MCXC:"3Q !4@$&Z S!YB[L.@"^+YC 4I(&=3>!\.I8>OCR=] M(G)3K/-'T6MP^N.AK&78B\= J[:U4_U-H3/I$71 P^CU!3H3H)['VZ S'@-T M@-6,QS'(9.=\C0 >KK0&<"P 3H= =C^'72&PMT>E..[4,1NBMK

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htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Cash flows from operating activities:    
Net loss $ (1,275) $ (469)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 5,207 5,599
Stock based compensation 1,984 2,150
Change in fair value of contingent consideration (448) 12
Gain on contingent consideration for IPR&D Write-off (175) (10)
Change in accounts receivable allowances (453) (228)
Fixed and intangible asset impairments and disposals 99 0
Write-off of other assets 593 0
Other (8) 25
Changes in operating assets and liabilities:    
Accounts receivable 11,474 (562)
Inventories (5,153) (761)
Prepaid expenses and other (746) (1,200)
Accounts payable, accrued and other liabilities (17,633) (13,429)
Net cash used in operating activities (6,534) (8,873)
Cash flows from investing activities:    
Additions to property, plant and equipment (1,391) (682)
Acquisition of intangibles (150) 0
Cash paid for acquisitions 0 (37,000)
Net cash used in investing activities (1,541) (37,682)
Cash flows from financing activities:    
Repayment of long-term debt (132,500) (1,250)
Deferred financing costs on long-term debt 741 0
Payment of acquisition related contingent consideration (1,208) (2,100)
Proceeds (outlays) from exercise of stock options and employee stock purchase plan (1,300) 705
Net cash used in financing activities (135,749) (2,645)
Effect of exchange rate changes on cash and cash equivalents (168) (134)
Decrease in cash and cash equivalents (143,992) (49,334)
Cash and cash equivalents at beginning of period 227,641 74,096
Cash and cash equivalents at end of period 83,649 24,762
Supplemental disclosure of non-cash investing and financing activities:    
Accrual for capital expenditures incurred during the period $ 477 $ 38

XML 81 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Intangible Assets
3 Months Ended
Aug. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.

The Company's annual testing for impairment of goodwill was completed as of December 31, 2018. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

Even though the Company determined that there was no goodwill impairment as of December 31, 2018, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2019. There were no adjustments to goodwill for the three months ended August 31, 2019.
Intangible assets consisted of the following:
 
Aug 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,968

 
$
(77,967
)
 
$
105,001

Customer relationships
60,147

 
(26,995
)
 
33,152

Trademarks
9,300

 
(6,470
)
 
2,830

Licenses
5,887

 
(5,215
)
 
672

 
$
258,302

 
$
(116,647
)
 
$
141,655

 
May 31, 2019
(in thousands)
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
Product technologies
$
182,971

 
$
(75,412
)
 
$
107,559

Customer relationships
60,166

 
(25,950
)
 
34,216

Trademarks
9,300

 
(6,404
)
 
2,896

Licenses
5,752

 
(5,036
)
 
716

 
$
258,189

 
$
(112,802
)
 
$
145,387


Amortization expense for the three months ended August 31, 2019 and 2018 was $3.9 million and $3.4 million, respectively.
Expected future amortization expense related to the intangible assets is as follows:
(in thousands)

Remainder of 2020
$
11,308

2021
14,022

2022
13,406

2023
13,369

2024
11,813

2025 and thereafter
77,737


$
141,655


XML 82 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation
3 Months Ended
Aug. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATION

The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan.

For the three months ended August 31, 2019 and 2018, share-based compensation expense was $1.9 million and $2.2 million, respectively.

During the three months ended August 31, 2019 and 2018, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.

As of August 31, 2019, there was $16.6 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.
XML 83 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition, Restructuring and Other Items, Net (Tables)
3 Months Ended
Aug. 31, 2019
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
For the three months ended August 31, 2019 and 2018 acquisition, restructuring and other items, net consisted of:
 
Three months ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Legal (1)
$
669

 
$
2,880

Mergers and acquisitions (2)
246

 
1,318

Transition service agreement (3)
(737
)
 

Divestiture (4)
758

 

Restructuring
26

 
130

Other
538

 
94

Total
$
1,500

 
$
4,422


(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.
(3) Transition services agreement that was entered into as a result of the sale of the Fluid Management business.
(4) Divestiture expenses incurred to transition manufacturing from Glens Falls, NY to Queensbury, NY.

Included in the $0.7 million in legal for the three months ended August 31, 2019 is a $0.4 million settlement received for the Biolitec bankruptcy litigation. The settlement received offsets legal expenses paid related to the settlement proceedings.
XML 84 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Earnings Per Share (Tables)
3 Months Ended
Aug. 31, 2019
Earnings Per Share [Abstract]  
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding
The following table reconciles basic to diluted weighted-average shares outstanding for the three months ended August 31, 2019 and 2018 (in thousands):
 
Three Months Ended
(in thousands)
Aug 31, 2019
 
Aug 31, 2018
Basic
37,783

 
37,323

Effect of dilutive securities

 

Diluted
37,783

 
37,323

 
 
 
 
Securities excluded as their inclusion would be anti-dilutive
2,503

 
2,309


XML 85 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue from Contracts with Customers (Tables)
3 Months Ended
Aug. 31, 2019
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three months ended August 31, 2019 and 2018:
 
Three months ended August 31, 2019
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,676

 
$
3,237

 
$
28,913

Vascular Access
19,284

 
3,875

 
23,159

Oncology
7,977

 
5,993

 
13,970

Total
$
52,937

 
$
13,105

 
$
66,042

 
Three months ended August 31, 2018
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies
$
25,851

 
$
2,747

 
$
28,598

Vascular Access
20,447

 
3,343

 
23,790

Oncology
5,198

 
6,357

 
11,555

Total
$
51,496

 
$
12,447

 
$
63,943

Contract Balances with Customers
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands)
Aug 31, 2019
 
May 31, 2019
Receivables
$
32,540

 
$
43,577

Contract assets
$

 
$

Contract liabilities
$
607

 
$
681


XML 86 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases
3 Months Ended
Aug. 31, 2019
Leases [Abstract]  
Leases LEASES

Adoption of ASU No. 2016-02, Leases (Topic 842)
On June 1, 2019, the Company adopted ASU No. 2016-02 using the modified retrospective approach. This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Comparative periods prior to adoption have not been retrospectively adjusted.

The Company elected the three practical expedients that permit an entity to a) not reassess whether expired or existing contracts contain leases, b) not reassess lease classification for existing or expired leases, and c) not consider whether previously capitalized initial direct costs would be appropriate under the new standard. Further, the Company has elected to not recognize leases with terms of 12 months or less on the balance sheet, and elected to account for lease and non-lease components as a single component for certain classes of assets.

The adoption of this standard resulted in the recording of an additional lease asset and lease liability of approximately $5.6 million. The standard did not have a material impact on the Company's Consolidated Statement of Operations, Stockholders Equity or Cash Flows.

Leases
The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing.

Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

The following table presents supplemental balance sheet information related to our leases:
(in thousands)
Balance Sheet Location
 
Aug 31, 2019
Assets
 
 
 
Operating lease ROU asset
Other assets
 
$
5,104

Liabilities
 
 
 
Current operating lease liabilities
Other current liabilities
 
1,606

Non-current operating lease liabilities
Other long-term liabilities
 
3,489

Total lease liabilities
 
 
$
5,095


The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a
collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate:
 
Aug 31, 2019
Weighted average remaining term (in years)
3.7

Weighted average discount rate
4.3
%

The following table presents the maturities of the lease liabilities:
(in thousands)
Aug 31, 2019
Remainder of 2020
$
1,142

2021
1,251

2022
1,118

2023
1,138

2024
576

2025 and thereafter

Total lease payments
$
5,225

Less: Imputed Interest
130

Total lease obligations
$
5,095

Less: Current portion of lease obligations
1,606

Long-term lease obligations
$
3,489



The Company recognized $0.7 million of operating lease expense during the three months ended August 31, 2019, which includes immaterial short-term leases. Within the accompanying Consolidated Statements of Operations, $0.3 million is classified in cost of sales and $0.4 million is classified as general and administrative.

In addition to the total lease obligations presented in the table above, we have a 7-year building operating lease with undiscounted payment obligations of $6.5 million and a 2-year building operating lease with undiscounted payment obligations of $0.4 million that are expected to commence during fiscal year 2020.

Future annual payments under non-cancelable operating leases in the aggregate at May 31, 2019, are summarized as follows:
(in thousands)
May 31, 2019
2020
$
2,920

2021
2,338

2022
2,133

2023
2,131

2024 and thereafter
3,227

Total lease payments
$
12,749



The following table presents supplemental cash flow and other information related to our leases:
 
Three Months Ended August 31, 2019
(in thousands)
Aug 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
563

ROU assets obtained in exchange for lease liabilities
 
Operating leases


XML 87 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Recently Issued Accounting Pronouncements
3 Months Ended
Aug. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
Recently Issued Accounting Pronouncements - Adopted
Standard
Description
Date Adopted
Effect on the Consolidated Financial Statements
ASU 2016-02, Leases (Topic 842)
This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.
June 1, 2019
Refer to Note 14, Leases, for the required disclosures related to adopting this standard.



Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
Standard
Description
Effective Date
Effect on the Consolidated Financial Statements
ASU 2018-13, Fair Value Measurement (Topic 820)

This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.

XML 88 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Divestitures (Tables)
3 Months Ended
Aug. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Results of Discontinued Operations The following table summarizes the financial results of our discontinued operations:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net sales
$
21,397

Cost of sales (exclusive of amortization)
12,882

Gross profit
8,515

Operating expenses
 
Research and development
288

Sales and marketing
1,028

General and administrative
62

Amortization of intangibles
682

Total operating expenses
2,060

Operating income
6,455

 
 
Income from discontinued operations before income taxes
6,455

Income tax expense
1,220

Income from discontinued operations
$
5,235


Total operating and investing cash flows of discontinued operations for the three months ended August 31, 2018 is comprised of the following, which excludes the effect of income taxes:
 
Three Months Ended
(in thousands)
Aug 31, 2018
Net cash provided by operating activities
$
524

Net cash provided by investing activities
224


XML 89 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Inventories - Schedule of Inventories (Detail) - USD ($)
$ in Thousands
Aug. 31, 2019
May 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 17,443 $ 16,045
Work in process 8,539 6,786
Finished goods 19,247 17,240
Inventories $ 45,229 $ 40,071
XML 90 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Divestitures - Results of Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Income from discontinued operations $ 0 $ 5,235
NAMIC Fluid Management Business | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Net sales 21,397  
Cost of sales (exclusive of amortization) 12,882  
Gross profit 8,515  
Research and development 288  
Sales and marketing 1,028  
General and administrative 62  
Amortization of intangibles 682  
Total operating expenses 2,060  
Operating income 6,455  
Income from discontinued operations before income taxes 6,455  
Income tax expense 1,220  
Income from discontinued operations 5,235  
Net cash provided by operating activities 524  
Net cash provided by investing activities $ 224  
XML 91 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Recently Issued Accounting Pronouncements (Tables)
3 Months Ended
Aug. 31, 2019
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements

The following table provides a description of recent accounting pronouncements that may have a material effect on the Company's consolidated financial statements:
Recently Issued Accounting Pronouncements - Adopted
Standard
Description
Date Adopted
Effect on the Consolidated Financial Statements
ASU 2016-02, Leases (Topic 842)
This ASU increases transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities.
June 1, 2019
Refer to Note 14, Leases, for the required disclosures related to adopting this standard.



Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted
Standard
Description
Effective Date
Effect on the Consolidated Financial Statements
ASU 2018-13, Fair Value Measurement (Topic 820)

This ASU removes, modifies and adds various disclosure requirements related to fair value disclosures. Disclosures related to transfers between fair value hierarchy levels will be removed and further detail around changes in unrealized gains and losses for the period and unobservable inputs used in determining level 3 fair value measurements will be added, among other changes.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.

ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates.
June 1, 2020
The Company is currently assessing the impact of this standard on the consolidated financial statements.





XML 92 R63.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value - Additional Information (Detail)
$ in Millions
Aug. 31, 2019
USD ($)
Minimum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Potential amount of undiscounted future contingent consideration $ 14.0
Maximum  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Potential amount of undiscounted future contingent consideration $ 34.0
XML 93 R67.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Non-Cancelable Payments Schedule (Details)
$ in Thousands
May 31, 2019
USD ($)
Leases [Abstract]  
2020 $ 2,920
2021 2,338
2022 2,133
2023 2,131
2024 and thereafter 3,227
Total lease payments $ 12,749
XML 94 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }